



(51) International Patent Classification:

Not classified

(21) International Application Number:

PCT/US2021/035603

(22) International Filing Date:

03 June 2021 (03.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/033,926 03 June 2020 (03.06.2020) US

63/119,717 01 December 2020 (01.12.2020) US

(71) Applicant: QURALIS CORPORATION [US/US]; 700

Main Street, North, Cambridge, MA 02139 (US).

(72) Inventors: ELBAUM, Daniel; 25 Sherrin Road, New-

ton, MA 02462 (US). HINCKLEY, Sandra; 4 Homestead

Street, Sudbury, MA 01776 (US).

(74) Agent: ZHANG, Clark et al.; Goodwin Procter LLP, 100

Northern Avenue, IP Docketing Dept./7th Fl, Boston, MA

02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: TREATMENT OF NEUROLOGICAL DISEASES USING MODULATORS OF GENE TRANSCRIPTS




FIG. 35

(57) **Abstract:** Disclosed herein are STMN2 oligonucleotides with one or more spacers. In various embodiments, STMN2 oligonucleotides with spacer(s) reduce STMN2 transcripts with cryptic exon and increase full length STMN2 transcripts, thereby imparting therapeutic efficacy against neurological diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), or Alzheimer's disease (AD).



TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*

TREATMENT OF NEUROLOGICAL DISEASES USING MODULATORS OF GENE TRANSCRIPTS

FIELD OF THE DISCLOSURE

[0001] This application relates generally to methods of treating neurological diseases with antisense oligonucleotides, in particular, antisense oligonucleotides with one or more spacers that target a transcript.

CROSS REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of and priority to U.S. Provisional Patent Application No. 63/033,926 filed on June 3, 2020 and U.S. Provisional Patent Application No. 63/119,717 filed on December 1, 2020, the entire disclosure of each of which is hereby incorporated by reference in its entirety for all purposes.

SEQUENCE LISTING

[0003] The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on May 28, 2021, is named QRL-006WO_SL.txt and is 510,394 bytes in size.

BACKGROUND

[0004] Motor neuron diseases are a class of neurological diseases that result in the degeneration and death of motor neurons – those neurons which coordinate voluntary movement of muscles by the brain. Motor neuron diseases may be sporadic or inherited, and may affect upper motor neurons and/or lower motor neurons. Motor neuron diseases include amyotrophic lateral sclerosis, progressive bulbar palsy, pseudobulbar palsy, primary lateral sclerosis, progressive muscular atrophy, spinal muscular atrophy, and post-polio syndrome.

[0005] Amyotrophic lateral sclerosis (ALS) is a group of motor neuron diseases affecting about 15,000 individuals in the United States of America. ALS is characterized by degeneration and death of upper and lower motor neurons, resulting in loss of voluntary muscle control. Motor neuron death is accompanied by muscle fasciculation and atrophy. Early symptoms of ALS include muscle cramps, muscle spasticity, muscle weakness (for example, affecting an arm, a leg, neck, or diaphragm), slurred and nasal speech, and difficulty chewing or swallowing. Loss of

strength and control over movements, including those necessary for speech, eating, and breathing, eventually occur. Disease progression may be accompanied by weight loss, malnourishment, anxiety, depression, increased risk of pneumonia, muscle cramps, neuropathy, and possibly dementia. Most individuals diagnosed with ALS die of respiratory failure within five years of the first appearance of symptoms. Currently, there is no effective treatment for ALS.

[0006] ALS occurs in individuals of all ages, but is most common in individuals between 55 to 75 years of age, with a slightly higher incidence in males. ALS can be characterized as sporadic or familial. Sporadic ALS appears to occur at random and accounts for more than 90% of all incidences of ALS. Familial ALS accounts for 5-10% of all incidences of ALS.

[0007] FTD refers to a spectrum of progressive neurodegenerative diseases caused by loss of neurons in frontal and temporal lobes of the brain. FTD is the third most common form of dementia (following Alzheimer's disease and dementia with Lewy bodies), and the second most common form of dementia in individuals below 65 years of age. FTD is estimated to affect 20,000 to 30,000 individuals in the United States of America. FTD is characterized by changes in behavior and personality, and language dysfunction. Forms of FTD include behavioral variant FTD (bvFTD), semantic variant primary progressive aphasia (svPPA), and nonfluent variant primary progressive aphasia (nfvPPA). ALS with FTD is characterized by symptoms associated with FTD, along with symptoms of ALS such as muscle weakness, atrophy, fasciculation, spasticity, speech impairment (dysarthria), and inability to swallow (dysphagia). Individuals usually succumb to FTD within 5 to 10 years, while ALS with FTD often results in death within 2 to 3 years of the first disease symptoms appearing.

[0008] Like ALS, there is no known cure for FTD, or ALS with FTD, nor a therapeutic known to prevent or retard either disease's progression.

[0009] Thus, there is a pressing need to identify compounds and/or compositions capable of preventing, ameliorating, and neurological diseases such as: amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), ALS with FTD, Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease, progressive supranuclear palsy (PSP), brain trauma, spinal cord injury, corticobasal degeneration (CBD), nerve injuries (e.g., brachial plexus injuries), neuropathies (e.g., chemotherapy induced neuropathy), and TDP43 proteinopathies (e.g., chronic traumatic encephalopathy, Perry Syndrome, Dementia with Lewy body in association with Alzheimer's disease, Parkinson's disease with or without dementia, and Limbic-predominant age-related TDP-43 encephalopathy (LATE)).

[0010] RNA-binding protein transactive response DNA-binding protein 43 (TDP-43) is involved in fundamental RNA processing activities including RNA transcription, splicing, and transport. TDP-43 binds to thousands of pre-messenger RNA/mRNA targets, with high affinity for GU-rich sequences, including autoregulation of its own mRNA via binding to 3' untranslated region.

5 Reduction in TDP-43 from an otherwise normal adult nervous system alters the splicing or expression levels of more than 1,500 RNAs, including long intron-containing transcripts. *See* Melamed et al., *Nat Neurosci.* (2019), 22(2):180-190.

[0011] In affected neurons in most instances of ALS and approximately 45% of patients with FTD, cytoplasmic accumulation and nuclear loss of TDP-43 have been reported. *See* Melamed et al., *Nat Neurosci.* (2019), 22(2):180-190. Moreover, TDP-43 has been shown to regulate expression of the neuronal growth-associated factor Stathmin-2 (STMN2). *See* Melamed (2019); *see also* Klim et al., *Nat Neurosci.* (2019), 22(2):167-179. STMN2 encodes a protein necessary for normal motor neuron outgrowth and repair. *See* Melamed (2019); *see also* Klim (2019). TDP-43 disruption is shown to drive premature polyadenylation and aberrant splicing in intron 1
15 of stathmin-2 pre-mRNA, producing a non-functional mRNA. *See* Melamed (2019).

SUMMARY

[0012] Described herein are oligonucleotides comprising one or more spacers and comprising a sequence that is between 85 and 98% complementary to an equal length portion of a STMN2 transcript. In one aspect, the present disclosure provides STMN2 oligonucleotides that target a
20 STMN2 transcript (for example, a STMN2 transcript comprising a cryptic exon). In various embodiments, the oligonucleotides target a transcript for the treatment of neurological diseases, including motor neuron diseases, and/or neuropathies. For example, STMN2 oligonucleotides can be used to treat PD, ALS, FTD, and ALS with FTD.

[0013] In one aspect the present disclosure provides a compound comprising a modified
25 oligonucleotide comprising a sequence that is between 85 and 98% complementary to an equal length portion of any one of SEQ ID NO: 1339 or SEQ ID NO: 1341, a sequence having 90% identity thereof, or to a 15 to 50 contiguous nucleobase portion thereof, wherein at least one (*i.e.*, one or more) nucleoside linkage of the oligonucleotide is a non-natural linkage, and further wherein the oligonucleotide comprises a spacer. In various embodiments, the oligonucleotide
30 comprises a segment with at most 11 linked nucleosides. In various embodiments, the oligonucleotide comprises a segment with at most 10, 9, or 8 linked nucleosides. In various

embodiments, the oligonucleotide comprises a segment with at most 7 linked nucleosides. In certain embodiments, the oligonucleotide comprises a segment with at most 6, 5, 4, 3, or 2 linked nucleosides. In certain embodiments, every segment of the oligonucleotide comprises at most 7 linked nucleosides.

5 **[0014]** In various embodiments, the oligonucleotide comprises a sequence that shares at least 85% identity with an equal length portion of any one of SEQ ID NOs: 1-466, SEQ ID NOs: 893-1338, SEQ ID NOs: 1342-1366, or SEQ ID NOs: 1392-1664. In various embodiments, the oligonucleotide comprises a sequence that shares at least 90% identity with an equal length portion of any one of SEQ ID NOs: 1-466, SEQ ID NOs: 893-1338, SEQ ID NOs: 1342-1366, or
10 SEQ ID NOs: 1392-1664. In various embodiments, the oligonucleotide comprises a sequence that shares 95% identity with an equal length portion of any one of SEQ ID NOs: 1451-1664. In various embodiments, the oligonucleotide comprises a sequence that shares 100% identity with an equal length portion of any one of SEQ ID NOs: 1451-1664.

[0015] In various embodiments, the oligonucleotide comprises a segment with at most 11 linked
15 nucleosides or at most 7 linked nucleosides, and wherein the oligonucleotide comprises a sequence that is between 85 and 98% complementary to an equal length portion within any one of positions 144-168, 173-197, 185-209, or 237-261 of SEQ ID NO: 1339. In various embodiments, the oligonucleotide comprises a segment with at most 11 linked nucleosides or at most 7 linked nucleosides, and wherein the oligonucleotide comprises a sequence that is between 85 and 98%
20 complementary to an equal length portion of nucleobases within any one of positions 144-164, 144-166, 145-167, 146-166, 146-168, 147-165, or 148-168 of SEQ ID NO: 1339. In various embodiments, the oligonucleotide comprises a segment with at most 11 linked nucleosides or at most 7 linked nucleosides, and wherein the oligonucleotide comprises a sequence that is between 85 and 98% complementary to an equal length portion of nucleobases within any one of positions
25 173-191, 173-193, 173-195, 173-197, 175-195, 175-197, 177-197, or 179-197 of SEQ ID NO: 1339.

[0016] In various embodiments, the oligonucleotide comprises a segment with at most 11 linked nucleosides or at most 7 linked nucleosides, and wherein the oligonucleotide comprises a sequence that is between 85 and 98% complementary to an equal length portion of nucleobases
30 within any one of positions 185-205, 187-209, 189-209, or 191-209 of SEQ ID NO: 1339. In various embodiments, the oligonucleotide comprises a segment with at most 11 linked nucleosides or at most 7 linked nucleosides, and wherein the oligonucleotide comprises a sequence that is between 85 and 98% complementary to an equal length portion of nucleobases

within any one of positions 237-255, 237-259, 239-259, 239-261, 241-261, or 243-261 of SEQ ID NO: 1339. In various embodiments, the oligonucleotide comprises a segment with at most 6, 5, 4, 3, or 2 linked nucleosides, and wherein the oligonucleotide comprises a sequence that is between 85 and 98% complementary to an equal length portion of nucleobases within any one of positions 144-168, 173-197, 185-209, or 237-261 of SEQ ID NO: 1339.

[0017] In various embodiments, the oligonucleotide comprises a segment with at most 6, 5, 4, 3, or 2 linked nucleosides, and wherein the oligonucleotide comprises a sequence that is between 85 and 98% complementary to an equal length portion of nucleobases within any one of positions 144-164, 144-166, 145-167, 146-166, 146-168, 147-165, 148-168, 173-191, 173-193, 173-195, 173-197, 175-195, 175-197, 177-197, 179-197, 185-205, 187-209, 189-209, 191-209, 237-255, 237-259, 239-259, 239-261, 241-261, or 243-261 of SEQ ID NO: 1339. In various embodiments, the oligonucleotide comprises a segment with at most 11 linked nucleosides or at most 7 linked nucleosides, and wherein the oligonucleotide comprises a sequence that shares at least 85% identity with an equal length portion of any one of SEQ ID NOs: 1-466, SEQ ID NOs: 893-1338, SEQ ID NOs: 1342-1366, or SEQ ID NOs: 1392-1664. In various embodiments, the oligonucleotide comprises a segment with at most 6, 5, 4, 3, or 2 linked nucleosides, and wherein the oligonucleotide comprises a sequence that shares at least 85% identity with an equal length portion of any one of SEQ ID NOs: 36, 55, 144, 173, 177, 181, 185, 197, 203, 209, 215, 237, 244, 252, 380, 385, 390, 395, 400, 928, 947, 1036, 1065, 1069, 1073, 1077, 1089, 1095, 1101, 1107, 1129, 1136, 1144, 1272, 1277, 1282, 1287, or 1292. In various embodiments, the oligonucleotide comprises a segment with at most 6, 5, 4, 3, or 2 linked nucleosides, and wherein the oligonucleotide comprises a sequence that shares at least 90% identity with an equal length portion of any one of SEQ ID NOs: 36, 55, 144, 173, 177, 181, 185, 197, 203, 209, 215, 237, 244, 252, 380, 385, 390, 395, 400, 928, 947, 1036, 1065, 1069, 1073, 1077, 1089, 1095, 1101, 1107, 1129, 1136, 1144, 1272, 1277, 1282, 1287, or 1292.

[0018] In various embodiments, the oligonucleotide is at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25 oligonucleotide units in length. In various embodiments, the oligonucleotide is at least 19 oligonucleotide units in length. In various embodiments, the spacer is a nucleoside-replacement group comprising a non-sugar substitute that is incapable of linking to a nucleotide base.


[0019] In various embodiments, the spacer is located between positions 10 and 15 of the oligonucleotide. In various embodiments, the spacer is located between positions 7 and 11 of the oligonucleotide. In various embodiments, the oligonucleotide further comprises a second spacer,

wherein the second spacer is located between positions 14 and 22 of the oligonucleotide. In various embodiments, the spacer and the second spacer are separated by at least 5 nucleobases, at least 6 nucleobases, or at least 7 nucleobases in the oligonucleotide. In various embodiments, the spacer is located between positions 7 and 9 of the oligonucleotide, and wherein the second spacer is located between positions 15 and 18 of the oligonucleotide. In various embodiments, the spacer is located at position 8 of the oligonucleotide, and wherein the second spacer is located at position 16 of the oligonucleotide. In various embodiments, the oligonucleotide further comprises a third spacer, wherein the third spacer is located between positions 21 and 24 of the oligonucleotide.

[0020] In various embodiments, the spacer is located between positions 2 and 5 of the oligonucleotide. In various embodiments, the oligonucleotide further comprises a second spacer, wherein the second spacer is located between positions 8 and 12 of the oligonucleotide. In various embodiments, the oligonucleotide further comprises a third spacer, wherein the third spacer is located between positions 18 and 22 of the oligonucleotide. In various embodiments, the oligonucleotide further comprises a second spacer and a third spacer, wherein the three spacers are located at positions in the oligonucleotide such that each segment of the oligonucleotide has at most 7 linked nucleosides. In various embodiments, at least two of the three spacers are adjacent to a guanine nucleobase. In various embodiments, each of the at least two of the three spacers immediately precede a guanine nucleobase.

[0021] In various embodiments, each of the first, second or third spacers is a nucleoside-replacement group comprising a non-sugar substitute wherein the non-sugar substitute does not contain a ketone, aldehyde, ketal, hemiketal, acetal, hemiacetal, aminal or hemiaminal moiety and is incapable of forming a covalent bond with a nucleotide base.

[0022] In certain embodiments, each of the first, second or third spacers is independently represented by Formula (X), wherein:




Formula (X)

Ring A is an optionally substituted 4-8 member monocyclic cycloalkyl group or a 4-8 member monocyclic heterocyclyl group, wherein the heterocyclyl group contains 1 or 2 heteroatoms selected from O, S and N, provided that A is not capable of forming a covalent bond to a nucleobase; and

the $\text{---}\overset{\text{O}}{\underset{\text{O}}{\text{---}}}\text{---}$ symbol represents the point of connection to an internucleoside linkage.

[0023] In various embodiments, each of the first, second or third spacers is independently represented by Formula (Xa), wherein:




Formula (Xa).

- 5 **[0024]** In some embodiments, ring A is an optionally substituted 4-8 member monocyclic cycloalkyl group selected from cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl; or a 4-8 member monocyclic heterocyclyl group, selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, 1,4-dioxanyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl and azepanyl.

[0025] In further embodiments, ring A is tetrahydrofuranyl.

- 10 **[0026]** In other embodiments, ring A is tetrahydropyranyl.

[0027] In various embodiments, each of the first, second or third spacers is independently represented by Formula I, wherein:




Formula (I)

X is selected from $\text{---CH}_2\text{---}$ and ---O--- ; and

- 15 n is 0, 1, 2 or 3.

[0028] In various embodiments, each of the first, second or third spacers is independently represented by Formula I', wherein:




Formula (I')

X is selected from $\text{---CH}_2\text{---}$ and ---O--- ; and

- 20 n is 0, 1, 2 or 3.


[0029] In various embodiments, each of the first, second or third spacers is independently represented by Formula (Ia), wherein:



Formula (Ia); and

n is 0, 1, 2 or 3.


5 [0030] In various embodiments, each of the first, second or third spacers is independently represented by Formula (Ia'), wherein:



Formula (Ia'); and

n is 0, 1, 2 or 3.


10 [0031] In certain embodiments, each of the first, second or third spacers is independently represented by Formula II, wherein:



Formula (II); and

X is selected from $-CH_2-$ and $-O-$.


[0032] In further embodiments, each of the first, second or third spacers is independently represented by Formula II', wherein:



Formula (II'); and


X is selected from $-CH_2-$ and $-O-$.

[0033] In various embodiments, each of the first, second or third spacers is independently represented by Formula (IIa), wherein:




Formula (IIa).

[0034] In further embodiments, each of the first, second or third spacers is independently represented by Formula (IIa'), wherein:



Formula (IIa').


5 [0035] In various embodiments, each of the first, second or third spacers is independently represented by Formula III, wherein:



Formula (III); and

X is selected from -CH₂- and -O-.


10 [0036] In further embodiments, each of the first, second or third spacers is independently represented by Formula III', wherein:



Formula (III'); and


X is selected from -CH₂- and -O-.

[0037] In some embodiments, each of the first, second or third spacers is independently represented by Formula (IIIa), wherein:



Formula (IIIa).

15 [0038] In further embodiments, each of the first, second or third spacers is independently represented by Formula (IIIa'), wherein:



Formula (IIIa').

[0039] In various embodiments, the oligonucleotide comprising the spacer has a GC content of at least 10%. In various embodiments, the oligonucleotide comprising the spacer has a GC content of at least 20%. In various embodiments, the oligonucleotide comprising the spacer has a GC content of at least 25%. In various embodiments, the oligonucleotide comprising the spacer has a GC content of at least 30%. In various embodiments, the oligonucleotide comprising the spacer has a GC content of at least 40%. In various embodiments, the oligonucleotide comprising the spacer has a GC content of at least 50%.

[0040] In various embodiments, the oligonucleotide is between 12 and 40 oligonucleotide units in length.

[0041] In various embodiments, at least one (*i.e.*, one or more) nucleoside linkage of the oligonucleotide is independently selected from the group consisting of a phosphodiester linkage, a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a thiophosphorodiamidate linkage, a phosphorodiamidate (*e.g.*, comprising a phosphorodiamidate morpholino (PMO), 3' amino ribose, or 5' amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage.

[0042] In various embodiments, one or more nucleoside linkages that link a base at position 3 or position 4 of the oligonucleotide are phosphodiester linkages. In various embodiments, only one nucleoside linkage that links a base at position 3 or position 4 of the oligonucleotide is a phosphodiester linkage. In various embodiments, nucleoside linkages that link bases at both position 3 and position 4 of the oligonucleotide are phosphodiester linkages. In various embodiments, one or more bases immediately preceding a spacer in the oligonucleotide are linked through phosphodiester bonds. In various embodiments, only the base immediately preceding the spacer in the oligonucleotide is linked to the spacer through a phosphodiester bond. In various embodiments, the base immediately preceding the spacer in the oligonucleotide is further linked

to a further preceding base through a phosphodiester bond. In various embodiments, the oligonucleotide comprises a second spacer, wherein a base immediately preceding the second spacer is linked to a further preceding base through a phosphodiester bond.

[0043] In various embodiments, one or more bases immediately succeeding a spacer in the oligonucleotide are linked through phosphodiester bonds. In various embodiments, only the base immediately succeeding the spacer in the oligonucleotide is linked to the spacer through a phosphodiester bond. In various embodiments, two bases immediately preceding the spacer in the oligonucleotide are linked through phosphodiester bonds. In various embodiments, one or more bases immediately preceding a spacer in the oligonucleotide are linked through phosphodiester bonds and wherein one or more bases immediately succeeding the spacer in the oligonucleotide are linked through phosphodiester bonds. In various embodiments, one base immediately preceding the spacer and one base immediately succeeding the spacer are linked through phosphodiester bonds. In various embodiments, the oligonucleotide includes a second spacer, and wherein one or more bases immediately preceding the second spacer in the oligonucleotide are linked through phosphodiester bonds and wherein one or more bases immediately succeeding the second spacer in the oligonucleotide are linked through phosphodiester bonds. In various embodiments, one base immediately preceding the second spacer and one base immediately succeeding the second spacer are linked through phosphodiester bonds. In various embodiments, the oligonucleotide comprises a range of bases that are linked through phosphodiester bonds, the range of bases comprising at least two bases. In various embodiments, the oligonucleotide comprises a range of bases that are linked through phosphodiester bonds, the range of bases comprising at least five bases. In various embodiments, the oligonucleotide comprises two or more spacers, and wherein the range of bases are positioned between the at least two spacers.

[0044] Additionally disclosed herein is a compound comprising an oligonucleotide comprising a nucleobase sequence that shares at least 90% identity to an equal length portion of any one of SEQ ID NOs: 1-466, SEQ ID NOs: 893-1338, SEQ ID NOs: 1342-1366, or SEQ ID NOs: 1392-1664. Additionally disclosed herein is an oligonucleotide comprising a nucleobase sequence that shares at least 90% identity to an equal length portion of any one of SEQ ID NOs: 1-466, SEQ ID NOs: 893-1338, SEQ ID NOs: 1342-1366, or SEQ ID NOs: 1392-1664. In various embodiments, the nucleobase sequence shares at least 95% identity to an equal length portion of any one of SEQ ID NOs: 1-466, SEQ ID NOs: 893-1338, SEQ ID NOs: 1342-1366, or SEQ ID NOs: 1392-1664. In various embodiments, the nucleobase sequence shares at least 100% identity to an equal length portion of any one of SEQ ID NOs: 1-466, SEQ ID NOs: 893-1338, SEQ ID NOs: 1342-1366, or

SEQ ID NOs: 1392-1664. In various embodiments, the oligonucleotide is any one of a 19mer, 21mer, 23mer, or 25mer.

[0045] In various embodiments, an internucleoside linkage of the oligonucleotide is a modified internucleoside linkage. In various embodiments, the modified internucleoside linkage of the oligonucleotide is a phosphorothioate linkage. In various embodiments, all internucleoside linkages of the oligonucleotide are phosphorothioate linkages. In various embodiments, the phosphorothioate linkage is in one of a *Rp* configuration or a *Sp* configuration. In various embodiments, the oligonucleotide comprises at least one modified sugar moiety. In various embodiments, the modified sugar moiety is one of a 2'-OMe modified sugar moiety, bicyclic sugar moiety, 2'-*O*-(2-methoxyethyl) (MOE), 2'-deoxy-2'-fluoro nucleoside, 2'-fluoro- β -D-arabinonucleoside, locked nucleic acid (LNA), a tricyclic nucleic acid, constrained ethyl 2'-4'-bridged nucleic acid (cEt), *S*-cEt, tcDNA, hexitol nucleic acids (HNA), and tricyclic analog (e.g., tcDNA).

[0046] In various embodiments, the oligonucleotide exhibits at least a 30%, 40%, 50%, 60%, 70%, 80%, or 90% increase of full length STMN2 protein. In various embodiments, the oligonucleotide exhibits at least a 100% increase of full length STMN2 protein. In various embodiments, the oligonucleotide exhibits at least a 200% increase of full length STMN2 protein. In various embodiments, the oligonucleotide exhibits at least a 300% increase of full length STMN2 protein. In various embodiments, the oligonucleotide exhibits at least a 400% increase of full length STMN2 protein. In various embodiments, increase of the full length STMN2 protein is measured in comparison to a reduced level of full length STMN2 protein achieved using a TDP43 antisense oligonucleotide. In various embodiments, the oligonucleotide exhibits at least a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% rescue of full length STMN2 protein. In various embodiments, the oligonucleotide exhibits at least a 50%, 60%, 70%, 80%, or 90% reduction of a STMN2 transcript with a cryptic exon.

[0047] Additionally disclosed is a method of treating a neurological disease and/or a neuropathy in a patient in need thereof, the method comprising administering to the patient an oligonucleotide of any of the oligonucleotides disclosed above. In various embodiments, the neurological disease selected from the group consisting of: amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), ALS with FTD, Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease, progressive supranuclear palsy (PSP), brain trauma, spinal cord injury, corticobasal degeneration (CBD), nerve injuries (e.g., brachial plexus injuries), neuropathies (e.g., chemotherapy induced neuropathy), and TDP43 proteinopathies (e.g., chronic traumatic

encephalopathy, Perry Syndrome, Dementia with Lewy body in association with Alzheimer's disease, Parkinson's disease with or without dementia, and Limbic-predominant age-related TDP-43 encephalopathy (LATE)). In various embodiments, the neurological disease is ALS. In various embodiments, the neurological disease is FTD. In various embodiments, the neurological disease is ALS with FTD. In various embodiments, the neuropathy is chemotherapy induced neuropathy.

[0048] Additionally disclosed is a method of restoring axonal outgrowth and/or regeneration of a neuron, the method comprising exposing the motor neuron to an oligonucleotide of any of the oligonucleotides disclosed above. Additionally disclosed is a method of increasing, promoting, stabilizing, or maintaining STMN2 expression and/or function in a neuron, the method comprising exposing the cell to an oligonucleotide of any of the oligonucleotides disclosed above.

[0049] In various embodiments, the neuron is a neuron of a patient in need of treatment of a neurological disease and/or a neuropathy. In various embodiments, the neuropathy is chemotherapy induced neuropathy. In various embodiments, the exposing is performed *in vivo* or *ex vivo*. In various embodiments, the exposing comprises administering the oligonucleotide to a patient in need thereof. In various embodiments, the oligonucleotide is administered topically, parenterally, intrathecally, intrathalamically, intracisternally, orally, rectally, buccally, sublingually, vaginally, pulmonarily, intratracheally, intranasally, transdermally, or intraduodenally. In various embodiments, the oligonucleotide is administered orally. In various embodiments, a therapeutically effective amount of the oligonucleotide is administered intrathecally, intrathalamically or intracisternally. In various embodiments, the patient is a human.

[0050] Additionally disclosed herein is a pharmaceutical composition comprising the oligonucleotide of any one of the oligonucleotides disclosed above, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. In various embodiments, the pharmaceutical composition is suitable for topical, intrathecal, intrathalamic, intracisternal, intracerebroventricular, parenteral, oral, pulmonary, intratracheal, intranasal, transdermal, rectal, buccal, sublingual, vaginal, or intraduodenal administration.

[0051] Additionally disclosed herein is a method of treating a neurological disease or a neuropathy in a patient in need thereof, the method comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition disclosed above. In various embodiments, the neurological disease is selected from the group consisting of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), ALS with FTD, Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease, progressive

supranuclear palsy (PSP), brain trauma, spinal cord injury, corticobasal degeneration (CBD), nerve injuries (e.g., brachial plexus injuries), neuropathies (e.g., chemotherapy induced neuropathy), and TDP43 proteinopathies (e.g., chronic traumatic encephalopathy, Perry Syndrome, Dementia with Lewy body in association with Alzheimer's disease, Parkinson's disease with or without dementia, and Limbic-predominant age-related TDP-43 encephalopathy (LATE)). In various embodiments, the neurological disease is ALS. In various embodiments, the neurological disease is FTD. In various embodiments, the neurological disease is ALS with FTD. In various embodiments, the neuropathy is chemotherapy induced neuropathy. In various embodiments, the pharmaceutical composition is administered topically, parenterally, orally, pulmonarily, rectally, buccally, sublingually, vaginally, intratracheally, intranasally, intracisternally, intrathecally, intrathalamically, intravenously, intramuscularly, transdermally, or intraduodenally. In various embodiments, wherein the pharmaceutical composition is administered intrathecally, intrathalamically intracerebroventricularly, or intracisternally. In various embodiments, a therapeutically effective amount of the oligonucleotide is administered intrathecally, intrathalamically or intracisternally. In various embodiments, the patient is human.

[0052] Additionally disclosed herein is a method for treating a neurological disease in a subject in need thereof, the method comprising administering to the subject an oligonucleotide comprising a segment with at most 7 linked nucleosides, and wherein oligonucleotide shares at least 85% identity with any one of SEQ ID NOs: 1-466, SEQ ID NOs: 893-1338, SEQ ID NOs: 1342-1366, or SEQ ID NOs: 1392-1664, or a pharmaceutically acceptable salt thereof; wherein at least one (*i.e.*, one or more) nucleoside linkage of the oligonucleotide is independently selected from the group consisting of: a phosphodiester linkage, a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a thiophosphorodiamidate linkage, a phosphorodiamidate (*e.g.*, comprising a phosphorodiamidate morpholino (PMO), 3' amino ribose, or 5' amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage, and/or wherein at least one (*i.e.*, one or more) nucleoside is substituted with a component selected from the group consisting of a 2'-O-(2-methoxyethyl) nucleoside, a 2'-O-methyl nucleoside, a 2'-deoxy-2'-fluoro nucleoside, a 2'-fluoro- β -D-arabinonucleoside, a locked nucleic acid (LNA), a tricyclic nucleic acid,

constrained methoxyethyl (cMOE), constrained ethyl (cET), and a peptide nucleic acid (PNA), optionally wherein the oligonucleotide further comprises a spacer.

[0053] Additionally disclosed herein is a method for treating ALS in a subject in need thereof, the method comprising administering to the subject an oligonucleotide comprising a segment with at most 7 linked nucleosides, and wherein oligonucleotide shares at least 85% identity with any one of SEQ ID NOs: 1-466, SEQ ID NOs: 893-1338, SEQ ID NOs: 1342-1366, or SEQ ID NOs: 1392-1664, or a pharmaceutically acceptable salt thereof; wherein at least one (*i.e.*, one or more) nucleoside linkage of the oligonucleotide is independently selected from the group consisting of: a phosphodiester linkage, a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a thiophosphorodiamidate linkage, a phosphorodiamidate (*e.g.*, comprising a phosphorodiamidate morpholino (PMO), 3' amino ribose, or 5' amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage, and/or wherein at least one (*i.e.*, one or more) nucleoside is substituted with a component selected from the group consisting of a 2'-O-(2-methoxyethyl) nucleoside, a 2'-O-methyl nucleoside, a 2'-deoxy-2'-fluoro nucleoside, a 2'-fluoro- β -D-arabinonucleoside, locked nucleic acid (LNA), a tricyclic nucleic acid, constrained methoxyethyl (cMOE), constrained ethyl (cET), and a peptide nucleic acid (PNA), optionally wherein the oligonucleotide further comprises a spacer.

[0054] Additionally disclosed herein is a method for treating FTD in a subject in need thereof, the method comprising administering to the subject an oligonucleotide comprising a segment with at most 7 linked nucleosides, and wherein oligonucleotide shares at least 85% identity with any one of SEQ ID NOs: 1-466, SEQ ID NOs: 893-1338, SEQ ID NOs: 1342-1366, or SEQ ID NOs: 1392-1664, or a pharmaceutically acceptable salt thereof; wherein at least one (*i.e.*, one or more) nucleoside linkage of the oligonucleotide is independently selected from the group consisting of: a phosphodiester linkage, a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a thiophosphorodiamidate linkage, a phosphorodiamidate (*e.g.*,

comprising a phosphorodiamidate morpholino (PMO), 3' amino ribose, or 5' amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage, and/or wherein at least one (*i.e.*, one or more) nucleoside is substituted with a component selected from the group consisting of a 2'-O-(2-methoxyethyl) nucleoside, a 2'-O-methyl nucleoside, a 2'-deoxy-2'-fluoro nucleoside, a 2'-fluoro- β -D-arabinonucleoside, locked nucleic acid (LNA), a tricyclic nucleic acid, constrained methoxyethyl (cMOE), constrained ethyl (cET), and a peptide nucleic acid (PNA), optionally wherein the oligonucleotide further comprises a spacer.

[0055] Additionally disclosed herein is a method for treating ALS with FTD in a subject in need thereof, the method comprising administering to the subject an oligonucleotide comprising a segment with at most 7 linked nucleosides, and wherein oligonucleotide shares at least 85% identity with any one of SEQ ID NOs: 1-466, SEQ ID NOs: 893-1338, SEQ ID NOs: 1342-1366, or SEQ ID NOs: 1392-1664, or a pharmaceutically acceptable salt thereof, wherein at least one (*i.e.*, one or more) nucleoside linkage of the oligonucleotide is independently selected from the group consisting of: a phosphodiester linkage, a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a thiophosphorodiamidate linkage, a phosphorodiamidate (*e.g.*, comprising a phosphorodiamidate morpholino (PMO), 3' amino ribose, or 5' amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage, and/or wherein at least one (*i.e.*, one or more) nucleoside is substituted with a component selected from the group consisting of a 2'-O-(2-methoxyethyl) nucleoside, a 2'-O-methyl nucleoside, a 2'-deoxy-2'-fluoro nucleoside, a 2'-fluoro- β -D-arabinonucleoside, locked nucleic acid (LNA), a tricyclic nucleic acid, constrained methoxyethyl (cMOE), constrained ethyl (cET), and a peptide nucleic acid (PNA), optionally wherein the oligonucleotide further comprises a spacer.

[0056] In various embodiments, one or more nucleoside linkages that link a base at position 3 or position 4 of the oligonucleotide are phosphodiester linkages. In various embodiments, only one nucleoside linkage that links a base at position 3 or position 4 of the oligonucleotide is a phosphodiester linkage. In various embodiments, nucleoside linkages that link bases at both

position 3 and position 4 of the oligonucleotide are phosphodiester linkages. In various embodiments, one or more bases immediately preceding a spacer in the oligonucleotide are linked through phosphodiester bonds. In various embodiments, only the base immediately preceding the spacer in the oligonucleotide is linked to the spacer through a phosphodiester bond. In various
5 embodiments, the base immediately preceding the spacer in the oligonucleotide is further linked to a further preceding base through a phosphodiester bond. In various embodiments, the oligonucleotide comprises a second spacer, wherein a base immediately preceding the second spacer is linked to a further preceding base through a phosphodiester bond.

[0057] In various embodiments, one or more bases immediately succeeding a spacer in the
10 oligonucleotide are linked through phosphodiester bonds. In various embodiments, only the base immediately succeeding the spacer in the oligonucleotide is linked to the spacer through a phosphodiester bond. In various embodiments, two bases immediately preceding the spacer in the oligonucleotide are linked through phosphodiester bonds. In various embodiments, one or more bases immediately preceding a spacer in the oligonucleotide are linked through phosphodiester
15 bonds and wherein one or more bases immediately succeeding the spacer in the oligonucleotide are linked through phosphodiester bonds. In various embodiments, one base immediately preceding the spacer and one base immediately succeeding the spacer are linked through phosphodiester bonds. In various embodiments, the oligonucleotide includes a second spacer, and wherein one or more bases immediately preceding the second spacer in the oligonucleotide are
20 linked through phosphodiester bonds and wherein one or more bases immediately succeeding the second spacer in the oligonucleotide are linked through phosphodiester bonds. In various embodiments, one base immediately preceding the second spacer and one base immediately succeeding the second spacer are linked through phosphodiester bonds. In various embodiments, the oligonucleotide comprises a range of bases that are linked through phosphodiester bonds, the range of bases comprising at least two bases. In various embodiments, the oligonucleotide comprises a range of bases that are linked through phosphodiester bonds, the range of bases comprising at least five bases. In various embodiments, the oligonucleotide comprises two or more spacers, and wherein the range of bases are positioned between the at least two spacers. In various embodiments, the oligonucleotide is any one of a 19mer, 21mer, 23mer, or 25mer.

25 **[0058]** In various embodiments, at least one (*i.e.*, one or more) internucleoside linkage of the oligonucleotide is a phosphorothioate linkage. In various embodiments, all internucleoside linkages of the oligonucleotide are phosphorothioate linkages.

[0059] Additionally disclosed herein is an oligonucleotide and a pharmaceutically acceptable excipient, the oligonucleotide comprising a sequence that is between 85 and 98% complementary to an equal length portion of any one of SEQ ID NO: 1339 or SEQ ID NO: 1341, a sequence having 90% identity thereof, or to a 15 to 50 contiguous nucleobase portion thereof, wherein the oligonucleotide comprises a spacer and wherein the oligonucleotide is capable of increasing, restoring, or stabilizing expression of the STMN2 mRNA capable of translation of a functional STMN2 and/or activity and/or function of STMN2 protein in a cell or a human patient of an immune-mediated demyelinating disease, and wherein the level of increase, restoration, or stabilization of expression and/or activity and/or function is sufficient for use of the oligonucleotide as a medicament for the treatment of the immune-mediated demyelinating disease.

[0060] In various embodiments, the oligonucleotide comprises one or more chiral centers and/or double bonds. In various embodiments, the oligonucleotide exist as stereoisomers selected from geometric isomers, enantiomers, and diastereomers.

[0061] Additionally disclosed herein is a method of treating a neurological disease and/or a neuropathy in a patient in need thereof, the method comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition disclosed above, in combination with a second therapeutic agent. In various embodiments, the second therapeutic agent is selected from Riluzole (Rilutek), Edaravone (Radicava), rivastigmine, donepezil, galantamine, selective serotonin reuptake inhibitor, antipsychotic agents, cholinesterase inhibitors, memantine, benzodiazepine antianxiety drugs, AMX0035 (ELYBRIO), ZILUCOPLAN (RA101495), pridopidine, dual AON intrathecal administration (*e.g.*, BIIB067, BIIB078, and BIIB105), BIIB100, levodopa/carbidopa, dopaminergic agents (*e.g.*, ropinirole, pramipexole, rotigotine), medroxyprogesterone, KCNQ2/KCNQ3 openers (*e.g.*, retigabine, XEN1101, QRL-101), anticonvulsants and psychostimulant agents, and/or a therapy (*e.g.*, selected from breathing care, physical therapy, occupational therapy, speech therapy, nutritional support), for treating said neurologic disease.

[0062] Additionally disclosed herein is a method of treating a neurological disease and/or a neuropathy in a patient in need thereof, the method comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition disclosed above, wherein at least one (*i.e.*, one or more) nucleoside linkage of the oligonucleotide is a non-natural linkage, wherein the oligonucleotide comprises a spacer, and wherein the oligonucleotide further

comprises a targeting or conjugate moiety selected from cholesterol, lipoic acid, panthothenic acid, polyethylene glycol, and an antibody for crossing the blood brain barrier.


[0063] In various embodiments, the spacer is a nucleoside-replacement group comprising a non-sugar substitute that is incapable of linking to a nucleotide base. In various embodiments, the spacer is located between positions 10 and 15 of the oligonucleotide. In various embodiments, the spacer is located between positions 7 and 11 of the oligonucleotide. In various embodiments, the oligonucleotide further comprises a second spacer, wherein the second spacer is located between positions 14 and 22 of the oligonucleotide. In various embodiments, the spacer and the second spacer are separated by at least 5 nucleobases, at least 6 nucleobases, or at least 7 nucleobases in the oligonucleotide. In various embodiments, the spacer is located between positions 7 and 9 of the oligonucleotide, and wherein the second spacer is located between positions 15 and 18 of the oligonucleotide. In various embodiments, the spacer is located at position 8 of the oligonucleotide, and wherein the second spacer is located at position 16 of the oligonucleotide.

[0064] In various embodiments, the oligonucleotide further comprises a third spacer, wherein the third spacer is located between positions 21 and 24 of the oligonucleotide. In various embodiments, the spacer is located between positions 2 and 5 of the oligonucleotide. In various embodiments, the oligonucleotide further comprises a second spacer, wherein the second spacer is located between positions 8 and 12 of the oligonucleotide. In various embodiments, the oligonucleotide further comprises a third spacer, wherein the third spacer is located between positions 18 and 22 of the oligonucleotide. In various embodiments, the oligonucleotide further comprises a second spacer and a third spacer, wherein the three spacers are located at positions in the oligonucleotide such that each segment of the oligonucleotide has at most 7 linked nucleosides.

[0065] In various embodiments, at least two of the three spacers are adjacent to a guanine nucleobase. In various embodiments, each of the at least two of the three spacers immediately precede a guanine nucleobase.

[0066] In various embodiments, of the methods described herein, each of the first, second or third spacers is a nucleoside-replacement group comprising a non-sugar substitute wherein the non-sugar substitute does not contain a ketone, aldehyde, ketal, hemiketal, acetal, hemiacetal, aminated or hemiaminal moiety and is incapable of forming a covalent bond with a nucleotide base.

[0067] In certain embodiments, each of the first, second or third spacers is independently represented by Formula (X), wherein:




Formula (X)

Ring A is an optionally substituted 4-8 member monocyclic cycloalkyl group or a 4-8 member monocyclic heterocyclyl group, wherein the heterocyclyl group contains 1 or 2 heteroatoms selected from O, S and N, provided that A is not capable of forming a covalent bond to a nucleobase; and

the $\text{---}\frac{\text{S}}{\text{---}}$ symbol represents the point of connection to an internucleoside linkage.

[0068] In various embodiments, each of the first, second or third spacers is independently represented by Formula (Xa), wherein:




Formula (Xa).

[0069] In some embodiments, ring A is an optionally substituted 4-8 member monocyclic cycloalkyl group selected from cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl; or a 4-8 member monocyclic heterocyclyl group, selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, 1,4-dioxanyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl and azepanyl.

[0070] In further embodiments, ring A is tetrahydrofuranyl.

[0071] In other embodiments, ring A is tetrahydropyranyl.

[0072] In various embodiments, each of the first, second or third spacers is independently represented by Formula (I), wherein:




Formula (I)

X is selected from -CH₂- and -O-; and

n is 0, 1, 2 or 3.


[0073] In various embodiments, the spacer or the second spacer is represented by Formula (I'), wherein:



X is selected from -CH₂- and -O-; and


5 n is 0, 1, 2 or 3.

[0074] In various embodiments, each of the first, second or third spacers is independently represented by Formula (Ia), wherein:



n is 0, 1, 2 or 3.


10 [0075] In various embodiments, each of the first, second or third spacers is independently represented by Formula (Ia'), wherein:



n is 0, 1, 2 or 3.


[0076] In certain embodiments, each of the first, second or third spacers is independently represented by Formula II, wherein:

15



X is selected from -CH₂- and -O-.


[0077] In further embodiments, each of the first, second or third spacers is independently represented by Formula II', wherein:



Formula (II'); and


5 X is selected from -CH₂- and -O-.

[0078] In various embodiments, each of the first, second or third spacers is independently represented by Formula (IIa), wherein:




Formula (IIa).

10 [0079] In further embodiments, each of the first, second or third spacers is independently represented by Formula (IIa'), wherein:



Formula (IIa').


[0080] In various embodiments, each of the first, second or third spacers is independently represented by Formula III, wherein:



Formula (III); and

15 X is selected from -CH₂- and -O-.


[0081] In further embodiments, each of the first, second or third spacers is independently represented by Formula III', wherein:



Formula (III'); and


X is selected from -CH₂- and -O-.

[0082] In some embodiments, each of the first, second or third spacers is independently represented by Formula (IIIa), wherein:



Formula (IIIa).

[0083] In further embodiments, each of the first, second or third spacers is independently represented by Formula (IIIa'), wherein:



Formula (IIIa').

- [0084]** In various embodiments, the oligonucleotide comprising the spacer has a GC content of at least 10%. In various embodiments, the oligonucleotide comprising the spacer has a GC content of at least 20%. In various embodiments, the oligonucleotide comprising the spacer has a GC content of at least 25%. In various embodiments, the oligonucleotide comprising the spacer has a GC content of at least 30%. In various embodiments, the oligonucleotide comprising the spacer has a GC content of at least 40%. In various embodiments, the oligonucleotide comprising the spacer has a GC content of at least 50%.

BRIEF DESCRIPTION OF THE DRAWINGS

[0085] FIG. 1 is a schematic depiction of portions of the STMN2 transcript and STMN2 antisense oligonucleotides that are designed to target certain portions of the STMN2 transcript.

- [0086]** FIG. 2 is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 antisense, and restoration of the full-length STMN2 transcript in the presence of 6 different STMN2 parent oligonucleotides (SEQ ID NO:

36, SEQ ID NO: 55, SEQ ID NO: 177, SEQ ID NO: 203, SEQ ID NO: 244, and SEQ ID NO: 395).

[0087] FIG. 3 is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels in the presence of 6 different STMN2 parent oligonucleotides (SEQ ID NO: 173, SEQ ID NO: 181, SEQ ID NO: 197, SEQ ID NO: 215, SEQ ID NO: 385, and SEQ ID NO: 400).

[0088] FIG. 4 is a bar graph showing the results of RT-qPCR analysis of STMN2 full-length mRNA levels in the presence of TDP43 antisense, and restoration of the full-length STMN2 transcript in the presence of 6 different STMN2 parent oligonucleotides (SEQ ID NO: 173, SEQ ID NO: 181, SEQ ID NO: 197, SEQ ID NO: 215, SEQ ID NO: 385, and SEQ ID NO: 400).

[0089] FIG. 5A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels in the presence of 6 different STMN2 parent oligonucleotides (SEQ ID NO: 185, SEQ ID NO: 209, SEQ ID NO: 237, SEQ ID NO: 252, SEQ ID NO: 380, and SEQ ID NO: 390).

[0090] FIG. 5B is a bar graph showing the results of RT-qPCR analysis of STMN2 full-length mRNA levels in the presence of TDP43 antisense, and restoration of the full-length STMN2 transcript in the presence of 6 different STMN2 parent oligonucleotides (SEQ ID NO: 185, SEQ ID NO: 209, SEQ ID NO: 237, SEQ ID NO: 252, SEQ ID NO: 380, and SEQ ID NO: 390).

[0091] FIG. 6A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels in the presence of 2 different STMN2 parent oligonucleotides (SEQ ID NO: 144 and SEQ ID NO: 237) over two duplicate experiments.

[0092] FIG. 6B is a bar graph showing the results of RT-qPCR analysis of STMN2 full-length mRNA levels in the presence of TDP43 antisense, and restoration of the full-length STMN2 transcript in the presence of 2 different STMN2 parent oligonucleotides (SEQ ID NO: 144 and SEQ ID NO: 237) over two duplicate experiments.

[0093] FIG. 7A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels in the presence of 5 different STMN2 parent oligonucleotides (SEQ ID NO: 36, SEQ ID NO: 173, SEQ ID NO: 177, SEQ ID NO: 181, and SEQ ID NO: 185).

[0094] FIG. 7B is a bar graph showing the results of RT-qPCR analysis of STMN2 full-length mRNA levels in the presence of TDP43 antisense, and restoration of the full-length STMN2 transcript in the presence of 5 different STMN2 parent oligonucleotides (SEQ ID NO: 36, SEQ ID NO: 173, SEQ ID NO: 177, SEQ ID NO: 181, and SEQ ID NO: 185).

5 **[0095]** FIG. 8A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels in the presence of 5 different STMN2 parent oligonucleotides (SEQ ID NO: 197, SEQ ID NO: 203, SEQ ID NO: 237, SEQ ID NO: 380, and SEQ ID NO: 395).

10 **[0096]** FIG. 8B is a bar graph showing the results of RT-qPCR analysis of STMN2 full-length mRNA levels in the presence of TDP43 antisense, and restoration of the full-length STMN2 transcript in the presence of 5 different STMN2 parent oligonucleotides (SEQ ID NO: 197, SEQ ID NO: 203, SEQ ID NO: 237, SEQ ID NO: 380, and SEQ ID NO: 395).

[0097] FIG. 9A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels in the presence of 3 different STMN2 parent oligonucleotides (SEQ ID NO: 144, SEQ ID NO: 173, and SEQ ID NO: 237).

15 **[0098]** FIG. 9B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript in the presence of 3 different STMN2 parent oligonucleotides (SEQ ID NO: 144, SEQ ID NO: 173, and SEQ ID NO: 237).

[0099] FIG. 10A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels across different dosages of a SEQ ID NO: 181 STMN2 parent oligonucleotide.

25 **[00100]** FIG. 10B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript across different dosages of a SEQ ID NO: 181 STMN2 parent oligonucleotide.

30 **[00101]** FIG. 11A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels across different dosages of a SEQ ID NO: 185 STMN2 parent oligonucleotide.

[00102] FIG. 11B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript across different dosages of a SEQ ID NO: 185 STMN2 parent oligonucleotide.

5 **[00103]** FIG. 12A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels across different dosages of a SEQ ID NO: 197 STMN2 parent oligonucleotide.

10 **[00104]** FIG. 12B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript across different dosages of a SEQ ID NO: 197 STMN2 parent oligonucleotide.

15 **[00105]** FIG. 13A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels across different dosages of a SEQ ID NO: 144 STMN2 parent oligonucleotide.

20 **[00106]** FIG. 13B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript across different dosages of a SEQ ID NO: 144 STMN2 parent oligonucleotide.

[00107] FIG. 14A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels across different dosages of a SEQ ID NO: 173 STMN2 parent oligonucleotide.

25 **[00108]** FIG. 14B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript across different dosages of a SEQ ID NO: 173 STMN2 parent oligonucleotide.

30 **[00109]** FIG. 15A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels across different dosages of a SEQ ID NO: 237 STMN2 parent oligonucleotide.

[00110] FIG. 15B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript across different dosages of a SEQ ID NO: 237 STMN2 parent oligonucleotide.

5 [00111] FIG. 16 is a protein blot and quantified bar graph showing the normalized quantity of STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript for 2 different STMN2 parent oligonucleotides (SEQ ID NO: 173 and SEQ ID NO: 237).

10 [00112] FIG. 17A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels using different variants of a SEQ ID NO: 237 STMN2 parent oligonucleotide.

15 [00113] FIG. 17B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript using different variants of a SEQ ID NO: 237 STMN2 parent oligonucleotide.

20 [00114] FIG. 18A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels using different variants of a SEQ ID NO: 185 STMN2 parent oligonucleotide.

[00115] FIG. 18B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript using different variants of a SEQ ID NO: 185 STMN2 parent oligonucleotide.

25 [00116] FIG. 19A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels using different variants of a SEQ ID NO: 173 STMN2 parent oligonucleotide.

30 [00117] FIG. 19B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript using different variants of a SEQ ID NO: 173 STMN2 parent oligonucleotide.

[00118] FIG. 20A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels using different variants of a SEQ ID NO: 237 STMN2 parent oligonucleotide.

5 **[00119]** FIG. 20B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript using different variants of a SEQ ID NO: 237 STMN2 parent oligonucleotide.

10 **[00120]** FIG. 21A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels using different variants of a SEQ ID NO: 173 STMN2 parent oligonucleotide.

15 **[00121]** FIG. 21B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript using different variants of a SEQ ID NO: 173 STMN2 parent oligonucleotide.

20 **[00122]** FIG. 22A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels using different variants of a SEQ ID NO: 144 STMN2 parent oligonucleotide.

[00123] FIG. 22B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript using different variants of a SEQ ID NO: 144 STMN2 parent oligonucleotide.

25 **[00124]** FIG. 23 is a bar graph showing reversal of cryptic exon induction using SEQ ID NO: 237 STMN2 parent oligonucleotide even in view of increasing proteasome inhibition.

[00125] FIG. 24 shows the dose response curve illustrating increasing restoration of full length STMN2 transcript with increasing concentrations of STMN2 AON.

30 **[00126]** FIG. 25A shows a protein blot assay demonstrating the qualitative increase of full length STMN2 protein in response to higher concentrations of STMN2 AON.

[00127] FIG. 25B shows the quantitated levels of full length STMN2 protein normalized to GAPDH in response to different concentrations of STMN2 AON.

[00128] FIG. 26A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels across different dosages of STMN2 AONs including a SEQ ID NO: 144 AON, a SEQ ID NO: 144 AON with two spacers (SEQ ID NO: 1589), a SEQ ID NO: 173 AON, a SEQ ID NO: 173 with two spacers (SEQ ID NO: 1590), a SEQ ID NO: 237 AON, and a SEQ ID NO: 237 AON with two spacers (SEQ ID NO: 1591).

[00129] FIG. 26B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript across different dosages of STMN2 AONs including a SEQ ID NO: 144 AON, a SEQ ID NO: 144 AON with two spacers (SEQ ID NO: 1589), a SEQ ID NO: 173 AON, a SEQ ID NO: 173 with two spacers (SEQ ID NO: 1590), a SEQ ID NO: 237 AON, and a SEQ ID NO: 237 AON with two spacers (SEQ ID NO: 1591).

[00130] FIG. 27A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels across different dosages of STMN2 AONs including SEQ ID NO: 173, SEQ ID NO: 1608, SEQ ID NO: 1609, SEQ ID NO: 1610, SEQ ID NO: 1611, SEQ ID NO: 1612, SEQ ID NO: 1613, SEQ ID NO: 1614, SEQ ID NO: 1615, SEQ ID NO: 1596, SEQ ID NO: 1597, and SEQ ID NO: 1418.

[00131] FIG. 27B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 antisense, and restoration of the full-length STMN2 transcript across different dosages of STMN2 AONs including SEQ ID NO: 173, SEQ ID NO: 1608, SEQ ID NO: 1609, SEQ ID NO: 1610, SEQ ID NO: 1611, SEQ ID NO: 1612, SEQ ID NO: 1613, SEQ ID NO: 1614, SEQ ID NO: 1615, SEQ ID NO: 1596, SEQ ID NO: 1597, and SEQ ID NO: 1418.

[00132] FIG. 28A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels across different dosages of STMN2 AONs including SEQ ID NO: 173, SEQ ID NO: 1632, SEQ ID NO: 1346, SEQ ID NO: 1631, SEQ ID NO: 1353, and SEQ ID NO: 1598.

[00133] FIG. 28B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 antisense, and restoration of the full-length

STMN2 transcript across different dosages of STMN2 AONs including SEQ ID NO: 173, SEQ ID NO: 1632, SEQ ID NO: 1346, SEQ ID NO: 1631, SEQ ID NO: 1353, and SEQ ID NO: 1598.

[00134] FIG. 29A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels across different dosages of STMN2 AONs including SEQ ID NO: 173 and SEQ ID NO: 1610.

[00135] FIG. 29B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 antisense, and restoration of the full-length STMN2 transcript across different dosages of STMN2 AONs including SEQ ID NO: 173 and SEQ ID NO: 1610.

[00136] FIG. 30A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels across different dosages of STMN2 AONs including SEQ ID NO: 185 and SEQ ID NO: 1635.

[00137] FIG. 30B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 antisense, and restoration of the full-length STMN2 transcript across different dosages of STMN2 AONs including SEQ ID NO: 185 and SEQ ID NO: 1635.

[00138] FIG. 31A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels across different dosages of STMN2 AONs including SEQ ID NO: 1347, SEQ ID NO: 1633, and SEQ ID NO: 1634.

[00139] FIG. 31B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 antisense, and restoration of the full-length STMN2 transcript across different dosages of STMN2 AONs including SEQ ID NO: 1347, SEQ ID NO: 1633, and SEQ ID NO: 1634.

[00140] FIG. 32A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels across different dosages of STMN2 AONs including SEQ ID NO: 197, SEQ ID NO: 1617, SEQ ID NO: 1618, and SEQ ID NO: 1619.

[00141] FIG. 32B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 antisense, and restoration of the full-length

STMN2 transcript across different dosages of STMN2 AONs including SEQ ID NO: 197, SEQ ID NO: 1617, SEQ ID NO: 1618, and SEQ ID NO: 1619.

[00142] FIG. 33A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels across different dosages of STMN2 AONs including SEQ ID NO: 252, SEQ ID NO: 1650, SEQ ID NO: 1434, SEQ ID NO: 1651, and SEQ ID NO: 1620.

[00143] FIG. 33B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 antisense, and restoration of the full-length STMN2 transcript across different dosages of STMN2 AONs including SEQ ID NO: 252, SEQ ID NO: 1650, SEQ ID NO: 1434, SEQ ID NO: 1651, and SEQ ID NO: 1620.

[00144] FIG. 34A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels across different dosages of STMN2 AONs including SEQ ID NO: 1434 and SEQ ID NO: 1620.

[00145] FIG. 34B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 antisense, and restoration of the full-length STMN2 transcript across different dosages of STMN2 AONs including SEQ ID NO: 1434 and SEQ ID NO: 1620.

[00146] FIG. 35 is a bar graph showing normalized STMN2 protein levels following treatment with TDP43 antisense and restoration using STMN2 AONs including SEQ ID NO: 144, SEQ ID NO: 1589, SEQ ID NO: 173, SEQ ID NO: 1616, SEQ ID NO: 237, and SEQ ID NO: 1591.

DETAILED DESCRIPTION

[00147] The features and other details of the disclosure will now be more particularly described. Certain terms employed in the specification, examples and appended claims are collected here. These definitions should be read in light of the remainder of the disclosure and understood as by a person of skill in the art. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by a person of ordinary skill in the art.

[00148] Disclosed herein are oligonucleotides capable of targeting a region of a transcript transcribed from a gene. In various embodiments, such oligonucleotides target a STMN2

transcript. Additionally disclosed herein are oligonucleotides, including antisense oligonucleotide sequences, and methods for treating neurological diseases, such as amyotrophic lateral sclerosis and frontotemporal dementia, and/or neuropathies such as chemotherapy induced neuropathy, using same. In one embodiment, the oligonucleotides target a cryptic exon sequence of STMN2 transcripts, thereby reducing levels of STMN2 transcripts with the cryptic exon sequence. Also disclosed are pharmaceutical compositions comprising STMN2 oligonucleotides that target a region of STMN2 transcripts that comprise a cryptic exon, for treating neurological diseases and/or neuropathies; and manufacture of medicaments containing a disclosed STMN2 oligonucleotide that targets a region of STMN2 transcripts that comprise a cryptic exon to be used in treating a neurological disease and/or neuropathy.

Definitions

[00149] The terms “treat,” “treatment,” “treating,” and the like are used herein to generally mean obtaining a desired pharmacological and/or physiological effect. The effect may be therapeutic in terms of partially or completely curing a disease and/or adverse effect attributed to the disease.

The term “treatment” as used herein covers any treatment of a disease in a mammal, particularly a human, and includes: (a) inhibiting the disease, *i.e.*, preventing the disease from increasing in severity or scope; (b) relieving the disease, *i.e.*, causing partial or complete amelioration of the disease; or (c) preventing relapse of the disease, *i.e.*, preventing the disease from returning to an active state following previous successful treatment of symptoms of the disease or treatment of the disease.

[00150] “Preventing” includes delaying the onset of clinical symptoms, complications, or biochemical indicia of the state, disorder, disease, or condition developing in a subject that may be afflicted with or predisposed to the state, disorder, disease, or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder, disease, or condition.

“Preventing” includes prophylactically treating a state, disorder, disease, or condition in or developing in a subject, including prophylactically treating clinical symptoms, complications, or biochemical indicia of the state, disorder, disease, or condition in or developing in a subject.

[00151] The term “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” as used herein interchangeably refers to any and all solvents, dispersion media, coatings, isotonic and absorption delaying agents, and the like, that are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. The compositions may also contain other active compounds providing supplemental, additional, or enhanced therapeutic functions.

[00152] The term “pharmaceutical composition” as used herein refers to a composition comprising at least one biologically active compound, for example, a STMN2 antisense oligonucleotide (AON), as disclosed herein formulated together with one or more pharmaceutically acceptable excipients.

5 [00153] “Individual,” “patient,” or “subject” are used interchangeably and include any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or non-human primates, and most preferably humans. The compounds of the invention can be administered to a mammal, such as a human, but can also be other mammals such as an animal in need of veterinary treatment, *e.g.*, domestic animals (*e.g.*, dogs, cats, and the like), farm
10 animals (*e.g.*, cows, sheep, pigs, horses, and the like) and laboratory animals (*e.g.*, rats, mice, guinea pigs, non-human primates, and the like). In some embodiments, the mammal treated in the methods of the invention is desirably a mammal in whom modulation of STMN2 expression and/or activity is desired.

[00154] As used herein, “STMN2” (also known as Superior Cervical Ganglion-10 Protein, Stathmin-Like 2, SCGN10, SCG10, Neuronal Growth-Associated Protein, Neuron-Specific
15 Growth-Associated Protein, or Protein SCG10 (Superior Cervical Ganglia NEAR Neural Specific 10) refers to the gene or gene products (*e.g.*, protein or mRNA transcript (including pre-mRNA) encoded by the gene) identified by Entrez Gene ID No. 11075 and allelic variants thereof, as well as orthologs found in non-human species (*e.g.*, non-human primates or mice).

20 [00155] The term “STMN2 transcript” refers to a STMN2 transcript comprising a cryptic exon. Such a STMN2 transcript comprising a cryptic exon can be a STMN2 pre-mRNA sequence or a STMN2 mature RNA sequence. The term “STMN2 transcript comprising a cryptic exon” refers to a STMN2 transcript that includes one or more cryptic exon sequences.

[00156] The term “STMN2 oligonucleotide,” “STMN2 antisense oligonucleotide,” or “STMN2
25 AON” refers to an oligonucleotide that is capable of increasing, restoring, or stabilizing full-length STMN2 activity *e.g.*, full length STMN2 expression, for example, full length STMN2 mRNA and/or full length STMN2 protein expression. Generally, a STMN2 oligonucleotide reduces the level of mature STMN2 transcripts with a cryptic exon by targeting a STMN2 transcript comprising a cryptic exon. For example, the STMN2 oligonucleotide reduces the level
30 of mature STMN2 transcripts with a cryptic exon by repressing premature polyadenylation of STMN2 pre-mRNA and/or increasing, restoring, or stabilizing activity or function of STMN2. In various embodiments, a STMN2 oligonucleotide comprises a sequence that is between 85 and 98% complementary to an equal length portion of a transcript comprising a sequence at least 90%

identity to SEQ ID NO: 1339 or SEQ ID NO: 1341, or a contiguous 15 to 50 nucleobase portion of SEQ ID NO: 1339 or SEQ ID NO: 1341.

[00157] In various embodiments, STMN2 oligonucleotides are characterized by having one or more spacers, where each spacer divides up the STMN2 oligonucleotide into segments of linked nucleosides. In various embodiments, STMN2 oligonucleotides have two spacers. In one embodiment, STMN2 oligonucleotides have two segments of linked nucleosides separated by one spacer. In one embodiment, STMN2 oligonucleotides have three segments of linked nucleosides separated by two spacers. In such embodiments, STMN2 oligonucleotides have one segment with at most 7 linked nucleosides. For example, a STMN2 oligonucleotide may have, from the 5' to the 3' end, 5 linked nucleosides, followed by a spacer, 10 linked nucleosides, followed by a second spacer, and 8 linked nucleosides. Thus, the first segment of 5 linked nucleosides satisfies the one segment with at most 7 linked nucleosides. In various embodiments, STMN2 oligonucleotides have three spacers that divide the STMN2 oligonucleotide into four segments. In various embodiments, each of the four segments of the STMN2 oligonucleotide have at most 7 linked nucleosides.

[00158] As used herein, the term “STMN2 oligonucleotide” encompasses a “STMN2 parent oligonucleotide,” a “STMN2 oligonucleotide with one or more spacers” (e.g., STMN2 oligonucleotide with two spacers or a STMN2 oligonucleotide with three spacers), a “STMN2 oligonucleotide variant with one or more spacers.” Examples of STMN2 oligonucleotides include oligonucleotides comprising a sequence of any one of SEQ ID NOs: 1-466, SEQ ID NO: 893-1338, SEQ ID NOs: 1342-1366, and SEQ ID NOs: 1392-1664.

[00159] The term “STMN2 parent oligonucleotide” refers to an oligonucleotide that targets a STMN2 transcript with a cryptic exon and is capable of increasing, restoring, or stabilizing full-length STMN2 activity e.g., full length STMN2 expression, for example, full length STMN2 mRNA and/or full length STMN2 protein expression. STMN2 parent oligonucleotides do not include a spacer. Examples of STMN2 parent oligonucleotides include oligonucleotides comprising a sequence of any one of SEQ ID NOs: 1-446 and SEQ ID NOs: 893-1338. As described hereafter, STMN2 oligonucleotide with spacers and STMN2 oligonucleotide variants are described in relation to a corresponding STMN2 parent oligonucleotide.

[00160] The term “STMN2 oligonucleotide variant” refers to a STMN2 oligonucleotide that represents a modified version of a corresponding STMN2 parent oligonucleotide. For example, a STMN2 oligonucleotide variant represents a shortened version of a STMN2 parent oligonucleotide. In various embodiments, a STMN2 oligonucleotide variant is any one of a

15mer, 16mer, 17mer, 18mer 19mer, 20mer, 21mer, 22mer or 23mer. Examples of STMN2 oligonucleotide variants include oligonucleotides comprising a sequence of any one of SEQ ID NOs: 1342-1366 or SEQ ID NOs: 1392-1521. In various embodiments, STMN2 oligonucleotide variants comprise one or more spacers. Such STMN2 oligonucleotide variants comprise a
5 sequence of any one of SEQ ID NOs: 1342-1366 and SEQ ID NOs: 1392-1416.

[00161] The term “oligonucleotide with one or more spacers” or “oligonucleotide comprising a spacer” refers to an oligonucleotide with at least one spacer. An oligonucleotide with one or more spacers can, in various embodiments, include one spacer, two spacers, three spacers, four spacer, five spacers, six spacers, seven spacers, eight spacers, nine spacers, or ten spacers. In various
10 embodiments, an oligonucleotide comprising one or more spacers includes at least one segment with at most 7 linked nucleosides. For example, as described in a 5' to 3' direction, an oligonucleotide comprising a spacer can include a segment with 7 linked nucleosides, followed by a spacer, a second segment with 9 linked nucleosides, followed by a second spacer, and a third segment with 7 linked nucleosides. Here, the first segment of 7 linked nucleosides and the third
15 segment of 7 linked nucleosides each represents segments with at most 7 linked nucleosides. As another example, an oligonucleotide comprising a spacer can include a segment with 10 linked nucleosides, followed by a spacer, a second segment with 10 linked nucleosides, followed by a second spacer, and a third segment with 3 linked nucleosides. Here, the third segment of 3 linked nucleosides represents the segment with at most 7 linked nucleosides. In various embodiments,
20 an oligonucleotide with one or more spacers includes multiple segments with at most 7 linked nucleosides. In various embodiments, every segment of an oligonucleotide with one or more spacers has at most 7 linked nucleosides. For example, the oligonucleotide may be a 23mer and include two spacers that divide the 23mer into three separate segments of 7 linked nucleosides each. Therefore, each segment of the oligonucleotide has at most 7 linked nucleosides.

[00162] Generally, STMN2 oligonucleotides comprising one or more spacers are described in reference to a corresponding STMN2 parent oligonucleotide or a corresponding STMN2 oligonucleotide variant. Example STMN2 oligonucleotides comprising one or spacers include any of SEQ ID NOs: 1417-1420 and SEQ ID NOs: 1451-1664.

[00163] In the present specification, the term “therapeutically effective amount” means the
30 amount of an oligonucleotide that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor, or other clinician. In one embodiment, the oligonucleotide comprises a sequence that is between 85 and 98% complementary to an equal length portion of a transcript comprising a sequence at least 90%

identity to SEQ ID NO: 1339 or SEQ ID NO: 1341, or a contiguous 15 to 50 nucleobase portion of SEQ ID NO: 1339 or SEQ ID NO: 1341. The oligonucleotide is administered in therapeutically effective amounts to treat and/or prevent a disease, condition, disorder, or state, for example, a neurological disease and/or a neuropathy. Alternatively, a therapeutically effective amount of an oligonucleotide is the quantity required to achieve a desired therapeutic and/or prophylactic effect, such as an amount which results in the prevention of or a decrease in the symptoms associated with a disease associated with reduced STMN2 activity in the motor neurons.

[00164] The phrase “a STMN2 oligonucleotide that targets a STMN2 transcript” refers to a STMN2 oligonucleotide that binds to a STMN2 transcript. Example regions of a STMN2 transcript are shown in Table 1, which depicts sequences corresponding to regions of branch points (*e.g.*, branch point 1, 2, and 3) a 3' splice acceptor region, an ESE binding region, TDP43 binding sites, a cryptic exon, and a Poly A region. In various embodiments, the oligonucleotide binds to a region of a STMN2 transcript with a cryptic exon, the region being located less than 75 nucleobases upstream or downstream to any of the branch points (*e.g.*, branch point 1, 2, and 3) a 3' splice acceptor region, an ESE binding region, TDP43 binding sites, a cryptic exon, and a Poly A region.

[00165] The term “pharmaceutically acceptable salt(s)” as used herein refers to salts of acidic or basic groups that may be present in a STMN2 oligonucleotide used in the present compositions.

A STMN2 oligonucleotide included in the present compositions that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, *i.e.*, salts containing pharmacologically acceptable anions, including but not limited to malate, oxalate, chloride, bromide, iodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, *p*-toluenesulfonate and pamoate (*i.e.*, 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)) salts. A STMN2 oligonucleotide included in the present compositions that include an amino moiety may form pharmaceutically acceptable salts with various amino acids, in addition to the acids mentioned above. Compounds included in the present compositions that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include alkali metal or alkaline

earth metal salts and, particularly, calcium, magnesium, sodium, and lithium salts.

Pharmaceutically acceptable salts of the disclosure include, for example, pharmaceutically acceptable salts of STMN2 oligonucleotides that include a sequence of any of SEQ ID NOs: 1-466, SEQ ID NO: 893-1338, SEQ ID NOs: 1342-1366, and SEQ ID NOs: 1392-1664.

5 **[00166]** A STMN2 oligonucleotide of the disclosure may contain one or more chiral centers, groups, linkages, and/or double bonds and, therefore, exist as stereoisomers, such as geometric isomers, enantiomers or diastereomers. The term “stereoisomers” when used herein consist of all geometric isomers, enantiomers or diastereomers. These compounds may be designated by the symbols “R” or “S” (or “*R_p*” or “*S_p*”) depending on the configuration of substituents around the
10 stereogenic atom, for example, a stereogenic carbon, phosphorous, or sulfur atom. In some embodiments, one or more linkages of the compound may have a *R_p* or *S_p* configuration (*e.g.*, one or more phosphorothioate linkages have either a *R_p* or *S_p* configuration). The configuration of each phosphorothioate linkage may be independent of another phosphorothioate linkage (*e.g.*, one phosphorothioate linkage has a *R_p* configuration and a second phosphorothioate linkage has a
15 *S_p* configuration). In various embodiments, the STMN2 oligonucleotide can have a mixed configuration of phosphorothioate linkages. For example, the STMN2 oligonucleotide may have five phosphorothioate linkages in a *R_p* configuration, followed by fifteen phosphorothioate linkages in a *S_p* configuration, followed by five phosphorothioate linkages in a *R_p* configuration. The present invention encompasses various stereoisomers of these compounds and mixtures
20 thereof. Stereoisomers include enantiomers and diastereomers. Mixtures of enantiomers or diastereomers may be designated “(±)” in nomenclature, but the skilled artisan will recognize that a structure may denote a chiral center implicitly.

[00167] Individual stereoisomers of a STMN2 oligonucleotide of the present invention can be prepared synthetically from commercially available starting materials that contain asymmetric or
25 stereogenic centers, or by preparation of racemic mixtures followed by resolution methods well known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary, (2) salt formation employing an optically active resolving agent, or (3) direct
30 separation of the mixture of optical enantiomers on chiral chromatographic columns. Stereoisomeric mixtures can also be resolved into their component stereoisomers by well-known methods, such as chiral-phase gas chromatography, chiral-phase super critical fluid chromatography, chiral-phase simulated moving bed chromatography, chiral-phase high

performance liquid chromatography, crystallizing the compound as a chiral salt complex, or crystallizing the compound in a chiral solvent. Stereoisomers can also be obtained from stereomerically-pure intermediates, reagents, and catalysts by well-known asymmetric synthetic methods.

5 [00168] The STMN2 oligonucleotide disclosed herein can exist in solvated as well as unsolvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms.

[00169] The disclosure also embraces isotopically labeled compounds of the invention (*i.e.*, isotopically labeled STMN2 oligonucleotide) which are identical to those recited herein, except
10 that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number abundantly found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as ^2H , ^3H , ^{11}C , ^{13}C , ^{14}C , ^{15}N , ^{18}O , ^{17}O , ^{31}P , ^{32}P , ^{33}P , ^{35}S , ^{18}F , and ^{36}Cl , respectively.

15 [00170] Certain isotopically labeled disclosed compounds (*e.g.*, those labeled with ^3H , ^{14}C , or ^{35}S) are useful in compound and/or substrate tissue distribution assays. Tritiated (*i.e.*, ^3H), carbon-14 (*i.e.*, ^{14}C), or ^{35}S methionine isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (*i.e.*, ^2H) may afford certain therapeutic advantages resulting from greater metabolic stability (*e.g.*, increased *in vivo*
20 half-life or reduced dosage requirements) and hence may be preferred in some circumstances.

[00171] As used herein, “2′-O-(2-methoxyethyl)” (also 2′-MOE and 2′-O(CH₂)₂OCH₃ and MOE) refers to an *O*-methoxyethyl modification of the 2′ position of a furanose ring. A 2′-O-(2-methoxyethyl) is used interchangeably as “2′-O-methoxyethyl” in the present disclosure. A sugar moiety in a nucleoside modified with 2′-MOE is a modified sugar.

25 [00172] As used herein, “2′-MOE nucleoside” (also 2′-O-(2-methoxyethyl) nucleoside) means a nucleoside comprising a 2′-MOE modified sugar moiety.

[00173] As used herein, “2′-substituted nucleoside” means a nucleoside comprising a substituent at the 2′-position of the furanose ring other than H or OH. In certain embodiments, 2′ substituted nucleosides include nucleosides with bicyclic sugar modifications.

30 [00174] As used herein, “5-methyl cytosine” (5-MeC) means a cytosine modified with a methyl group attached to the 5 position. A 5-methyl cytosine (5-MeC) is a modified nucleobase.

[00175] As used herein, “bicyclic sugar” means a furanose ring modified by the bridging of two atoms. A bicyclic sugar is a modified sugar.

[00176] As used herein, “bicyclic nucleoside” (also BNA) means a nucleoside having a sugar moiety comprising a bridge connecting two carbon atoms of the sugar ring, thereby forming a bicyclic ring system. In certain embodiments, the bridge connects the 4'-carbon and the 2'-carbon of the sugar ring.

5 **[00177]** As used herein, “cap structure” or “terminal cap moiety” means chemical modifications, which have been incorporated at either terminus of an antisense compound.

[00178] As used herein, “cEt” or “constrained ethyl” means a bicyclic nucleoside having a sugar moiety comprising a bridge connecting the 4'-carbon and the 2'-carbon, wherein the bridge has the formula: 4'-CH(CH₃)—O-2'.

10 **[00179]** As used herein, “constrained ethyl nucleoside” (also cEt nucleoside) means a nucleoside comprising a bicyclic sugar moiety comprising a 4'-CH(CH₃)—O-2' bridge. In some embodiments, cEt can be modified. In some embodiments, the cEt can be *S*-cEt (in an *S*-constrained ethyl 2'-4'-bridged nucleic acid). In some other embodiments, the cEt can be *R*-cEt.

[00180] As used herein, “internucleoside linkage” refers to the covalent linkage between adjacent
15 nucleosides in an oligonucleotide. In some embodiments, as used herein, “non-natural linkage” refers to a “modified internucleoside linkage.”

[00181] As used herein, “contiguous” in the context of an oligonucleotide refers to nucleosides, nucleobases, sugar moieties, or internucleoside linkages that are immediately adjacent to each other. For example, “contiguous nucleobases” means nucleobases that are immediately adjacent to
20 each other in a sequence. As an example to the contrary, two nucleosides separated by a spacer are not contiguous.

[00182] As used herein, “locked nucleic acid” or “LNA” or “LNA nucleosides” means nucleic acid monomers having a bridge (*e.g.*, methylene, ethylene, aminooxy, or oxyimino bridge) connecting two carbon atoms between the 4' and 2' position of the nucleoside sugar unit, thereby
25 forming a bicyclic sugar. Examples of such bicyclic sugar include, but are not limited to (A) α -L-Methyleneoxy (4'-CH₂—O-2') LNA, (B) β -D-Methyleneoxy (4'-CH₂—O-2') LNA, (C) Ethyleneoxy (4'-(CH₂)₂—O-2') LNA, (D) Aminooxy (4'-CH₂—O—N⁺(R)-2') LNA and ⁺Oxyamino (4'-CH₂—N⁺(R)—O-2') LNA; wherein R is H, C₁-C₁₂ alkyl, or a protecting group (see U.S. Pat. No. 7,427,672, issued on Sep. 23, 2008).

30 **[00183]** As used herein, LNA compounds include, but are not limited to, compounds having at least one bridge between the 4' and the 2' position of the sugar wherein each of the bridges independently comprises 1 or from 2 to 4 linked groups independently selected from —[C(R₁)(R₂)]_n—, —C(R₁)=C(R₂)—, —C(R₁)=N—, —C(=NR₁)—, —C(=O)—, —C(=S)—, —

O—, —Si(R₁)₂—, —S(=O)_x— and —N(R₁)—; wherein: x is 0, 1, or 2; n is 1, 2, 3, or 4; each R₁ and R₂ is, independently, H, a protecting group, hydroxyl, C₁-C₁₂ alkyl, substituted C₁-C₁₂ alkyl, C₂-C₁₂ alkenyl, substituted C₂-C₁₂ alkenyl, C₂-C₁₂ alkynyl, substituted C₂-C₁₂ alkynyl, C₅-C₂₀ aryl, substituted C₅-C₂₀ aryl, a heterocycle radical, a substituted heterocycle radical, heteroaryl, substituted heteroaryl, C₅-C₇ alicyclic radical, substituted C₅-C₇ alicyclic radical, halogen, OJ₁, NJ₁J₂, SJ₁, N₃, COOJ₁, acyl (C(=O)—H), substituted acyl, CN, sulfonyl (S(=O)₂-J₁), or sulfoxyl (S(=O)-J₁); and each J₁ and J₂ is, independently, H, C₁-C₁₂ alkyl, substituted C₁-C₁₂ alkyl, C₂-C₁₂ alkenyl, substituted C₂-C₁₂ alkenyl, C₂-C₁₂ alkynyl, substituted C₂-C₁₂ alkynyl, C₅-C₂₀ aryl, substituted C₅-C₂₀ aryl, acyl (C(=O)—H), substituted acyl, a heterocycle radical, a substituted heterocycle radical, C₁-C₁₂ aminoalkyl, substituted C₁-C₁₂ aminoalkyl or a protecting group.

[00184] Examples of 4'-2' bridging groups encompassed within the definition of LNA include, but are not limited to one of formulae: —[C(R₁)(R₂)]_n—, —[C(R₁)(R₂)]_n—O—, —C(R₁R₂)—N(R₁)—O— or —C(R₁R₂)—O—N(R₁)—. Furthermore, other bridging groups encompassed with the definition of LNA are 4'-CH₂-2', 4'-(CH₂)₂-2', 4'-(CH₂)₃-2', 4'-CH₂—O-2', 4'-(CH₂)₂—O-2', 4'-CH₂—O—N(R₁)-2' and 4'-CH₂—N(R₁)—O-2' bridges, wherein each R₁ and R₂ is, independently, H, a protecting group or C₁-C₁₂ alkyl.

[00185] Also included within the definition of LNA according to the invention are LNAs in which the 2'-hydroxyl group of the ribosyl sugar ring is connected to the 4' carbon atom of the sugar ring, thereby forming a bridge to form the bicyclic sugar moiety. The bridge can be a methylene (—CH₂—) group connecting the 2' oxygen atom and the 4' carbon atom, for which the term methyleneoxy (4'-CH₂—O-2') LNA is used. Furthermore, in the case of the bicyclic sugar moiety having an ethylene bridging group in this position, the term ethyleneoxy (4'-CH₂CH₂—O-2') LNA is used. A-L-methyleneoxy (4'-CH₂-O-2'), an isomer of methyleneoxy (4'-CH₂—O-2') LNA is also encompassed within the definition of LNA, as used herein.

[00186] As used herein, a “spacer” refers to a nucleoside-replacement group (*e.g.*, a non-nucleoside group that replaces a nucleoside present in a STMN2 parent oligonucleotide). The spacer is characterized by the lack of a nucleotide base and by the replacement of the nucleoside sugar moiety with a non-sugar substitute. The non-sugar substitute group of a spacer lacks an aldehyde, ketone, acetal, ketal, hemiacetal or hemiketal group. The non-sugar substitute group of a spacer is thus capable of connecting to the 3' and 5' positions of the nucleosides adjacent to the spacer through an internucleoside linker as described herein, but not capable of forming a covalent bond with a nucleotide base (*i.e.*, not capable of linking a nucleobase to another group, such as an internucleoside linkage, conjugate group, or terminal group in an oligonucleotide).

Generally, a STMN2 oligonucleotide with a spacer is described in relation to a STMN2 parent oligonucleotide, wherein the spacer replaces a nucleoside of the STMN2 parent oligonucleotide. In all embodiments of the present disclosure, a spacer cannot hybridize to a nucleoside comprising a nucleobase at the corresponding position of a STMN2 transcript, within the numerical order of the length of the AON oligonucleotide (*i.e.*, if the spacer is positioned after nucleoside 4 of an AON (*i.e.*, at position 5 from the 5'-end), the spacer is not complementary to the nucleoside (A, C, G, or U) at the same corresponding position of the target STMN2 transcript)).

[00187] As used herein, “mismatch” or a “non-complementary group” refers to the case when a group (e.g., nucleobase) of a first nucleic acid is not capable of pairing with the corresponding group (e.g., nucleobase) of a second or target nucleic acid.

[00188] As used herein, “modified internucleoside linkage” refers to a substitution or any change from a naturally occurring internucleoside linkage (*e.g.*, a phosphodiester internucleoside bond).

[00189] As used herein, “modified nucleobase” means any nucleobase other than adenine, cytosine, guanine, thymine, or uracil. Examples of a modified nucleobase include 5-methyl cytosine, pseudouridine, or 5-methoxyuridine. An “unmodified nucleobase” means the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C), and uracil (U).

[00190] As used herein, a “modified nucleoside” means a nucleoside having, independently, a modified sugar moiety and/or modified nucleobase. A universal base is a modified nucleobase that can pair with any one of the five unmodified nucleobases. Modified nucleosides include abasic nucleosides, which lack a nucleobase. However, modified nucleosides do not include spacers or other groups that are incapable of linking a nucleobase.

[00191] As used herein, “linked nucleosides” are nucleosides that are connected in a contiguous sequence (*i.e.*, no additional nucleosides are presented between those that are linked). In various embodiments, an oligonucleotide may have different segments of linked nucleosides connected through a spacer. Here, the spacer (*i.e.*, nucleoside replacement) is not considered a nucleoside and therefore, divides up the oligonucleotide into two segments of linked nucleosides. The oligonucleotide may have a first segment of Y linked nucleosides (*e.g.*, Y nucleosides that are connected in a contiguous sequence), followed by a spacer, and then a second segment of Z linked nucleosides. Here, the Y and Z linked nucleosides is described in either the 5' to 3' direction or the 3' to 5' direction. In various embodiments, the first segment consists of 7 or fewer linked nucleosides (*e.g.*, Y = 7 or fewer) whereas the second segment comprises 8 or more linked nucleosides (*e.g.*, Z = 8 or more).

[00192] As used herein, “modified oligonucleotide” means an oligonucleotide comprising at least one (*i.e.*, one or more) modified internucleoside linkage, modified sugar, and/or modified nucleobase.

[00193] As used herein, “modified sugar” or “modified sugar moiety” means a modified furanosyl sugar moiety or a modified sugar moiety having other than a furanosyl moiety that can link a nucleobase to another group, such as an internucleoside linkage, conjugate group, or terminal group in an oligonucleotide.

[00194] As used herein, “monomer” means a single unit of an oligomer. Monomers include, but are not limited to, nucleosides and nucleotides, whether naturally occurring or modified.

[00195] As used herein, “motif” means the pattern of unmodified and modified nucleosides in an antisense compound.

[00196] As used herein, “natural sugar moiety” means a sugar moiety found in DNA (2'-H) or RNA (2'-OH).

[00197] As used herein, “naturally occurring internucleoside linkage” means a 3' to 5' phosphodiester linkage.

[00198] As used herein, “non-complementary nucleobases” refers to a pair of nucleobases that do not form hydrogen bonds with one another or otherwise support hybridization.

[00199] As used herein, “nucleic acid” refers to molecules composed of monomeric nucleotides. A nucleic acid includes, but is not limited to, ribonucleic acids (RNA), deoxyribonucleic acids (DNA), single-stranded nucleic acids, double-stranded nucleic acids, non-coding RNA, small interfering ribonucleic acids (siRNA), short-hairpin RNA (shRNA), and microRNAs (miRNA).

[00200] As used herein, “nucleobase” means a heterocyclic moiety capable of base pairing with a base of another nucleic acid.

[00201] As used herein, “nucleobase complementarity” refers to a nucleobase that is capable of base pairing with another nucleobase. For example, in DNA, adenine (A) is complementary to thymine (T). For example, in RNA, adenine (A) is complementary to uracil (U). In certain embodiments, complementary nucleobase refers to a nucleobase of an antisense compound that is capable of base pairing with a nucleobase of its target nucleic acid. For example, if a nucleobase at a certain position of an antisense compound is capable of hydrogen bonding with a nucleobase at a certain position of a target nucleic acid, then the position of hydrogen bonding between the oligonucleotide and the target nucleic acid is considered to be complementary at that nucleobase pair.

[00202] As used herein, “nucleobase sequence” means the order of nucleobases independent of any sugar, linkage, and/or nucleobase modification.

[00203] As used herein, “nucleoside” refers to a nucleobase linked to a sugar. The term “nucleoside” also includes a “modified nucleoside” which has independently, a modified sugar moiety and/or modified nucleobase.

[00204] As used herein, “nucleoside mimetic” includes those structures used to replace the sugar or the sugar and the base and not necessarily the linkage at one or more positions of an oligomeric compound such as for example nucleoside mimetics having morpholino, cyclohexenyl, cyclohexyl, tetrahydropyranyl, bicyclo, or tricyclo sugar mimetics, *e.g.*, non-furanose sugar units.

Nucleotide mimetic includes those structures used to replace the nucleoside and the linkage at one or more positions of an oligomeric compound such as for example peptide nucleic acids or morpholinos (morpholinos linked by a phosphorodiamidate or other non-phosphodiester linkage). Sugar surrogate overlaps with the slightly broader term nucleoside mimetic but is intended to indicate replacement of the sugar unit (furanose ring) only. The tetrahydropyranyl rings provided herein are illustrative of an example of a sugar surrogate wherein the furanose sugar group has been replaced with a tetrahydropyranyl ring system. “Mimetic” refers to groups that are substituted for a sugar, a nucleobase, and/or internucleoside linkage. Generally, a mimetic is used in place of the sugar or sugar-internucleoside linkage combination, and the nucleobase is maintained for hybridization to a selected target.

[00205] As used herein, “nucleotide” means a nucleoside having a phosphate group covalently linked to the sugar portion of the nucleoside.

[00206] As used herein, “oligomeric compound” or “oligomer” means a polymer of linked monomeric subunits which is capable of hybridizing to at least a region of a nucleic acid molecule.

[00207] As used herein, “oligonucleotide” means a polymer of one or more segments of linked nucleosides each of which can be modified or unmodified, independent one from another.

[00208] As used herein, “hotspot region” is a range of nucleobases on a target nucleic acid amenable to oligomeric compound-mediated modulation of the splicing of the target nucleic acid.

[00209] As used herein, “hybridization” means the pairing or annealing of complementary

oligonucleotides and/or nucleic acids. While not limited to a particular mechanism, the most common mechanism of hybridization involves hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding between complementary nucleobases.

[00210] As used herein, “increasing the amount of activity” refers to more transcriptional expression, more accurate splicing resulting in full length mature mRNA and/or protein expression, and/or more activity relative to the transcriptional expression or activity in an untreated or control sample.

5 Antisense Therapeutics

[00211] Antisense therapeutics are a class of nucleic acid-based compounds that can be used to modulate a transcript, such as mRNA. In various embodiments, antisense therapeutics comprise one or more spacers and can be used to modulate a transcript that is transcribed from a gene, such as a STMN2 pre-mRNA comprising a cryptic exon.

10 [00212] Antisense therapeutics may be single- or double-stranded deoxyribonucleic acid (DNA)-based, ribonucleic acid (RNA)-based, or DNA/RNA chemical analogue compounds. In general, antisense therapeutics are designed to include a sequence that is complementary or nearly complementary to an mRNA or pre-mRNA sequence transcribed from a given gene in order to promote binding between the antisense therapeutic and the pre-mRNA or mRNA. In certain
15 embodiments, antisense therapeutics act by binding to an mRNA or pre-mRNA, thereby inhibiting protein translation, altering pre-mRNA splicing into mature mRNA (e.g., by preventing appropriate proteins such as splicing activator proteins from binding), and/or causing destruction of mRNA. In certain embodiments, the antisense therapeutic sequence is complementary to a portion of a targeted gene’s or mRNA’s sense sequence. In certain embodiments, antisense
20 therapeutics described herein are oligonucleotide-based compounds that include an oligonucleotide sequence complementary to a pre-mRNA sense, or a portion thereof, and one or more spacers. In certain embodiments, antisense therapeutics described herein can also be nucleotide chemical analog-based compounds.

[00213] In certain embodiments, an oligonucleotide, such as disclosed herein, may be an
25 oligonucleotide sequence of 5 to 100 oligonucleotide units in length, for example, 10 to 60 oligonucleotide units in length, for example, 12 to 50 oligonucleotide units in length, 14 to 40 oligonucleotide units in length, 10 to 30 oligonucleotide units in length, for example, 14 to 30 oligonucleotide units in length, for example, 14 to 25 or 15 to 22 oligonucleotide units in length, or 18, 19, 20, 21, 22, 23, 24, or 25 oligonucleotide units in length. As used herein, an
30 “oligonucleotide unit” refers to either a nucleoside (e.g., a nucleoside which includes a sugar and/or a nucleobase) or a nucleoside-replacement group (e.g., a spacer) of the oligonucleotide.

[00214] In particular embodiments, the oligonucleotides are 25 oligonucleotide units in length. In particular embodiments, the oligonucleotides are 23 oligonucleotide units in length. In particular

embodiments, the oligonucleotides are 21 oligonucleotide units in length. In particular embodiments, the oligonucleotides are 19 oligonucleotide units in length. In various embodiments, the oligonucleotide is at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25 oligonucleotide units in length. In various embodiments, the oligonucleotide is at least 18 oligonucleotide units in length. In various embodiments, the oligonucleotide is at least 19 oligonucleotide units in length. In various embodiments, the oligonucleotide is at least 20 oligonucleotide units in length. In various embodiments, the oligonucleotide is at least 21 oligonucleotide units in length. In various embodiments, the oligonucleotide is at least 22 oligonucleotide units in length. In various embodiments, the oligonucleotide is at least 23 oligonucleotide units in length. In various embodiments, the oligonucleotide is at least 24 oligonucleotide units in length. In various embodiments, the oligonucleotide is at least 25 oligonucleotide units in length.

[00215] In certain embodiments, AONs may include chemically modified nucleosides (for example, 2'-O-methylated nucleosides or 2'-O-(2-methoxyethyl) nucleosides) as well as modified internucleoside linkages (for example, phosphorothioate linkages). In certain embodiments, AONs described herein include oligonucleotide sequences that are complementary to RNA sequences, such as STMN2 mRNA sequences. In certain embodiments, AONs described herein can include chemically modified nucleosides and modified internucleoside linkages (for example, phosphorothioate linkages). In particular embodiments, AONs described herein include one or more spacers.

[00216] In various embodiments, the oligonucleotides comprise one or more spacers. In particular embodiments, the oligonucleotides comprise one spacer. In various embodiments, the oligonucleotides comprise two spacers. For example, the oligonucleotide includes 23 oligonucleotide units with 21 nucleobases and two nucleoside replacement groups (e.g., two spacers). Further embodiments of oligonucleotides with one spacer and oligonucleotides with two spacers are described herein.

[00217] In some embodiments, an antisense oligonucleotide can be, but is not limited to, inhibitors of a gene transcript (for example, shRNAs, siRNAs, PNAs, LNAs, 2'-O-methyl (2'Ome) antisense oligonucleotide (AON), 2'-O-(2-methoxyethyl) (MOE) AON, or morpholino oligomers (e.g., phosphorodiamidate morpholino (PMO))), or compositions that include such compounds. In some embodiments an oligonucleotide is an antisense oligonucleotide (AON) comprising 2'Ome (e.g., a AON comprising one or more 2'Ome modified sugar), MOE (e.g., a AON comprising one or more MOE modified sugar), peptide nucleic acids (e.g., a AON

comprising one or more *N*-(2-aminoethyl)-glycine units linked by amide bonds or carbonyl methylene linkage as repeating units in place of a sugar-phosphate backbone), locked nucleic acids (*e.g.*, a AON comprising one or more locked ribose, and can be a mixture of 2'-deoxy nucleotides or 2'Ome nucleotides), c-ET (*e.g.*, a AON comprising one or more cET sugar),
5 constrained methoxyethyl (cMOE) (*e.g.*, a AON comprising one or more cMOE sugar), morpholino oligomer (*e.g.*, a AON comprising a backbone comprising one or more PMO), deoxy-2'-fluoro nucleoside (*e.g.*, a AON comprising one or more 2'-fluoro- β -D-arabinonucleoside), tricyclo-DNAs (tcDNA) (*e.g.*, a AON comprising one or more tcDNA modified sugar), 2'-O,4'-C-Ethylene-bridged nucleic acid (ENA) (*e.g.*, a AON comprising one or more ENA modified
10 sugar), or hexitol nucleic acids (HNA) (*e.g.*, a AON comprising one or more HNA modified sugar). In some embodiments, a AON comprises one or more internucleoside linkage independently selected from a phosphorothioate linkage, phosphodiester linkage, phosphotriester linkage, methylphosphonate linkage, phosphoramidate linkage, a phosphoramidothioate linkage, a thiophosphorodiamidate linkage, phosphorodiamidate morpholino (PMO) (morpholino) linkage,
15 PNA linkage, or any combination of phosphorothioate linkage, phosphodiester linkage, a phosphotriester linkage, methylphosphonate linkage, phosphoramidate linkage, a phosphoramidothioate linkage, thiophosphorodiamidate linkage, phosphorodiamidate morpholino (PMO) (morpholino) linkage, and PNA linkage. In some embodiments, a STMN2 AON comprises one or more phosphorothioate linkage, phosphodiester linkage, or a combination of
20 phosphorothioate and phosphodiester linkages.

[00218] Peptide nucleic acids (PNAs) are short, artificially synthesized polymers with a structure that mimics DNA or RNA. PNAs include a backbone composed of repeating *N*-(2-aminoethyl)-glycine units linked by peptide bonds. In certain embodiments, PNAs described herein can be used as antisense therapeutics that bind to RNA sequences with high specificity and increase,
25 restore, and/or stabilize levels (*e.g.*, full length STMN2 mRNA or protein levels) and/or activity (*e.g.*, biological activity, for example, STMN2 activity).

[00219] Locked nucleic acids (LNAs) are oligonucleotide sequences that include one or more modified RNA nucleotides in which the ribose moiety is modified with an extra bridge connecting the 2' oxygen and 4' carbon. LNAs are believed to have higher *T_m*'s than analogous
30 oligonucleotide sequences. In certain embodiments, LNAs described herein can be used as antisense therapeutics that bind to RNA sequences with high specificity. For example, LNAs can bind to STMN2 pre-RNA and repress premature polyadenylation of STMN2 pre-mRNA, and

increase, restore, and/or stabilize STMN2 levels (*e.g.*, STMN2 mRNA or protein levels) and/or activity (*e.g.*, biological activity, for example, STMN2 activity).

[00220] Morpholino oligomers are oligonucleotide compounds that include DNA bases attached to a backbone of methylenemorpholine rings linked through phosphorodiamidate groups. In certain embodiments, morpholino oligomers of the present invention can be designed to bind to specific pre-RNA sequence of interest. For example, morpholino oligomers bind to STMN2 pre-RNA thereby repressing premature polyadenylation of the pre-mRNA, and increase, restore, and/or stabilize STMN2 levels (*e.g.*, STMN2 mRNA or protein levels) and/or activity (*e.g.*, biological activity, for example, STMN2 activity). In certain embodiments, STMN2 morpholino oligomers described herein can be used as antisense therapeutics that bind to STMN2 pre-mRNA sequences with high specificity and repress premature polyadenylation of STMN2 pre-mRNA, and increase, restore, and/or stabilize STMN2 levels (*e.g.*, STMN2 mRNA or protein levels) and/or activity (*e.g.*, biological activity, for example, STMN2 activity). In certain embodiments, STMN2 morpholino oligomers described herein can also be used to bind STMN2 pre-mRNA sequences, altering STMN2 pre-mRNA splicing and STMN2 gene expression, and increase, restore, and/or stabilize STMN2 levels (*e.g.*, STMN2 mRNA or protein levels) and/or activity (*e.g.*, biological activity, for example, STMN2 activity).

STMN2 Oligonucleotides Complementary to STMN2 Transcript with a Cryptic Exon

[00221] In some embodiments, a STMN2 AON includes a sequence that is between 85 and 98% complementary to a sequence that shares at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to a region of a STMN2 transcript that includes a cryptic exon (*e.g.*, SEQ ID NO: 1339 or SEQ ID NO: 1341). In some embodiments, a STMN2 AON includes a sequence that is between 90-95% complementary to a sequence that shares at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to a region of a STMN2 transcript that includes a cryptic exon (*e.g.*, SEQ ID NO: 1339 or SEQ ID NO: 1341). In particular embodiments, a STMN2 AON includes a sequence that is between 85% and 90% complementary to a sequence that shares at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to a region of a STMN2 transcript that includes a cryptic exon (*e.g.*, SEQ ID NO: 1339 or SEQ ID NO: 1341). In particular embodiments, a STMN2 AON includes a sequence that is between 84% to 88% complementary to a sequence that shares at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to a region of a STMN2 transcript that includes a cryptic exon (*e.g.*, SEQ ID NO: 1339 or SEQ ID NO:

1341). In particular embodiments, a STMN2 AON includes a sequence that is between 89% to 92% complementary to a sequence that shares at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to a region of a STMN2 transcript that includes a cryptic exon (e.g., SEQ ID NO: 1339 or SEQ ID NO: 1341). In particular embodiments, a

5 STMN2 AON includes a sequence that is between 94% to 96% complementary to a sequence that shares at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to a region of a STMN2 transcript that includes a cryptic exon (e.g., SEQ ID NO: 1339 or SEQ ID NO: 1341).

[00222] In various embodiments, a STMN2 AON comprises a sequence that shares at least 85%
10 identity with an equal length portion of any one of SEQ ID NOs: 1-466, SEQ ID NOs: 893-1338, SEQ ID NOs: 1342-1366, or SEQ ID NOs: 1392-1664. In various embodiments, a STMN2 AON comprises a sequence that shares at least 90% identity with an equal length portion of any one of SEQ ID NOs: 1-466, SEQ ID NOs: 893-1338, SEQ ID NOs: 1342-1366, or SEQ ID NOs: 1392-1664.

15 [00223] In various embodiments, the region of the STMN2 transcript targeted by the STMN2 AON is the cryptic exon sequence. In various embodiments, the region of the STMN2 transcript targeted by the STMN2 AON is a sequence located upstream or downstream (e.g., 100 or 200 bases upstream or downstream) of the cryptic exon sequence. In some embodiments, the STMN2 AON comprises a spacer and has a segment having at most 7 linked nucleosides. In some
20 embodiments, the STMN2 AON comprises a spacer and has a segment having at most 6, 5, 4, 3, or 2 linked nucleosides.

[00224] STMN2 AON binding specificity can be assessed via measurement of parameters such as dissociation constant, melting temperature θ , or other criteria such as changes in protein or RNA expression levels or other assays that measure STMN2 activity or expression.

25 [00225] In some embodiments, a STMN2 AON can include a non-duplexed oligonucleotide. In some embodiments, a STMN2 AON can include a duplex of two oligonucleotides where the first oligonucleotide includes a nucleobase sequence that is completely or almost completely complementary to a STMN2 pre-mRNA sequence and the second oligonucleotide includes a nucleobase sequence that is complementary to the nucleobase sequence of the first
30 oligonucleotide.

[00226] In some embodiments, a STMN2 AON can target STMN2 pre-mRNAs that include a cryptic exon produced from STMN2 genes of one or more species. For example, a STMN2 AON can target a STMN2 pre-mRNA, which includes a cryptic exon, of a mammalian STMN2 gene,

for example, a human (*i.e.*, *Homo sapiens*) STMN2 gene. In particular embodiments, the STMN2 AON targets a human STMN2 pre-mRNA, which includes a cryptic exon. In some embodiments, the STMN2 AON includes a nucleobase sequence that is complementary to a nucleobase sequence of a STMN2 gene or a STMN2 pre-mRNA, which includes a cryptic exon, or a portion thereof.

[00227] STMN2 AONs described herein include antisense oligonucleotides comprising the oligonucleotide sequences listed in Table 1 below:

Table 1. STMN2 AON Sequences, in each one or more spacers described in the present disclosure are incorporated for generation of an oligonucleotide of the present invention

SEQ ID NO:	AON Sequence* (5' → 3')	Region	SEQ ID NO:	Target Sequence (5' → 3')
1	GGAGGGATACCTGTATATTACAAGT		447	ACTTGTAATATACAGGTATCCCTCC
2	AGGAGGGATACCTGTATATTACAAG		448	CTTGTAATATACAGGTATCCCTCCT
3	CAGGAGGGATACCTGTATATTACAA		449	TTGTAATATACAGGTATCCCTCCTG
4	CCAGGAGGGATACCTGTATATTACA		450	TGTAATATACAGGTATCCCTCCTGG
5	ACCAGGAGGGATACCTGTATATTAC		451	GTAATATACAGGTATCCCTCCTGGT
6	TACCAGGAGGGATACCTGTATATTA		452	TAATATACAGGTATCCCTCCTGGTA
7	TTACCAGGAGGGATACCTGTATATT		453	AATATACAGGTATCCCTCCTGGTAA
8	CTTACCAGGAGGGATACCTGTATAT		454	ATATACAGGTATCCCTCCTGGTAAG
9	GCTTACCAGGAGGGATACCTGTATA		455	TATACAGGTATCCCTCCTGGTAAGC
10	AGCTTACCAGGAGGGATACCTGTAT		456	ATACAGGTATCCCTCCTGGTAAGCT
11	GAGCTTACCAGGAGGGATACCTGTA		457	TACAGGTATCCCTCCTGGTAAGCTC
12	AGAGCTTACCAGGAGGGATACCTGT		458	ACAGGTATCCCTCCTGGTAAGCTCT
13	CAGAGCTTACCAGGAGGGATACCTG		459	CAGGTATCCCTCCTGGTAAGCTCTG
14	CCAGAGCTTACCAGGAGGGATACCT		460	AGGTATCCCTCCTGGTAAGCTCTGG
15	ACCAGAGCTTACCAGGAGGGATACC		461	GGTATCCCTCCTGGTAAGCTCTGGT
16	TACCAGAGCTTACCAGGAGGGATAC		462	GTATCCCTCCTGGTAAGCTCTGGTA
17	ATACCAGAGCTTACCAGGAGGGATA		463	TATCCCTCCTGGTAAGCTCTGGTAT
18	AATACCAGAGCTTACCAGGAGGGAT		464	ATCCCTCCTGGTAAGCTCTGGTATT
19	TAATACCAGAGCTTACCAGGAGGGA		465	TCCCTCCTGGTAAGCTCTGGTATTA
20	ATAATACCAGAGCTTACCAGGAGGG		466	CCCTCCTGGTAAGCTCTGGTATTAT
21	CATAATACCAGAGCTTACCAGGAGG		467	CCTCCTGGTAAGCTCTGGTATTATG
22	ACATAATACCAGAGCTTACCAGGAG		468	CTCCTGGTAAGCTCTGGTATTATGT
23	GACATAATACCAGAGCTTACCAGGA		469	TCCTGGTAAGCTCTGGTATTATGTC
24	AGACATAATACCAGAGCTTACCAGG		470	CCTGGTAAGCTCTGGTATTATGTCT
25	AAGACATAATACCAGAGCTTACCAG		471	CTGGTAAGCTCTGGTATTATGTCTT
26	TAAGACATAATACCAGAGCTTACCA		472	TGGTAAGCTCTGGTATTATGTCTTA
27	TTAAGACATAATACCAGAGCTTACC		473	GGTAAGCTCTGGTATTATGTCTTAA

28	GTTAAGACATAATACCAGAGCTTAC		474	GTAAGCTCTGGTATTATGTCTTAAC
29	TGTTAAGACATAATACCAGAGCTTA		475	TAAGCTCTGGTATTATGTCTTAACA
30	ATGTTAAGACATAATACCAGAGCTT	branch point 1	476	AAGCTCTGGTATTATGTCTTAACAT
31	AATGTTAAGACATAATACCAGAGCT	branch point 1	477	AGCTCTGGTATTATGTCTTAACATT
32	AAATGTTAAGACATAATACCAGAGC	branch point 1	478	GCTCTGGTATTATGTCTTAACATTT
33	AAAATGTTAAGACATAATACCAGAG	branch point 1	479	CTCTGGTATTATGTCTTAACATTTT
34	AAAAATGTTAAGACATAATACCAGA	branch point 1	480	TCTGGTATTATGTCTTAACATTTTT
35	TAAAAATGTTAAGACATAATACCAG	branch point 1	481	CTGGTATTATGTCTTAACATTTTTA
36	TTAAAAATGTTAAGACATAATACCA	branch point 1	482	TGGTATTATGTCTTAACATTTTTTAA
37	TTTAAAAATGTTAAGACATAATACC	branch point 1	483	GGTATTATGTCTTAACATTTTTTAAA
38	ATTTAAAAATGTTAAGACATAATAC	branch point 1	484	GTATTATGTCTTAACATTTTTTAAAT
39	GATTTAAAAATGTTAAGACATAATA	branch point 1	485	TATTATGTCTTAACATTTTTTAAATC
40	AGATTTAAAAATGTTAAGACATAAT	branch point 1	486	ATTATGTCTTAACATTTTTTAAATCT
41	TAGATTTAAAAATGTTAAGACATAA	branch point 1	487	TTATGTCTTAACATTTTTTAAATCTA
42	ATAGATTTAAAAATGTTAAGACATA	branch point 1	488	TATGTCTTAACATTTTTTAAATCTAT
43	CATAGATTTAAAAATGTTAAGACAT	branch point 1	489	ATGTCTTAACATTTTTTAAATCTATG
44	CCATAGATTTAAAAATGTTAAGACA	branch point 1	490	TGTCTTAACATTTTTTAAATCTATGG
45	ACCATAGATTTAAAAATGTTAAGAC	branch point 1	491	GTCTTAACATTTTTTAAATCTATGGT
46	TACCATAGATTTAAAAATGTTAAGA	branch point 1	492	TCTTAACATTTTTTAAATCTATGGTA
47	TTACCATAGATTTAAAAATGTTAAG		493	CTTAACATTTTTTAAATCTATGGTAA
48	ATTACCATAGATTTAAAAATGTTA		494	TTAACATTTTTTAAATCTATGGTAAT
49	GATTACCATAGATTTAAAAATGTTA		495	TAACATTTTTTAAATCTATGGTAATC
50	AGATTACCATAGATTTAAAAATGTT	Branch point 2	496	AACATTTTTTAAATCTATGGTAATCT
51	AAGATTACCATAGATTTAAAAATGT	Branch point 2	497	ACATTTTTTAAATCTATGGTAATCTT
52	AAAGATTACCATAGATTTAAAAATG	Branch point 2	498	CATTTTTTAAATCTATGGTAATCTTT
53	TAAAGATTACCATAGATTTAAAAAT	Branch point 2	499	ATTTTTTAAATCTATGGTAATCTTTA
54	GTAAAGATTACCATAGATTTAAAAA	Branch point 2	500	TTTTTAAATCTATGGTAATCTTTAC

55	TGTAAAGATTACCATAGATTTAAAA	Branch point 2	501	TTTTAAATCTATGGTAATCTTTACA
56	TTGTAAAGATTACCATAGATTTAAA	Branch point 2	502	TTTAAATCTATGGTAATCTTTACAA
57	TTTGTAAAGATTACCATAGATTTAA	Branch point 2	503	TTAAATCTATGGTAATCTTTACAAA
58	TTTTGTAAAGATTACCATAGATTTA	Branch point 2	504	TAAATCTATGGTAATCTTTACAAAA
59	ATTTTGTAAAGATTACCATAGATTT	Branch point 2	505	AAATCTATGGTAATCTTTACAAAAT
60	TATTTTGTAAAGATTACCATAGATT	Branch point 2	506	AATCTATGGTAATCTTTACAAAATA
61	ATATTTTGTAAAGATTACCATAGAT	Branch point 2	507	ATCTATGGTAATCTTTACAAAATAT
62	AATATTTTGTAAAGATTACCATAGA	Branch point 2	508	TCTATGGTAATCTTTACAAAATATT
63	AAATATTTTGTAAAGATTACCATAG	Branch point 2	509	CTATGGTAATCTTTACAAAATATTT
64	AAAATATTTTGTAAAGATTACCATA	Branch point 2	510	TATGGTAATCTTTACAAAATATTTT
65	TAAAATATTTTGTAAAGATTACCAT	Branch point 2	511	ATGGTAATCTTTACAAAATATTTTA
66	GTAAAATATTTTGTAAAGATTACCA	Branch point 2	512	TGGTAATCTTTACAAAATATTTTAC
67	AGTAAAATATTTTGTAAAGATTACC		513	GGTAATCTTTACAAAATATTTTACT
68	AAGTAAAATATTTTGTAAAGATTAC		514	GTAATCTTTACAAAATATTTTACTT
69	GAAGTAAAATATTTTGTAAAGATTA		515	TAATCTTTACAAAATATTTTACTTC
70	GGAAGTAAAATATTTTGTAAAGATT		516	AATCTTTACAAAATATTTTACTTCC
71	CGGAAGTAAAATATTTTGTAAAGAT		517	ATCTTTACAAAATATTTTACTTCCG
72	TCGGAAGTAAAATATTTTGTAAAGA		518	TCTTTACAAAATATTTTACTTCCGA
73	TTCGGAAGTAAAATATTTTGTAAAG		519	CTTTACAAAATATTTTACTTCCGAA
74	GTTTCGGAAGTAAAATATTTTGTAAA		520	TTTACAAAATATTTTACTTCCGAAC
75	AGTTCGGAAGTAAAATATTTTGTAA		521	TTACAAAATATTTTACTTCCGAAC
76	GAGTTCGGAAGTAAAATATTTTGTAA		522	TACAAAATATTTTACTTCCGAAC
77	TGAGTTCGGAAGTAAAATATTTTGT		523	ACAAAATATTTTACTTCCGAAC
78	ATGAGTTCGGAAGTAAAATATTTTG		524	CAAAAATATTTTACTTCCGAAC
79	TATGAGTTCGGAAGTAAAATATTTT		525	AAAATATTTTACTTCCGAAC
80	ATATGAGTTCGGAAGTAAAATATTT		526	AAATATTTTACTTCCGAAC
81	TATATGAGTTCGGAAGTAAAATATT		527	AATATTTTACTTCCGAAC
82	GTATATGAGTTCGGAAGTAAAATAT		528	ATATTTTACTTCCGAAC
83	GGTATATGAGTTCGGAAGTAAAATA		529	TATTTTACTTCCGAAC
84	AGGTATATGAGTTCGGAAGTAAAAT		530	ATTTTACTTCCGAAC
85	CAGGTATATGAGTTCGGAAGTAAAA		531	TTTACTTCCGAAC
86	CCAGGTATATGAGTTCGGAAGTAAA		532	TTTACTTCCGAAC
87	CCCAGGTATATGAGTTCGGAAGTAA		533	TTACTTCCGAAC

88	CCCCAGGTATATGAGTTCGGAAGTA		534	TACTTCCGAACTCATATACCTGGGG
89	TCCCCAGGTATATGAGTTCGGAAGT		535	ACTTCCGAACTCATATACCTGGGGA
90	ATCCCCAGGTATATGAGTTCGGAAG		536	CTTCCGAACTCATATACCTGGGGAT
91	AATCCCCAGGTATATGAGTTCGGAA		537	TTCCGAACTCATATACCTGGGGATT
92	AAATCCCCAGGTATATGAGTTCGGA		538	TCCGAACTCATATACCTGGGGATTT
93	AAAATCCCCAGGTATATGAGTTCGG		539	CCGAACTCATATACCTGGGGATTTT
94	TAAAATCCCCAGGTATATGAGTTCG		540	CGAACTCATATACCTGGGGATTTTA
95	ATAAAATCCCCAGGTATATGAGTTC		541	GAACTCATATACCTGGGGATTTTAT
96	AATAAAATCCCCAGGTATATGAGTT		542	AACTCATATACCTGGGGATTTTATT
97	TAATAAAATCCCCAGGTATATGAGT		543	ACTCATATACCTGGGGATTTTATTA
98	GTAATAAAATCCCCAGGTATATGAG		544	CTCATATACCTGGGGATTTTATTAC
99	AGTAATAAAATCCCCAGGTATATGA		545	TCATATACCTGGGGATTTTATTACT
100	GAGTAATAAAATCCCCAGGTATATG		546	CATATACCTGGGGATTTTATTACTC
101	AGAGTAATAAAATCCCCAGGTATAT		547	ATATACCTGGGGATTTTATTACTCT
102	CAGAGTAATAAAATCCCCAGGTATA		548	TATACCTGGGGATTTTATTACTCTG
103	CCAGAGTAATAAAATCCCCAGGTAT		549	ATACCTGGGGATTTTATTACTCTGG
104	CCCAGAGTAATAAAATCCCCAGGTA		550	TACCTGGGGATTTTATTACTCTGGG
105	TCCCAGAGTAATAAAATCCCCAGGT		551	ACCTGGGGATTTTATTACTCTGGGA
106	TTCCCAGAGTAATAAAATCCCCAGG		552	CCTGGGGATTTTATTACTCTGGGAA
107	ATTCCCAGAGTAATAAAATCCCCAG		553	CTGGGGATTTTATTACTCTGGGAAT
108	AATTCCCAGAGTAATAAAATCCCCA		554	TGGGGATTTTATTACTCTGGGAATT
109	TAATTCCCAGAGTAATAAAATCCCC		555	GGGGATTTTATTACTCTGGGAATTA
110	ATAATTCCCAGAGTAATAAAATCCC		556	GGGATTTTATTACTCTGGGAATTAT
111	CATAATTCCCAGAGTAATAAAATCC		557	GGATTTTATTACTCTGGGAATTATG
112	ACATAATTCCCAGAGTAATAAAATC		558	GATTTTATTACTCTGGGAATTATGT
113	CACATAATTCCCAGAGTAATAAAAT		559	ATTTTATTACTCTGGGAATTATGTG
114	ACACATAATTCCCAGAGTAATAAAA		560	TTTTATTACTCTGGGAATTATGTGT
115	AACACATAATTCCCAGAGTAATAAA		561	TTTATTACTCTGGGAATTATGTGTT
116	GAACACATAATTCCCAGAGTAATAA		562	TTATTACTCTGGGAATTATGTGTTCT
117	AGAACACATAATTCCCAGAGTAATA		563	TATTACTCTGGGAATTATGTGTTCT
118	CAGAACACATAATTCCCAGAGTAAT		564	ATTACTCTGGGAATTATGTGTTCTG
119	GCAGAACACATAATTCCCAGAGTAA		565	TTACTCTGGGAATTATGTGTTCTGC
120	GGCAGAACACATAATTCCCAGAGTA		566	TACTCTGGGAATTATGTGTTCTGCC
121	GGGCAGAACACATAATTCCCAGAGT		567	ACTCTGGGAATTATGTGTTCTGCCC
122	GGGGCAGAACACATAATTCCCAGAG		568	CTCTGGGAATTATGTGTTCTGCCCC
123	TGGGGCAGAACACATAATTCCCAGA		569	TCTGGGAATTATGTGTTCTGCCCCA
124	ATGGGGCAGAACACATAATTCCCAG		570	CTGGGAATTATGTGTTCTGCCCCAT
125	GATGGGGCAGAACACATAATTCCCA		571	TGGGAATTATGTGTTCTGCCCCATC
126	TGATGGGGCAGAACACATAATTCCC		572	GGAATTATGTGTTCTGCCCCATCA
127	GTGATGGGGCAGAACACATAATTCC		573	GGAATTATGTGTTCTGCCCCATCAC
128	AGTGATGGGGCAGAACACATAATTC		574	GAATTATGTGTTCTGCCCCATCACT

129	GAGTGATGGGGCAGAACACATAATT	Branch point 3	575	AATTATGTGTTCTGCCCCATCACTC
130	AGAGTGATGGGGCAGAACACATAAT	Branch point 3	576	ATTATGTGTTCTGCCCCATCACTCT
131	GAGAGTGATGGGGCAGAACACATAA	Branch point 3	577	TTATGTGTTCTGCCCCATCACTCTC
132	AGAGAGTGATGGGGCAGAACACATA	Branch point 3	578	TATGTGTTCTGCCCCATCACTCTCT
133	GAGAGAGTGATGGGGCAGAACACAT	Branch point 3	579	ATGTGTTCTGCCCCATCACTCTCTC
134	AGAGAGAGTGATGGGGCAGAACACA	Branch point 3	580	TGTGTTCTGCCCCATCACTCTCTCT
135	AAGAGAGAGTGATGGGGCAGAACAC	Branch point 3	581	GTGTTCTGCCCCATCACTCTCTCTT
136	TAAGAGAGAGTGATGGGGCAGAACAA	Branch point 3	582	TGTTCTGCCCCATCACTCTCTCTTA
137	TTAAGAGAGAGTGATGGGGCAGAAC	Branch point 3	583	GTTCTGCCCCATCACTCTCTCTTAA
138	ATTAAGAGAGAGTGATGGGGCAGAA	Branch point 3	584	TTCTGCCCCATCACTCTCTCTTAAT
139	AATTAAGAGAGAGTGATGGGGCAGA	Branch point 3	585	TCTGCCCCATCACTCTCTCTTAATT
140	CAATTAAGAGAGAGTGATGGGGCAG	Branch point 3	586	CTGCCCCATCACTCTCTCTTAATTG
141	CCAATTAAGAGAGAGTGATGGGGCA	Branch point 3	587	TGCCCCATCACTCTCTCTTAATTGG
142	TCCAATTAAGAGAGAGTGATGGGGC	Branch point 3	588	GCCCCATCACTCTCTCTTAATTGGA
143	ATCCAATTAAGAGAGAGTGATGGGG	Branch point 3	589	CCCCATCACTCTCTCTTAATTGGAT
144	AATCCAATTAAGAGAGAGTGATGGG	Branch point 3	590	CCCATCACTCTCTCTTAATTGGATT
145	AAATCCAATTAAGAGAGAGTGATGG	Branch point 3	591	CCATCACTCTCTCTTAATTGGATTT
146	AAAATCCAATTAAGAGAGAGTGATG		592	CATCACTCTCTCTTAATTGGATTTT
147	AAAAATCCAATTAAGAGAGAGTGAT		593	ATCACTCTCTCTTAATTGGATTTTT
148	TAAAAATCCAATTAAGAGAGAGTGA		594	TCACTCTCTCTTAATTGGATTTTTA
149	TTAAAAATCCAATTAAGAGAGAGTG		595	CACTCTCTCTTAATTGGATTTTTAA
150	TTTAAAAATCCAATTAAGAGAGAGT		596	ACTCTCTCTTAATTGGATTTTTAAA
151	TTTTAAAAATCCAATTAAGAGAGAG		597	CTCTCTCTTAATTGGATTTTTAAAA
152	ATTTTAAAAATCCAATTAAGAGAGA		598	TCTCTCTTAATTGGATTTTTAAAAT
153	AATTTTAAAAATCCAATTAAGAGAG		599	CTCTCTTAATTGGATTTTTAAAATT
154	TAATTTTAAAAATCCAATTAAGAGA		600	TCTCTTAATTGGATTTTTAAAATTA
155	ATAATTTTAAAAATCCAATTAAGAG		601	CTCTTAATTGGATTTTTAAAATTAT
156	TATAATTTTAAAAATCCAATTAAGA		602	TCCTTAATTGGATTTTTAAAATTATA
157	ATATAATTTTAAAAATCCAATTAAG		603	CTTAATTGGATTTTTAAAATTATAT
158	AATATAATTTTAAAAATCCAATTAA		604	TTAATTGGATTTTTAAAATTATATT

159	GAATATAATTTTAAAAATCCAATTA		605	TAATTGGATTTTTTAAAATTATATTC
160	TGAATATAATTTTAAAAATCCAATT		606	AATTGGATTTTTTAAAATTATATTCA
161	ATGAATATAATTTTAAAAATCCAAT		607	ATTGGATTTTTTAAAATTATATTCAT
162	TATGAATATAATTTTAAAAATCCAA		608	TTGGATTTTTTAAAATTATATTCATA
163	ATATGAATATAATTTTAAAAATCCA		609	TGGATTTTTTAAAATTATATTCATAT
164	AATATGAATATAATTTTAAAAATCC		610	GGATTTTTTAAAATTATATTCATATT
165	CAATATGAATATAATTTTAAAAATC		611	GATTTTTTAAAATTATATTCATATTG
166	GCAATATGAATATAATTTTAAAAAT		612	ATTTTTTAAAATTATATTCATATTGC
167	TGCAATATGAATATAATTTTAAAAA		613	TTTTTAAAATTATATTCATATTGCA
168	CTGCAATATGAATATAATTTTAAAA		614	TTTTTAAAATTATATTCATATTGCAG
169	CCTGCAATATGAATATAATTTTAAA		615	TTTAAAATTATATTCATATTGCAGG
170	TCCTGCAATATGAATATAATTTTAA		616	TTAAAATTATATTCATATTGCAGGA
171	GTCTGCAATATGAATATAATTTTA	Acceptor site	617	TAAAATTATATTCATATTGCAGGAC
172	AGTCCTGCAATATGAATATAATTTT	Acceptor site	618	AAAATTATATTCATATTGCAGGACT
173	GAGTCCTGCAATATGAATATAATTT	Acceptor site	619	AAATTATATTCATATTGCAGGACTC
174	CGAGTCCTGCAATATGAATATAATT	Acceptor site	620	AATTATATTCATATTGCAGGACTCG
175	CCGAGTCCTGCAATATGAATATAAT	Acceptor site	621	ATTATATTCATATTGCAGGACTCGG
176	GCCGAGTCCTGCAATATGAATATAA	Acceptor site	622	TTATATTCATATTGCAGGACTCGGC
177	TGCCGAGTCCTGCAATATGAATATA	Acceptor site	623	TATATTCATATTGCAGGACTCGGCA
178	CTGCCGAGTCCTGCAATATGAATAT	Acceptor site	624	ATATTCATATTGCAGGACTCGGCAG
179	TCTGCCGAGTCCTGCAATATGAATA	Acceptor site	625	TATTCATATTGCAGGACTCGGCAGA
180	TTCTGCCGAGTCCTGCAATATGAAT	Acceptor site	626	ATTCATATTGCAGGACTCGGCAGAA
181	CTTCTGCCGAGTCCTGCAATATGAA	Acceptor site	627	TTCATATTGCAGGACTCGGCAGAAG
182	TCTTCTGCCGAGTCCTGCAATATGA	Acceptor site	628	TCATATTGCAGGACTCGGCAGAAGA
183	GTCTTCTGCCGAGTCCTGCAATATG	Acceptor site	629	CATATTGCAGGACTCGGCAGAAGAC
184	GGTCTTCTGCCGAGTCCTGCAATAT	Acceptor site	630	ATATTGCAGGACTCGGCAGAAGACC
185	AGGTCTTCTGCCGAGTCCTGCAATA	Acceptor site	631	TATTGCAGGACTCGGCAGAAGACCT
186	AAGGTCTTCTGCCGAGTCCTGCAAT	Acceptor site	632	ATTGCAGGACTCGGCAGAAGACCTT
187	GAAGGTCTTCTGCCGAGTCCTGCAA	Acceptor site	633	TTGCAGGACTCGGCAGAAGACCTTC

188	CGAAGGTCTTCTGCCGAGTCCTGCA	Acceptor site	634	TGCAGGACTCGGCAGAAGACCTTCG
189	TCGAAGGTCTTCTGCCGAGTCCTGC	Acceptor site	635	GCAGGACTCGGCAGAAGACCTTCGA
190	CTCGAAGGTCTTCTGCCGAGTCCTG	Acceptor site	636	CAGGACTCGGCAGAAGACCTTCGAG
191	TCTCGAAGGTCTTCTGCCGAGTCCT	ESE Binding	637	AGGACTCGGCAGAAGACCTTCGAGA
192	CTCTCGAAGGTCTTCTGCCGAGTCC	ESE Binding	638	GGACTCGGCAGAAGACCTTCGAGAG
193	TCTCTCGAAGGTCTTCTGCCGAGTC	ESE Binding	639	GA CT CGGCAGAAGACCTTCGAGAGA
194	TTCTCTCGAAGGTCTTCTGCCGAGT	ESE Binding	640	ACTCGGCAGAAGACCTTCGAGAGAA
195	TTTCTCTCGAAGGTCTTCTGCCGAG	ESE Binding	641	CTCGGCAGAAGACCTTCGAGAGAAA
196	CTTTCTCTCGAAGGTCTTCTGCCGA	ESE Binding	642	TCGGCAGAAGACCTTCGAGAGAAAG
197	CCTTTCTCTCGAAGGTCTTCTGCCG	ESE Binding	643	CGGCAGAAGACCTTCGAGAGAAAGG
198	ACCTTTCTCTCGAAGGTCTTCTGCC	ESE Binding	644	GGCAGAAGACCTTCGAGAGAAAGGT
199	TACCTTTCTCTCGAAGGTCTTCTGC	ESE Binding	645	GCAGAAGACCTTCGAGAGAAAGGTA
200	CTACCTTTCTCTCGAAGGTCTTCTG	ESE Binding	646	CAGAAGACCTTCGAGAGAAAGGTAG
201	TCTACCTTTCTCTCGAAGGTCTTCT	ESE Binding	647	AGAAGACCTTCGAGAGAAAGGTAGA
202	TTCTACCTTTCTCTCGAAGGTCTTC	ESE Binding	648	GAAGACCTTCGAGAGAAAGGTAGAA
203	TTTCTACCTTTCTCTCGAAGGTCTT	ESE Binding	649	AAGACCTTCGAGAGAAAGGTAGAAA
204	TTTTCTACCTTTCTCTCGAAGGTCT	ESE Binding	650	AGACCTTCGAGAGAAAGGTAGAAAA
205	ATTTTCTACCTTTCTCTCGAAGGTC	ESE Binding	651	GACCTTCGAGAGAAAGGTAGAAAAT
206	TATTTTCTACCTTTCTCTCGAAGGT	ESE Binding	652	ACCTTCGAGAGAAAGGTAGAAAATA
207	TTATTTTCTACCTTTCTCTCGAAGG	ESE Binding	653	CCTTCGAGAGAAAGGTAGAAAATAA
208	CTTATTTTCTACCTTTCTCTCGAAG	ESE Binding	654	CTTCGAGAGAAAGGTAGAAAATAAG
209	TCTTATTTTCTACCTTTCTCTCGAA	ESE Binding	655	TTCGAGAGAAAGGTAGAAAATAAGA
210	TTCTTATTTTCTACCTTTCTCTCGA	ESE Binding	656	TCGAGAGAAAGGTAGAAAATAAGAA
211	ATTCTTATTTTCTACCTTTCTCTCG	ESE Binding	657	CGAGAGAAAGGTAGAAAATAAGAAT
212	AATTCTTATTTTCTACCTTTCTCTC	ESE Binding	658	GAGAGAAAGGTAGAAAATAAGAATT

213	AAATTCTTATTTTCTACCTTTCTCT	ESE Binding	659	AGAGAAAGGTAGAAAATAAGAATTT
214	CAAATTCTTATTTTCTACCTTTCTC	ESE Binding	660	GAGAAAGGTAGAAAATAAGAATTTG
215	CCAAATTCTTATTTTCTACCTTTCT	ESE Binding	661	AGAAAGGTAGAAAATAAGAATTTGG
216	GCCAAATTCTTATTTTCTACCTTTC	ESE Binding	662	GAAAGGTAGAAAATAAGAATTTGGC
217	AGCCAAATTCTTATTTTCTACCTTT	ESE Binding	663	AAAGGTAGAAAATAAGAATTTGGCT
218	GAGCCAAATTCTTATTTTCTACCTT	ESE Binding	664	AAGGTAGAAAATAAGAATTTGGCTC
219	AGAGCCAAATTCTTATTTTCTACCT	ESE Binding	665	AGGTAGAAAATAAGAATTTGGCTCT
220	GAGAGCCAAATTCTTATTTTCTACC	ESE Binding	666	GGTAGAAAATAAGAATTTGGCTCTC
221	AGAGAGCCAAATTCTTATTTTCTAC	ESE Binding	667	GTAGAAAATAAGAATTTGGCTCTCT
222	CAGAGAGCCAAATTCTTATTTTCTA		668	TAGAAAATAAGAATTTGGCTCTCTG
223	ACAGAGAGCCAAATTCTTATTTTCT		669	AGAAAATAAGAATTTGGCTCTCTGT
224	CACAGAGAGCCAAATTCTTATTTTC		670	GAAAATAAGAATTTGGCTCTCTGTG
225	ACACAGAGAGCCAAATTCTTATTTT		671	AAAATAAGAATTTGGCTCTCTGTGT
226	CACACAGAGAGCCAAATTCTTATTT	Overlaps TDP-43 site 1	672	AAATAAGAATTTGGCTCTCTGTGTG
227	TCACACAGAGAGCCAAATTCTTATT	Overlaps TDP-43 site 1	673	AATAAGAATTTGGCTCTCTGTGTGA
228	CTCACACAGAGAGCCAAATTCTTAT	Overlaps TDP-43 site 1	674	ATAAGAATTTGGCTCTCTGTGTGAG
229	GCTCACACAGAGAGCCAAATTCTTA	Overlaps TDP-43 site 1	675	TAAGAATTTGGCTCTCTGTGTGAGC
230	TGCTCACACAGAGAGCCAAATTCTT	Overlaps TDP-43 site 1	676	AAGAATTTGGCTCTCTGTGTGAGCA
231	ATGCTCACACAGAGAGCCAAATTCT	Overlaps TDP-43 site 1	677	AGAATTTGGCTCTCTGTGTGAGCAT
232	CATGCTCACACAGAGAGCCAAATTC	Overlaps TDP-43 site 1	678	GAATTTGGCTCTCTGTGTGAGCATG
233	ACATGCTCACACAGAGAGCCAAATT	Overlaps TDP-43 site 1	679	AATTTGGCTCTCTGTGTGAGCATGT
234	CACATGCTCACACAGAGAGCCAAAT	Overlaps TDP-43 site 1	680	ATTTGGCTCTCTGTGTGAGCATGTG

235	ACACATGCTCACACAGAGAGCCAAA	Overlaps TDP-43 site 1	681	TTTGGCTCTCTGTGTGAGCATGTGT
236	CACACATGCTCACACAGAGAGCCAA	Overlaps TDP-43 site 1 & 2	682	TTGGCTCTCTGTGTGAGCATGTGTG
237	GCACACATGCTCACACAGAGAGCCA	Overlaps TDP-43 site 1 & 2	683	TGGCTCTCTGTGTGAGCATGTGTGC
238	CGCACACATGCTCACACAGAGAGCC	Overlaps TDP-43 site 1 & 2	684	GGCTCTCTGTGTGAGCATGTGTGCG
239	ACGCACACATGCTCACACAGAGAGC	Overlaps TDP-43 site 1 & 2	685	GCTCTCTGTGTGAGCATGTGTGCGT
240	CACGCACACATGCTCACACAGAGAG	Overlaps TDP-43 site 1 & 2	686	CTCTCTGTGTGAGCATGTGTGCGTG
241	ACACGCACACATGCTCACACAGAGA	Overlaps TDP-43 site 1 & 2	687	TCTCTGTGTGAGCATGTGTGCGTGT
242	CACACGCACACATGCTCACACAGAG	Overlaps TDP-43 site 1 & 2	688	CTCTGTGTGAGCATGTGTGCGTGTG
243	ACACACGCACACATGCTCACACAGA	Overlaps TDP-43 site 1 & 2	689	TCTGTGTGAGCATGTGTGCGTGTGT
244	CACACACGCACACATGCTCACACAG	Overlaps TDP-43 site 1 & 2 & 3	690	CTGTGTGAGCATGTGTGCGTGTGTG
245	GCACACACGCACACATGCTCACACA	Overlaps TDP-43 site 1 & 2 & 3	691	TGTGTGAGCATGTGTGCGTGTGTGC
246	CGCACACACGCACACATGCTCACAC	Overlaps TDP-43 site 2 & 3	692	GTGTGAGCATGTGTGCGTGTGTGCG
247	TCGCACACACGCACACATGCTCACA	Overlaps TDP-43	693	TGTGAGCATGTGTGCGTGTGTGCGA

		site 2 & 3		
248	CTCGCACACACGCACACATGCTCAC	Overlaps TDP-43 site 2 & 3	694	GTGAGCATGTGTGCGTGTGTGCGAG
249	TCTCGCACACACGCACACATGCTCA	Overlaps TDP-43 site 2 & 3	695	TGAGCATGTGTGCGTGTGTGCGAGA
250	CTCTCGCACACACGCACACATGCTC	Overlaps TDP-43 site 2 & 3	696	GAGCATGTGTGCGTGTGTGCGAGAG
251	TCTCTCGCACACACGCACACATGCT	Overlaps TDP-43 site 2 & 3	697	AGCATGTGTGCGTGTGTGCGAGAGA
252	CTCTCTCGCACACACGCACACATGC	Overlaps TDP-43 site 2 & 3	698	GCATGTGTGCGTGTGTGCGAGAGAG
253	TCTCTCTCGCACACACGCACACATG	Overlaps TDP-43 site 2 & 3	699	CATGTGTGCGTGTGTGCGAGAGAGA
254	CTCTCTCTCGCACACACGCACACAT	Overlaps TDP-43 site 2 & 3	700	ATGTGTGCGTGTGTGCGAGAGAGAG
255	TCTCTCTCTCGCACACACGCACACA	Overlaps TDP-43 site 2 & 3	701	TGTGTGCGTGTGTGCGAGAGAGAGA
256	CTCTCTCTCTCGCACACACGCACAC	Overlaps TDP-43 site 3	702	GTGTGCGTGTGTGCGAGAGAGAGAG
257	TCTCTCTCTCTCGCACACACGCACA	Overlaps TDP-43 site 3	703	TGTGCGTGTGTGCGAGAGAGAGAGA
258	GTCTCTCTCTCTCGCACACACGCAC	Overlaps TDP-43 site 3	704	GTGCGTGTGTGCGAGAGAGAGAGAC
259	TGTCTCTCTCTCTCGCACACACGCA	Overlaps TDP-43 site 3	705	TGCGTGTGTGCGAGAGAGAGAGACA
260	CTGTCTCTCTCTCTCGCACACACGC	Overlaps TDP-43 site 3	706	GCGTGTGTGCGAGAGAGAGAGACAG

261	TCTGTCTCTCTCTCTCGCACACACG	Overlaps TDP-43 site 3	707	CGTGTGTGCGAGAGAGAGAGACAGA
262	GTCTGTCTCTCTCTCTCGCACACAC	Overlaps TDP-43 site 3	708	GTGTGTGCGAGAGAGAGAGACAGAC
263	TGTCTGTCTCTCTCTCTCGCACACA	Overlaps TDP-43 site 3	709	TGTGTGCGAGAGAGAGAGACAGACA
264	CTGTCTGTCTCTCTCTCTCGCACAC		710	GTGTGCGAGAGAGAGAGACAGACAG
265	GCTGTCTGTCTCTCTCTCTCGCACA		711	TGTGCGAGAGAGAGAGACAGACAGC
266	GGCTGTCTGTCTCTCTCTCTCGCAC		712	GTGCGAGAGAGAGAGACAGACAGCC
267	AGGCTGTCTGTCTCTCTCTCTCGCA		713	TGCGAGAGAGAGAGACAGACAGCCT
268	CAGGCTGTCTGTCTCTCTCTCTCGC		714	GCGAGAGAGAGAGACAGACAGCCTG
269	GCAGGCTGTCTGTCTCTCTCTCTCG		715	CGAGAGAGAGAGACAGACAGCCTGC
270	GGCAGGCTGTCTGTCTCTCTCTCTC		716	GAGAGAGAGAGACAGACAGCCTGCC
271	AGGCAGGCTGTCTGTCTCTCTCTCT		717	AGAGAGAGAGACAGACAGCCTGCCT
272	TAGGCAGGCTGTCTGTCTCTCTCTC		718	GAGAGAGAGACAGACAGCCTGCCTA
273	TTAGGCAGGCTGTCTGTCTCTCTCT		719	AGAGAGAGACAGACAGCCTGCCTAA
274	CTTAGGCAGGCTGTCTGTCTCTCTC		720	GAGAGAGACAGACAGCCTGCCTAAG
275	TCTTAGGCAGGCTGTCTGTCTCTCT		721	AGAGAGACAGACAGCCTGCCTAAGA
276	TTCTTAGGCAGGCTGTCTGTCTCTC		722	GAGAGACAGACAGCCTGCCTAAGAA
277	CTTCTTAGGCAGGCTGTCTGTCTCT		723	AGAGACAGACAGCCTGCCTAAGAAG
278	TCTTCTTAGGCAGGCTGTCTGTCTC		724	GAGACAGACAGCCTGCCTAAGAAGA
279	TTCTTCTTAGGCAGGCTGTCTGTCT		725	AGACAGACAGCCTGCCTAAGAAGAA
280	TTTCTTCTTAGGCAGGCTGTCTGTC		726	GACAGACAGCCTGCCTAAGAAGAAA
281	ATTTCTTCTTAGGCAGGCTGTCTGT		727	ACAGACAGCCTGCCTAAGAAGAAAT
282	CATTTCTTCTTAGGCAGGCTGTCTG		728	CAGACAGCCTGCCTAAGAAGAAATG
283	TCATTTCTTCTTAGGCAGGCTGTCT		729	AGACAGCCTGCCTAAGAAGAAATGA
284	TTCATTTCTTCTTAGGCAGGCTGTC		730	GACAGCCTGCCTAAGAAGAAATGAA
285	ATTCATTTCTTCTTAGGCAGGCTGT		731	ACAGCCTGCCTAAGAAGAAATGAAT
286	CATTCATTTCTTCTTAGGCAGGCTG		732	CAGCCTGCCTAAGAAGAAATGAATG
287	ACATTCATTTCTTCTTAGGCAGGCT		733	AGCCTGCCTAAGAAGAAATGAATGT
288	CACATTCATTTCTTCTTAGGCAGGC		734	GCCTGCCTAAGAAGAAATGAATGTG
289	TCACATTCATTTCTTCTTAGGCAGG		735	CCTGCCTAAGAAGAAATGAATGTGA
290	TTCACATTCATTTCTTCTTAGGCAG		736	CTGCCTAAGAAGAAATGAATGTGAA
291	ATTCACATTCATTTCTTCTTAGGCA		737	TGCCTAAGAAGAAATGAATGTGAAT
292	CATTCACATTCATTTCTTCTTAGGC		738	GCCTAAGAAGAAATGAATGTGAATG
293	GCATTCACATTCATTTCTTCTTAGG		739	CCTAAGAAGAAATGAATGTGAATGC
294	CGCATTCACATTCATTTCTTCTTAG		740	CTAAGAAGAAATGAATGTGAATGCG
295	CCGCATTCACATTCATTTCTTCTTA		741	TAAGAAGAAATGAATGTGAATGCGG
296	GCCGCATTCACATTCATTTCTTCTT		742	AAGAAGAAATGAATGTGAATGCGGC
297	AGCCGCATTCACATTCATTTCTTCT		743	AGAAGAAATGAATGTGAATGCGGCT

298	AAGCCGCATTCACATTCATTTCTTC		744	GAAGAAATGAATGTGAATGCGGCTT
299	CAAGCCGCATTCACATTCATTTCTT		745	AAGAAATGAATGTGAATGCGGCTTG
300	ACAAGCCGCATTCACATTCATTTCT		746	AGAAATGAATGTGAATGCGGCTTGT
301	CACAAGCCGCATTCACATTCATTTCT		747	GAAATGAATGTGAATGCGGCTTGTG
302	CCACAAGCCGCATTCACATTCATTT		748	AAATGAATGTGAATGCGGCTTGTGG
303	GCCACAAGCCGCATTCACATTCATT		749	AATGAATGTGAATGCGGCTTGTGGC
304	TGCCACAAGCCGCATTCACATTCAT		750	ATGAATGTGAATGCGGCTTGTGGCA
305	GTGCCACAAGCCGCATTCACATTCA		751	TGAATGTGAATGCGGCTTGTGGCAC
306	TGTGCCACAAGCCGCATTCACATTC		752	GAATGTGAATGCGGCTTGTGGCACA
307	CTGTGCCACAAGCCGCATTCACATT		753	AATGTGAATGCGGCTTGTGGCACAG
308	ACTGTGCCACAAGCCGCATTCACAT		754	ATGTGAATGCGGCTTGTGGCACAGT
309	AACTGTGCCACAAGCCGCATTCACA		755	TGTGAATGCGGCTTGTGGCACAGTT
310	CAACTGTGCCACAAGCCGCATTCAC		756	GTGAATGCGGCTTGTGGCACAGTTG
311	TCAACTGTGCCACAAGCCGCATTCAC		757	TGAATGCGGCTTGTGGCACAGTTGA
312	GTCAACTGTGCCACAAGCCGCATTC		758	GAATGCGGCTTGTGGCACAGTTGAC
313	TGTCAACTGTGCCACAAGCCGCATT		759	AATGCGGCTTGTGGCACAGTTGACA
314	TTGTCAACTGTGCCACAAGCCGCAT		760	ATGCGGCTTGTGGCACAGTTGACAA
315	CTTGTCAACTGTGCCACAAGCCGCA		761	TGCGGCTTGTGGCACAGTTGACAAG
316	CCTTGTCAACTGTGCCACAAGCCGC		762	GCGGCTTGTGGCACAGTTGACAAGG
317	TCCTTGTCAACTGTGCCACAAGCCG		763	CGGCTTGTGGCACAGTTGACAAGGA
318	ATCCTTGTCAACTGTGCCACAAGCC		764	GGCTTGTGGCACAGTTGACAAGGAT
319	CATCCTTGTCAACTGTGCCACAAGC		765	GCTTGTGGCACAGTTGACAAGGATG
320	TCATCCTTGTCAACTGTGCCACAAG		766	CTTGTGGCACAGTTGACAAGGATGA
321	ATCATCCTTGTCAACTGTGCCACAA		767	TTGTGGCACAGTTGACAAGGATGAT
322	TATCATCCTTGTCAACTGTGCCACA		768	TGTGGCACAGTTGACAAGGATGATA
323	TTATCATCCTTGTCAACTGTGCCAC		769	GTGGCACAGTTGACAAGGATGATAA
324	TTTATCATCCTTGTCAACTGTGCCA		770	TGGCACAGTTGACAAGGATGATAAA
325	ATTTATCATCCTTGTCAACTGTGCC		771	GGCACAGTTGACAAGGATGATAAAT
326	GATTATCATCCTTGTCAACTGTGC		772	GCACAGTTGACAAGGATGATAAATC
327	TGATTATCATCCTTGTCAACTGTG		773	CACAGTTGACAAGGATGATAAATCA
328	TTGATTATCATCCTTGTCAACTGT		774	ACAGTTGACAAGGATGATAAATCAA
329	ATTGATTATCATCCTTGTCAACTG		775	CAGTTGACAAGGATGATAAATCAAT
330	TATTGATTATCATCCTTGTCAACT		776	AGTTGACAAGGATGATAAATCAATA
331	TTATTGATTATCATCCTTGTCAAC		777	GTTGACAAGGATGATAAATCAATAA
332	ATTATTGATTATCATCCTTGTCAA		778	TTGACAAGGATGATAAATCAATAAT
333	CATTATTGATTATCATCCTTGTCA		779	TGACAAGGATGATAAATCAATAATG
334	GCATTATTGATTATCATCCTTGTG		780	GACAAGGATGATAAATCAATAATGC
335	TGCATTATTGATTATCATCCTTGT		781	ACAAGGATGATAAATCAATAATGCA
336	TTGCATTATTGATTATCATCCTTG		782	CAAGGATGATAAATCAATAATGCAA
337	CTTGCATTATTGATTATCATCCTT		783	AAGGATGATAAATCAATAATGCAAG
338	GCTTGCATTATTGATTATCATCCT		784	AGGATGATAAATCAATAATGCAAGC

339	AGCTTGCATTATTGATTTATCATCC		785	GGATGATAAATCAATAATGCAAGCT
340	AAGCTTGCATTATTGATTTATCATC		786	GATGATAAATCAATAATGCAAGCTT
341	TAAGCTTGCATTATTGATTTATCAT		787	ATGATAAATCAATAATGCAAGCTTA
342	GTAAGCTTGCATTATTGATTTATCA		788	TGATAAATCAATAATGCAAGCTTAC
343	AGTAAGCTTGCATTATTGATTTATC		789	GATAAATCAATAATGCAAGCTTACT
344	TAGTAAGCTTGCATTATTGATTTAT		790	ATAAATCAATAATGCAAGCTTACTA
345	ATAGTAAGCTTGCATTATTGATTTA		791	TAAATCAATAATGCAAGCTTACTAT
346	GATAGTAAGCTTGCATTATTGATTT		792	AAATCAATAATGCAAGCTTACTATC
347	TGATAGTAAGCTTGCATTATTGATT		793	AATCAATAATGCAAGCTTACTATCA
348	ATGATAGTAAGCTTGCATTATTGAT		794	ATCAATAATGCAAGCTTACTATCAT
349	AATGATAGTAAGCTTGCATTATTGA		795	TCAATAATGCAAGCTTACTATCATT
350	AAATGATAGTAAGCTTGCATTATTG		796	CAATAATGCAAGCTTACTATCATTT
351	TAAATGATAGTAAGCTTGCATTATT		797	AATAATGCAAGCTTACTATCATTTA
352	ATAAATGATAGTAAGCTTGCATTAT		798	ATAATGCAAGCTTACTATCATTTAT
353	CATAAATGATAGTAAGCTTGCATTA		799	TAATGCAAGCTTACTATCATTTATG
354	TCATAAATGATAGTAAGCTTGCATT		800	AATGCAAGCTTACTATCATTTATGA
355	TTCATAAATGATAGTAAGCTTGCAT		801	ATGCAAGCTTACTATCATTTATGAA
356	ATTCATAAATGATAGTAAGCTTGCA		802	TGCAAGCTTACTATCATTTATGAAT
357	TATTCATAAATGATAGTAAGCTTGC		803	GCAAGCTTACTATCATTTATGAATA
358	CTATTCATAAATGATAGTAAGCTTG		804	CAAGCTTACTATCATTTATGAATAG
359	GCTATTCATAAATGATAGTAAGCTT		805	AAGCTTACTATCATTTATGAATAGC
360	TGCTATTCATAAATGATAGTAAGCT		806	AGCTTACTATCATTTATGAATAGCA
361	TTGCTATTCATAAATGATAGTAAGC		807	GCTTACTATCATTTATGAATAGCAA
362	ATTGCTATTCATAAATGATAGTAAG		808	CTTACTATCATTTATGAATAGCAAT
363	TATTGCTATTCATAAATGATAGTAA		809	TTACTATCATTTATGAATAGCAATA
364	GTATTGCTATTCATAAATGATAGTA		810	TACTATCATTTATGAATAGCAATAC
365	AGTATTGCTATTCATAAATGATAGT		811	ACTATCATTTATGAATAGCAATACT
366	CAGTATTGCTATTCATAAATGATAG		812	CTATCATTTATGAATAGCAATACTG
367	TCAGTATTGCTATTCATAAATGATA		813	TATCATTTATGAATAGCAATACTGA
368	TTCAGTATTGCTATTCATAAATGAT		814	ATCATTTATGAATAGCAATACTGAA
369	CTTCAGTATTGCTATTCATAAATGA		815	TCATTTATGAATAGCAATACTGAAG
370	TCTTCAGTATTGCTATTCATAAATG		816	CATTTATGAATAGCAATACTGAAGA
371	TTCTTCAGTATTGCTATTCATAAAT		817	ATTTATGAATAGCAATACTGAAGAA
372	TTTCTTCAGTATTGCTATTCATAAA		818	TTTATGAATAGCAATACTGAAGAAA
373	ATTTCTTCAGTATTGCTATTCATAA		819	TTATGAATAGCAATACTGAAGAAAT
374	AATTTCTTCAGTATTGCTATTCATA		820	TATGAATAGCAATACTGAAGAAATT
375	TAATTTCTTCAGTATTGCTATTCAT		821	ATGAATAGCAATACTGAAGAAATTA
376	TTAATTTCTTCAGTATTGCTATTC		822	TGAATAGCAATACTGAAGAAATTAA
377	TTTAATTTCTTCAGTATTGCTATTC	poly A signal	823	GAATAGCAATACTGAAGAAATTAAA
378	TTTTAATTTCTTCAGTATTGCTATT	poly A signal	824	AATAGCAATACTGAAGAAATTAAAA

379	GTTTTAATTTCTTCAGTATTGCTAT	poly A signal	825	ATAGCAATACTGAAGAAATTAAAC
380	TGTTTTAATTTCTTCAGTATTGCTA	poly A signal	826	TAGCAATACTGAAGAAATTAAACA
381	TTGTTTTAATTTCTTCAGTATTGCT	poly A signal	827	AGCAATACTGAAGAAATTAAACAA
382	TTTGTTTTAATTTCTTCAGTATTGC	poly A signal	828	GCAATACTGAAGAAATTAAACAAA
383	TTTTGTTTTAATTTCTTCAGTATTG	poly A signal	829	CAATACTGAAGAAATTAAACAAAA
384	CTTTTGTTTTAATTTCTTCAGTATT	poly A signal	830	AATACTGAAGAAATTAAACAAAAG
385	TCTTTTGTTTTAATTTCTTCAGTAT	poly A signal	831	ATACTGAAGAAATTAAACAAAAGA
386	ATCTTTTGTTTTAATTTCTTCAGTA	poly A signal	832	TACTGAAGAAATTAAACAAAAGAT
387	AATCTTTTGTTTTAATTTCTTCAGT	poly A signal	833	ACTGAAGAAATTAAACAAAAGATT
388	CAATCTTTTGTTTTAATTTCTTCAG	poly A signal	834	CTGAAGAAATTAAACAAAAGATTG
389	GCAATCTTTTGTTTTAATTTCTTCA	poly A signal	835	TGAAGAAATTAAACAAAAGATTGC
390	AGCAATCTTTTGTTTTAATTTCTTC	poly A signal	836	GAAGAAATTAAACAAAAGATTGCT
391	CAGCAATCTTTTGTTTTAATTTCTT	poly A signal	837	AAGAAATTAAACAAAAGATTGCTG
392	ACAGCAATCTTTTGTTTTAATTTCT	poly A signal	838	AGAAATTAAACAAAAGATTGCTGT
393	GACAGCAATCTTTTGTTTTAATTTCT	poly A signal	839	GAAATTAAACAAAAGATTGCTGTC
394	AGACAGCAATCTTTTGTTTTAATTT	poly A signal	840	AAATTAAACAAAAGATTGCTGTCT
395	GAGACAGCAATCTTTTGTTTTAATT	poly A signal and site	841	AATTAAACAAAAGATTGCTGTCTC
396	TGAGACAGCAATCTTTTGTTTTAAT	poly A signal and site	842	ATTAAACAAAAGATTGCTGTCTCA
397	TTGAGACAGCAATCTTTTGTTTTAA	poly A site	843	TTAAACAAAAGATTGCTGTCTCAA
398	ATTGAGACAGCAATCTTTTGTTTAA	poly A site	844	TAAACAAAAGATTGCTGTCTCAAT
399	TATTGAGACAGCAATCTTTTGTTTT	poly A site	845	AAACAAAAGATTGCTGTCTCAATA
400	ATATTGAGACAGCAATCTTTTGTTT	poly A site	846	AAACAAAAGATTGCTGTCTCAATAT
401	TATATTGAGACAGCAATCTTTTGTT	poly A site	847	AACAAAAGATTGCTGTCTCAATATA
402	ATATATTGAGACAGCAATCTTTTGT	poly A site	848	ACAAAAGATTGCTGTCTCAATATAT

403	GATATATTGAGACAGCAATCTTTTG	poly A site	849	CAAAAGATTGCTGTCTCAATATATC
404	AGATATATTGAGACAGCAATCTTTT	poly A site	850	AAAAGATTGCTGTCTCAATATATCT
405	AAGATATATTGAGACAGCAATCTTT	poly A site	851	AAAGATTGCTGTCTCAATATATCTT
406	TAAGATATATTGAGACAGCAATCTT	poly A site	852	AAGATTGCTGTCTCAATATATCTTA
407	ATAAGATATATTGAGACAGCAATCT	poly A site	853	AGATTGCTGTCTCAATATATCTTAT
408	TATAAGATATATTGAGACAGCAATC	poly A site	854	GATTGCTGTCTCAATATATCTTATA
409	ATATAAGATATATTGAGACAGCAAT	poly A site	855	ATTGCTGTCTCAATATATCTTATAT
410	AATATAAGATATATTGAGACAGCAA	poly A site	856	TTGCTGTCTCAATATATCTTATATT
411	AAATATAAGATATATTGAGACAGCA	poly A site	857	TGCTGTCTCAATATATCTTATATTT
412	TAAATATAAGATATATTGAGACAGC	poly A site	858	GCTGTCTCAATATATCTTATATTTA
413	ATAAATATAAGATATATTGAGACAG		859	CTGTCTCAATATATCTTATATTTAT
414	AATAAATATAAGATATATTGAGACA		860	TGTCTCAATATATCTTATATTTATT
415	TAATAAATATAAGATATATTGAGAC		861	GTCTCAATATATCTTATATTTATTA
416	ATAATAAATATAAGATATATTGAGA		862	TCTCAATATATCTTATATTTATTAT
417	AATAATAAATATAAGATATATTGAG		863	CTCAATATATCTTATATTTATTATT
418	AAATAATAAATATAAGATATATTGA		864	TCAATATATCTTATATTTATTATTT
419	TAAATAATAAATATAAGATATATTG		865	CAATATATCTTATATTTATTATTTA
420	GTAAATAATAAATATAAGATATATT		866	AATATATCTTATATTTATTATTTAC
421	GGTAAATAATAAATATAAGATATAT		867	ATATATCTTATATTTATTATTTACC
422	TGGTAAATAATAAATATAAGATATA		868	TATATCTTATATTTATTATTTACCA
423	TTGGTAAATAATAAATATAAGATAT		869	ATATCTTATATTTATTATTTACCAA
424	TTTGGTAAATAATAAATATAAGATA		870	TATCTTATATTTATTATTTACCAAA
425	ATTTGGTAAATAATAAATATAAGAT		871	ATCTTATATTTATTATTTACCAAAT
426	AATTTGGTAAATAATAAATATAAGA		872	TCTTATATTTATTATTTACCAAATT
427	TAATTTGGTAAATAATAAATATAAG		873	CTTATATTTATTATTTACCAAATTA
428	ATAATTTGGTAAATAATAAATATAA		874	TTATATTTATTATTTACCAAATTAT
429	AATAATTTGGTAAATAATAAATATA		875	TATATTTATTATTTACCAAATTATT
430	GAATAATTTGGTAAATAATAAATAT		876	ATATTTATTATTTACCAAATTATTC
431	AGAATAATTTGGTAAATAATAAATA		877	TATTTATTATTTACCAAATTATTCT
432	TAGAATAATTTGGTAAATAATAAAT		878	ATTTATTATTTACCAAATTATTCTA
433	TTAGAATAATTTGGTAAATAATAAA		879	TTTATTATTTACCAAATTATTCTAA
434	CTTAGAATAATTTGGTAAATAATAA		880	TTATTATTTACCAAATTATTCTAAG
435	TCTTAGAATAATTTGGTAAATAATA		881	TATTATTTACCAAATTATTCTAAGA
436	CTCTTAGAATAATTTGGTAAATAAT		882	ATTATTTACCAAATTATTCTAAGAG
437	ACTCTTAGAATAATTTGGTAAATAA		883	TTATTTACCAAATTATTCTAAGAGT

438	TACTCTTAGAATAATTTGGTAAATA		884	TATTTACCAAATTATTCTAAGAGTA
439	ATACTCTTAGAATAATTTGGTAAAT		885	ATTTACCAAATTATTCTAAGAGTAT
440	AATACTCTTAGAATAATTTGGTAAA		886	TTTACCAAATTATTCTAAGAGTATT
441	AAATACTCTTAGAATAATTTGGTAA		887	TTACCAAATTATTCTAAGAGTATTT
442	GAAATACTCTTAGAATAATTTGGTA		888	TACCAAATTATTCTAAGAGTATTTC
443	AGAAATACTCTTAGAATAATTTGGT		889	ACCAAATTATTCTAAGAGTATTCT
444	AAGAAATACTCTTAGAATAATTTGG		890	CCAAATTATTCTAAGAGTATTTCTT
445	GAAGAAATACTCTTAGAATAATTTG		891	CAAATTATTCTAAGAGTATTTCTTC
446	GGAAGAAATACTCTTAGAATAATTT		892	AAATTATTCTAAGAGTATTTCTTCC

* At least one (*i.e.*, one or more) nucleoside linkage of the oligonucleotide sequence is

independently selected from a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a thiophosphorodiamidate linkage, a phosphorodiamidate (*e.g.*, comprising a phosphorodiamidate morpholino (PMO), 3' amino ribose, or 5' amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage.

[00228] Table 2 below identifies additional STMN2 AON sequences:

Table 2. Additional STMN2 AON Sequences (corresponding to SEQ ID NOs: 1-446 but with thymine bases replaced with uracil bases)

SEQ ID NO:	AON Sequence* (5' → 3')
893	GGAGGGAUACCUGUAUAUUACAAGU
894	AGGAGGGAUACCUGUAUAUUACAAG
895	CAGGAGGGAUACCUGUAUAUUACAA
896	CCAGGAGGGAUACCUGUAUAUUACA
897	ACCAGGAGGGAUACCUGUAUAUUAC
898	UACCAGGAGGGAUACCUGUAUAUUA
899	UUACCAGGAGGGAUACCUGUAUAUU
900	CUUACCAGGAGGGAUACCUGUAUAU
901	GCUUACCAGGAGGGAUACCUGUAUA
902	AGCUUACCAGGAGGGAUACCUGUAU
903	GAGCUUACCAGGAGGGAUACCUGUA
904	AGAGCUUACCAGGAGGGAUACCUGU
905	CAGAGCUUACCAGGAGGGAUACCUG

906	CCAGAGCUUACCAGGAGGGGAUACCU
907	ACCAGAGCUUACCAGGAGGGGAUACC
908	UACCAGAGCUUACCAGGAGGGGAUAC
909	AUACCAGAGCUUACCAGGAGGGGAUA
910	AAUACCAGAGCUUACCAGGAGGGGAU
911	UAAUACCAGAGCUUACCAGGAGGGGA
912	AUAAUACCAGAGCUUACCAGGAGGGG
913	CAUAAUACCAGAGCUUACCAGGAGGG
914	ACAUAAUACCAGAGCUUACCAGGAGG
915	GACAUAAUACCAGAGCUUACCAGGA
916	AGACAUAAUACCAGAGCUUACCAGG
917	AAGACAUAAUACCAGAGCUUACCAG
918	UAAGACAUAAUACCAGAGCUUACCA
919	UUAAGACAUAAUACCAGAGCUUACC
920	GUUAAGACAUAAUACCAGAGCUUAC
921	UGUUAAGACAUAAUACCAGAGCUUA
922	AUGUUAAGACAUAAUACCAGAGCUU
923	AAUGUUAAGACAUAAUACCAGAGCU
924	AAAUGUUAAGACAUAAUACCAGAGC
925	AAAAUGUUAAGACAUAAUACCAGAG
926	AAAAAUGUUAAGACAUAAUACCAGA
927	UAAAAAUGUUAAGACAUAAUACCAG
928	UUAAAAAUGUUAAGACAUAAUACCA
929	UUUAAAAAUGUUAAGACAUAAUACC
930	AUUUAAAAAUGUUAAGACAUAAUAC
931	GAUUUAAAAAUGUUAAGACAUAAUA
932	AGAUUUAAAAAUGUUAAGACAUAAU
933	UAGAUUUAAAAAUGUUAAGACAUAA
934	AUAGAUUUAAAAAUGUUAAGACAUAA
935	CAUAGAUUUAAAAAUGUUAAGACAU
936	CCAUAGAUUUAAAAAUGUUAAGACA
937	ACCAUAGAUUUAAAAAUGUUAAGAC
938	UACCAUAGAUUUAAAAAUGUUAAGA
939	UUACCAUAGAUUUAAAAAUGUUAAG
940	AUUACCAUAGAUUUAAAAAUGUUA
941	GAUUACCAUAGAUUUAAAAAUGUUA
942	AGAUUACCAUAGAUUUAAAAAUGUU
943	AAGAUUACCAUAGAUUUAAAAAUGU
944	AAAGAUUACCAUAGAUUUAAAAAUG
945	UAAAGAUUACCAUAGAUUUAAAAAU
946	GUAAAGAUUACCAUAGAUUUAAAAA

947	UGUAAAGAUUACCAUAGAUUUAAAA
948	UUGUAAAGAUUACCAUAGAUUUAAA
949	UUUGUAAAGAUUACCAUAGAUUUAA
950	UUUUGUAAAGAUUACCAUAGAUUUA
951	AUUUUGUAAAGAUUACCAUAGAUUU
952	UAUUUUGUAAAGAUUACCAUAGAUU
953	AUAUUUUGUAAAGAUUACCAUAGAU
954	AAUAUUUUGUAAAGAUUACCAUAGA
955	AAAUAUUUUGUAAAGAUUACCAUAG
956	AAAAUAUUUUGUAAAGAUUACCAUA
957	UAAAAUAUUUUGUAAAGAUUACCAU
958	GUAAAAUAUUUUGUAAAGAUUACCA
959	AGUAAAAUAUUUUGUAAAGAUUACC
960	AAGUAAAAUAUUUUGUAAAGAUUAC
961	GAAGUAAAAUAUUUUGUAAAGAUUA
962	GGAAGUAAAAUAUUUUGUAAAGAUU
963	CGGAAGUAAAAUAUUUUGUAAAGAU
964	UCGGAAGUAAAAUAUUUUGUAAAGA
965	UUCGGAAGUAAAAUAUUUUGUAAAG
966	GUUCGGAAGUAAAAUAUUUUGUAAA
967	AGUUCGGAAGUAAAAUAUUUUGUAA
968	GAGUUCGGAAGUAAAAUAUUUUGUA
969	UGAGUUCGGAAGUAAAAUAUUUUGU
970	AUGAGUUCGGAAGUAAAAUAUUUUG
971	UAUGAGUUCGGAAGUAAAAUAUUUU
972	AUAUGAGUUCGGAAGUAAAAUAUUU
973	UAUAUGAGUUCGGAAGUAAAAUAUU
974	GUAUAUGAGUUCGGAAGUAAAAUAU
975	GGUAUAUGAGUUCGGAAGUAAAAUA
976	AGGUAUAUGAGUUCGGAAGUAAAAU
977	CAGGUAUAUGAGUUCGGAAGUAAAA
978	CCAGGUAUAUGAGUUCGGAAGUAAA
979	CCCAGGUAUAUGAGUUCGGAAGUAA
980	CCCCAGGUAUAUGAGUUCGGAAGUA
981	UCCCCAGGUAUAUGAGUUCGGAAGU
982	AUCCCCAGGUAUAUGAGUUCGGAAG
983	AAUCCCCAGGUAUAUGAGUUCGGA
984	AAAUCCCCAGGUAUAUGAGUUCGGA
985	AAAAUCCCCAGGUAUAUGAGUUCGG
986	UAAAAUCCCCAGGUAUAUGAGUUCG
987	AUAAAAUCCCCAGGUAUAUGAGUUC

988	AAUAAAAUCCCCAGGUUAUAUGAGUU
989	UAAUAAAAUCCCCAGGUUAUAUGAGU
990	GUAAUAAAAUCCCCAGGUUAUAUGAG
991	AGUAAUAAAAUCCCCAGGUUAUAUGA
992	GAGUAAUAAAAUCCCCAGGUUAUAUG
993	AGAGUAAUAAAAUCCCCAGGUUAUAU
994	CAGAGUAAUAAAAUCCCCAGGUUAUA
995	CCAGAGUAAUAAAAUCCCCAGGUUAU
996	CCCAGAGUAAUAAAAUCCCCAGGUUA
997	UCCCAGAGUAAUAAAAUCCCCAGGU
998	UUCCCAGAGUAAUAAAAUCCCCAGG
999	AUCCCAGAGUAAUAAAAUCCCCAG
1000	AAUCCCAGAGUAAUAAAAUCCCCA
1001	UAAUCCCAGAGUAAUAAAAUCCCC
1002	AUAAUCCCAGAGUAAUAAAAUCCC
1003	CAUAAUCCCAGAGUAAUAAAAUCC
1004	ACAUAAUCCCAGAGUAAUAAAAUC
1005	CACAUAAUCCCAGAGUAAUAAAAU
1006	ACACAUAAUCCCAGAGUAAUAAAA
1007	AACACAUAAUCCCAGAGUAAUAAA
1008	GAACACAUAAUCCCAGAGUAAUAA
1009	AGAACACAUAAUCCCAGAGUAAUA
1010	CAGAACACAUAAUCCCAGAGUAAU
1011	GCAGAACACAUAAUCCCAGAGUAA
1012	GGCAGAACACAUAAUCCCAGAGUA
1013	GGGCAGAACACAUAAUCCCAGAGU
1014	GGGGCAGAACACAUAAUCCCAGAG
1015	UGGGGCAGAACACAUAAUCCCAGA
1016	AUGGGGCAGAACACAUAAUCCCAG
1017	GAUGGGGCAGAACACAUAAUCCCCA
1018	UGAUGGGGCAGAACACAUAAUCCC
1019	GUGAUGGGGCAGAACACAUAAUCC
1020	AGUGAUGGGGCAGAACACAUAAUUC
1021	GAGUGAUGGGGCAGAACACAUAAU
1022	AGAGUGAUGGGGCAGAACACAUAAU
1023	GAGAGUGAUGGGGCAGAACACAUAA
1024	AGAGAGUGAUGGGGCAGAACACAU
1025	GAGAGAGUGAUGGGGCAGAACACAU
1026	AGAGAGAGUGAUGGGGCAGAACACA
1027	AAGAGAGAGUGAUGGGGCAGAACAC
1028	UAAGAGAGAGUGAUGGGGCAGAACACA

1029	UUAAGAGAGAGUGAUGGGGCAGAAC
1030	AUUAAGAGAGAGUGAUGGGGCAGAA
1031	AAUUAAGAGAGAGUGAUGGGGCAGA
1032	CAAUUAAGAGAGAGUGAUGGGGCAG
1033	CCAAUUAAGAGAGAGUGAUGGGGCA
1034	UCCAAUUAAGAGAGAGUGAUGGGGC
1035	AUCCAAUUAAGAGAGAGUGAUGGGG
1036	AAUCCAAUUAAGAGAGAGUGAUGGG
1037	AAAUCCAAUUAAGAGAGAGUGAUGG
1038	AAAAUCCAAUUAAGAGAGAGUGAUG
1039	AAAAAUCCAAUUAAGAGAGAGUGAU
1040	UAAAAAUCCAAUUAAGAGAGAGUGA
1041	UUAAAAAUCCAAUUAAGAGAGAGUG
1042	UUUAAAAAUCCAAUUAAGAGAGAGU
1043	UUUUAAAAAUCCAAUUAAGAGAGAG
1044	AUUUUAAAAAUCCAAUUAAGAGAGA
1045	AAUUUUAAAAAUCCAAUUAAGAGAG
1046	UAAUUUUAAAAAUCCAAUUAAGAGA
1047	AUAAUUUUAAAAAUCCAAUUAAGAG
1048	UAUAAUUUUAAAAAUCCAAUUAAGA
1049	AUAUAAUUUUAAAAAUCCAAUUAAG
1050	AAUAUAAUUUUAAAAAUCCAAUUA
1051	GAAUAUAAUUUUAAAAAUCCAAUUA
1052	UGAAUAUAAUUUUAAAAAUCCAAU
1053	AUGAAUAUAAUUUUAAAAAUCCAAU
1054	UAUGAAUAUAAUUUUAAAAAUCCAA
1055	AUAUGAAUAUAAUUUUAAAAAUCCA
1056	AAUAUGAAUAUAAUUUUAAAAAUCC
1057	CAUAUGAAUAUAAUUUUAAAAAUC
1058	GCAAUAUGAAUAUAAUUUUAAAAAU
1059	UGCAAUAUGAAUAUAAUUUUAAAA
1060	CUGCAAUAUGAAUAUAAUUUUAAAA
1061	CCUGCAAUAUGAAUAUAAUUUUAAA
1062	UCCUGCAAUAUGAAUAUAAUUUUAA
1063	GUCCUGCAAUAUGAAUAUAAUUUUA
1064	AGUCCUGCAAUAUGAAUAUAAUUUU
1065	GAGUCCUGCAAUAUGAAUAUAAUUU
1066	CGAGUCCUGCAAUAUGAAUAUAAUU
1067	CCGAGUCCUGCAAUAUGAAUAUAAU
1068	GCCGAGUCCUGCAAUAUGAAUAUAA
1069	UGCCGAGUCCUGCAAUAUGAAUAUA

1070	CUGCCGAGUCCUGCAAUAUGAAU
1071	UCUGCCGAGUCCUGCAAUAUGAAUA
1072	UUCUGCCGAGUCCUGCAAUAUGAAU
1073	CUUCUGCCGAGUCCUGCAAUAUGAA
1074	UCUUCUGCCGAGUCCUGCAAUAUGA
1075	GUCUUCUGCCGAGUCCUGCAAUAUG
1076	GGUCUUCUGCCGAGUCCUGCAAUAU
1077	AGGUCUUCUGCCGAGUCCUGCAAUA
1078	AAGGUCUUCUGCCGAGUCCUGCAAU
1079	GAAGGUCUUCUGCCGAGUCCUGCAA
1080	CGAAGGUCUUCUGCCGAGUCCUGCA
1081	UCGAAGGUCUUCUGCCGAGUCCUGC
1082	CUCGAAGGUCUUCUGCCGAGUCCUG
1083	UCUCGAAGGUCUUCUGCCGAGUCCU
1084	CUCUCGAAGGUCUUCUGCCGAGUCC
1085	UCUCUCGAAGGUCUUCUGCCGAGUC
1086	UUCUCUCGAAGGUCUUCUGCCGAGU
1087	UUUCUCUCGAAGGUCUUCUGCCGAG
1088	CUUUCUCUCGAAGGUCUUCUGCCGA
1089	CCUUCUCUCGAAGGUCUUCUGCCG
1090	ACCUUUCUCUCGAAGGUCUUCUGCC
1091	UACCUUUCUCUCGAAGGUCUUCUGC
1092	CUACCUUUCUCUCGAAGGUCUUCUG
1093	UCUACCUUUCUCUCGAAGGUCUUCU
1094	UUCUACCUUUCUCUCGAAGGUCUUC
1095	UUUCUACCUUUCUCUCGAAGGUCUU
1096	UUUUCUACCUUUCUCUCGAAGGUCU
1097	AUUUUCUACCUUUCUCUCGAAGGUC
1098	UAUUUUCUACCUUUCUCUCGAAGGU
1099	UUAUUUUCUACCUUUCUCUCGAAGG
1100	CUUAUUUUCUACCUUUCUCUCGAAG
1101	UCUUAUUUUCUACCUUUCUCUCGAA
1102	UUCUUAUUUUCUACCUUUCUCUCGA
1103	AUUCUUAUUUUCUACCUUUCUCUCG
1104	AAUUCUUAUUUUCUACCUUUCUCUC
1105	AAAUUCUUAUUUUCUACCUUUCUCU
1106	CAAAUUCUUAUUUUCUACCUUUCUC
1107	CCAAAUUCUUAUUUUCUACCUUUCU
1108	GCCAAAUUCUUAUUUUCUACCUUUC
1109	AGCCAAAUUCUUAUUUUCUACCUUU
1110	GAGCCAAAUUCUUAUUUUCUACCUU

1111	AGAGCCAAAUUCUUAUUUUCUACCU
1112	GAGAGCCAAAUUCUUAUUUUCUACC
1113	AGAGAGCCAAAUUCUUAUUUUCUAC
1114	CAGAGAGCCAAAUUCUUAUUUUCUA
1115	ACAGAGAGCCAAAUUCUUAUUUUCU
1116	CACAGAGAGCCAAAUUCUUAUUUUC
1117	ACACAGAGAGCCAAAUUCUUAUUUU
1118	CACACAGAGAGCCAAAUUCUUAUUU
1119	UCACACAGAGAGCCAAAUUCUUAUU
1120	CUCACACAGAGAGCCAAAUUCUUAU
1121	GCUCACACAGAGAGCCAAAUUCUUA
1122	UGCUCACACAGAGAGCCAAAUUCUU
1123	AUGCUCACACAGAGAGCCAAAUUCU
1124	CAUGCUCACACAGAGAGCCAAAUUC
1125	ACAUGCUCACACAGAGAGCCAAAUU
1126	CACAUGCUCACACAGAGAGCCAAAU
1127	ACACAUGCUCACACAGAGAGCCAAA
1128	CACACAUGCUCACACAGAGAGCCAA
1129	GCACACAUGCUCACACAGAGAGCCA
1130	CGCACACAUGCUCACACAGAGAGCC
1131	ACGCACACAUGCUCACACAGAGAGC
1132	CACGCACACAUGCUCACACAGAGAG
1133	ACACGCACACAUGCUCACACAGAGA
1134	CACACGCACACAUGCUCACACAGAG
1135	ACACACGCACACAUGCUCACACAGA
1136	CACACACGCACACAUGCUCACACAG
1137	GCACACACGCACACAUGCUCACACA
1138	CGCACACACGCACACAUGCUCACAC
1139	UCGCACACACGCACACAUGCUCACA
1140	CUCGCACACACGCACACAUGCUCAC
1141	UCUCGCACACACGCACACAUGCUC
1142	CUCUCGCACACACGCACACAUGCUC
1143	UCUCUCGCACACACGCACACAUGC
1144	CUCUCUCGCACACACGCACACAUGC
1145	UCUCUCUCGCACACACGCACACAUG
1146	CUCUCUCUCGCACACACGCACACAU
1147	UCUCUCUCUCGCACACACGCACACA
1148	CUCUCUCUCUCGCACACACGCACAC
1149	UCUCUCUCUCUCGCACACACGCACA
1150	GUCUCUCUCUCUCGCACACACGCAC
1151	UGUCUCUCUCUCUCGCACACACGC

1152	CUGUCUCUCUCUCUCUCGCACACACGC
1153	UCUGUCUCUCUCUCUCUCGCACACACG
1154	GUCUGUCUCUCUCUCUCUCGCACACAC
1155	UGUCUGUCUCUCUCUCUCUCGCACACA
1156	CUGUCUGUCUCUCUCUCUCUCGCACAC
1157	GCUGUCUGUCUCUCUCUCUCUCGCACA
1158	GGCUGUCUGUCUCUCUCUCUCUCGCAC
1159	AGGCUGUCUGUCUCUCUCUCUCUCGCA
1160	CAGGCUGUCUGUCUCUCUCUCUCUCGC
1161	GCAGGCUGUCUGUCUCUCUCUCUCUCG
1162	GGCAGGCUGUCUGUCUCUCUCUCUCUC
1163	AGGCAGGCUGUCUGUCUCUCUCUCUCU
1164	UAGGCAGGCUGUCUGUCUCUCUCUCUC
1165	UUAGGCAGGCUGUCUGUCUCUCUCUCU
1166	CUUAGGCAGGCUGUCUGUCUCUCUCUC
1167	UCUUAGGCAGGCUGUCUGUCUCUCUCU
1168	UUCUUAGGCAGGCUGUCUGUCUCUCUC
1169	CUUCUUAGGCAGGCUGUCUGUCUCUCU
1170	UCUUCUUAGGCAGGCUGUCUGUCUCUC
1171	UUCUUCUUAGGCAGGCUGUCUGUCUCU
1172	UUUCUUCUUAGGCAGGCUGUCUGUCUC
1173	AUUUCUUCUUAGGCAGGCUGUCUGUCU
1174	CAUUUCUUCUUAGGCAGGCUGUCUGUC
1175	UCAUUUCUUCUUAGGCAGGCUGUCUCU
1176	UUCAUUUCUUCUUAGGCAGGCUGUCUC
1177	AUUCAUUUCUUCUUAGGCAGGCUGUCU
1178	CAUUCAUUUCUUCUUAGGCAGGCUGUC
1179	ACAUUCAUUUCUUCUUAGGCAGGCUCU
1180	CACAUUCAUUUCUUCUUAGGCAGGCUC
1181	UCACAUUCAUUUCUUCUUAGGCAGGCUC
1182	UUCACAUUCAUUUCUUCUUAGGCAGGCUC
1183	AUUCACAUUCAUUUCUUCUUAGGCAGGC
1184	CAUUCACAUUCAUUUCUUCUUAGGCAGGC
1185	GCAUUCACAUUCAUUUCUUCUUAGGCAGGC
1186	CGCAUUCACAUUCAUUUCUUCUUAGGCAGGC
1187	CCGCAUUCACAUUCAUUUCUUCUUAGGCAGGC
1188	GCCGCAUUCACAUUCAUUUCUUCUUAGGCAGGC
1189	AGCCGCAUUCACAUUCAUUUCUUCUUAGGCAGGC
1190	AAGCCGCAUUCACAUUCAUUUCUUCUUAGGCAGGC
1191	CAAGCCGCAUUCACAUUCAUUUCUUCUUAGGCAGGC
1192	ACAAGCCGCAUUCACAUUCAUUUCUUCUUAGGCAGGC

1193	CACAAGCCGCAUUCACAUUCAUUUC
1194	CCACAAGCCGCAUUCACAUUCAUUU
1195	GCCACAAGCCGCAUUCACAUUCAUU
1196	UGCCACAAGCCGCAUUCACAUUCAU
1197	GUGCCACAAGCCGCAUUCACAUUCA
1198	UGUGCCACAAGCCGCAUUCACAUUC
1199	CUGUGCCACAAGCCGCAUUCACAUU
1200	ACUGUGCCACAAGCCGCAUUCACAU
1201	AACUGUGCCACAAGCCGCAUUCACA
1202	CAACUGUGCCACAAGCCGCAUUCAC
1203	UCAACUGUGCCACAAGCCGCAUUCA
1204	GUCAACUGUGCCACAAGCCGCAUUC
1205	UGUCAACUGUGCCACAAGCCGCAUU
1206	UUGUCAACUGUGCCACAAGCCGCAU
1207	CUUGUCAACUGUGCCACAAGCCGCA
1208	CCUUGUCAACUGUGCCACAAGCCGC
1209	UCCUUGUCAACUGUGCCACAAGCCG
1210	AUCCUUGUCAACUGUGCCACAAGCC
1211	CAUCCUUGUCAACUGUGCCACAAGC
1212	UCAUCCUUGUCAACUGUGCCACAAG
1213	AUCAUCCUUGUCAACUGUGCCACAA
1214	UAUCAUCCUUGUCAACUGUGCCACA
1215	UUAUCAUCCUUGUCAACUGUGCCAC
1216	UUUAUCAUCCUUGUCAACUGUGCCA
1217	AUUUAUCAUCCUUGUCAACUGUGCC
1218	GAUUUAUCAUCCUUGUCAACUGUGC
1219	UGAUUUUAUCAUCCUUGUCAACUGUG
1220	UUGAUUUUAUCAUCCUUGUCAACUGU
1221	AUUGAUUUUAUCAUCCUUGUCAACUG
1222	UAUUGAUUUUAUCAUCCUUGUCAACU
1223	UUAUUGAUUUUAUCAUCCUUGUCAAC
1224	AUUUAUUGAUUUUAUCAUCCUUGUCA
1225	CAUUAUUGAUUUUAUCAUCCUUGUCA
1226	GCAUUAUUGAUUUUAUCAUCCUUGUC
1227	UGCAUUAUUGAUUUUAUCAUCCUUGU
1228	UUGCAUUAUUGAUUUUAUCAUCCUUG
1229	CUUGCAUUAUUGAUUUUAUCAUCCUU
1230	GCUUGCAUUAUUGAUUUUAUCAUCCU
1231	AGCUUGCAUUAUUGAUUUUAUCAUCC
1232	AAGCUUGCAUUAUUGAUUUUAUCAUC
1233	UAAGCUUGCAUUAUUGAUUUUAUCAU

1234	GUAAGCUUGCAUUAUUGAUUUUAUCA
1235	AGUAAGCUUGCAUUAUUGAUUUUAUC
1236	UAGUAAGCUUGCAUUAUUGAUUUUAU
1237	AUAGUAAGCUUGCAUUAUUGAUUUUA
1238	GAUAGUAAGCUUGCAUUAUUGAUUUU
1239	UGAUAGUAAGCUUGCAUUAUUGAUUU
1240	AUGAUAGUAAGCUUGCAUUAUUGAU
1241	AAUGAUAGUAAGCUUGCAUUAUUGA
1242	AAAUGAUAGUAAGCUUGCAUUAUUG
1243	UAAAUGAUAGUAAGCUUGCAUUAUU
1244	AUAAAUGAUAGUAAGCUUGCAUUAU
1245	CAUAAAUGAUAGUAAGCUUGCAUUA
1246	UCAUAAAUGAUAGUAAGCUUGCAUU
1247	UUCAUAAAUGAUAGUAAGCUUGCAU
1248	AUUCAUAAAUGAUAGUAAGCUUGCA
1249	UAUUCAUAAAUGAUAGUAAGCUUGC
1250	CUAUUCAUAAAUGAUAGUAAGCUUG
1251	GCUAUUCAUAAAUGAUAGUAAGCUU
1252	UGC AUUCAUAAAUGAUAGUAAGCU
1253	UUGC AUUCAUAAAUGAUAGUAAGC
1254	AUUGC AUUCAUAAAUGAUAGUAAG
1255	UAUUGC AUUCAUAAAUGAUAGUAA
1256	GUAUUGC AUUCAUAAAUGAUAGUA
1257	AGUAUUGC AUUCAUAAAUGAUAGU
1258	CAGUAUUGC AUUCAUAAAUGAUAG
1259	UCAGUAUUGC AUUCAUAAAUGAUA
1260	UUCAGUAUUGC AUUCAUAAAUGAU
1261	CUUCAGUAUUGC AUUCAUAAAUGA
1262	UCUUCAGUAUUGC AUUCAUAAAUG
1263	UUCUUCAGUAUUGC AUUCAUAAAU
1264	UUUCUUCAGUAUUGC AUUCAUAAA
1265	AUUUCUUCAGUAUUGC AUUCAUAA
1266	AAUUUCUUCAGUAUUGC AUUCAUA
1267	UAAUUUCUUCAGUAUUGC AUUCAU
1268	UUAUUUCUUCAGUAUUGC AUUCA
1269	UUUAAUUUCUUCAGUAUUGC AUUC
1270	UUUUAAUUUCUUCAGUAUUGC AUU
1271	GUUUUAAUUUCUUCAGUAUUGC AU
1272	UGUUUUAAUUUCUUCAGUAUUGC UA
1273	UUGUUUUAAUUUCUUCAGUAUUGC U
1274	UUUGUUUUAAUUUCUUCAGUAUUGC

1275	UUUUGUUUUAAUUUCUUCAGUAUUG
1276	CUUUUGUUUUAAUUUCUUCAGUAUU
1277	UCUUUUGUUUUAAUUUCUUCAGUAU
1278	AUCUUUUGUUUUAAUUUCUUCAGUA
1279	AAUCUUUUGUUUUAAUUUCUUCAGU
1280	CAAUCUUUUGUUUUAAUUUCUUCAG
1281	GCAAUCUUUUGUUUUAAUUUCUUCA
1282	AGCAAUCUUUUGUUUUAAUUUCUUC
1283	CAGCAAUCUUUUGUUUUAAUUUCUU
1284	ACAGCAAUCUUUUGUUUUAAUUUCU
1285	GACAGCAAUCUUUUGUUUUAAUUUC
1286	AGACAGCAAUCUUUUGUUUUAAUUU
1287	GAGACAGCAAUCUUUUGUUUUAAUU
1288	UGAGACAGCAAUCUUUUGUUUUAAU
1289	UUGAGACAGCAAUCUUUUGUUUUAA
1290	AUUGAGACAGCAAUCUUUUGUUUUA
1291	UAUUGAGACAGCAAUCUUUUGUUUU
1292	AUAUUGAGACAGCAAUCUUUUGUUU
1293	UAUAUUGAGACAGCAAUCUUUUGUU
1294	AUAUAUUGAGACAGCAAUCUUUUGU
1295	GAUAUAUUGAGACAGCAAUCUUUUG
1296	AGAUUAUUGAGACAGCAAUCUUUU
1297	AAGAUUAUUGAGACAGCAAUCUUU
1298	UAAGAUUAUUGAGACAGCAAUCUU
1299	AUAAGAUUAUUGAGACAGCAAUCU
1300	UAUAAGAUUAUUGAGACAGCAAUC
1301	AUAUAAGAUUAUUGAGACAGCAAU
1302	AAUAUAAGAUUAUUGAGACAGCAA
1303	AAUAUAAGAUUAUUGAGACAGCA
1304	UAAUAUAAGAUUAUUGAGACAGC
1305	AUAAUAUAAGAUUAUUGAGACAG
1306	AAUAAUAUAAGAUUAUUGAGACA
1307	UAAUAAUAUAAGAUUAUUGAGAC
1308	AUAAUAAUAUAAGAUUAUUGAGA
1309	AAUAAUAAUAUAAGAUUAUUGAG
1310	AAAUAAUAAUAUAAGAUUAUUGA
1311	UAAAUAAUAAUAUAAGAUUAUUG
1312	GUAAAUAAUAAUAUAAGAUUAUU
1313	GGUAAAUAAUAAUAUAAGAUUAU
1314	UGGUAAAUAAUAAUAUAAGAUUA
1315	UUGGUAAAUAAUAAUAUAAGAUU

1316	UUUGGUAAAUAUAUAAUAUAAGAUA
1317	AUUUGGUAAAUAUAUAAUAUAAGAU
1318	AAUUUGGUAAAUAUAUAAUAUAAGA
1319	UAAUUUGGUAAAUAUAUAAUAUAAG
1320	AUAAUUUGGUAAAUAUAUAAUAUAA
1321	AAUAAUUUGGUAAAUAUAUAAUAUA
1322	GAAUAAUUUGGUAAAUAUAUAAUAU
1323	AGAAUAAUUUGGUAAAUAUAUAAUA
1324	UAGAAUAAUUUGGUAAAUAUAUAAU
1325	UUAGAAUAAUUUGGUAAAUAUAUAA
1326	CUUAGAAUAAUUUGGUAAAUAUAUAA
1327	UCUUAGAAUAAUUUGGUAAAUAUAU
1328	CUCUUAGAAUAAUUUGGUAAAUAUAU
1329	ACUCUUAGAAUAAUUUGGUAAAUAUA
1330	UACUCUUAGAAUAAUUUGGUAAAUA
1331	AUACUCUUAGAAUAAUUUGGUAAAUA
1332	AAUACUCUUAGAAUAAUUUGGUAAA
1333	AAAUACUCUUAGAAUAAUUUGGUAA
1334	GAAAUACUCUUAGAAUAAUUUGGUA
1335	AGAAAUACUCUUAGAAUAAUUUGGU
1336	AAGAAAUACUCUUAGAAUAAUUUGG
1337	GAAGAAAUACUCUUAGAAUAAUUUG
1338	GGAAGAAAUACUCUUAGAAUAAUUU

* At least one (*i.e.*, one or more) nucleoside linkage of the oligonucleotide sequence is independently selected from a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a thiophosphorodiamidate linkage, a phosphorodiamidate (*e.g.*, comprising a phosphorodiamidate morpholino (PMO), 3' amino ribose, or 5' amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage.

[00229] Table 3 below identifies exemplary STMN2 AON sequences:

Table 3. Exemplary STMN2 AON Sequences, in each one or more spacers described in the present disclosure are incorporated for generation of an oligonucleotide of the present invention

SEQ ID NO: (legacy ID*)	Oligonucleotide sequence (5' → 3')
SEQ ID NO: 31	AATGTTAAGACATAATACCAGAGCT
SEQ ID NO: 36	TTAAAAATGTTAAGACATAATACCA
SEQ ID NO: 41	TAGATTTAAAAATGTTAAGACATAA
SEQ ID NO: 46	TACCATAGATTTAAAAATGTTAAGA
SEQ ID NO: 55	TGTAAAGATTACCATAGATTTAAAA
SEQ ID NO: 144	AATCCAATTAAGAGAGAGTGATGGG
SEQ ID NO: 146	AAAATCCAATTAAGAGAGAGTGATG
SEQ ID NO: 150	TTAAAAATCCAATTAAGAGAGAGT
SEQ ID NO: 169	CCTGCAATATGAATATAATTTTAAA
SEQ ID NO: 170	TCCTGCAATATGAATATAATTTTAA
SEQ ID NO: 171	GTCCTGCAATATGAATATAATTTTA
SEQ ID NO: 172	AGTCCTGCAATATGAATATAATTTT
SEQ ID NO: 173	GAGTCCTGCAATATGAATATAATTT
SEQ ID NO: 177	TGCCGAGTCCTGCAATATGAATATA
SEQ ID NO: 181	CTTCTGCCGAGTCCTGCAATATGAA
SEQ ID NO: 185	AGGTCTTCTGCCGAGTCCTGCAATA
SEQ ID NO: 197	CCTTTCTCTCGAAGGTCTTCTGCCG
SEQ ID NO: 203	TTTCTACCTTTCTCTCGAAGGTCTT
SEQ ID NO: 209	TCTTATTTTCTACCTTTCTCTCGAA
SEQ ID NO: 215	CCAAATTCTTATTTTCTACCTTTCT
SEQ ID NO: 237	GCACACATGCTCACACAGAGAGCCA
SEQ ID NO: 244	CACACACGCACACATGCTCACACAG
SEQ ID NO: 249	TCTCGCACACACGCACACATGCTCA
SEQ ID NO: 252	CTCTCTCGCACACACGCACACATGC
SEQ ID NO: 380	TGTTTTAATTTCTTCAGTATTGCTA
SEQ ID NO: 385	TCTTTTGTTTTAATTTCTTCAGTAT
SEQ ID NO: 390	AGCAATCTTTTGTTTTAATTTCTTC
SEQ ID NO: 395	GAGACAGCAATCTTTTGTTTTAATT
SEQ ID NO: 400	ATATTGAGACAGCAATCTTTTGTTT

* At least one (*i.e.*, one or more) nucleoside linkage of the oligonucleotide sequence is

independently selected from a phosphorothioate linkage, an alkyl phosphate linkage, a

- 5 phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a thiophosphorodiamidate linkage, a phosphorodiamidate (*e.g.*,

comprising a phosphorodiamidate morpholino (PMO), 3' amino ribose, or 5' amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage.

- 5 **[00230]** In some embodiments, all internucleoside linkages of the STMN2 AON oligonucleotides listed in Table 3 are phosphorothioate linkages (except when a spacer is present, the linkage may or may not be a phosphorothioate linkage), and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides, and each "C" is replaced with a 5-MeC. In some embodiments, all internucleoside linkages of the STMN2 AON
- 10 oligonucleotides listed in Table 3 are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides, and not all or none of the 'C' is replaced with 5-MeC.

[00231] Table 4 below identifies additional exemplary STMN2 AON sequences:

Table 4. Additional Exemplary STMN2 AON Sequences (corresponding to AONs shown in Table

- 15 3 but with thymine bases replaced with uracil bases)

SEQ ID NO:	Oligonucleotide sequence (5'→3')
SEQ ID NO: 923	AAUGUUAAGACAUAAUACCAGAGCU
SEQ ID NO: 928	UUAUAAAUGUUAAGACAUAAUACCA
SEQ ID NO: 933	UAGAUUUUAAAAUGUUAAGACAUAA
SEQ ID NO: 938	UACCAUAGAUUUUAAAAUGUUAAGA
SEQ ID NO: 947	UGUAAAGAUUACCAUAGAUUUUAAA
SEQ ID NO: 1036	AAUCCAAUUAAGAGAGAGUGAUGGG
SEQ ID NO: 1038	AAAAUCCAAUUAAGAGAGAGUGAUG
SEQ ID NO: 1042	UUUAAAAUCCAAUUAAGAGAGAGU
SEQ ID NO: 1061	CCUGCAAUAUGAAUAUAAUUUUAAA
SEQ ID NO: 1062	UCCUGCAAUAUGAAUAUAAUUUUAA
SEQ ID NO: 1063	GUCCUGCAAUAUGAAUAUAAUUUUA
SEQ ID NO: 1064	AGUCCUGCAAUAUGAAUAUAAUUUU
SEQ ID NO: 1065	GAGUCCUGCAAUAUGAAUAUAAUUU
SEQ ID NO: 1077	AGGUCUUCUGCCGAGUCCUGCAAUA
SEQ ID NO: 1089	CCUUUCUCUCGAAGGUCUUCUGCCG
SEQ ID NO: 1095	UUUCUACCUUUCUCUCGAAGGUCUU
SEQ ID NO: 1101	UCUUAUUUUCUACCUUUCUCUCGAA
SEQ ID NO: 1107	CCAAUUCUUAUUUUCUACCUUUCU
SEQ ID NO: 1129	GCACACAUGCUCACACAGAGAGCCA
SEQ ID NO: 1136	CACACACGCACACAUGCUCACACAG

SEQ ID NO: 1141	UCUCGCACACACGCACACAUGCUCU
SEQ ID NO: 1144	CUCUCUCGCACACACGCACACAUGC
SEQ ID NO: 1272	UGUUUUAAUUUCUUCAGUAUUGC
SEQ ID NO: 1277	UCUUUUGUUUUAAUUUCUUCAGUAU
SEQ ID NO: 1282	AGCAAUCUUUUGUUUUAAUUUCUUC
SEQ ID NO: 1287	GAGACAGCAAUCUUUUGUUUUAAUU
SEQ ID NO: 1292	AUAUUGAGACAGCAAUCUUUUGUUU

STMN2 Transcript with a Cryptic Exon

[00232] In one embodiment, a STMN2 AON targets a region of a STMN2 transcript comprising a cryptic exon sequence, the STMN2 transcript comprising the sequence provided as SEQ ID NO:

5 1339.

ACTTGTAATATACAGGTATCCCTCCTGGTAAGCTCTGGTATTATGTCTTAACATTTTAA
AATCTATGGTAATCTTTACAAAATATTTTACTTCCGAATCATATACCTGGGGATTTT
ATTACTCTGGGAATTATGTGTTCTGCCCCATCACTCTCTCTTAATTGGATTTTAAAT
TATATTCATATTGCAGGACTCGGCAGAAGACCTTCGAGAGAAAGGTAGAAAATAAGA
10 ATTTGGCTCTCTGTGTGAGCATGTGTGCGTGTGTGCGAGAGAGAGACAGACAGCC
TGCCTAAGAAGAAATGAATGTGAATGCGGCTTGTGGCACAGTTGACAAGGATGATAA
ATCAATAATGCAAGCTTACTATCATTTATGAATAGCAATACTGAAGAAATTAAAACA
AAAGATTGCTGTCTCAATATATCTTATATTTATTATTACCAAATTATTCTAAGAGTAT
TTCTTCC

15 **(SEQ ID NO: 1339)**

[00233] A cryptic exon sequence within the STMN2 transcript is provided as SEQ ID NO: 1340.

GACTCGGCAGAAGACCTTCGAGAGAAAGGTAGAAAATAAGAATTTGGCTCTCTGTGT
GAGCATGTGTGCGTGTGTGCGAGAGAGAGAGACAGACAGCCTGCCTAAGAAGAAAT
GAATGTGAATGCGGCTTGTGGCACAGTTGACAAGGATGATAAATCAATAATGCAAGC
20 TTACTATCATTTATGAATAGCAATACTGAAGAAATTAAAACAAAAGATTGCTGTCTC
(SEQ ID NO: 1340) (Source: NCBI Reference Sequence: NC_000008.11).

[00234] In various embodiments, the STMN2 transcript with a cryptic exon shares between 90-100% identity with SEQ ID NO: 1339. In various embodiments, the STMN2 transcript with a cryptic exon shares at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity
25 with SEQ ID NO: 1341.

[00235] In one embodiment, a STMN2 transcript with a cryptic exon can comprise a pre-mRNA STMN2 transcript. In one embodiment, a STMN2 transcript with a cryptic exon can comprise the sequence provided as SEQ ID NO: 1341.

AGCTCCTAGGAAGCTTCAGGGCTTAAAGCTCCACTCTACTTGGACTGTACTATCAGGC
30 CCCCAAAATGGGGGGAGCCGACAGGGAAGGACTGATTTCCATTTCAAAGTGCATTCT
GGTACTTTGTACTCCAGCACCATTGGCCGATCAATATTTAATGCTTGGAGATTCTGAC

TCTGCGGGAGTCATGTCAGGGGACCTTGGGAGCCAATCTGCTTGAGCTTCTGAGTGA
TAATTATTCATGGGCTCCTGCCTCTTGCTCTTTCTCTAGCACGGTCCCCTCTGCAGAC
TCAGTGCCTTATTCAGTCTTCTCTCTCGCTCTCTCCGCTGCTGTAGCCGGACCCTTTGC
CTTCGCCACTGCTCAGCGTCTGCACATCCCTACAATGGCTAAAACAGCAATGGTAAG
5 GCACTGCGCCTCGTTCTCCGTCGGCTCTACCTGGAGCCCACCTCTCACCTCCTCTCTTG
AGCTCTAGAAGCATTTCAGAGATATTTTATAAAGAAAAAGATGTTAATGGTAACACAG
GACCAGGAAGGACAGGGCAGTTCTGGGGGAGGTGGGAGGGCAGAGAAGAGGTCTAT
GGAAATCTAAAGCGAAGAATTTCTTTTAAAAGGTAGAAGCGGGTAAGTTGCCCTCCT
ATGGGTAGAGAATTTATTCTGTTTCCATATTTAAAATTAGGACTCAATCGTGAGGGGA
10 GGAAGCTACCTTAACCTGTTTGCCTTAAATGGGCTTAAGGGACATTTTGGAAAGTGCTT
TATAACGACCTTTTTTTTTTTTTATTTCTTCTCTAGTTTAAAGAAAGAAATAGGAAAGGG
GTAAAGGGAAGGTGGGAGAAAGGAAAAAGAAAATTGCAAAGTCAAAGCGGTCCCCT
CCCGCTGTTTGAAAGATGGGTGGAGACGGGGGGAGGGGATGGAGAGAACTGGGCAC
ATTTTACGGTATTGTCTCGTCGAAGAAACCGCTAGTCCTGGGGTGCGGTGCAGGGAG
15 GTAAGACGGCGGGGGACAGGGTGGGGGTAGGACCTCCGCTCCTTTGTTTTAGGGCAA
GGGAGGGGAAGGAGAGAGGAAGTCGCGGAGGGGCGTGGAGGGCGCGGGTGGGCAGC
TGCAGGGGCGGGGAAGCGCGCGGCAGGGAGGGGTGGAGGGACAGCGGCTTCGAAG
GCGCTGGGGTGGGGTTTCTTTGTGTGCGGACCAGCGGTCCCGGGGGGAGGCACCTGC
AGCGCTGGGCGCACAAATGCGGACAGCCCCACCCAGTGCGGAACCGCGCAGCCCCGC
20 CCCCCCGCCCGGTGCTGCATCTTCATTCGAAAGGGGGTTCGGGTGGGGAGCGCAGCGT
GACACCCAGGAGCCCAACCCTGCGGGGACAGCGGCGCCACGCCCCGCGCTCCCCGCT
CCCGACTCCCCGCCGCGGCTTCCAAGAGAGACCTGACCCTGACCCCCGCCCTCCCCA
CGCTGGCCTCATTGTTCTGCTTTTAAAGAGAGATGGGAAAAGTGGGTAAACATTTTTCT
TTTCGGAAGCAAATTACATAGAGTGTTTAGACATAGACACAGATAAAGGGTTCTTTG
25 AAGACCTTTGATCGTTTGCGGGAAGCTTCTAGAACCTAGACATGTGTATGTATAAT
AATAGAGATGACATGAAATCGTATATAAAGCAAAAGAGGTCAAAGTCTTAAGTTAA
GCCACGCGAAATTTCCGTTTTGTGGGTGAGACAGTGCCAAATATCGGCAATTTCATAA
GCTCAGAGAGACAAGACAGTGGAGACACAGGATGACCGGAAAAGATTCTGGATTCA
GGGCCTTCATCCGCAATTGGTCTTGTGCCTTGAGTGCCACCGTTCCTGGCGCTCAGTG
30 GCCCCGGGGTGAAAAGGCAGGGTGGGGCCTGGGGTCCTGTGGCAGCTGGAAGCACG
TGTCCCCCGGGACTTGTTGTCAGGATGCGGAGACAGGGAAAGCTGCCGAAAGGACTC
CATCTGCGCGGCTCCGCCCTGCCCTACCCTCCCCGCGGAGCCGGGGAGACCTCAGGC
TCCGAGACTGGCGGGGAAGAGGAATATGGGAGGGGCGAGTTGAGCTGTATGCAGTCC
TGGAACCTCTTTTTTCAGCCCCGAGTCCACAACGGCCCGAGCACCCCTTGATGTGCG
35 CAGACCCCCGGCGTGGCTCTCAGCCCCAGCACCGAGCCCTCCCAGCCAAGCGGGTG
GCTCTGCAGAAAAGCTGGCTCGAGCCCCGCCCGGCCACACAAAGGCGCGGGCCCCACC
CAGCCCCGGGCGCGAGACCGCAGAGGTGACCCCTTCCCAGGGATTACAGGGAGGGCT
GTCTCTTCTCGCCACCCACGGTCCGCGGAGCTCGGGGCTTTTTTTCCCCCAGCCCAA
GCCCCCGCCACCCCTCTGTTCTCTATGATTTTCCAGAATGGAGACCCCGCGAGGGGC
40 TTCTCTAAGGGAGACCCTCGCTCCTCCAGCGGGGCGCGGCTCGGCCCCACCCCTCCCA
GCTGAGGCCCAGAGCCGCTACCGCTGGCCGGGTGGGGGCGCACGTGGCGACTGGGT
GTGTGGAGCGCAGCCAGCCCTGCAGAGCCCCGCGCCGCGCCCTGCGCTCCCCCTCCCC
GGAGTTGGGCGCTCGCCCCCGCGGTGCAGCCGGGGAGACCGGTTTCTGCGCAGTGTC
CTGAGCTACCCCCGCTTTCCACAATTTCGAGTTCACTCGCACGTCCAGAAAGGTTCTG
45 AGAATGGGTGGTGGGGGCGATCTCGCCTCGCTTTCTGCACCCCTCAGAAAGGTTTCC
GCTGCAGGCTAGTGGCTGCAAATCATCGTCATCATCAGTATTATTATCATTTCAAAT
CGTTGTTATTATTTAATGATTCAGTAGCCTTGTTTGTTCATTGTTCAAAGGGACG
TGGATTGCTCTTGTTAAGGATTAACCCTTGTTGCGTTTCGCTTTGCTTCCTCCTAATTG
CCCTCATCCCTTTCCCCCACAAAAGGTAAATTTGTCTCCAGTTGTTCAATTTAAGTTA

TAAAGCAAATATATTTTTGCTTCCTGCCAGGATTATGTATGTTCATGTGGCTAAGATA
CATGTGCAAGTGCTTGCTAAGAGCAGGGTTTGTGTGCCAACGATTGCTGGAAAATTC
TCTGCAAAGAATTGTTTGTGGCTGCAATGGGTGAGAATACACATATATAATTGAGAT
GATCTTCAACATAAGGTTATATCTATAAATATATAAATATAGTTTATGCACAAAATTT
5 TAAGTTTTTTCCCTGAAACTGTTCTTCCAACCTGCTGATTCTTGATACAGCCTCAATCC
TACACAGATACATGGATCGTGAAATGGTAGCCGCCATCCAAATAAAAAATCCCACCCC
AAATATGACAAACGCAAGCATCCTTTCTGGCCATAATTTAACTGCATTTGCAAATCAT
GAAAAAAACACTACTTCTGCAGTATTAATAAATAATAGATTTTGAAATTAATTCCAATTT
CAAAGATAATTAATTATCAGGGCGAGTGCTTTTTTCTGATTCATTAAACAATTATGT
10 ATTCAGCATGATTGTAAGAGGTGCATATAATATTCCCCATTATCTTTTCTAATGAAGT
GGGCACCTTCTGAATGGATATATAAGTAACTAGAAATGAAAAGCTGAGGATTTGGTC
AGAATTTTCAGGATAAAACTGAAAGAAATGGCAGTAGTTTATCAATTAATCTCATGTA
TTTAGTTTATACCAGGTGAGTAAGCTGAGCCTGCAATAAACACTCTCTGTCCCAGTGT
AACACGTCGCAGGTAGCTAGAATGATAGGATAAATTAATAGACCTTGTGGTGTTTGT
15 CTATGCACGTTAAAATTCTCTGAGAGAAAGTATATTTTAAAATGATAATTAAGATTGG
ACATTTGTGCTATTAAAATCTACAACCTTTAGTCAAAATTCACAATGGTTTTTTTTTACA
ATAATGTGACTTACAGATTTGTAGTAAATTATTCTATTCTAAAAGAGAAATGAGTGTT
TTTATTGTTACAGCTATTACCTCATTAAATATTTTTAGCAAACCTTTTATTTGTTGCATTG
AAAGCAGTTTTAATTACTTTGGGTTTTTATTTTTCAAATTACTAATGGATAGATGGTG
20 GAATAAGCATTTAATCATTGTCACAAATATGACTTCCATCAAATAGCTCATTCTCAGT
GATTAATAAATGCTACAAGAGGCTACAATTTACTCAGATTCAGGAAATGTCCTTTCA
GAGTGCCATAAGGCTGATTCATATAATAAAATAGTTTTCTTCCCTATAATTTAAGATC
AAATAGTTACTTAGTTCTGTGAATACCTAGCAGTAGCTATCAAACAGAATTTTAAAGT
TAAATCTGTACAATAACAATGAAGTGGAGGATGAATCGATACATATTGAATGGAAG
25 ACTTTGTCATTGATAAATTCAGGCCATCTTTAGGAAAATTCGGGATTTATCAATCACC
ATTATTTTTTACTTCAACTGAGTGTGACTGATCACATGCTCAGGCTACCTTGGTAGCT
CATTGCTCACAGGAGGCTGAAAAAAGCTGGCCTCCGAGCAGGAGGAAGCTCAGAGC
ACAAACCTAGGCCTGGGCGTGGCCACTGGGAGCTGCTGATAGCGAACCCAGCTCAC
ACCAGTTTCTTTTTTGGTCTGGGAAGAAAAACACATATTATCCTGTTGTCACAAGAT
30 CTGTGACCTTATATGAAAAAATGCTAGAATTTTTTCATTAAAAAAGAAAATACTGAA
CTAGCCAGTGACCCAGATGTTTTCAGAACCTAGACTGGTTCTGTCCATTGGAAAACCT
CGGTGTCTGCATTAACCTTTTACCACACTAGAGGGCAATCATGTTCTCTAAAAAAGCA
GATGATTGATGTAAACCTAGTTCCAAATATTAACCTGTTTAATAAAATCTTTTCTTTTAC
CAGGAACATTCAAGTGTTTATTCAATAAGCTGATGCCATGCTTTACCCTAGTGGATGA
35 ACAGAGCTTGTACAATTTTCAAGGAGACAGGATGAAATGAGTGGTCATAATCTGAAA
GTAGATACACGCCCTGGTTAATTATCCCTGATGGTTTTACTTCTCAGTTTTTATTACAT
TGTTATTATAATACCATTTATGTTACTTCTGAGATTTTGTAGTGGATAAATAGTAGAA
AAATGTCAGTAGTAATAGCAAAGTTATTTAGCAGCCGAATATTTAATGCTTAAAAA
TAAAGGAATAAATTAAGAAAAATCATTGTTTACTTCTTCATCGATTGAAATGTGCCCC
40 CTGTTTACAGAGCACATCTGAATATCAGAGTCTCCACCTGCAGAGAACATGCAGCTTAG
CGAGTAAAACAGGCAGGTATGTGATACTGAGGAGGTGTACCAAAAACCTGACTGCTGT
TATTTTTCCCATCTTCTAAGTCTGTCTTTCTTTTCCATTTAAAGATACCTTTTTTAAATCT
AATCCAATGTGATTTCAATCTAGTTTTATCAGATTTCAACAATTATTGAGCATCTCCTT
GTAGTGGTTTTCTGTTTATTAGAAAATCGATGTTAATTTTAAACGAAGTAAGAAGAAAT
45 ATATAAGTATAAACTAATTTTGGGTATCATCAAAAGTGGATTTTTTAAATATGCATTG
ATAGAATTATTTTTTGATTACATTTTATGTAATTCTAATCCAGCTATAAAATATTTAAT
AGTGTCAATATTACTGTGTTCTCAAACTTTGATGTGCATATGAATTACCTTTGATTTTC
ATTAAAATGCAAATTCTGATTCAATACATCTGGCTTGAGGCAGACATTCTGTCTTCCG
AACAAAGCTCCCAGATGATGCTGATTCTGACCACTAAACACATCAGTTTTAGGGATATT

AACTTGTAATATACAGGTATCCCTCCTGGTAAGCTCTGGTATTATGTCTTAACATTTTT
AAATCTATGGTAATCTTTACAAAATATTTTACTTCCGAACATCATATACCTGGGGATTT
TATTACTCTGGGAATTATGTGTTCTGCCCCATCACTCTCTCTTAATTGGATTTTTTAAAA
TTATATTCATATTGCAGGACTCGGCAGAAAGACCTTCGAGAGAAAGGTAGAAAATAAG
5 AATTTGGCTCTCTGTGTGAGCATGTGTGCGTGTGTGCGAGAGAGAGAGACAGACAGC
CTGCCTAAGAAGAAATGAATGTGAATGCGGCTTGTGGCACAGTTGACAAGGATGATA
AATCAATAATGCAAGCTTACTATCATTTATGAATAGCAATACTGAAGAAATTTAAAC
AAAAGATTGCTGTCTCAATATATCTTATATTTATTATTTACCAAATTATTCTAAGAGT
ATTTCTTCCTGAATACCATGTGAGAAAATTCTTAAGAATTTATTGAGTATGACTGTAT
10 ATTTGAAAAGAGTGTTTTCTTCTGCTTATCTAAGCCAATAAAGGATCTTCATTATTCA
ATTCTAACTTTCTAAGGAAGTCAACCTACAGATCAGAAAGAGGATCTTCAAGGAATA
GCATCAAAGACATAGTCAGGTCTCCCATGCAGTGACTGGCTGACCATGCAGCCATTA
CCACCTTTCTGGAAATATTATGCTGCAAAAATGATACAATACACGAAATATCTCAAA
TTAAAAAATATAACATTTCCCAAATAGGGCACTAAAAACATGATCCCAAATAAAACT
15 AGCTTCAGGGTTTGCAGAATATACTGTTACTCAACACAAAGTTGGACTAAGTCTCAA
AGTTAGCCATTGAGTTGTTGTTAACAGTTTCATTTGAGGGTCTCTCAGAAGCTGGGAAA
CTTTCCATTTTTGCAATTTCTTGTACATTGAAGGAAAGGAAGACACACTTAAGACAGC
ATTACAAAAGTAATTCATGTTTTAAATGTTTAATTCTGGCAGTCGGGCAGGGCTCTCT
GTATAACCTCATTTGGAGATGACAAAAATCTAACTTGAGGGCCTCGAGCCAATAAG
20 TCTTCCTATTTCTTTACTCAAACATTTTCCCGCAATGGTGCTTTCTTTCAACTGTTTTTC
TGGTGTATTCATAAATTCCAGATTCTCTATGGGAAGTAACTTTTATTGATTGATTAA
CCCTTGTATAGCACATATAACATGCAAGGCATTGTTCTAAGAACTTTCCACATATTAA
CTGTGTTAATCACTTAATAATCCTAAGTAGGTTCTATTACAGATATGGAACTGAGGC
ACAGAAAGTTGAAGTATCTTACTCAAGGTCACACAGTTAGTCAGATCCAGAATTTGG
25 GCCCAGGCCATCTGGCTTCGGAATCCATCTTTCACCGATTGCTGCTAGTCTCATATCT
GTTCCATGTTAGAGGTGAGCTCCCATTCGAGAGGTCACACCTGTGATATCACCATTTT
ATTTAAACAGACCAGAGATGGTCTTCTCCTTTCTGATCACAGACTCACCTTGAAGAGA
AAATACTTCCAAATTGATGCCTAGTTTTAATAGCTTACCTGGGGCTTATTCAAATAAT
TGCCATGATTTAGGCTTTGGGAGAAAGAGAGCTATGAGGCCGTGTGGGTTGTAACGT
30 ATGAGACACATGGCGTTCTGCAGGCTCAGCACAGCATCGATTTCTGGTGGGAACACA
CTCTGATGACCAGTTCCAGAAATAACATTGACTTAATCTCCTCAGTCCCATCATGGTT
AGCACATTTCAAATGCCTCCTTAACCTACTTCCATAGGCCAGAGATATTTAGTTTTAA
CATTTTGTGTAATAAAATAAATTTACACATTCACATTTAATATAACTATTAGATGTTA
TTTCAAGATTCTCTTCATATTACCATCAAAGCAGGCAGGCAGGCAGGAGAGAACTGT
35 AGGAAGGTTTTGAATCCCTTGTGAAACATTTTTAATTATCTTTTAAATAAAGGAATCAG
GCCCTGTCATTTGTCAAGGAGACATTTGCAGTAGTAAAGCTTGTGTTTATAATATCCA
TTTTTATTAGTCATGATTAAAGATAACATTTGTGTACATTTGTTCTCACAAAACACTTT
TATATGAGTGTAAGGTTAATTAATGCATTTTCAGCCATCATTTTGGTGGTCATGTGGA
AATATAGCTTCTTTAGGAATTGTACTTAGAGTAGGAGCCACATATTATACTATAAAAC
40 CATAACAAAATATTTTAAGTTTGTCTCACTTGTTGTTGACCTCCAGAGTAAAATAT
TTAATACTCTGGAAAGTTATGGGTTTCAAATTTATTTTATGGCAAGAAATAGATAAT
TACAGTTCTCATAGAGCACATTTAAAATAATTTATTTTTATAGGGCAAAAATATTGCC
TAGGACTGAATGATTTTTTTTTTTTTTACAAAGATTGTAAAGCAACGCCTGCAAGAGTG
CCCATTTAGCAGTTATTCTTCTGGAATAATTGTATTTTGGATGTTGGAGTTCGCACATT
45 AACCATTAGTACAAGTACCCAATATAACAATAGATCATCAGGATAATAAATCTGTCC
ATCTTTTAGTTGTATGTCTTTATATCAGGATAAAGAGAATTGAGTGAAATTTATCTAA
ACCTAGTCCCACAAATACTTTTACAAGAGAGCATGTTAAAGTGTAATTAATTTTAA
TTAGCATTCTACTCTGTCTTTGGAAGTTTTTTTTTCTTATGAAATGCAGCCATAAAGTT
TAACTTCCATTAACAAAGCTGCTCACAGTAAACCTATTATAATAATAGTTTCCCAGTT

TGGGCTTCCTAGTGAGGAGCAACCTAACTCACACGAAACAACCCCAACTTATAATAT
ATTGACTGTTACAAAACCTGAGACCAGAAAATCCCATCAAGATGGTACTGTTATCATTT
CCAGACTCTCGGGAAGAACATTAATCATCTCAGGCACTTTTAGGATAGACTTATTGCA
GCCTCCCTGGGAACTCTGCTTCAGAACATAATTATTTTATTAATGCAGAGTTACTTTT
5 TATTTCCAACAAAAATATCTATTGTTATTATTTAAGTCTTACAGCTTTATCTGAGAAAT
TCCAATTAGCACCCCTTCTCATAATAAATATTCAAACACATGAAAAATTACCAAAGTTG
TTCTAGTCTTTTAATGACATATTACATGATCCTGCCTCTTGTCACTTTAAAAAATTATC
TTTTTATTATATTTCTGATGATTTTTTTTCTTATATAGTTTTTTTAAAAGGAGCAGGCAAG
CATAGAAGACTAAAAAATGTTCAAAAGAAAAATTAAATCGCATGATCTATCTATATG
10 GGACCTTGTCATTTTTAGAAAACATTCACCTGCTTCATCCTTTTGAATCTTCATATAAT
CCCTCTGAGATGGGCATACTATACAAGTTGTCTTATTTAAAGATTGGTAAATTTAAGC
TCAAATAATTTATTCAGTGGCAAGCCTCAGAGGCAGACTCGGAACACAGGTCTAATA
TATATTATATATATATTATAACATATAATATATATATTACATATAATAAAGTTGTGTA
TATTATTTACCTATCAAAATATTTATATGTAATATATAAATATGTTATATATCATGTAT
15 GTGCCTATTTTCATACATATATACACATTCATGCAAAATAAGGTTTAGCACTCCCTCCA
CTGTCCTGTAATAAAACATGCACAGTGAGAATAGTCATACACGAGGCATATTTGTCTT
CAGTTTAAAGTCATTGATAGTCAGTGTCACTAACTAAAGTAAAAATAGATTGGAGCAC
CAACTTTGTTCTGAAGCCTGTGCCAGGTATTATGAGAACAAAAATAAAAAATGTTCCCTC
ACCCTTGTTGGATTAGTCTTTTGCAGAAAAAAGATCCTGTACATGTCAGAAAGTTC
20 AATAGTAATAATGGTAATTTATAACTATAAATGGAAGTCACCATCTCACAATTTCAAC
ATCTTAACAATTTTGTAACTGCCCTACAATATTACAAGATAGTACATAATGATACA
CTAGTAACATCAACTAGGAAGTACCAAGATCCACCAAAAGGCTGAAAAATTTAAATA
TTAATGAGTCCATCAACCAATCTGGCCAGAGAATTCTTTAATTAATAATGCTTCCCAA
ATTTTACTGAGAATCAGCAGCGTTTGAGGAGCTAGCCTCCACCCCCAGAGGTCTCAC
25 TCTATTAGGTCTGAAGCAGGTCCCATGGATTTGCATTTCTAACAAGCTCCAGGTGGT
GCTGATGAGGCTGATTCAGAACCACACTTGGAGTAGACCTAAACAGCAGTGACCTG
TAGGGTCCCCAAGCAGCAGGCCAGGACAGCATGTGAGTTACGTCTCTGTGGAGCTC
TGCAACAAGGCGTCAAGAGGTCAGAGTCTAAGTCCCCATCAGCTCTGCCCTTCTCCA
CCAGTGCTGCTGGTGCTGCATGGAAGGAAGAGCCCAGAAGGGATTCTGAGTTTCAGT
30 CTTTACTCTTGCTGACGCACCTTGGTCAGGTCAATTTTCCTGTTTGTTCCTCTAATTCA
GCATCTGTAAAAATAGCCATGTGAACTGCCTTGTCCATATCAGAGGGTCTTTTTTCAGAC
TCAAGGAAAAAACGTGAAAGTGATTAGTGTCTGTCAAGTAGTATATAAATGCAAGA
AGTTGAGTTTTTAAATTGTCATTAGATATAAATACCCATGTGCATGCATTTAGAATGA
GTAAAGAGGGGAACAAGGAGCGCAATCAAAAACCTGCGTCATTTGCTTTTTGAAAAATA
35 CTTTCTATGTAATGAAAAGTGAAATAAAATGTTAATTGAGTCCCTCTGACAACAGCAT
CAGACGTTTTTGAGTTCTTGTGATTAGAACCCACCTGGCCAGCCCTTCTTCCTCCTAA
AGAAGAGCCTTCTTCTTCTTAAATGAAGGTTGGCTCAGAAGAAGCAATTAACCTCATTC
AACGTTTTGTACAGTCAATCCACATCCAACCTTTTCCCCAACTCAATCTGCTTTAAGG
GAAGGATGGTAAGTGGTGGCCCAAGATGGCAACCATCAAGCTTAGAGAATCTCTAGA
40 AGCAGGGGTGTCCCAGCAAGTAGACACTGAAAATATGAGAGGGGCTGATAAGCCAG
AGATAAAACCTCAGTACTTACTTTGCTTCTAGTCCATGTCTACCCCTTTCTTGGCACCAC
CTTGACACTACCCTCTGAGTCCACCTTCCTGAGATGGTACAACTCTGCTTAGACAAA
GCAGCCCATGTCCAAAGGTGTTAGGGGCTCAGTTTAAAGCTGCCTTCAAAAGTTAAAA
CAGAAGTGTAAGTTCTGTGCAATTAAAAATAATCAGCTTGTCTTGGAACCTCAAACG
45 AATGTAAATCCTATGAAAATTAATAAAGCAGTACCACAAGTTACCCCAAAAGTCCTT
AGGTCAGTAACTGTTCTGTTACAGGTAAGAGAGAGCATGGATTAGAGGTGGGCGTG
GGTATCCAGTGGACATGGTTTTGAACCATGCTCCACTACTACTACTATCTGAGAATT
CTTAAATTTATTAATCATTTCTATATTATAATTTTCTCAGTTATGAAATGGGAAAACA
ATACCTAAATCACATGGTTGTAAAGTAAGCAATTGATTGTAAAGCATTGTTGTCATCAA

AAATATTAATCCCCTTCCCTGATTCCCTAGATAAATGATGAAAATACTAAATAAAAAT
AATAAAAATTTAAAGTGAACATCTCAATTCTTATACTTTGTTAATTTCTACATGTATT
ACAAATCTACTAGAAATTACTTGGAATTGAGGAAATGATTACTGCTTAATAATTCTTT
GTGGTAGAGGGAGAGTTGGTATCATATTTATGAGACAGCAGCCAATATAGTATATCT
5 CAAAGGAAAAAATCCATTCTACATAATGCCAGAATTTAATAGTTAAGCATTTTATCTA
GGTCACAGCACAATAAGCAAGATGGATAATTTAAAATAAAAAGTATATTTCTCTTGCAT
ATATTTCTCATTTTCATGTTTCCCTATCATATTTTATATCTTACCTTACTTCAAATACATA
TATACCTTCAATAAAACTGAGCCTTCTTGCTTACCCAGGAAGTTTCATCATTTCAGTAG
AAATAAAAGATGACTTTAGAAATATTTAAAATACAAAAATCTACACTGAGGTCTTTTG
10 AATGCAGGAAAAAGAATTATATCACACACACACGTACACGCACGCATGCATACACAC
ACACAGAACCTCTCGTTCTTTCTTAACATCTTATCAATCCATCAGTTTCACTCCCACTC
CGTATCACCTGACTGTGCACAATATCTCATTGCCACCTCCCAGTCTTCTCCCTGCCTG
GCACCCTCCTGCTCTCCTGCTTCCACTTTAAACACCCTTCCTTCAGCTAGGTCTTTTCT
TTCAGGGATCCTCCCGTTGCTTTCTTATCTGGATCAATTTAGCCTTCCTCTTCTCCACC
15 CATTAGTGGATAAGCACGACAAAGACACTAGAGTCAAATAATACAAACAGAATATA
CCTTAGATGAGTATGGTGATGAAAAGGATATGGATACTTAGAGTTTAGCACTATTCTC
TCAGCCACTCAGGAAAGCAACGCCTTTACAATCAATAGTGTTTCAGGTACCAATCAA
TAATCTGTTATTGCTATTTTTTAAAATCTATAAGGTATCAGTAAAATGTAATTACTAGA
GCAACAAAGATATCTTGTGAAATCAAATTAGTATTCATCCAGCAACTGAGTACAAAG
20 GTTTAAGGGAGGATAACTACCAATACCAAAACATTTTAAAGCATTTTGTGTTTGCCTCCT
AAATATCAAATCATGTAAATGTGTGGTACATAAATTAGGAATTATTTTATGACATA
GCTGCAGACATATTAAGAGAAATATGTGCTTATATTTACAAGTATAGTACAGTTCTTT
TTCATATTAGATACTGTTGATGATAATCTGCATATAAAAAATGCTCAATATTTTTTTCAC
ATTTATAAGCCATAAAAATACAGCTAATAAAAATGTGTTTCTACTTTCTCATAAACATGG
25 AATAGTGACAAACAAGGAGCTTTATATGAAAGCACCATTACAATTTAAACTCTCACA
AGGTCATAATATATTGCACTAAGCAGGAGAGTTTCAGCTTATTTAAAAAAAAAAAAATAA
ACTCTAATGAGGTTCTGGAATGCAGAGCCAAAGCATAAAGATGGAAATAAAAAGAAT
TGCATGTCTTCTGAACTGACTTGGTTGATGATTTTTTTTAAAAAAGGTTTTGTGTCTTCT
GACTTGGTTGATGATTTTTTTTAAAAAAACGTTTTTGTGGTAGAACAAATAAGGTAAATG
30 AAATTCAGTATTTAGGATGAAAAGTTTTTCTAATTTTCAGGAACAACATTGAAGAAAT
ATTGAACTAAGCAGCTTTGAAAGAATCAGATTCCATTTGTTGAAATTTTTCTGAGAAT
GAATTTTTTTAAGACAGTGTACACAGTTGCAGTGTGTATTGGTTATGGATTGTGGCAA
GCTATATTACAACCTTACCCAAGAAATAAAGGAGGCTGGGCGTGGTGGCTCACACCTGT
AATCCCAGCACTTTGGGTGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGA
35 CCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAGTACAAAAAATTAGCCG
GGTGTGGTGGCGGGTGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATG
GCGTGAATCCGGGAGGGGGAGTTTGCAGTGAGCCGAGATTGTACCACTGCACTCCAG
CCTGGGCGACAGAGCGAGACTCCGTCTCAAAAAAAAAAAAAAAAAAAAAAAAAAAGA
AAGAAAGAAAGAAGGAAAAAAGTCACTTGAAAAGAATACTGGACTTTGTGTCCAGC
40 TTGCATAGCTGAAAAGAATAAAAACCTGTCCACTTAACTCATTGCAAAAAGAAGAT
GTCACCTCTACAAATAGCAAAGAGTCATGAAATTATTCTATCCAGAAAAGTATACAT
TTCATCCCTTTGGATAAATTTTAGAAGTGAACATATGAATACATACGGTGAGGATAGCC
AGCTAAGAAGTCAAGAAGGATTTCTCAAATTTGCTGCTCAGAAAGATCATACTCTCC
ACAAAACAAATAATAGCAGGCTTTCCAAGTCAACCTTGAATCCAGCTTTCCTTTATCT
45 TTCCTTCTTGTGAACTTTCCTAGTTTACTATCTAACAATGAATTTGACGATAGCCAC
ATACCATCTTATAGCAATATTTGTTATCATATCCCTTGTTATTTATCATTACCTGCTC
TGCTTGAGCCAGCTACAAGTCACATGTCCACGCACTTTTTCTGTTTGATTTTTTACA
GCACTTTGAGACATGTCTCATTATTCCTACTTGACAGGAAAGAAGCCATGGAAAGTT
GAGTGAAGTGTCTCCTGATCACAAATGCTGGCCAAGGAAGAGTCGAGTTTCAAATCTA

ATGATCTTTCCACTGCACTCTAGATTCCTCATTTTGAACATTTTTTTTATTTTTTGCCT
ATAGACTTTTTTCCACATTTTGAACGTTTTTTTATTTTTTGCCTATAGACTTTTCTCTT
ATACCCAATATATTGATGACTTCTTTTAGGCTAGAACTTGTTTCACTTACTTTCCCT
TTCTTCAGATTGCTGCAATATTGGCCAACATGTATTGGGTACTTACTGAGTCAAGTAC
5 TGTGATTGTGCCAAGTATCTTATAGGAGGATTATCATCCTCATTTTTTACAGGTGAGAA
AGGAAAGGAGGTAAAGTCACACACAGCCAACAAAAATGGTAGCACCAGGATTTGAA
ACAAATCAGTCTGACCCAAGTTGACTTTTGTTAACCAGTGTATGCACAGTCTTCTTAGA
CATAGTAAGAGCTCTAATTGTGTTTGGTGATTTGATTATTATGACAAAGTAAGTAAGG
GAAGCAGGGAGAATTATAAGAAATAAGGCTCCACAACACTTGGCTATAGCAAAGCC
10 CCTTAAACTTCAAAAGGTCACCCAAAGAATAAAGATCAGGCTGGGAGCAGTGGCTC
ACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGTGGGTGGATCACCTGAGTTCAGG
AGTTCGAGACCAGCCTGGACAACATGGTGAAACCTGTCTCTACTAAAAATACAAAA
ATTAGCTGGATGTGGTGGTTGCCGCCTGTAATCCCAGCTACTTGGGAGGCTGAGGCA
GGGAGAATCGCTTGAACCCAGGAGGTGGAGGTTGCAGTGAGCCGAGATCATGCCACT
15 GCACTCCAGCCTGGGCAACAAGAGCAAAAAACTCTGACTCAAAAAAATAAATAAAT
CAATCAATAAAATAAAGATCAATTTGGAGAAATTAATGCTTATTAATAAGCAATGTC
TTGCACAGCACTTCAGTTTCTCAATACATTACCTAACTCAATCCTTACAACAACACCC
TATCCCCATTTTGTGGATAAATAAACTCATGTTTCAAGAGGTTGAATAAATTATCTAAG
GTTAATAGTTCCTGACCTAGAGCTCAAATCTTCAGTTTCTATCATATTCTTGCCCTTAC
20 CCTGGGGTAGCTAACATTCACCTACTAGTATTGGAGCTAAAATAAGGGAGAGAACAT
ATAAATGAATACAAAGGAGACATTCACCTGCCTTCTCTTTCTCCTTACATAGAGAAGG
TTGATTATCTGCTATTGTGAAGTTTGCCTTTTGAAGGATAGAAATGAGAAGACTTTCT
TAAATTTTGCCTCTACGCCAAGAAATTAGAGTGGTACCACCAGTAGTTCCATTTTCAA
ACTATCACTGTAGCTAAAGCTATGTGGTAAGGGCCAAGGAAAAGAAGTATTCTTGCA
25 CTTCAAAATGCACTGAAATACCAGTCAGTAGCATAATATAAAGGAATTTAGTGGAGA
GAAGAGTTGACCTCAATCTGGCTCCAACATCTCGGCTCTTAACCCCTACCCTACACTT
GTTCTTCATGGGGAAGCTAATTGGGCCACTGGAAGATTCAGCAGCTACCATTTGCAG
CTGAGGGACAGCCCCTCCCTGCTTAGCAACCAATGGATATGCATTTATGGAACACCT
GCTAACTGCGACACACACTCCTATGTATGAGGGAAAATACAAAAAATGTTAAAGGAG
30 ATGCCTTCCCTTGCCCTCAGGAACTTAAGTATAGTTGCAAAGAAATGATTAGCAGC
AAACGAAACCATGGAGAAGTAAGGGCTAAGGTCTGTGAAACAAGCCTAGAAAATAA
CCTTGTCCTTGAAAAACACAAAAAGAAAGAAAGAAAGAAAGAAACTCCAAGGCC
TTGTGAAGGAAACCATTAAGTTTGCTTCACTTCTGTGTTTAGGAAGACACAAACCCAG
TCTTAATGAACCTCAAGGCCACAACACTACTGGAGACATTTAGGAATTGTCACCACATTC
35 TAATGTATATATCCTCTGTTTGGCCCTTCTATTAATATTTTGTAAAATTTTTGAAGAT
ATGAGCAATGTTTAAAACCATGAATCCCCCTTTTTTTATAAGTAATATTTAGGCTGAA
TAAACAAGAGAAAATAGGACATAAAGGGGAGCCAACGTGTGCCTTCATTTATAATGT
ATTCCCAAGTTGTGAGTTTGGTTTATCAGCAATTTATCATGCCAAATTCCAAGTCATA
TTTATCTATGCAGATCAAACACTTGATTCTATTTTTGCCTTAATTTTTTTATTGGGTAT
40 GTTTATGACCAAGTCATATGGTATTTTCTGTGACAGATAAAATGCACAGGTTATTCCA
ATCTGGCTCAGCCAGTCATAGCAACATGTAGTCCTTCTCATGTCTTAAGAATGAGTAT
CAAGAATTCAAAGGGAGTTCCAGATGGCATCCAAAAAGCTTACAGTTTATGCATCAC
TTATTCTAACAGTAGAAAAAGAATATTTGAAGCCAAAAATAGACCTTGCATGTAGCA
TGTGGAAGAGTAGAAATTGCCCTGATAGTTAAACAATTTGAAATTCAAGACATTAAT
45 TTCTTTATGAAGCATTGTGTCACATCATAGGTAATATTTTATGCCTATCATATATATACT
TATTATGAAATACAAAGAAATTATTCATTCTATCTAAGACTTTGTATCCTTTACCAAT
ATCTCTCCATTCTCCACCTCCACCCTAGCCCCTGGAAACCACCCTTCTACTCTCTGCT
TCTATGAGTTCTTTTTTAGTGAGATCATGCAGTATTTGTCTTTCTGTTCTGCTTATTT
CACTTGACATAATGTCCTTCAGGCTTATCCATGTTGTCACAAATGACAGAATTTCTT

CTTAAGGCTGAATAGTATTCCATTGTGTGTATGTAGCACATTTTCTTTATTAATTCATT
TGTTGATGGATACTCATATTGATTCCATATCTTGGGTCTTGTGAATAATGATGCAGTG
AACATAGGAGTGCAGATATCTTTTTGACATACTGATTCCACTTTGATGGGATATATAC
CCAGTAGTGGGACTGCTGGATCATCTAGTAGTTTTATTTTTTTTTATTTTTTATTTTTT
5 TATTTTGAGACAGAGCCTTGCTATGTCGCCCAGGCTGGAGTACAGTGGTGCCATCTAG
GCTCACTGCAATCTCTGCCTCCTGGGTTCAAGCAATTTTCCTGCCTCAGCCTCCTGAG
TAGCTGGGATTACAGGCACGCACCACCATGCCCGGCTAATTTTTGTATGTTTAGTAGA
GACGGGGTTTCACCATGTCTCGAACTCCTGTCTTCAAGTGATCCGTCCACCTCAGACT
CCCAAAGTGCTGCGATTACAGGTGTGAGCCACCACGCCTGGCCTAGTAGTTCTGTTTT
10 TAATTTTTTGAGGAGCCTCCATACTGCTTTCCATAATGGCTCTAGGAATTTACATTCC
ACCAGCAGTGCACAAGGATTGCTTTTCTCCACATTCTGGCTAACCAGTCTCCTGTCTT
TTTGAGAACAGACATTTCAACACGTGTGAGATAATATCTCATTGTGGTTTTGATTTGC
ATTTCCCTGATGATTAGTGATCTTGTGCCTTTTTTTCATATAACTGCTGGACATTAATAT
GCCTTCCTTTGAGAACTGTGTATACAGGAGAAAATAATCACTTCTCAGAGGAGCTTTC
15 ATTTCAAATATCCGGGAAAAAAATAGAAAAAATGGAAAATTTATCCTAGAGTAAGT
TGTCTTTTATATTTTGACCCTGTTTGTGACATAAACTGGATGATACAAAACCTGGAATG
CAAAGGCTTTAGGAGGATTACTTACTTACTTGTATATTGCTTTAGGTTGTTTGCAGAA
AATTATACTAATTGAAGTTCAGGCTATGATGTGATAAAATCTATGTCAGGAGATGAG
TCTACATGCAAAGTTTGAGGAAGTGACATTTGAGTTTCAAACAAAAAAGCAATTTT
20 CAATGTCATATCTAGGTTAACCCAAAAGATTTCTTTCACCCTATTTAGCTGCCTCTAA
GATGGATGCTGAGGATAATTACACTGTAGAACAATAGGACGATGCTTCACACTCACC
TCACAGGCTCTGTTATTCCACATACTGCCAGAGATACTCCAAAATAAAATCACTGCA
ACATCAGGCAGTTATAAACCTCAACGGTATTATTTTCTATTTATATACAGTATATTTT
ATATTTTACAAGTATAAAATAGAATATATTTATTCTATTCTCTTTGACACAAAGTGAC
25 CATAAGACATATTACTTAAGTATGACTAGCAAAGTCATGGGGCTTGTCAATTCAGGAG
GAAACTCTTAACCTAAGTGTTCAGTTTTTGTTCACTGCACCATTTACATAAGCCAACT
AATGCTTCACACTGTGCAAAACAATGCACAGTGTTGTGAATGAATGGCTAAAATAAA
ACTCTAATGAGTGGGGTTTGAAAAATGCAACTTTAGAAAACTGTTGAGAAAATGTTG
CACACTGCGCATTTTACAAAATTTTCGTTGAAGGACACTGGATATTCTTTTTTAGGATTA
30 TGGAGGGAAGCAAAATTTTGGCTCCTACATGCAGTTTTTGTGGCCTTTGCCTGAAATA
GTCATCTCCCATTAATTATTTAGATATCATTCAATTCCTAAGACAACATTTAGGGAGA
CTGCCTTAAGTACAATTTGTACACTACCCAGATAAGAATTCTTTTTTGGTGAAACATCG
ATAAATATTACTTGGCAGTAACACCAAGTTAAATATTTGTTTCACAGTCGACGTAA
TAATATTATAGATAAAGTGAATTTTATAAGACATACTCAGATCTAAAACAGCAATA
35 TGGAGCTCTTCAAATCCATTGAACTTCATACCAGCCTACGGAAGTAGAGGTTTTTAT
GCAAACCTCTTCAAGAAATATGCTCTGAACTTTTAATTCCTTAGATTGATAGAGGAATT
AAATCATGATATACTAATAGGTTTGTGGTACAAATTGCTGCTGCTTAATCTGACTCT
GTGTCTTCCAGTGTTCTATATGAATTAGATATTCCATTATCTAAAGACAATCAACCC
CATCCACGGTGATAGCTCTAGGACTCCCTTTGAGTTCATTAATCTGTATTCTCAGT
40 CTCCAAACTTCTGGTTAATTCAAACAGAAAAGTCAACTGGCCCATGAACTAAAATAA
AGTCATCTGAATTTTTTTTTTTATTTTGCAGTGTGATAAAAGTCTCGCACTTTTTATTTT
TGAAAGTTTCTGCTTTCCTGAGAGCATAATAGGCTATCCACCCTTATGCAATCTTAC
ATACAAAGTCATAGTCAGGCTAAATTCAAAAACACATGTGAGATAGAAGTCAACGTT
TATTTTCTGGAGAAAAGCCACACATTACAACAAAGTGAACAATGAAGCTGGCATCCT
45 TATCACTGGTGACCAAAACATTTGTGACTCTGGACATTGGCCCCACAAATGCGATAA
ACATTCTGCATAGGAAGTGAGTTTTGCTAATTAATAAATGGATCCAAAATACTTTCTAC
TCTTCAGCCAAGAATTAATAAAGTAATAGGGAGGAATTGAAATCACTTGGGTGCTACA
TTGAGCCATTCTGGAGAAGCAATTCAGAGAATGTCATGGCAGCCTCAAATTGCTGCT
CAGGAGCATCCCAGCTTAGAAGATTGCAGGAAAGGAAGAGCAAAGTCATTCTTACAT

GAGAACTGTCCTTAACCAGATGAATAGACTCTCCATTTTTTTACCCTGGCTTTGTCTCA
TTTAAGTCCCAACCAATCTAGCTATCATTTTTAGGTTTTACTACCTGCTAGTATTTAGGA
GCTTAGGGGGATAAAAAAATCCCTCAATACTCAGAATTAGACTTGGTGATAAAAAATC
TTGACACATAAACAGAATAAAGCGCTTTCATTACTCCTCTAAACCACAGTGTCAATTTG
5 GTCTCTATCAAGGACTGTAAGAATTTCTTTCATCAGGGGAAAGAAAAAAGGACAAG
AGCCTGCAAGATGTAGCGGAACCTCTCATTAAACACAGCAGGAGCTTTAACTGGAATC
CAGAGTAAGGTGAGGTACCAGGTTACAACAATTTACTGCTTTTATTACAATTTTGATC
ACAAGGACTGATTCATGTCATCTAGTTTCTTTTCCTTGTCACTATCACTGGTGCTAAG
AATACATCAAATTGAAATTTAAGAGCCTCATATGTTTCTGTATAACCCAGTGATGGGT
10 TGTACTGCTTTGACCTTCTTAAATGTCCCTTTATTTTCATTTGATATCCATTCCCATAGA
AAAACCTATAATGCTTTGGTTGGTCAAAATATTAATCTTTCAAACCTCCCTGGCTTAG
AAAACCAAATTTTTGTAGAGAGAGATGGGTAGAATCTAATTTTATTCTAAAGCAATT
AGCATTACATCATCACAGCAGAAATATCTAGAATATTACCTCATGTCAGTGATCTTCT
GATATGTTAAAAAGGGTATTTTAAATCTGAGTTATTTCTTTTTCTTTTTAAAGTTACA
15 TCATTAATTACATACTCATCAACCAAAATATTTTATGCTCCAAATTTGAACCGATATA
GTATGTAAGAAGTGTTCAAAATGAAATTATTTTGGTCTATTTTGTCTTTGAAGAAGAT
CACAGGGATGGACCTCCCAAAAGGATTTTTAAATGGGATTACATATCTGACTTTTAA
AAAAAATTATCTGACCTTGAGTTATAGTGCCCCAAAGTAAGCAAAGTTCCAAACACA
CAGTATCATCAGAATTGAGTTAAAATTATCACCAGGGGCTTAATTTCTGAAATTAAA
20 AAGGAAATGTTATTTCTTATGAAAAGAAAAGGAACCAAAATGAACTTCAAGGTAG
CTGATTTTCTGTCTATGTTAAGACTTAGGTAATGGGAGAAAGGGAAAAGGAAGGACAG
AATTAGGAGAGGAGCAGTGTTTAAACAATTGCGGGTGCAAGACTCAAGTTTTTTAGAA
TCCATTAGCAGAGAACCCTATTTCTCCCATTAAGTGTCTGCTTTTAAATCCTGGCAC
CAGCTCTGAGGACTGCAGGGTCCATAGCTAGTGCCCCACTCTACCCAGTTTAAAGAC
25 ACCACTGCCTGGAAATGACAGGGGTTTTTTTTCTTAAGGAAAGAGGTGCTTTCTGCCAC
GTATATATAAATTGGTAAGCTTCAAATAAAGTGCTTTTGTCTTTCTGTCTATCAGAA
ACTGTGCAAATCGAATTGCTGTAAAACCAAGGGCAAGAGACATCAATCCTGCATTCT
ATAGCATCTGATTTTATCCTTTATCCCCAGGCACATTTCAAAGGAAAAAAATGAGGT
TGCATTTAAATTGAGTATTTGGGACTTGCCAGGAAAACCTCCCGCTAGACTAATATGA
30 TTGCAGGGAAAACAAGAGAAAGGAAAAGTGGAGAGGGAGTGTGCTAACAGATCCTG
GGCCTCGTCAGCAGAGCCGTCCTGAGCACAAGGCCATGGTCAGACATCTGGTCCCGC
GAATGACGTTTTCTTTATGGTCATTAAGAACACCAGTGTGTGCGGGACACAAACAAGT
ATTCCTTTCAGGGATTATGACACATTTTCTCCCAAAGTAGTATATTAATGACATTTCC
AGAGCATTCTTTACTATCTTTTATATGTGATCAGGAAGACTAATACATATCACTACTT
35 CTTTTACACACAGCATTAGCCAAAATAAAGTGTCAAATACAATTTTGCCTAGGATG
AATAAACAGAAGAAATTTTTATGATACTGCACTATCAATTCCAAATTAAATAACAAC
AAAATGATAAGTGTTAAAATTCATATTAATGATTGTTCCACACAAGCCGGAAAAAA
TCTTTCTAAGAAGTCTTTTCATGAGTTAATCCCATCTTTCAAAGTGTTCAAGTGGCTCCG
AATTCAGTTACTGTTTCTATCAGTTCTTCTTTTCAATTAAGTCTCTTCCCTTTTTTTCTC
40 TTTGCACTATTTCCCTTAGCCGGGTACATAATCTGCTGTGCTTTATTCATTTGTGTCTT
AAGTTTGTTCCTGATGACATACCTTTCCAGCAACGCCATCTGGGGAGTTTGGGCAAC
TGTACCACGTTAGGAGGAAACCCTTCTTCACAGGAGAGTGTGCCTTTGCTGCAGGGA
AGGAATTAGGATTTGCTTGGACTGTGGTTGCAGCTGGCTTTTAAGGATCTCCTTAGAA
TGCAAGCAACTCATCAATGAGAATCTCTGCAATGGTTGTCACTGGGTAGAGTCATGC
45 TATGTGGGGTCATAGCCTTTGAAACAAATAACAGTAAAGATAAAAAATGCTATTAAAG
GAATCACCAACCCACAGAGGTTAACTGGGTTTTGTCCCCAGACCACCTCGAACAAGAA
AGAACATTTTTATCAGTCATTTTCTTAGTTTTAGCTGATAAAACAAAGTACCATAGAC
TAGGTGGCTTATAAACAACAGAAATTTATTTTTTACAGCTTTGGAAACTGGAAGTCTG
AGATCAGGCCGCCAGAATGATCAGATTCTAGTTAGGGCCTACTTTGCTTTTGCAGACT

GCCAACTTCTAGCTGCATTTTTCATGTGGCAAAAGGAGATTGAGCTAGCTCTCTGGTCT
CTTCTTATAAGGACACTAATCCCATTCATGAAGGCTTCACCTTCATCATCTAATTACT
CTCCAAAGACCCACCTCCAAATACTATCACATTGGGAATTAGATTTCAAATACAAA
TTTTGCGGGGACACAAATATTCAGTCCATAATAGTAATGATTACTCATTATACATAGG
5 GCTCTAAATGTGCTAGCTTCTGATAGTTTTTACACTCACTTCTCTTTATTAGCTTGTC
AGCATAATTAGGGCAGTGGCCTTACTGAAAATTATTGAATTTAGTTTCCTAAGGACA
GATATTGAGGAGTTTTTTCTTCACTAAAAATTACGTTCCGATACAGCTTTCATCTGTT
ACTACTTTGTGAGATGGAAAATCTTTTATTTTATTTTATGTTTGGATTGACCCTTCTT
AATAAAGTCGGCATGTAATATGCTTCATGTGTTTCTAATATGTGCTTAATTTTGCAA
10 ATGTTTTGCATACCAGAATGCATTTCTCTTCCAAAAAAGGTACCAGCCTACAAAACCT
TGCTGTTACTGTTTTCAATTAGTTCATGGAATTAAATGTATTAAATGTTTTATGCTCTG
GCAGAAATTATGATTCTCACTTAACCTCCATATAAATCTGGATCTGCCTGGGCCTTTAT
AAGTGACACAATTTTCATTAACCTGAATAAACAAATGATACAAAGAAATTTGGTTTAGC
CTTCTAAAATTCCAAAGGCGTTCAACAAAATATCTCAGAATGGATGTTCCAGGACTTT
15 TATGGCACAGGACAACATGTATTGCTTATTTTAAGAAAATAAGCTAAATAGTGAGGG
GATTCTTTTAGCAGATCCTCAGGATGTGTTAGGTTGAATCATAGGCAAATGATATTTG
ATCATTGCACCTGTAAACACATTGAACCTCATCCTAAAATTGTAGAGCTAGAAGAAA
GCCTTCTGGCAGTTTTTAAATAGATTGATTTACTGCAATTTATCCAGAAGCTTCACCG
TTGTCACTGGCTACATGTGACTTTGGCCTCTGTGGGGCTATATCCTCATTGTAAAATT
20 GGTGGTGAGGTAGGTGGACAGTTGACTAAATAATCTCTTAGAATAATTCTAGTATCT
GTGGATCTAAAGCATCCAGGGGTGAATATGTTTCTTTCTGGCCAAGAAAAGATGCA
CCTGTCAATAATGCCCAAACCTCATCTTCTGAGAATCCTCTTTCCCAAGATACCCACTC
TCCCTTGGGTTATATTATAGTAATGATCAGAAGCCCCTGCCAAGAAGAACTGTAA
CCTGGGAGGTCTATATTTTATTTACAGCCATCTGTTTATACTTTCTCACAAGTTAGTG
25 CACAGTATACCCATCATTTTCTACCATTTTCCTTAATTTATTAATTTTACTAATTGCAT
AATTAACAAAAGTAAGAAGATTTTACCTCCTTATCCCCATCTGGTAGTTTGCAGATAC
TTGGCCTGATGACAACTGACAGTGATGAGATACTCACCAAGTTTACCAGGGCAGGAG
GCTTCCTAGAGAAAAAATGAGAAAAATGAAATGGGGAAGGGGAGTGAAGGATTGAGG
AGGTGACAATCTGGACTCTTGCAACTGCATGGCAAGGTTGGCACACAAGCTGGGTTG
30 CAACGGAGGGAAGGAGATCCTTATCAGATGTAATCAGAGCTCAGATCGAGGGCTTTG
GTGTGTGTAGAAAGAGGGAGAGACAAAGAACTTAAAACAGAGCTGCCATTTGACCTT
GCAATCCCATTACTTGGTGTATACCCAAAGGAGAATAAATCATTCTATTA AAAAAGAC
ACATGTGCTTGTATGTTTCATGGCAGCACTATTACAAATAGCTAAGACATGGAATCAA
ACTAGGTGTCCATCTATGGCAGATTGGATAAAGAAAATGGGGTAAATATAAAGCATG
35 CAATACAACATGGCCATAAGAAAAAATGAAATCATGTCCTTTGCTGCAACATGGATG
CAGTTGGGACCCATAATCCTAAGTGAATTAACACAGGAACAGAAAACCAAATACAG
CATGTTCTCACTTATAAGTGGGAGCTAAACACTGAGCACACATGGACATAAATATGA
GAACAATAAACACTGTGGACTACTAGAGGGGGGAAGGAGAGAGGTTTGTAAAATA
CCTATCAGGTGCTATGCTCAATACCTGGGTGATGGGATTTACACCCCAAACATCAGC
40 ATCATTTAATATTCCCATGTAAAAAGACTGCACATATACCCCTTGTATCTAAAATAAA
ACTTGAAATTAAAAAAGAAAGAAAGAAAGAGGCTGGAAATAGAGGCTCACAC
CTGTAATCCCAGCACTTTGGGTGGCCAAGGTGGGTGGATTGCTTGAGCCCGGGAATT
CAAGACCAGCCTGAGAAACCTGGTGAACTCTGTCTGTACAAAAAATACAAAAATTA
TCCAGGCATGGTGGAGCGCACCTGTAGTCCCAGCTAATGGGGAGGCTGAGGGGGGA
45 ACATCACTTGAGCCCAGGAGGTGGAGGTTGCAGTGAGCTGGGATCACACCACTGCAC
TACAGCCTGGGTAACAGAGCAACTCTGTCTCAAAGAGAGAGAGGAAAGAAAAAAGA
AAAGATGGACAGATAAGAAAATGCACTTGGAGATTAAGAGAAAGCAGCAACATAGG
ACCCTGGATAATGTGTTTGCTTAATAACTATCCTGATGAGTTATCTGACTATTCCCAA
ATGAGTACGTGGCAATTCAGGCTGAACCATCAGAGTAGCCCTCCGGAATCTTACTTA

TGTACAATAGACCTGCATGCACATTTACTAGAATGAGCCTCTCTCTCTGGTAATCATG
TCTGCTTCCACTAATTCCATCTGTTTCCTCTCTCTCCCTCCTATCCTGCTAGATCTTAAT
TCCTTCGACCTTCCTTTGTTTTCTAACTCCCTTTCTTTCTCTTGTTATTTAACCTGCTA
TACTATGCAATTGATCTCCTCTGACTAAGGAACATGCACTTCAGAATTCTGTTGACA
5 TCTTGCATTCCCTTTATATTTAGTGAAAGAATGCAAAGGAGTCTACCTGGCAATATTCA
CTCTGCAGGAGGCAATAATTATTATTCAAATTAAGGAAGCAGTAAAGAGAAATTCA
GAAAAAATGAAATATACTAATCTTCAGCTTTTCATTTTCAGCCTACAAGGAAAAAATG
AAGGAGCTGTCCATGCTGTCACTGATCTGCTCTTGCTTTTACCCGGAACCTCGCAACA
TCAACATCTATACTTACGATGGTGAGTAACCTAGGATAGACATAACCCCTGCTAGCTA
10 GATCATTGGAAGGTTGACATATATTTGTTTCTTACAGCTCCTGATATAATTACATC
AATATTTTGTAGCTCTCACTATTGACTTGCCGTGTCTAGCTATTATGTCCAATTGATTA
CCTATTGCTGAAAACAGTTTGAATTTGGTGCTAATAACAACACATCAATGTCTGTAA
GAAATGTGGATGGATTCTTATTAACAGCCACATCCAGCATATCAACATCCACAATAT
GTCTAAGGTCTTTCTTTGCAAATAATTTAATAGGCTAAGCCATAATTGGAGTAGATCA
15 TAATTTGTAAGAAAATGCTTTATACTTAGAAAACTCAAGAGAAAAGAAATCAACAACCA
TAATTGTTTTTGCTTTATTGTAGTCTTTATAAAGTTTCTATACTTTGTATATACATGTC
AACCAGCTAATGATAATAAATTGGCTCAATAAATAAACTGACTTACGACTGAGG
CCCTAGATAAAGAGGGTCTGAAAAGAAAAGCCTAAAGAATTAGCATGGCAATTAAC
ATGATTGAGGTGCAACTCTTTAGGTTTGATTTATCCTGATTCATTTTGCTTACTTTGGC
20 TCTGCCACAATCCACATGATCTTGGTCAAATAGATACTTGGATTCTCTAAGTCTCATT
TAACTCTAGCATCTTCCTCTTGAGTTGTTGTGAGGTTTAAACGGTTTAAATGTAAGTC
AAATATGCAAAACCAAGCCTAGCTCATTATATCACTCTACAATGATAGCTATCATTAT
CAACATCATCCTTACCTAATTCAGTCAATTTAACTAAAATATTTTATACAGTTCTATGT
ATCCTAGATATCCCTAAGGCATATTTTACTAACTCTCAGGCTCACAAATATTTTTCTTT
25 TCCATATATGTAAAGAAAGACATTAATGACAAAACAACTGACCTTGTGGCAGTTAA
CCCCTTCTGCACCTTTAAAGCCTATTCAAGGACTCAAAGGCATTTACCTTCCAAAGTT
ATTCTATCGTAGCACAAAAATCATAAATGCTAATTAAGTGTCCATAAGGAAATGTCC
TCCATGTGAAAGGAATTCTGTCTCCAAACAAAACATTTCATTAGAATGCAGGGCCAAT
GCCTACTTTGTACAAATTCATTCGGTCAGCAAATAAATTAGACAGACCTTTATTATTT
30 GCTAGATGTAGCTGTGAAGAAGGATCCAGCTATGTTTCTTATGAGACTAATGTCGAA
CTATGGGTTGTCACTGAGGATCCAGAGTTCCATAGGGCGTAGTCCTCACCTTCAAAG
AATTCAGGGCTTAGTAGAAGAGTCTTACACAAATGACTAGAATGTAGAACACAGAGT
GGTTAGGACAAAGGAGCCAGGGATGGTTTTTGTCTGGGTTAGGGAATGAAAAAAGGG
GAAGAAAATATGTGAAGTTATGTGTGAGCTGATTCTTGAAATAAGCTGTTTTTATTG
35 CCTGCGTTCTCTTATAATCCTTTTCCATAGGCTTCCATAATTTTTATTGAGCTGTATTT
AAAGTTGAATAGATAATTCAACATTTCTCGTAAACTGTGCTTCCTAAAAGAGTCCGTA
GAGAATTTCAAATTTCTGCAGTCTTTAACTTGACCTGGTATTTCTATGTTAGATAATA
ACGTGACTTGTATTGTCAGGCAAACATTATAACAATAAATTATTATTGTTTACA
TTTGTAAAGCACTAAGTATATGGCTTGTGCTTTGCATTCAGCATCCTTTATCATTTAATC
40 TTCACAACCACCTTAGAAGGAAGGTACTCTTTTTATTTCCATCTTTTAAATGAGGAAA
TAAAAGCATAAAGAAGTTAATTAACCTACCTAGTGTCACACAGCTATTAAGAGGGGC
TTACTATTTGGATGCAAATATAGGCAGTTCTAATTCCAGAGCCTCTAATCTAAGGCAT
TTAAAACCCCATCACCTTATCAAATAAGCTGTTTTTATTGCCCCGTGTTCTCTTATAAT
CCTTATCCATAGGTTTCCATAATTTTTATAAAATTGTATTTAAAATTTAAGTATAATCT
45 TGGATGCCATCAGGAAAATGAAAAACATTTTACATTTGTGAAGGAAAAAGCCCACA
TCATTTCCAATATAGTTATTGAGTTAGTATTATCTAGACTATCTATTAGCAGCTAAGG
ATCTGAGGTCAAGGCCTGCCAGCCTGGCATTTTACTTGACCACAACCTCCATGTGCAC
TAACCAGGCTGCTAAAAGAACATTAACGGGAACATAACCTGCTGGCTTGGTTGCCAC
AATTTTAAAAAGACGTTAATAAATTAGAGAGCACTTAGAGGTTAGGAAATAATATGG

TGGTAAAGATCTAGAAACAGTGTCAATTCTGGGGCACTTGAAGATGTTTAGCCTGGGG
GAACAACCTTGAAATGGAACATAACTGTTTTCAAATACTTGAAAAATGGTGGTGCACC
ACAGAGAATGGCCTAATCATGGGTAGCTTCAGACTTCAAACAAGGATCAGTGGGCTA
AAACCAGAGAGATGGAGTTTGGGACTCAAAGAATGCTCATCTGAAATTGAGGGCTGA
5 CCAGCGAGGTTCTTTTAAAAATCATTGCATTTTACTAAATTGTGAGTTCTGTAATTAT
AAATGTCCTAGCAGGTGCTAGCTGTCATCTTTTCTATTATAAATTATACTATTTTATGT
TATAATTTGTATTATACAGGCTTAAAACATAAGGGTCTGATAATCTGCTTATCTTTAA
TACATAAGCCACTGATAGAAAATAAGTGGCTAACCATTCTTCAGTTCTTTTTTTAATT
GACAAAAATTGTATATGTTTGCGGTGTATGGCATATTTTGAAATATGTATACATTAGA
10 GAATGGCTAAGTGAAGCAAATTCACATATGCATTACCTCACACACCTGTCATTTATTT
GTGATGAGAACAAAAAATCTACTCTTTCAGTGATTTTCAAGAATACAGTACATTGTTA
TTAACAATAGTCAGCATGGTGTACAATAAGTCTTCTGCGGCCGGGCGTGGTGGCTCA
CGCCTATAATCCCAGCACTTTGGGAGGCCAAGGCTGGCAGATCACGAGGTCAGGAGT
TCGAGACCAGCCTGACCAACATGCTGAAACCTTGCCCTCTACTAAAAATAGAAAAATT
15 AGCTGAGTGTGGTGGTAAGCGCCTGTAGTCCCAGCTACTCAGGAGGCTGAGGCAGGA
GAATTGCTTGAACCTGGGAGGCGGAGGTTGCAGTGAGTCGAGATAGTGCCACTGCAC
TCCAGCCTGGCAAAAGAGGGAACTCCGTCTCAATAATAAGTCTCTTGCAATTTGTTCT
TCCTGTTTAACTGAAATTATGTATTCTTTGATCAACATCTCCCCAGTCTCCACCCCTAA
CCCCTGGTAACCACAATTCTACTCTGCTTCCGTGAGTTCAACTTTATGAATAGTCCAC
20 ATGTAAGTGAGATCATGTGGTATTTGTCTTTCTGTGCCTAGCTTATTTCACTTAGCATA
GTGTCCTCCAGGTTCACCCATGTTGTCAAAAATGACAGGATTTCCCCCACTTTTTTA
AGGCTGAACAGTATTCCATGTGTATGTGTATAAATTAGATTAGTAGATGTTGCCACTC
CCTCCTCCACCACAGTGGCTCTATCCCTGGCTCCTGGCTCCAGCCGAGTACACTAGAG
GAGGATATTCTAAACAGCAACAACACAGGAGCAAAGACATTACAATGGGGTGTTGTC
25 TTATTGCCCCCATTAGACTGTAAGCATCTTGAAGACAAGGACCCCCATCACAGAGTG
ATGTTGTCATCCCTGGAGTGGGCACTGTGCATGATTGATGACTGGAAGCAATGAACA
TACAGAAGGGCAAAACAGAAATCAGCAGGATGCTTTGCATTTCAAGCATTGACTTTGC
CAAATATGCCCAACTGTTCAAGGAGTTACATTGGTTCTAACGAAGCTCCTGTGATTCC
TAAGCACAGGAATGGTGATAATATATATAATGGTGCATGCATATATACGCATATCTA
30 GATAATGATATCTCATTATATGTGAGAACTGAAGAACTCCGTTATGTTTCTCGTCTAA
CCAAAAAGGGCCTACAGCTACGATAATTTCCAAACAAATAAATCTGTGCTACTTGAT
TTTCATGCAAAGCTCATATTTGTTCAAAAGGAAATAAAGCTTAATTTAAAATCAATT
TAGGCTATTTTTATCTAAGTATGCTTACCGTTATTCAACTCCCTGCAGATATTGTCAAA
TTTCTCAATATGGTAAATATTTATTCTGTAAATATATCCATAGTTACACTAAAGAC
35 AGAGAGGTCTTATATGTTCTAAACAACATAGAGCAAATGCTCATAAACAGCATTTTA
TTCCTATCTCCCGGAATAACAACGCTACTTCCAATTGCTGGAATCTAAATTATTAATA
TAAACCCATGCTGCAAGCTTTGTATGCTTAACATTCTCAAATGTTCACTTTTCAGATA
TGGAAGTGAAGCAAATCAACAAACGTGCCTCTGGCCAGGCTTTTGAGCTGATCTTGA
AGCCACCATCTCCTATCTCAGAAGCCCCACGAACCTTAGCTTCTCCAAAGAAGAAAG
40 ACCTGTCCCTGGAGGAGATCCAGAAGAACTGGAGGCTGCAGAGGAAAGAAGAAAG
GTAACTTTTTCCATAGGTTTTCTTCTCTCTCTCCCTCCCCTGCTCCTCCCTCTCACACA
CTCGGGCACACATGCACGCACACACACACACACACACACACACACACACACACACA
CACACATACAGAGAGCAATGACAGCTGAACCTGTGCCATGCCAACATGTATAGGTTT
TCAGTAGACACAGAGCCAGGCTAGTTGGGGTAAAACTGTAAGATAGATGCTAATTT
45 TAGGCTAGCCAAACCAGAGCTCTCAGAAATCCAAAGAGCTTCAGTGCTCTAGTGCCC
CTTCCCGTATATTGAATCCCCTTATTATAAAAGCCTCCCTTCCCTAGACCATCAGGCA
GAAGCACTGTAGAGAAAACACAGCCCTGGCGAACTCCAGTGGTGGGGAGGGGAAGA
AGTGCTGCTTCCCTCTCAGGATCTGTGTACCCCCCTTTGTCAGGCGTGGTTTTCT
TGGAATTACAAATTACCAGATCTTCCCTCCAAGATCTTCCCTGCCAGGGTAAGGGCC

AAGAGCTTGCCCCCTTTCCTCTTCAGAGTCCCCTGCCTGCCCTGGAAGTTGGTCCTTC
CAAGATCAGGACCTTCTCTGAGTTCTTTGAATATGTTCTTTATCTTTTTCTAAGACTTG
ATGGGGATTTTTCTCTTTTTGCCATTGGTCCCTGCTTATATTAAAGAGCTTTCCTTTTG
CCAAATCTTTACTTTTTCCATAATCACATGGCTAAGAAGAGCCAAGGGTATTATTTGAG
5 AACACTTAGAAATCCTAGGGACTGTGTACACAAACAGAAGTTGTTTGAATGTGTCTG
TTCCAACCATGTGGTTATGGTAGTTAATCCCATCAAGGTACTCACGATCATCCAAAAA
TGGAATTCTTTTATGTAATTCATCCCCACATTGTATTTCCCAATATTTTTTATGATATA
ATTTTAGAATCAGGTAATCACTAAGAACATGTTCCCTGCACAGTTTTTATGATGTTTTTCT
TCTAAAAAGTCAGCCAAAACCTTTGGACACTTCTATGTTGGATAATTAAAAACAGAAT
10 GAAGATAATCCTCCTCCTAAAGATTGAATTCTCCAAGAGAGAATGCAGGACAAACAC
AGATGTGCTGTGTATAGTATATGTGCATATATACATGCATATATGTACACAAATATGT
GTATTATCAAATAATGAGGCTCAAACATTAGAAATCCTTAGATTAAATTTTCTAAACA
AGAAAACACTAATCTTTGTAGTTGAAAAAAAATCCTCCTATGATATGTAATATGCTG
ATCTCAATTTTTCACCTAAGAGTGATGTTCTCCAAATGTCCGATGAGCATGTCATATAT
15 ATATATATGAATTTTTATATATATAATTACAATGGTAATTGGTATATAGAGATATCTA
TATTATAGATATATATAGCTATCTCTATATATTACATATACCAATTATAGATATAAAT
ATAACAATGGTAACTGGTGTATATGTGATGTGTATATATGTATATGTATACCATAATT
ATATATTAATATTGTATATATGCCATAATTATATATTAATATTGGTATATATACACCA
TGATTATATATTAATATTGGTGTGTGTATGTGTGTGTGTATATATATATATATATATAA
20 AATACTAGTTATCATTGTTCTAGATTTAAAAAACAGGAACCTGAGCTACTAACTCGAC
TATATATATATATATATATACAGGAAGTTGCTTTAAACATTTTTATCAGCTTTTTTAT
TGTTATTTTTAGCTTTATTCTCATAGTAAAGCTAAAATAAATTATTCAACATTATCAA
AACTTTGCTGCCAGCAGATGTAAGCAATACCTAAAACAGTGGAGAGCATGTTGCACC
CAAAGCAGTTTAAAGCTCTGACCCAAGCACTGGCATCTTATAGGCACTGGGTAGAGAT
25 AAGAGTCATAGGTCGACATATATTGAGATGCTATGACTTGATTAGAATATGGAGTCA
GTGACTGAGGTGAAATTAAACTCAAACCACAATTCAACATCCTGATTTAGGATGTT
GCTGGTGTCTTAGGTACTACACTTAATTTGAAAGAAATTATTGAGGATAAAAAAAG
AACTGGGATCAACAAAATTAAGTGGTCTTATAAGAGTCCCTGAGGTTACTAATT
AATGAACTGATAAAGCTCCTGCACCCTGACAGCAAGAAATTATCAATGATTATACA
30 TTTAAACAATTGAATTGAACTAGAACTGGCCACATGGTTAAAAGACATTTACAAAT
GTAATCATCCAGTGTTATGATGCCCAGAAAAAAAATTCCTTAGAATGCTTTAAAA
GCCGTATCCATCACCTTTCCAGTTATTTGTTAAACATTTTGTAATGCAAAAATAACC
ATATAGATTATGCCCTAGTGGTCGGGTTTTATTTTTAGTTTTTTTATGGTTTTTTTTTGT
AATGGTAGAGTTTTTAATTAAGAAATAACAATAATTAGCAGAAAGTGCCAACTTT
35 AAAAAATCACTAATTGATTTTTATTCTATTGGGTTATACTGACTTAATTAGCACTAATT
TAAAGAATTAATTATCTTTAAAGAGTCTTTAGCAAGTGCATATATCTCAGTAATT
ATGTTAGTAAGGACATGCCTATAACCAAAACCCAACTCACTAGTTAAAACAAAAG
CAAATATGTGACTAAAAAGTCTAGGAGTGGCTACAGCATCAGGAACAGCTGGATCCA
GGGATCACAGTATTATCAGAAAACCTTTCTTTCAGTGCCTGTCATCTCTCCTGCATTTA
40 ACTGGTTTCATTATCAAGAAAGTTTAATTTCAATAGTCAGTTCCAAATTATTTTTCTCA
CACTTAGCAACTCCAGCAGAAACAGAGCTTCTTTTTCCCAATAGTTTAACAAAAGTC
CCGAAATTGAGTCTCAATGGCCTGGCCTGGATCACAGGCCCAACCCAGAACCAATCA
TTATGGCCAAGAGGATGTAGTAGTTTGATATGCTAGCCTGAATCACATGCCCACT
GACCTGCAAAGGATTTTAGGTAAGATCCCTGGGGTAAGAATTGTGGAGGGGTAGTTC
45 CCCAGAAGAAAATCGAGGTGTTCTCACAAGAGGAAGGGGTAATGGATCTTAAATAA
ACAAAATATAGATGTCCACATTTTCTATCTATAAATGTTTAGTGTTACTATAACAAT
TAGAATAATTATTTAGTTCATACACTATTCAATTTGTATCTCCCTTCTGTTGCCCTGTT
GCCGTTATTTTCTTACAGATAGAATGAAAAATATTAATCTAGGCAGCTCTGTGAAACA
GTACTGTCCAAGGAATATAACGTGAGCCAGGCCGGGTGTGGTGGCTCATGGCTATAA

TCCCAGCACTTTGGGACGCCGAGGCAGGTGGATCACCTGAGATCAGGAGTTCAAGAC
CAGCCTGGCCAACATGGCAAAACCCCATCTCTACTAAAAATACAAAAATTTCGACAGG
CATAGTGGCGAGTGCCTGTAATCCCAGCTACTGGGGAGGCTGAGGCAGAAGAATTGC
TTGAACCCAGGAGGTGGAGGTTGCAGTGAACCAAGATGGTACCATTGCACTCCAGCC
5 TGGATGACAGAGCAAGACTCCATCTCAAAAAAAAAAAAAAGAAAGAAATGTAATGGGA
GCCATATGTGTATTTTTTAAATGTTCTAGAAGCCACATTTTTTTTAAAATAAAAGAAATAT
GAAATGAATTTTAGTAAAATATTCTTCACCCAATATATTCAAAACATTATTTCAATAT
GCATGTAATCAATATAGAAGTATTAATGAGCTGTTTCACATTATTTTATTCATACTAA
GTGTTTGAAATCCAGTGTGTATTTTACGTTTACAACCTCATTTCAATTTCATGTTAGACAT
10 ATTCCTAGTGCCTAGTAGCCAAAGGCAGCCAGTAGCACAGATACGGATATTAAAACA
GAAAACACCTAGTGAATAATGGGGAAATTTTAGGCCTAAGTTTTTTAAAATCCATACC
AGATAATTATTCAGATTCAAATTTACTTTGTTTTTTTCATATATATTCTTTAAAATTAC
ATTAATATGGGAACTCAGAAAGTTCAAAAGAAATTTCCATTCTATGGTTTTAGTCTTT
ACATTGTCAGAACTAATGCAAGTGTGAAGTTTAGGATGTACTGTAAGTAATAGGATC
15 TTCTAAATCTCATGCCTTCTTCAGCTACCTACTCTGTTTCTATTTTCAGTTCCCTCACTGT
GGGGAGGGGACTTCTCTGAACCTAGGTTTCATCTCTCACTCTCGTTTCATGGTAAACAG
GTTTTCTTTGTGGCACCTAGCACAAATTAGTAAGTAATTAGTATTTACTGGCATATTA
GTATATATATGCATATGTATTTATTTAACCCTATGTCTTCTACTAGATTATAAACTCCA
TGAAGATAGAACTTGTCTTTTGTTTAATAGTGCTTGGCAATAGTTATTACTGTAAACA
20 TTTTTTTCTTTCTTATTCAACTCCTGTTAGTCATTGCCTGAGTACTACAAATGTTTTTA
AGTAAATTAATAAATAAATACTTTTCAGGGCCAAATGTGAAAGCGGCAATATATAGCT
TGTTTTGATTTTTTATTCCACCCTCCCATCCTAAAACAATTATAGTCACTAAGTTTCCA
AATGACATCTGAAATTGCACTAAGGAAATCCTAGTCTGGGCAAAATCACTCAGTCAA
CAGATATTTATCAAGCACTTACTATTTGGCAGGCCCTGTTCTAGACACAGGGGATACT
25 CATCAAACCTTACATTCCAGTGGGGGAGAAAGAGCTAATAAATACATACACAGCATAT
TAGATGATGCAAAATTAGCAGGACAAAGAGAACTGGGGGTGTGGGGGTGAAAGAAG
CTAATATTATATGTTATTATTACTATATATAATAATATAATTATTGGATAGTCAAAAA
AAAACCTCTTGAATAAGACATTTGAAAAGAAGCACAAAGGTAGCAAGGGAGTAGGG
CGGGCAGCTCTTCTCTGGGACCTGAACATTCAAAATGATGAGAGCAGCAGGTGCGGA
30 GGCCCTGAAATAGGAATGTATGAGGTGTGTTTGAGAAATAACATGGAGGCCAGCGTG
GCTGAAGCTGAGAGCAGGGGGAGAGTGGTAGCAACTGAAGTCAGAGGTCACAATTA
AGGACTTTGACTTCACATGAAATGGGAGATCATGAAGGATAATAAAGCCATTTCACT
ACTTTATGTGAATCACAGCATCTTTTTTAAAGAAGTATCCTTTTTTTAAAGGGGGAGATG
ACTAGAAAAATAAATAGTGTTAGATAAATAGAGAAAACAGGAAAACATTCTAGACT
35 AAGACAGTGATTCCAGAACTAAGGATCCACAGAGGCGAGAATGCAGAAAGTGTAGG
TTTCAGAGCAGTGGGTAGACTAAGGGTTTGGACTAGTGGATTTGGATAGGGAGTTGG
AGAGTAGCGAGGTGGGATTAGGGAGGGCTGTGAATGCCAGGTTAGTGTGCAAACTCC
ATTATATAAGCAGTAAGGAGTCACTACAGACTTTTCAAAAATACATACATGTTCCAC
CTGGCCACGGGTTAGCAACATTTTCGTTGCCCTGGACCCATTTCCCTTCCCAATAAGT
40 TACAGGTTTGTGAAGATTCTACCTAGCAAACATATTACTTTTAAATAACTATTAATAA
ATTATCTTACCATGATTATAATCAAAGGAATCTGTAATTGCTAATTATTTCTGATTATT
AAAAGATAAGCAGTATTGCACTAAATTGACATAATTCTAACTCAAAGTAAATATACA
GATAGACATGGCTATAGATGTGAAATATGATTTCTGTTAGGGCTTTTTTAAATTTAAAA
AACTTACGAGTTCTCCTCCCTCCCCCTACCCTTAATACCTTGAAGGCCTCTTTGTGG
45 GACTTCAGGGACCCCTTCAGGGAACCTATGACCTAGGCTGTATTTGGGGGGCTTTCTGG
GTTTATAGCTGGAAGGCTGCCACAGAGGCATCGCCACTTGGGCTCAGATTCACCTTGT
GTTCAATGTTTTTGCAATGTCCCCACCTCCCCATTCCATCTGTTGACACTATTGCAGC
ACTGACCATCTGGTTACTAGGTTGGAGGATACTCCCTCGGGCTCCTTTGAACCAGAAT
TAGTGCTCCAGTGATTAGATAATAGAAGAAGCTTGTCATAAAAAGAATAAGCCCTTT

CCCTGCTTTTTCTCCATTCTTTGATTATCGCTGGTAGTCAGTGATGATCATCTCTATGA
GTCTATATCAATCTCATCAGGTCAGTTTGAACCTCATCTCTTGAAATCAAAGTTTCCA
TAATGCAACTGACCCACAAGGGTGAAATGACATGAATGCTTTAACCATCCATTTATC
ATTTATTCATTCATTCAACCAACATGTATTTAGCAAGAGGCAGCAGAGTTAGCATAAC
5 TATACATCCCAGTTGGCCCAGGACAACCTCCAGCTAACTCTCGTTGTTTTGATACCATT
ATTAATTATTTCTCTTTACTCTCATAAGTGTTCCACTTTGGACAATCAATTACATGAGC
ATCCTTAGCAGGGCACAGTGTTTAAGGGCATCTTTAAAATATTGTCTTTAAGAACATG
TGGTTAAGAGAATGTCTGTGTTCAAATCCTGGTTCCACCACTTAAAAGCTGTGTGACC
TCAAGCAAGTGACTTAATCTCCGTATGTCCTCCTTTGTCAATCTGTAAAATGAGACTA
10 GTAATAGAACTTATGGAGTTAGTGTGAGAATTGGAAGGTTACTCTACAATAAAGACA
TATAACCAGCATGGTAAAAGGGTTAGCAATTACTATGTGAAGAAGCATCCAGTTTCT
GACCTCACAGAGATTATCTAGCAAACCTCATGATTTTATAAAGAAAAGAAGTTTCTCA
TCAACAGAGACTGAAATGCTACCATAACAATATACGTTGCTTTTTTTTTTTTTTTTTT
TGAGACGGAGTCTCGCTCTGCCACTCAGGCTCAGGCTGGAGTGCAGTGTGCCACCTT
15 GGCTAATTGCAACCTCCACCTCCCAGGTTCAAGCAATTCTCCTGCCTCAGTCTCCCAA
GTAGCTGGGATTATAGGCACCCACCACACCCAGCTAATTTTTATATTTTATAGTAG
AGACAAGGTTTTGTCATGTTGGCCAGACTGGTCTCAAACCTCCTGACCTCAGGTGATCC
ACCCACCTCAGCCTTCCGAAGTGCTGGCATTACAGGCATGAGCCACCATGCCCCGGCC
AATATTTTTAAATATTATAAAATATTCTTTATCAAATTGCATAGAAGAAAAGACAGTT
20 TGATAGGTAATAGATATATAAATAGGTCAGGCCAACTAAAAGTGTCTGAAAAAATT
AATATTGTGAAAACAAAAGGATTTTAATGACATTGATAAAATCTCACCTAAAAGAG
ATTAAATTAAAAATCACCTACTTGAACCAGTTCAGTGAGATTTTCATTAGCATGCTCT
CATTACTGGCATAATCAGCTTCAAAGTCACTAAGCCTCTGAAAGGAAGATGTGTTGC
TTATTCTTAATAAAATGGCATAAAAGTAGATCATTAGTCACCAAACATGATAGACTT
25 ACCTTTTCCATTTGTTGGCATCTCACATTGTAGATGGCAATTAAAATGGAATCCAGGG
AAAGAGGGGGTGGTTTGTATAGCAATGGATTATGAAACAAAGTACTGGATTATTCAC
CGCTTGACATTCAGGAAACATTCTGCTCCTTACAGAATATGGCACGTGGGCCACAGA
ATCTTCCGTGTGCTACCTTCTCGGTGAAGAAGAGCACCCCCAAGTTTCTTTTCCTAGG
AGCTAACACAGTAAACCCATTACACACTTTAGCAGAAGGGCTCATTCTAAAGGTCT
30 TAGGATTTTAATCATTTTAAATTTCTGTTATGCTTCAGGCTCTTCAACACAAAGTGA
ATATTGTACTCTTTGGTTTTACATAATTATATTCAATTGTCATATTTCAACAGGACATT
ATTTGTGACTTTAGATGGGTCAATAATGATTTTCATTGTCAGCAGTAAAGTCAATAAT
TACAGACACATCACCTACCCTACTTGTGTAAAAGCATTTTTTGGTACTAGGAGATTTA
GTGTCTGATCAACGGTCCTGGATAGCAAGTAATATATCCCCCAAATAATGAAAAGTG
35 ACAAGAAAATAAATATGTTTACTTCAGAAATAAATGGAAAATTAGTGCTATCTAAAA
TGTAGTCTTAAGTCTCATCTGTGTACATAAAGTAAAATGAGTTTTATGTACTAGTTAC
TCAAATTTATCTTCCACTCCATTTGTATAGTAATTAACTCTTACACTCAGTAATATAC
AAATTGGTAATTAACCTCTTTGCAAAATGTTAAAGTGTTTCTAAATGTACAATAAGTC
TCCTTTCTGTCTCATTGTTTTTCGCTTCACGTACCTCTCATGTAATTATTTCAATGATT
40 GAGTTCAGTGTGAGGAGGTTTATGCCTAGAAAAGGTGCTCACCAATAACGTGCCTCA
GTTCCCATAAATAGCAAGATCGAGAAGGTTCTTTAGTCTCCCGGAACGTACGTTGAA
CATCTCAGTTCTATATTTTGCCTTGACATTTGCATTATATCAGCTGATCATTGTCTTGC
CCTAATTTTCCCTTTTAAATATTTTAGTGACCTTCTATGTTAGGTACAGGTTATTTAGAA
GTGTTCTCCAAGGCCAGATACTTTTCTTGAACAATTTATTTTAACTTTTAGC
45 GATTTTCTCACTTCACCACCCTCCGTTTCATAAGTCCACGCAATCACAATTCCTTTCTG
CTAATCTGCACAGTCAAGATATAAAGTAAGAATACCTATTTGAACATGTAGTGAGAA
CTTTACTTCTCTGCCAAAAATGAAGGAAAATGCTGCCACTTTTGTATGTCACATGTTT
TTTATTCTACAGCCTCACTCACTTCATGTCATGTTTTAGTGCAGTTTTCTGGACTAACT
GCTTATTTTCTCATTGATTAACTGCCTATTTGCTCATTGGAATTAGAGCCAATTTTTT

TCCTTGAGGGTCTGACTAGAAAGATTAAACTATGTTCATGTGAGAATCAATTTCTACCT
AAGAAATGAGTTAGAGGAGTTATGGGCAGCAATATCTATCTGGATGCTACACTGTGA
AAAAGGAAGCGAGGTTATGCCTTTCTACCCCAATGGGGTAGCAGAGACCTCAGGAAC
TGAGGTAGATGCCCCCTGGTTATTAGCGCCCCTGAATAATTTGTTCAAAAATTGACT
5 GCTGGACAGGTGTCGTGTTGCACGCCTGTAGTCCCAGCTGTGCAGGAGGCTGAGGCA
AGAGGATCTCTTGAGCCCAGGAATTTGAGGCTATAGTAAACTAAGGTCACACCACTA
TACTCCAGCCTGAGCAACAAAGCAAGACCCTGTCTCTAAATTTAAAAAAAATATTG
AATGCTTATGAATAGAGACTAATATAGGAAGTCATAAGTATTTCTTGGGATAGAAT
GCTTTCCACCATAATTGACTTGACATCCTGTATTTTTGTATGTGTGGACTTAAGTTTAA
10 AATATTTGAAACACAGACAATTATTAAGTCCTGCAAATGTGTGAGTTAATAGTGGAT
ATAACATTCCCTTCCAGGGTGTAAGAAAAGGTACCACAGAAGTGAGCAGCCCTGAAG
CACAGCCTGGCCTAGTTTGGCAGGTCTCTGTGAGTTAGCAGCAGACTCACGTGACCA
CACTCTGTACTGCCTTCTGTTTCTGTTTCACCCCATTAATTGTGCTAAAGAAATGCACT
TGACACCTATGCTGTGTAATCTCATTAGCCCCAATAGCAACAAAAGTACTAACCCCA
15 TTAAATTGAGTCATTTCAAACCTGAGCCAAATGTTGCACTCCAGTAAATGGAGTAGGC
ATTGGTTATAATGGGAATTCTCCATTATTCATAATGGAAACCACAGGAGTTTGTTCAT
GCAGATCAAATGTGTCCCACCAAGGCAAGAAGTATGGAAAAGTGGTGTGCTGTATT
ACCTTGTAATTTCAAAGCCTTCCCGTCTGAATCTTATTTCCCTGCTGTTTCCTCTTGAC
TTTGGTTCTTTACAAAGGAAAATTAAGAACACAAATATAAACATTAAGTTAAAACA
20 CAACTGAACAAAGTGCCAAACTTAATTGGAGCATCTGAAAATGAAACATTAGGCAGT
TGCAGTGGCCTCTTGATAATAATTCACAGTAACTCTCTGTAAGCTGATCCTGTCTGAA
GAGCAGCAGGCACAAGGCCCTGGCCATGAAGTCCATCTCAAAGGGCCAGGCTCAG
CAAAGCAGGATGCAAACCCAGGCTTTCCAAATACCAGGTTGGGGCTCATGTCACTGT
GCCACAGGAGCTTCTGTAGAAAGGCTACTTGAAAAAAGTGGCCATTAAAAATCCAGG
25 TGGATCCTATCTAGGGCAGTGTTGGAAACACTGATCTATGGGAGGAGGAGCAGGAAG
GAATTGTTTAACCACTGAGCAGAAATGTTACATTGCTACCTGCCTTTAGCAGCTGTGG
CTGATGGGTACCAGTTGCTAAGAAGAGCATTACCTAACAGTGTATTAAGATAGAAAA
ATGATTTTAAAGCACGGCACTTAGAGAATGTTGAAGTTTACTTTGCTTTATTTTGATT
TGTTTGGTTTGACTTTGTCTCCTGGAGCATCCTCCATGGATTTCTGTTCATTACAAGAG
30 AAACCTAGGGCTCTAACCCAATTCCTAATTCTTGGACACATTGCACCCTTGTTTTGTG
ATAATCCAGCCTTCTTCCTTGAGAAGGTTTGCTGGACTGGAGGTTACATGTATTGAAT
TTTCTAAAATGAAGGTGCAAAGCTGTCTCCTCTTATTTCTTTGTGGTGCTCACTTCACT
GTGAGATTTCTTATCAATACAGCCCAAGTCAGTGGGCATGCATGAGGTGGAGATGAG
GGAGTTAGGAAGGACTTGGA CTCTCATCAACCATCAGGATCCCTGAATCCACTAACT
35 GTTCATAATCAAAGAAGTTTGAACAAATACTTCACACACATGAAATTGCCAAAATTT
TGCATTTGAGTTGTTATACCAGTAAGTCCAGTTGCCATCATCTCCTTGTCACAAGTGT
CTTAAATTTTGCTTTTGATAATAATGATTACCACTCATTCACTACTAACTTACTTGATA
TTAGACACTGCATTAAATACCTTGCAAACATTATTTTGTTTGATCCTGACAACCATAT
GAGATAGGTACTATTCTTATCCATTACCAAAAAAATTAATTTTCATGAAGACTTTTCCC
40 AGAGAGAGAACTTTAAATATTTACACACACACCTCTCTCCCTGTAACAATTCCGTAG
TCCTGATAACAGCAAATAAGCAAAGTCTGTGTAGGATGCTTTACCAACAGTCCCACC
TAGAGGCAGGAGAGTGAACCAGCTAGAAAATATTTTATTCATATTTCTTCCAGAAAG
GCTCCATTGGAGTTTGA ACTCAATTTATGTTATAATTTTCTTATTATTTTGTATTGGT
TTTCTGAAACCAATACAAAGTAAGAAAGCATTGGTTCCACTAAAAATGTCCTAAAA
45 CCAGCCAAGCACAGTGGCTCACACCTATAATCCCAGTACTTTGGGAGGCCGAGGCGG
GTGGATCACTTAAGCCAGGAGTTCAAGACTAGCCTGGCCAACATGACGAAACCCCAT
CTCTACTAAAAATACAAAAATTAGCAGGGTGTGGTAGCACACACCTGTAATCTCAGC
TACTCAGGAAGCTGAGACATGAGAATCGCTTGAACCTCAGAGGCAGAGATTACAGTG
AGCAGAGATCACGCCACTGTACTTCTGCCTGGGTGACAGAGCGAGACTCTATCTAAA

AAAAAATAAACACATAAATAGTAAAATGTCCTGAAACCATTATGGGGTTAAAGCAA
GAGGCAGGGCTGGTTCCAGGATTTTCTGTCTAATCTCCAGTGAGCCACAGACCTATT
CCTGATCAACTTGAGAATAAACACATCAGTAAAGATGTGTAAGGCTGTCTGACTTTC
CCATTTCTGTAGAAATTTTATTTGAAGAGAAGTTTCTCCTTTCTCCAGGCCCATATTGT
5 TTATACAAAAAGACCTTTCCAGTAAATGTCCACAACCACTACCATCAACTAAAATGTT
TTCCCACTAATGCTTTCAATGGTAATCAGTATTTAACAGGGCACTTAGGATTATTTTTT
GATCAACCATTGTTTAGATATTCCCACTTATAATTACTCCTGTGAAGGATTGCCTCGG
GGCATCAGCTGATCCTGAGAAATTATCCAGAAGCCATGAGTGTGTAATAATTTAGTC
TAAACCTAAATAGGTCAGTATTGGGTGGGACTTTTCTCAGCTGCATAATGGGGAGA
10 ATAAAAAGAATATGGAAAGAAGTTACGTAACACATCCTGGGTACAAACAGAGGTA
AGACTTGAACACAGGCCTGACATCAAAGCCCATGCCAGTATGACTTACAAAAGGTAG
ACTGGACTACCTGCATTTGAGTCACTAGTGATGCTTATCACTGGGCCTCACCAAAGAA
CCTTGGAATCAGAATCTTTGGAGGTAGATGCCAGGCACCTGCATTGTTATCAAGTGCT
CCAGTGATTACCATTCACTGTACAGAGCCAAACAGACTCCTGATGCTGGAAGAAAAT
15 TACAGTGCTCAAAGTGCAGGGCAGGGTGTACATCTGGATCTAAATCACTGAGCAACC
ACAGGGTTTCAAGAGAGGGTCAAAACAAGGACTTTCTGCTCTCTGTGGCCAAGGGGA
CACTAAGTTTGCCTGTTCTCAGATCTCCAAAGAGACTTTGGTGTATGGGGGATAGG
GAGGGGGGAAGGGGGTGTGAAATAAAAGGAGAAAGTGAATTTGATTATTTGATTGA
TGAAAATTGAAAAGCTTATTGTAGGGCCTAGCCTACAGTTGATGAAAAACAATGGA
20 TCAGGAAGAAGATCAGAACTTGTCTCAGTCCTCAACTGTTTTCTCAGGCTTTGGTTG
AATATTGCCATCCTGTAATTCATTATAGCATTCTTCTGTTGCATAAACGCTTAGCAACA
AAGCCTTTTTTTTAAAAAAATTTGTAACCTCAATGAGGATTAAATGCTTCTTCTTCTA
AGACAGTCCGAAATATACTCACAGCTGAAAATTCAGCTAACCGCATTTCCTCACTAG
CCACATTCTATAGAAAATCTAAGCCATGCAGATGAGTACAGACTTGACAATAGTGC
25 TCAAGGCTGGGAGTACTATTCATCTGAAAAGAATGCTCCCTCCAATTGGTGGGCGGTT
ATTCTGCTAGGTTTGTGTTTGGATAATTATAAGATGGCTATGTTTTTCTTCCCCAGTCT
CAGGAGGCCCAGGTGCTGAAACAATTGGCAGAGAAGAGGGGAACACGAGCGAGAAGT
CCTTCAGAAGGCTTTGGAGGAGAACAACTTCAGCAAGATGGCGGAGGAAAAGC
TGATCCTGAAAATGGAACAAATTAAGGAAAACCGTGAGGCTAATCTAGCTGCTATTA
30 TTGAACGTCTGCAGGAAAAGGTAATCTCAGCAGAGTCCTGAGCAGATGGATATATTC
ATATGCAGCACAGCTGGGTGAACTTCCATATGCCTGAGCACAGAGACGAAGTCAAAA
TTTGCTGCAGGTGTGAGGACAATACTCCCATGGGCAGGGTCTCACAGTGTAGCAT
TGAGTTAGCAGGAGGTGCAACATGGTAGAGAAATGGGAATCCATCATGAAAGCTGG
AATTTTGTCAAATTTTCCCATGGTGAGTGGATTACAGGGAGGCTGATTCATGCTTTTGA
35 AATGTGTAAGACTTCTATACAAGCCTCACGAGGCAATCTGTAGGAAAAATGTTACAC
TGGAATATTAATGTCTATATATTATATTGATATAAGTATAAATAACATTTGATTTAA
TATTTGTTTAATATATGACATTAAATATATATTTAATTAAAATATTAAATTAGAAAA
TATATTTGCCAGAAAAGGCCAGGGTATTTATGAACACTGGTAAGCCCATTCTAGGGT
ATAATAGCATCACATGGGACCATAGCAAAGATTAGCTCATAGGGGATGTTTCATCCA
40 GTTCTGGTATCCTGGTGCCCTTCTCTTCAACAACCTAAACATATATTCAATCCCATGA
GTCAGGAGGAGCTGTGCTGGAGTTCTTCTGAAAAATGCTGTCTTTCACTTTTGTACTC
TCTATGCTGTCTCCACCTATCCCCTCAAAAAACCTTTCTTTGAAAATATACAGTAT
AGCTGTGAGTAGTTTAGCTGTGTCCGTTTCCAGAAATTGGAATAAGCATTGAGAAAT
GGGATGTTTGAGAAAGACGCCTCAATCCTTTTCTGAGCAGTCAGTCACCCCTTCCCGCC
45 AGTAGCAAGTGCCTTTGTGTGATAGGCATTGGAGATGCAGAGCAAAACAGGAGTGTG
CCTGTCATCAGAGCCCTGAGAGTTTAATTAGATGAGCCTCCTGTTTTCTATTTCTCAG
AGTTTCATGTCTTCTGTAGAGATGGCCCTTCTCATCTAAGGTTCAAAAAACCTTATC
CTGAAGTTCTGATGATTCTGTTTTTCAATCTCAGTCTCTGACTGCAATATCCAACCTAG
AAACAAAGGAAATCAGGCATGAAAACCTTTTAAAGATATAATTGCATGGAGATCTTCA

TTTGTGCTCGTGAGGAATTTTTGAAAGCATTGCTGGGGAAGGGTGTGTGGGCTCTGAT
GCAGCAGTAAGACACTGAGGCTCTCAGAGGTCCGTGGACGAGTACTGCTGACTTGGG
CAAGAACCGGAATAGTTACCTGATGCCTTATCCGAAACATGAAAGTTCGGATTAAAT
TTGTATTTATAAGCTAGTGTTTTTATACTCTCAGAACAATGTCATTGCGTTTCACCCAA
5 GTGAGTCAAGTCACGATTTGGAAGAGGCAACAGAATTTGGCTCTCTCCAGGTGATTT
ATGGCGGTATAGGAACACATGTTTTACTCAGATACAGGGGAGCAAAGTTCCATTTGC
TAAAGTTTACTCCCCTGACCTTCAACCAGTCAGTCTTCCTCCATCTGCCACCACTTTGC
ACTTCTCCAGAGAACTAAGGATGTTCCCGCTTGACCAGTGCTCATAACATGGACAGC
AGAGGGCCACTGTGTGATCTCTTTGAGATCACTGTGACTCAACCTTCTTCTCACATCC
10 TAGGCCCTAAAACAATTAAGTGAAGTTGCTAGGAACGGTACCTGCTGATCTTATTGC
AGCATTCTCAATTAGGCCTCAATGCAAGATTTATATCACTGGCAGTCCTGGAGCATTT
TTGTTTTTCAAATTACACATACCCAAACACACGGCATAGCCTCCTTTTTTTGTTTGTGTTG
TTTTTTTGAGATAGAGTCTCGCTGTGTGCGCCAGGCTGGAGTGCAGTGGCACGATCTC
AGCTCACTGCAACCTCTGCCTCCTGGGTTCAAGTGATTCTCATGTCTCAGCCTCCCAA
15 GTAGCTGAGATTACAGGCGTATACCACCACGCCCAGCTAATTTTTGTATTTTTAGTAG
AGACAGGGTTTTTGCCGTGTTGGCCAAGCTGGTCTCAAACCTCCTGACCTCAAGTGATCC
ACCCACCTCGGCCTCCCGAAGTGCTGGGATTACAGGTGTGAGCCACCGTGCCCAGCC
AGGGCATATCCTTCTTGATTTCAATTGTAAAATAGTTCAAAAATTTTCCATATTTTATC
TAATATTTCCAGAAGTGCTAGCTTTTAACGGACCATTTTTTTTCTCTGTGTGTTTTTTT
20 CTCTTCACCTAGCCCAGCCATGCTCAGCTCATTTTTGTACTCTTTCCACTCCCAACCAA
ATTTAGTGCCCTCCCCCATACATGCATACATGTACATCTGCACACCACTTTTCTGCA
AATAATCAACCCAAAGAGTGCTTAAAATTCTGACATCAACCCACAGAATCTCCAAG
GATGGGACCCAGCATCCATACATTTTAAAACTCTCCATATAGTTCCAATATGCAGCC
AGATTTGAGAACTAGTGGTTCGTAGCCTGTTCTGATTTAAATCTCAGCTCTCAGCAGT
25 CTATCCCACGTCACATAATGCAGCCCAGAGAAATTCTAGGACCACATTTTTTTCTGGT
ATTTCATAGCTAATGAGGTGCTTTTCAAATCTAATAGGATCTTTGGCCAGTGTCAGTC
AAGATCTTTTATCTCCTCAATAAAAAGGAAATACCATATTTACTTTGATTTGATGTAT
ATCACATAGGTGGATTTAATACAAAATTGTGGTTTACATATTGTGAATGTGTATACTA
AACTACTTTGCTTTTTTCTTAAAATAAGACAAAGTTTTATATTGGAAGTAATATTTAG
30 CATTTTGTGTTGAATGAAGTTACTCCTATTAAATTAGAAATTTAAAAGAGGGTCAGTAA
TAACAGTAAAGCCAAAAGGCATGACACTGCCAACGTAACATAAGCTGCTCTGAAATC
TACCATATCAAAAGATAATTATGCTGGGCATGGTGGCTCACACCTGTAATCCCAGCA
CTTTGGGAGGCCAAGGCAAGAGAATTGCTTGAAGCCAGGAGTTCGAGACCAGCCTGG
GAAATATAATGATACCTTGCTTCAAACAAAAATTCAAAAATTAGCCAGCAGTGGTGG
35 CACACTTGTA AAAATGCCTGTAGTCATAGCTACTTCAGAGGCTGAGATGAAAGGATT
GCTTGGGCCAAGGAGTTCGAGACTGCACTCCAACCTGGGAAATATTGTGCCACTGCA
CTCCAACCTGGGAAACAGAACAAAGACCCTGTCTCTAAAATAAAAAAGAAAAAAAAG
ATGACCACTTCTGAAATGACACCTATCAATGAGTTAATCATTCAATGAATATGTATTG
AGTCCCTACTATATGCTTAGGAACCTTTGTAATATCATTACCAACCATGTCTTTCCCA
40 ATACAGACAATACAAAATTCAGCAATAAATAATATAGCACCAACAATTAGAGAATA
AGACAACATGTAGTATGGTCCAATATAGACAGTAAATACAAAGACACTGAATAATAT
CAGTAAAAGTAAATTCACATCAAGGTCCTACACCATGCGCCCCACCCTTATGATAGC
CCTCACTGGCCCTATCAATTAAGCAAGAGACATGATACAACTCTGTGCAAGCTTTTCC
ACAATCTGCCTACCATTGAGCACTCAGTCGCTCTTCCCTTCAATTAAGAGAATTGAGC
45 ATTC AAGCATATTTTACCATGATGCCATAATGGTATCTTCAATGTC ACTGACTGAT
AAATTCCCAGAAACCCCTCAGAGCCCCAGCCATGTTAGCTCAAAGCCTTTAGCTAAA
ACTGAAAGCCTAAAGCAAAAGCAGCCCTGGCTGCACTTCGGAATCTACTGGACAGCT
CTTTAAGGGATTCTGATTTAATGTCTGGAATAGGGCCAAGAACCTTGTATTATTTTAA
AGGCTCACTAGTAGGCTCTAATATTTAGCCGTGGTTGAGAACCACTGTGCTAAATGTT

TCTTAAATATGCTTTGTGATGTCATCATAAATTATATTTTAGTATTTTTTGTCTTTGTTG
CATAAGTGTTCTTTCTTCCTCCAAAGAAGAATGTTACACTCATTCTTATTTTCAGTTTC
CTGTTTTTCATAGCACCTCATCTTAACACTCCAGGCTATTATATAGAAAAGAATCAAAT
GTGGAGAAGGCTGTGGGAGAAGGGATGCCTGTGCCACAAAGGCCTGCATTAGGCTG
5 ACCTATTGATGTCATATCCAGGACTCAAAAGACTAGTCTGTGGATTATGACTGGTGA
AGTTCAAAATGTTCTTATTCTTAGAGTGGTATGAGAAGTAGAAAGAGAGAGAAACAG
AGAAGGGGAGGAGAGGGGAAGAGAGGAAGATGAGAGAAAGGAAAGAGAGGGGGA
AACACCTGTTCTTGACATACAGGAATGATTCAAGACATTTTCTTCCTCCCCTGATGTG
TCCCTTTCTCCCCTAACGCACTATGCAGCATCCTGCAGAAAATTCACCACCTGACCCT
10 TTTAGAAACCCTGAGTAGTAGGAGCGCCAAATGACCCAATCAAGAATTGCAGTGAGA
CAGTTAGTTTTGAAAAATCAGTTAAAGCATGTATAATCATTTTAACAACAATACATCT
ATTCACTAAACATATAATTTTAATGTCAAATATTTACGTGTAAACATATTGACCAATC
TTTCGATGTAGTTGGGCCCAATACCTTTTCCAAAAATTGATCAGTTAATGGGGGTTCT
ATGGGGGTTTCTTTTCTTGCCATTATTCACACTTATGTCACATTAGCTATGATTTGCAG
15 TTTTAATTTCTTTAAAATTGAGTAGGGACTAAAGACATCTCCAAAAAGCCTGGATATA
GACTTTTTACAACCTTTTCCATAGCTTTTATAGTTGACTCACCCAGTATCTACTAAATAC
TTCACTTTCTCACGTATTTCCAAAGGTTTCTCTCCACCCTCACAATTTTCCATTAATGT
AGTACTTAATTAATTAGATAGTTAAATTTTCAAATGTGAATTGCTAAACAGGTGTGG
AAATACCATTGGCTATAATCAAGCATATAACACAACCATTTGAGAAGGAAAGTATGT
20 GGCAATATTAGGGAAGAGCCCTTTCTCTCAAGCAATTCAGCATTAGGAACCATCA
GACAGCAGGACGATGGAGGGAACAGAGAGGGTTAACATGGCAAGTTACTGAAGAGG
ACTTCTACTGAATCTTGTTGAATTCCCCACTTAATCCAGATTGTATCATATCTTCTTTC
TTTTGTAATTCTACCATATCATCTTAGTCAATGCCAAGACTTCTGAGCTCATAACATG
GTAACAAATACCAAAGGAGCTTTTAGTATCGTTTAGAAAGGAGAGAAGCAAGTAAC
25 CCAGACAACTTGACAACTGCTTTCCCCTATCCAACCATGAAGTACAGTACTTAGGA
AATAAAAGAAATTGCTTCACTATAATTCATCATTTCACTTCTAATATCTAGAAAATGT
CAAATGAAAATATTATAGCCATATTTTAGTGGCAATAGTAGCACATAATATGATGCA
ACTTAAATGATAAAAATATTTTCAGGGAATAAGATTCTGTGATTCTTTCCCTAAGAG
GTAATTTTGATAATATGTACCTGTTTTGTAAATGTCAATAGTCTTGGGGATACAGGTG
30 GTGTTTGGTTACATGGAAAAGTTCCTTAGTGGTGATTTCTGAGATTTTAGTGCACCCA
ATACCCAAGCAGTGTACACTGTACCCAATATGTAGTCTTTCATCCCTCGCCCCCACTC
CCAACCTTCCCCCACAAGTCTCTAAAGTCCATTATATCACTCTTATATCTTTGCATACT
CATAGCTTAGCTCCCACCTTATGAGAACATATGATAGTTAGTGCTCAATTCCTGAGTTA
CTTCACTTAGAATAATGGCCTCCAGCTCCACCCAAGTTGCTGCAAAAGACACTATTTA
35 GTTCTTTTTATGGCTGAGTAGTATTACATGGTGTATATATACCACATTTTATTTATCC
ACTTGTTGGTCAATGGACACTTAACATTAGTTCCATATCTTTGTAATTTCAAGTTGTGC
TGCTATAAGCATGCATGAGCCTGTGTCTTTTTCATATAATTACTTCTTTTCTTTGGGT
AGATACCCAGCAGTGGGATTGCTGGATCAAATGATAGTTCTACTTTTCAAGTTCTTTATG
TTTTCCACAGTGGTCATACTAATTTACATTCCCATCAACAGTGTAAGTGTTCCCTTTT
40 CATCACACCCATGCCAACACCTATTGTTTTTTGACTTTTTTAATTACGGCCATTCTTGCA
GGAGTAAGGTGGTATTTTCATTGTGGTTTTTAATTTGCATTTCCCTGATGTTGACAATATT
TAACTCTTTAGTTATAGATTCCAGCTATTATCAATTTACACCTATTGCATTCTTCTCAT
CTTTTGTTTTCTTGTTGATTCTGATGCACAAATATCATTTGTGCAACCACTTACTGTTGA
ACATGTCTGATGAACACTTACTATTGAACATGTCTGATGAATGAATAATGAAATAGG
45 AAAAGGGATTAAACTAGCCTTTATTAATTGTTTGCTATAGGCCAGACATTTTTGGAT
GTACTATCACATTTTCATCCAAACAACAACCTAAAAGAAAATACTGTGATTATCCCCAT
TTCACATCTAAGGAACCTGGTCTTTAGGAAGATTAAGTCATTTGGCCAAGATCACAA
GTAGACCACAGAGACTAGATTTGAATGCAAGTCTGTTTGACTCCAAACCTTTTTACTA
TCTGCCCATGACCCCTGATCACCAACATCTCAATGTATGAACATGTGCTTTCTTAGCT

CACACAACCTCACTCCTGACCCCTTTTTTATATTGCAAGTGCATAGTCATTAGTAAAAA
GAAGGATTTTTGATGATACTGACCTCATCTTGAATTTAATTAGGCTCATATGACAGAA
TTCCATAGATGGAATTGACATCCTAGGTCATATAGTCCAAGTCCTTGTTTATATTTGA
TACCTAGTGAGATTAAAGGGACATTAAAAAGTAAAGAAAGGAAAGACCTCATATTTT
5 TTACCTTCCAGTAGAGAAATCTTTCTATGAAATCAGAGGAAAGAATTAGAGGACCAG
AATTTTTTCTAAAATCAACTTTCATACATCTTTTTTTCATATAAAAGGCATAGCTGCAT
ACAATGCTAAAATATTGTATTACATTTCTTTTATATTGATGGGAGGAAGGGGGTAAAT
TGCAGAAAACATTGTAAATTTAGATATGCTTGGGCCTCTGACAGTGCCTAGCAAATA
TCAGGAGATCAATAATGAAATAAATATTATCAAAGAGTAGTCTTCTTGATGAACCTT
10 CTCTGAGTATCACAACCTGCTTTAGGAACCTCTAGATTCAAGGTCTAGTAATTGCAAAC
AGTGAGCTGATAAGAAAAACAGACTGTATGGGAAATTACATGCTTCCTGCATGACTG
CCTTTTGTCTCCACATTTTGATATAAAGTCACATTAACAGTTCATGAGTAAATATTC
GATAATGTGAACGTAAAGTGTTCAAATAATAGAGTGAATAAATGCCTGAAAACAAA
TAATTTTTTAATTAGAACTCATAATCATTTATTTTCTCTTTTTTCCACATTATCTCAAGC
15 TCACAAATTATATTTATTCTTTTCTATGGCAAAATCCATTTTGTAAACACTAATTTTGA
GTTTAACAAGAAGTGTACTCCAAAGTAGCCTAATAATACTAATTATAATGTTTCCTGC
TATGTTATCAGTTTGAATTTATATGAATCTTTAGACTTGAGGCTTCTTTTTCTAGCAT
AGTGATGGTCTGGGCTTTTTCTCAATTTTGGCCAGAGCTCAGCTCTCACTAATTAGTTT
CTTTCTGCATGAGAAAAAGATTTTGCTTCATCTTTTTCTTATAATAGCAGAACAAAA
20 AGAAGAATCAGCTGCATCCATGCTAATTTCCCCTGTGACATTTCCAAACAGGATTTGA
TTTCTCTATGCATGCCTCTTTCTTCTCTTCATGGTTTTTGAACATATACAAAAGCTCA
TTTAAACCAATTAAATAAAATTGTTTTTAATCTCTTTCTCTAGAGTCAACTTCCTGCTT
ACTCCAACCTCTGTATCTTTGAAGGAAGTATAGGGTGGTCTATGCCTTTTTTCTCCAG
AATCTACACTTGAAAAGACACATTTTCCATGCAACTATAAAATGTTCTCCTCACTCA
25 ACATTGAAATTGTATAGCAGTGATTAAGAGAGTGAGCTGTAGAGCCAGGTTCCCTGG
GTTTAAATCCCCTTGTTAGTATCATGAAGATGGGCAAGTTACTTACCCTTCCTGTGT
TTCAGTTTCTTCATCTGCAAAATGGGGACAATAATAGAATGTCCACTATAAGATTATT
GTGAGGATTAAGGGAATTAATACAGGTAAACGTGTACTGATGCAGGTCTGGTACAC
ATTAAGTGCCTAATAAATATTCAGTATTATGATATAAAGAACCCTATAAGTGTAGACT
30 CCTTGAGATTAATAGAGTTTAAACGATAAGTTTTACTTTATAGCTGGTCAAGTTTATTT
CTTCTGAACTAAAAGAATCTATAGAGTCTCAATTTCTGGAGCTTCAGAGGGAAGGAG
AGAAGCAATGTAAGCAACATTCTACAGAAATATAAATAATACTACTAATAATTAGCA
TCTTAAATTTCAATTCAATGAACATTTATTTAGCGCCTATGATATATGCAAGACAGT
TTGATTTTAGTCATCTGATGTATAGCCACATACTAAAAAATACTGATTTTAGTCATCT
35 GATGTATAGCCACATACTAAAAAATACTTCCTCCATCAGTTCCTCCTCAGGAAGTTC
AGTTCCCAATCCCAGGCTAGTACCTTGGTTCCTTATGTAAATAAACATCCACCAATTA
CATGCTATCTGCAAAGCACTCTGCTAGGCCCTGCAAATGGAAAAAAAATGATAAAA
CATAGTCCAGGCCCTCAATGAGCTTACAGTCAAATATAATAGAGGAGACAAGAACAG
AGAGGCTCATAATACAACCTAGAATAAAATGACTGCCGAATAAAAGGAAAGATTTAT
40 GCAGGTGTTCAAATGGAAAGTGAGATAAGTTTGCAGGTTAGTCTTTGCAGTCTCATA
AAAATCTTTATGGAGAAAAGGACAATGGTCATAGGGCTTAAAGAGTAAGTTTATAAT
CCTGACCAGTGGAGATGAAAGACTAGCATTGAAAATTGCATGACAAGACAATTCCAT
TAACTGAAACATCAAGTGTGTGTAGGAAAAGATGGGGGTTATGACTGGAAACGTCA
CTTGACTGCAATTATGAAGGGCCTTGACAAACAGGTCAAGAGTTTAAAGAAGCAGTA
45 TAGAAAGTCTTCGTCTGATCTAGCCCTCCAGAGTGTCCATCAGGATTATAAAGTC
CTTAAATATTAGTCAAAAGGAACGACATCATTAGAAATGATAGAGAAACAATAATG
TGATGTTTTATTACCTTTCTCTGGATTTATACTCTGATCCTAATATTCAAACTATCTT
AATAACATGAACTTTTGGTCATAGTTTTTAAACAAAAACAGTGTTAAATATATTTTTTA
AAACACAGTAAGTCTTGTAAGATCTTTTCTAACATGACATTTTGCAGGGCCCATATTT

TCCTTCTGAAATGGGAAAAATTCATAAAAGTAGACACCAAACCTGGGTTACTTCTAGT
 CAAGCGCATGGTACGCAAAGGACCAGACAAAAAGGGCCTGTGACATTTCTTCTTCTCCT
 TTTGTGTTTTTTAGGAGAGGCATGCTGCGGAGGTGCGCAGGAACAAGGAACTCCAGG
 TTGAACTGTCTGGCTGAAGCAAGGGAGGGTCTGGCACGCCCCACCAATAGTAAATCC
 5 CCCTGCCTATATTATAATGGATCATGCGATATCAGGATGGGGAATGTATGACATGGTT
 TAAAAAGAACTCATTATAAAAAAAAAAAAAACAAAAAAATCAAAAATTAAAAAAAA
 TCAATGCGGTCTCTTTGCAGAATGTTTTGCTTGATGTTTAAAAAATACCTTGGATCTT
 ATTTTGTAAATACTTACATTTTTGTAAAAAATACAAGTATTGCATTATGCAAGTTAT
 TTCATAATCTTACATGTCCTGTAACAGGCTTTTGATGTTGTGTCTTTCCACTCAAATGA
 10 ATTTGCTAGGTCTGTTCTTTTTGAAGCTCCCCATGTCTAACTCCATTCCAAAAGAAAA
 ATGAGGTCAGTAGACAGTCTATGGTGCTAGAAACCCACCATTGCCTAATGACCTAGA
 AGGCTTTGTTGTCTCTGAGCTTGACTAAGACCATACCTAGATCACAGGTATTATGACT
 CCACATGAACCTTCACATTTGTTGCTCATAATCTACTTACTGCCTAAAAACTACAAA
 ACCAGGCTAAGAAATACCACCAGTCATAGCATTTACTTCTGCTTCTCCTGGATTATGT
 15 GCTACAAATGTGCTTTGGCTTTAGAAAGGGATGGATGAGAAGACAGACCTGAGACCA
 ATCTGGGTAGAAGCAAAAAGTTGAACCTTTTAAAGTGCTGAACACAAATCCAAATTC
 GAATGGTTCAAGCAGCCGTGAAATCGCTCTTCATAAAGTGGGCTTAATTCTCTAGTTT
 AAGTTCTTTTGATGGAATGAATTAATTAATGTGTCAGGTGGCTTATTTGTGGATGCCA
 TGATTGATGATGTTTCATTTTAAGCTCTTACCTATAGTACAAGTACATGATGCTACTGA
 20 ATATTTTTTCCACTTGAAACTGTGAGCTGGTTGTTGCATTAAACACACATACAAACA
 AAATCAAAAACACTGCGGACTTTCACTCAAGCTGGTCTTTCTTCCCCAGTGTAAGGCA
 ATCCTGCCTACTAACAACACCAACAACAAAACACTCCATCTGTGAAGCTGACGCAGT
 TAAGGGGGCTAGGCAGGGCATTGTGCCAACTAAGAATCACCAGATACCCACCATAA
 GTACCTATCGCAGTTTTGAAGTCGTTTCTCCCCAACTCCCAACTCCTGAAGGTTGCTG
 25 CCTGCATATTTACTCTTCATTAGTGCTATTTTCCTGTATGTCATTGTGAGCAAGCTGTG
 ATTAATAAAGAATTGGAGTTCTGTGAACATAAAGGTTTGGTCTGTT

(SEQ ID NO: 1341)

STMN2 Oligonucleotides Targeting Regions of the STMN2 Transcript

[00236] In various embodiments, STMN2 AON disclosed herein are complementary to specific
 30 regions of STMN2 transcripts (for example, a STMN2 pre-mRNA comprising a cryptic exon)
 comprising a sequence that shares at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%,
 97%, 98%, 99%, or 100%) identity to SEQ ID NO: 1341. In some embodiments, a STMN2 AON
 comprises a sequence that is complementary to a specific region of the STMN2 transcript (for
 example, a STMN2 pre-mRNA comprising a cryptic exon) comprising a sequence that shares at
 35 least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to
 SEQ ID NO: 1339 or SEQ ID NO: 1341. In some embodiments, a STMN2 AON comprises a
 sequence that is between 85 and 98% complementary to a specific region of the STMN2
 transcript. In some embodiments, a STMN2 AON comprises a sequence that is 90 to 95%
 complementary to a specific region of the STMN2 transcript.
 40 **[00237]** In some embodiments, the STMN2 AON (*e.g.*, STMN2 AON) has a segment that has, at
 most, 7 linked nucleosides. In some embodiments, the STMN2 AON has a segment that has, at

most, 6, 5, 4, 3, or 2 linked nucleosides. The segments of the STMN2 AON may be separated from other segments of the STMN2 AON through a spacer. The segment of the STMN2 AON is complementary to a specific region of the STMN2 transcript (for example, a STMN2 transcript comprising a cryptic exon) comprising a sequence that shares at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to SEQ ID NO: 1339 or SEQ ID NO: 1341.

[00238] In some embodiments, a STMN2 AON targets a specific portion of the STMN2 transcript, the specific portion of the STMN2 transcript comprising any one of positions 144-168, 173-197, 185-209, or 237-261 of SEQ ID NO: 1339. In some embodiments, a STMN2 AON targets a specific portion of the STMN2 transcript, the specific portion of the STMN2 transcript comprising any one of positions 121-144, 146-170, 150-170, 150-172, 150-170, 150-172, 150-174, 169-193, 170-194, 171-195, 172-196, 197-221, 249-273, 252-276, or 276-300. In some embodiments, a STMN2 AON targets a specific portion of the STMN2 transcript, the specific portion of the STMN2 transcript comprising any one of positions 144-164, 144-166, 145-167, 146-166, 146-168, 147-165, or 148-168 of SEQ ID NO: 1339. In some embodiments, a STMN2 AON targets a specific portion of the STMN2 transcript, the specific portion of the STMN2 transcript comprising any one of positions 173-191, 173-193, 173-195, 173-197, 175-195, 175-197, 177-197, or 179-197 of SEQ ID NO: 1339. In some embodiments, a STMN2 AON targets a specific portion of the STMN2 transcript, the specific portion of the STMN2 transcript comprising any one of positions 185-205, 187-209, 189-209, or 191-209 of SEQ ID NO: 1339. In some embodiments, a STMN2 AON targets a specific portion of the STMN2 transcript, the specific portion of the STMN2 transcript comprising any one of positions 237-255, 237-259, 239-259, 239-261, 241-261, or 243-261 of SEQ ID NO: 1339.

[00239] In some embodiments, a STMN2 AON targets a specific portion of the STMN2 transcript, the specific portion of the STMN2 transcript consisting of any one of positions 144-168, 173-197, 185-209, or 237-261 of SEQ ID NO: 1339. In some embodiments, a STMN2 AON targets a specific portion of the STMN2 transcript, the specific portion of the STMN2 transcript consisting of any one of positions 144-164, 144-166, 145-167, 146-166, 146-168, 147-165, or 148-168 of SEQ ID NO: 1339. In some embodiments, a STMN2 AON targets a specific portion of the STMN2 transcript, the specific portion of the STMN2 transcript consisting of any one of positions 173-191, 173-193, 173-195, 173-197, 175-195, 175-197, 177-197, or 179-197 of SEQ ID NO: 1339. In some embodiments, a STMN2 AON targets a specific portion of the STMN2 transcript, the specific portion of the STMN2 transcript consisting of any one of positions 185-

205, 187-209, 189-209, or 191-209 of SEQ ID NO: 1339. In some embodiments, a STMN2 AON targets a specific portion of the STMN2 transcript, the specific portion of the STMN2 transcript consisting of any one of positions 237-255, 237-259, 239-259, 239-261, 241-261, or 243-261 of SEQ ID NO: 1339.

5 STMN2 Oligonucleotide Variants

[00240] In various embodiments, STMN2 AONs include different variants, hereafter referred to as STMN2 AON variants. A STMN2 AON variant may be an oligonucleotide sequence of 5 to 100 nucleobases in length, for example, 10 to 40 nucleobases in length, for example, 14 to 40 nucleobases in length, 10 to 30 nucleobases in length, for example, 14 to 30 nucleobases in length, for example, 16 to 28 nucleobases in length, for example, 19 to 23 nucleobases in length, for example, 21 to 23 nucleobases in length, for example, or 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleobases in length. A STMN2 AON variant may be an oligonucleotide sequence complementary to a portion of a STMN2 pre-mRNA sequence or a STMN2 gene sequence.

[00241] In various embodiments, a STMN2 AON variant represents a modified version of a corresponding STMN2 parent oligonucleotide that includes a nucleobase sequence selected from any one of SEQ ID NOs: 1-446 or SEQ ID NOs: 893-1338. In some embodiments, a STMN2 AON variant includes a nucleobase sequence that represents a shortened version of a nucleobase sequence of a STMN2 AON selected from any one of SEQ ID NOs: 1-446 or SEQ ID NOs: 893-1338. As one example, if a STMN2 parent oligonucleotide includes a 25mer (*e.g.*, 25 nucleotide bases in length) a variant (*e.g.*, a STMN2 variant) may include a shorter version (*e.g.*, 15mer, 17mer, 19mer, 21mer, or 23mer) of the 25mer STMN2 parent oligonucleotide. In one embodiment, a nucleobase sequence of a STMN2 AON variant differs from a corresponding nucleobase sequence of a STMN2 parent oligonucleotide in that 1, 2, 3, 4, 5, or 6 nucleotide bases are removed from one or both of the 3' and 5' ends of the nucleobase sequence of the STMN2 parent oligonucleotide. In one embodiment, the corresponding STMN2 AON variant may include a 23mer where two nucleotide bases were removed from one of the 3' or 5' end of a 25mer included in the STMN2 parent oligonucleotide. In one embodiment, the corresponding STMN2 AON variant may include a 23mer where one nucleotide base is removed from each of the 3' and 5' ends of the 25mer included in the STMN2 parent oligonucleotide. In one embodiment, the corresponding STMN2 AON variant may include a 21mer where two nucleotide bases are removed from each of the 3' and 5' ends of the 25mer included in the STMN2 parent oligonucleotide. In one embodiment, the corresponding STMN2 AON variant may include a 21mer where four nucleotide bases are removed from either the 3' or 5' end of the 25mer included

in the STMN2 parent oligonucleotide. In one embodiment, the corresponding STMN2 AON variant may include a 19mer where three nucleotide bases are removed from each of the 3' and 5' ends of the 25mer included in the STMN2 parent oligonucleotide. In one embodiment, the corresponding STMN2 AON variant may include a 19mer where six nucleotide bases are removed from either the 3' or 5' end of the 25mer included in the STMN2 parent oligonucleotide.

5 [00242] Example sequences of STMN2 AON variants are shown below in Tables 5A and 5B.

Table 5A. STMN2 Oligonucleotide Variant Sequences

SEQ ID NO:	AON Sequence* (5' → 3')	SEQ ID NO:	Target Sequence (5' → 3')
1342	ATCCAATTAAGAGAGAGTGATGG	1367	CCATCACTCTCTCTTAATTGGAT
1343	AATCCAATTAAGAGAGAGTGATG	1368	CATCACTCTCTCTTAATTGGATT
1344	TCCAATTAAGAGAGAGTGATGGG	1369	CCCATCACTCTCTCTTAATTGGA
1345	GAGTCCTGCAATATGAATATAAT	1370	ATTATATTCATATTGCAGGACTC
1346	GTCCTGCAATATGAATATAATTT	1371	AAATTATATTCATATTGCAGGAC
1347	GTCTTCTGCCGAGTCCTGCAATA	1372	TATTGCAGGACTCGGCAGAAGAC
1348	GCACACATGCTCACACAGAGAGC	1373	GCTCTCTGTGTGAGCATGTGTGC
1349	ACACATGCTCACACAGAGAGCCA	1374	TGGCTCTCTGTGTGAGCATGTGT
1350	TCCAATTAAGAGAGAGTGATG	1375	CATCACTCTCTCTTAATTGGA
1351	AATCCAATTAAGAGAGAGTGGA	1376	TCACTCTCTCTTAATTGGATT
1352	CAATTAAGAGAGAGTGATGGG	1377	CCCATCACTCTCTCTTAATTG
1353	GTCCTGCAATATGAATATAAT	1378	ATTATATTCATATTGCAGGAC
1354	GAGTCCTGCAATATGAATATA	1379	TATATTCATATTGCAGGACTC
1355	CCTGCAATATGAATATAATTT	1380	AAATTATATTCATATTGCAGG
1356	AGGTCTTCTGCCGAGTCCTGC	1381	GCAGGACTCGGCAGAAGACCT
1357	CTTCTGCCGAGTCCTGCAATA	1382	TATTGCAGGACTCGGCAGAAG
1358	ACACATGCTCACACAGAGAGC	1383	GCTCTCTGTGTGAGCATGTGT
1359	GCACACATGCTCACACAGAGA	1384	TCTCTGTGTGAGCATGTGTGC
1360	ACATGCTCACACAGAGAGCCA	1385	TGGCTCTCTGTGTGAGCATGT
1361	CCAATTAAGAGAGAGTGAT	1386	ATCACTCTCTCTTAATTGG
1362	GAGTCCTGCAATATGAATA	1387	TATTCATATTGCAGGACTC
1363	TGCAATATGAATATAATTT	1388	AAATTATATTCATATTGCA
1364	TCTGCCGAGTCCTGCAATA	1389	TATTGCAGGACTCGGCAGA
1365	GCACACATGCTCACACAGA	1390	TCTGTGTGAGCATGTGTGC
1366	ATGCTCACACAGAGAGCCA	1391	TGGCTCTCTGTGTGAGCAT

10 * At least one nucleoside linkage of the nucleobase sequence is selected from a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an

alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a thiophosphorodiamidate linkage, a phosphorodiamidate (*e.g.*, comprising a phosphorodiamidate morpholino (PMO), 3' amino ribose, or 5' amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage.

Table 5B: Additional STMN2 Oligonucleotide Variant Sequences

SEQ ID NO:	AON Sequence* (5' → 3')
1421	CCTGCAATATGAATATAATTTTA
1422	TGCAATATGAATATAATTTTAAA
1423	CTGCAATATGAATATAATTTTAA
1424	TGCAATATGAATATAATTTTA
1425	TCCTGCAATATGAATATAATTTT
1426	CTGCAATATGAATATAATTTT
1427	AGTCCTGCAATATGAATATAATT
1428	TCCTGCAATATGAATATAATT
1429	TTTCTCTCGAAGGTCTTCTGCCG
1430	CCTTTCTCTCGAAGGTCTTCTGC
1431	CTTTCTCTCGAAGGTCTTCTGCC
1432	CTCTCGCACACACGCACACATGC
1433	CTCTCTCGCACACACGCACACAT
1434	TCTCTCGCACACACGCACACATG
1435	CTCTCGCACACACGCACACAT

* At least one nucleoside linkage of the nucleobase sequence is selected from a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a thiophosphorodiamidate linkage, a phosphorodiamidate (*e.g.*, comprising a phosphorodiamidate morpholino (PMO), 3' amino ribose, or 5' amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage.

[00243] Table 6 below identifies additional variants of STMN2 AON sequences:

Table 6. Additional STMN2 Oligonucleotide Variant Sequences

SEQ ID NO:	AON Sequence* (5' → 3')
1392	AUCCAAUUAAGAGAGAGUGAUGG
1393	AAUCCAAUUAAGAGAGAGUGAUG
1394	UCCAAUUAAGAGAGAGUGAUGGG
1395	GAGUCCUGCAAUAUGAAUAUAAU
1396	GUCCUGCAAUAUGAAUAUAAUUU
1397	GUCUUCUGCCGAGUCCUGCAAUA
1398	GCACACAUGCUCACACAGAGAGC
1399	ACACAUGCUCACACAGAGAGCCA
1400	UCCAAUUAAGAGAGAGUGAUG
1401	AAUCCAAUUAAGAGAGAGUGA
1402	CAAUUAAGAGAGAGUGAUGGG
1403	GUCCUGCAAUAUGAAUAUAAU
1404	GAGUCCUGCAAUAUGAAUAUA
1405	CCUGCAAUAUGAAUAUAAUUU
1406	AGGUCUUCUGCCGAGUCCUGC
1407	CUUCUGCCGAGUCCUGCAAUA
1408	ACACAUGCUCACACAGAGAGC
1409	GCACACAUGCUCACACAGAGA
1410	ACAUGCUCACACAGAGAGCCA
1411	CCAAUUAAGAGAGAGUGAU
1412	GAGUCCUGCAAUAUGAAUA
1413	UGCAAUAUGAAUAUAAUUU
1414	UCUGCCGAGUCCUGCAAUA
1415	GCACACAUGCUCACACAGA
1416	AUGCUCACACAGAGAGCCA
1436	CCUGCAAUAUGAAUAUAAUUUUA
1437	UGCAAUAUGAAUAUAAUUUUAAA
1438	CUGCAAUAUGAAUAUAAUUUUAA
1439	UGCAAUAUGAAUAUAAUUUUA
1440	UCCUGCAAUAUGAAUAUAAUUUU
1441	CUGCAAUAUGAAUAUAAUUUU
1442	AGUCCUGCAAUAUGAAUAUAAUU
1443	UCCUGCAAUAUGAAUAUAAUU
1444	UUUCUCUCGAAGGUCUUCUGCCG
1445	CCUUUCUCUCGAAGGUCUUCUGC
1446	CUUUCUCUCGAAGGUCUUCUGCC

1447	CUCUCGCACACACGCACACAUGC
1448	CUCUCUCGCACACACGCACACAU
1449	UCUCUCGCACACACGCACACAUG
1450	CUCUCGCACACACGCACACAU

* At least one nucleoside linkage of the nucleobase sequence is selected from a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a thiophosphorodiamidate linkage, a phosphorodiamidate (*e.g.*, comprising a phosphorodiamidate morpholino (PMO), 3' amino ribose, or 5' amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage.

10 **Antisense Oligonucleotides with One or more Spacers**

[00244] In various embodiments, antisense oligonucleotides comprise one or more spacers. In particular embodiments, an antisense oligonucleotide includes one spacer. In particular embodiments, an antisense oligonucleotide includes two spacers. In particular embodiments, an antisense oligonucleotide includes three spacers. Generally, a spacer refers to a nucleoside-replacement group lacking a nucleotide base and wherein the nucleoside sugar moiety is replaced by a non-sugar substitute group. The non-sugar substitute group is not capable of linking to a nucleobase, but is capable of linking with the 3' and 5' positions of nucleosides adjacent to the spacer through an internucleoside linking group.

[00245] In certain embodiments, an oligonucleotide with one or more spacers, such as disclosed herein, may be an oligonucleotide with 5 to 100 oligonucleotide units in length, for example, 10 to 60 oligonucleotide units in length, for example, 12 to 50 oligonucleotide units in length, 14 to 40 oligonucleotide units in length, 10 to 30 oligonucleotide units in length, for example, 14 to 30 oligonucleotide units in length, for example, 14 to 25 or 15 to 22 oligonucleotide units in length, or 18, 19, 20, 21, 22, 23, 24, or 25 oligonucleotide units in length. As used herein, an

“oligonucleotide unit” refers to either a nucleoside (*e.g.*, a nucleoside which includes a sugar and/or a nucleobase) or a nucleoside-replacement group (*e.g.*, a spacer) of the oligonucleotide.

[00246] In particular embodiments, oligonucleotides with one or more spacers are 25 oligonucleotide units in length. In particular embodiments, the oligonucleotides with one or more spacers are 23 oligonucleotide units in length. In particular embodiments, the oligonucleotides


with one or more spacers are 21 oligonucleotide units in length. In particular embodiments, the oligonucleotides with one or more spacers are 19 oligonucleotide units in length. In various embodiments, the oligonucleotides with one or more spacers are at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25 oligonucleotide units in length. In

5 various embodiments, the oligonucleotides with one or more spacers are at least 18 oligonucleotide units in length. In various embodiments, the oligonucleotides with one or more spacers are at least 19 oligonucleotide units in length. In various embodiments, the oligonucleotides with one or more spacers are at least 20 oligonucleotide units in length. In various embodiments, the oligonucleotides with one or more spacers are at least 21

10 oligonucleotide units in length. In various embodiments, the oligonucleotides with one or more spacers are at least 22 oligonucleotide units in length. In various embodiments, the oligonucleotides with one or more spacers are at least 23 oligonucleotide units in length. In various embodiments, the oligonucleotides with one or more spacers are at least 24 oligonucleotide units in length. In various embodiments, the oligonucleotides with one or more spacers are at least 25 oligonucleotide units in length.

[00247] In various embodiments, a STMN2 AON comprises a sequence that shares at least 80% identity with an equal length portion of any one of SEQ ID NOs: 1451-1664. In various embodiments, a STMN2 AON comprises a sequence that shares at least 85% identity with an equal length portion of any one of SEQ ID NOs: 1451-1664. In various embodiments, a STMN2 AON comprises a sequence that shares at least 90% identity with an equal length portion of any one of SEQ ID NOs: 1451-1664. In various embodiments, a STMN2 AON comprises a sequence that shares at least 95% identity with an equal length portion of any one of SEQ ID NOs: 1451-1664. In various embodiments, a STMN2 AON comprises a sequence that shares 100% identity with an equal length portion of any one of SEQ ID NOs: 1451-1664.


25 [00248] In some embodiments, the spacer is of Formula (X):



Formula (X)

wherein ring A is as defined herein.


[00249] In some embodiments, the spacer is of Formula (Xa):



Formula (Xa)

wherein ring A is as defined herein and the -CH₂-O- group is on a ring A atom adjacent to the -O- group.

- [00250]** As generally defined herein, ring A of formulae (X) and (Xa), is an optionally substituted 4-8 member monocyclic cycloalkyl group (*e.g.* ring A is cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl) or a 4-8 member monocyclic heterocyclyl group, wherein the heterocyclyl group contains 1 or 2 heteroatoms selected from O, S and N (*e.g.* ring A is oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, 1,4-dioxanyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, azepanyl). In some embodiments, ring A is tetrahydrofuranyl. In some embodiments, ring A is tetrahydropyranyl. In some embodiments, ring A is pyrrolidinyl. In some embodiments, ring A is cyclopentyl. In some embodiments, the monocyclic cycloalkyl or monocyclic heterocyclyl is not further substituted. In some embodiments, the cycloalkyl or heterocyclyl is further substituted with 0, 1, 2 or 3 substituents selected from halo (*e.g.*, -F, -Cl), -Ome, -Oet -O(CH₂)Ome, -O(CH₂)₂Ome and CN. In some embodiments, the spacer is represented by Formula (I), wherein:




Formula (I)

X is selected from -CH₂- and -O-; and

n is 0, 1, 2 or 3.

- [00251]** In some embodiments, the spacer is represented by Formula (I'), wherein:




Formula (I')

X is selected from -CH₂- and -O-; and

n is 0, 1, 2 or 3.


[00252] In some embodiments, the spacer is represented by Formula (Ia), wherein:



Formula (Ia)

and n is 0, 1, 2 or 3.

5 [00253] In some embodiments, the spacer is represented by Formula (Ia'), wherein:




Formula (Ia')

and n is 0, 1, 2 or 3.

[00254] As generally defined herein, X is selected from -CH₂- and -O-. In some embodiments, X is -CH₂-. In other embodiments, X is -O-.

10 [00255] As generally defined herein, n is 0, 1, 2 or 3. In some embodiments, n is 0. In some embodiments, n is 1 or 2. In some embodiments, n is 1. In other embodiments, n is 2. In certain embodiments, n is 3.


[00256] In some embodiments, the spacer is represented by Formula (II), wherein:



Formula (II)

15 X is selected from -CH₂- and -O-.


[00257] In some embodiments, the spacer is represented by Formula (II'), wherein:



Formula (II')


X is selected from -CH₂- and -O-.

[00258] In some embodiments, the spacer is represented by Formula (Iia), wherein:




Formula (Iia).

5 [00259] In some embodiments, the spacer is represented by Formula (Iia'), wherein:



Formula (Iia').


[00260] In some embodiments, the spacer is represented by Formula (III), wherein:



Formula (III)

X is selected from -CH₂- and -O-.


10 [00261] In some embodiments, the spacer is represented by Formula (III'), wherein:



Formula (III')


X is selected from -CH₂- and -O-.

[00262] In some embodiments, the spacer is represented by Formula (IIIa), wherein:



Formula (IIIa).

[00263] In some embodiments, the spacer is represented by Formula (IIIa'), wherein:



Formula (IIIa').

5 [00264] In some embodiments, the open positions of Formulae (I), (I'), (Ia), (Ia'), (II), (II'), (Iia), (Iia'), (III), (III'), (IIIa) and (IIIa') (*i.e.*, the positions not specifically depicted as bearing exclusively hydrogen atoms, including the -CH₂- group of X) are further substituted with 0-3 substituents selected from halo (*e.g.*, -F, -Cl), -Ome, -Oet -O(CH₂)Ome, -O(CH₂)₂Ome and CN. In some embodiments, Formulae (I), (I'), (Ia), (Ia'), (II), (II'), (Iia), (Iia'), (III), (III'), (IIIa) and
10 (IIIa') are not further substituted.

[00265] As described further below, a STMN2 oligonucleotide with one or more spacers is described in reference to a corresponding STMN2 parent oligonucleotide. In various embodiments, a STMN2 oligonucleotide with a spacer differs from a STMN2 parent oligonucleotide in that the spacer replaces a nucleoside in the STMN2 parent oligonucleotide. As
15 used hereafter, the "position" of the STMN2 oligonucleotide refers to a particular location as counted from the 5' end of the STMN2 oligonucleotide. In various embodiments, the spacer replaces a nucleoside at any one of positions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 of the STMN2 parent oligonucleotide. In particular
20 embodiments, a spacer replaces a nucleoside at one of positions 7, 8, 11, 14, 16, 19, or 22 of the STMN2 parent oligonucleotide.

[00266] In various embodiments, a STMN2 oligonucleotide includes one spacer that replaces a nucleoside in the STMN2 parent oligonucleotide (*e.g.*, one spacer replaces one nucleoside of the STMN2 parent oligonucleotide). In particular embodiments, the spacer replaces a nucleoside between positions 9 and 15 of the STMN2 parent oligonucleotide. In particular embodiments, the
25 spacer replaces a nucleoside between positions 9 and 12 of the STMN2 parent oligonucleotide. In

particular embodiments, the spacer replaces a nucleoside at position 10 of the STMN2 parent oligonucleotide. In particular embodiments, the spacer replaces a nucleoside at position 11 of the STMN2 parent oligonucleotide. In particular embodiments, the spacer replaces a nucleoside at position 12 of the STMN2 parent oligonucleotide. In particular embodiments, the spacer replaces a nucleoside between positions 12 and 16 of the STMN2 parent oligonucleotide. In particular embodiments, the spacer replaces a nucleoside at position 15 of the STMN2 parent oligonucleotide.

[00267] In various embodiments, a STMN2 oligonucleotide including one spacer has 2 segments, where at least one of the 2 segments has at most 11 linked nucleosides. For example, the STMN2 oligonucleotide may be 23 oligonucleotide units in length, and the spacer can be located at position 12. Therefore, the STMN2 oligonucleotide has 2 segments divided by the spacer, where both of the 2 segments are 11 nucleobases in length. In various embodiments, a STMN2 oligonucleotide including one spacer has 2 segments, where at least one of the 2 segments has at most 10 linked nucleosides. For example, the STMN2 oligonucleotide may be 21 oligonucleotide units in length, and the spacer can be located at position 11. Therefore, the STMN2 oligonucleotide has 2 segments divided by the spacer, where both of the 2 segments are 10 nucleobases in length. As another example, the STMN2 oligonucleotide may be 25 oligonucleotide units in length, and the spacer can be located at position 15. Therefore, the STMN2 oligonucleotide has 2 segments divided by the spacer, where one of the 2 segments is 14 nucleobases in length and the second of the 2 segments is 10 nucleobases in length.

[00268] In various embodiments, a STMN2 oligonucleotide includes two spacers that each replace a nucleoside in the STMN2 parent oligonucleotide (e.g., two spacers replace two separate nucleosides of the STMN2 parent oligonucleotide). In various embodiments, a first spacer and a second spacer are separated by at least 5 nucleobases, at least 6 nucleobases, at least 7 nucleobases, at least 8 nucleobases, at least 9 nucleobases, or at least 10 nucleobases in the oligonucleotide. In particular embodiments, a first spacer and a second spacer are separated by at least 5 nucleobases, at least 6 nucleobases, or at least 7 nucleobases. In particular embodiments, the first spacer and the second spacer are not adjacent to one another in the oligonucleotide.

[00269] In particular embodiments, the first spacer replaces a nucleoside between positions 7 and 11 of the STMN2 parent oligonucleotide. In various embodiments, the first spacer replaces a nucleoside between positions 8 and 11, positions 9 and 11, positions 10 and 11, positions 7 and 10, positions 7 and 9, positions 7 and 8, positions 8 and 10, positions 8 and 9, or positions 9 and 10 of the STMN2 parent oligonucleotide. In particular embodiments, the second spacer replaces a

nucleoside between positions 14 and 22 of the STMN2 parent oligonucleotide. In various embodiments, the second spacer replaces a nucleoside between positions 15 and 22, positions 16 and 22, positions 17 and 22, position 18 and 22, position 19 and 22, positions 20 and 22, positions 21 and 22, positions 15 and 21, position 16 and 21, positions 17 and 21, positions 18 and 21, positions 19 and 21, positions 20 and 21, positions 15 and 20, positions 16 and 20, positions 17 and 20, positions 18 and 20, positions 19 and 20, positions 15 and 19, positions 16 and 19, positions 17 and 19, positions 18 and 19, positions 15 and 18, position 16 and 18, position 17 and 18, positions 15 and 17, positions 16 and 17, or positions 15 and 16 of the STMN2 parent oligonucleotide.

[00270] In preferred embodiments, the first spacer replaces a nucleoside at position 7 of the STMN2 parent oligonucleotide and the second spacer replaces a nucleoside at position 14 of the STMN2 parent oligonucleotide. In preferred embodiments, the first spacer replaces a nucleoside at position 8 of the STMN2 parent oligonucleotide and the second spacer replaces a nucleoside at position 16 of the STMN2 parent oligonucleotide. In preferred embodiments, the first spacer replaces a nucleoside at position 11 of the STMN2 parent oligonucleotide and the second spacer replaces a nucleoside at position 22 of the STMN2 parent oligonucleotide. In preferred embodiments, the first spacer replaces a nucleoside at position 9 of the STMN2 parent oligonucleotide and the second spacer replaces a nucleoside at position 19 of the STMN2 parent oligonucleotide.

[00271] In various embodiments, a STMN2 oligonucleotide includes three spacers that each replace a nucleoside in the STMN2 parent oligonucleotide (e.g., three spacers replace three separate nucleosides of the STMN2 parent oligonucleotide). In particular embodiments, the first spacer replaces a nucleoside between positions 7 and 11 of the STMN2 parent oligonucleotide. In particular embodiments, the second spacer replaces a nucleoside between positions 14 and 22 of the STMN2 parent oligonucleotide. In particular embodiments, the third spacer replaces a nucleoside between positions 21 and 24 of the STMN2 parent oligonucleotide. In some embodiments, the first spacer replaces a nucleoside between positions 2 and 5 of the STMN2 parent oligonucleotide. In particular embodiments, the second spacer replaces a nucleoside between positions 8 and 12 of the STMN2 parent oligonucleotide. In particular embodiments, the third spacer replaces a nucleoside between positions 18 and 22 of the STMN2 parent oligonucleotide.

[00272] In various embodiments, the three spacers in a STMN2 oligonucleotide are positioned such that each of the four segments of the STMN2 oligonucleotide are at most 7 linked

nucleosides in length. For example, a STMN2 oligonucleotide may have a first segment with 7 linked nucleosides connected to a first spacer, then a second segment with 7 linked nucleosides connected on one end to the first spacer and connected on another end to a second spacer, then a third segment with 6 linked nucleosides connected on one end to the second spacer and connected on another end to a third spacer, then a fourth segment with 6 linked nucleosides connected to the third spacer.

[00273] In various embodiments, the one or more spacers are positioned in the oligonucleotide to replace one or more adenosine or thymine nucleosides (as opposed to guanine or cytosine nucleosides). For example, the one or more spacers can replace one, two, three, four, five, six, seven, eight, or nine adenosine or thymine nucleosides in the oligonucleotide. In various embodiments, the one or more spacers are positioned in the oligonucleotide to replace one or more guanine or cytosine nucleosides (as opposed to adenosine or thymine nucleosides).). For example, the one or more spacers can replace one, two, three, four, five, six, seven, eight, or nine guanine or cytosine nucleosides in the oligonucleotide. In various embodiments, the spacers are positioned in the oligonucleotide to replace an equal number of adenosine/thymine nucleosides and guanine/cytosine nucleosides. For example, a first spacer in the oligonucleotide may replace an adenosine/thymine nucleoside and a second spacer in the oligonucleotide may replace a guanine/cytosine nucleoside.

[00274] In various embodiments, the one or more spacers are positioned in the oligonucleotide to control the sequence content in the oligonucleotide. For example, the one or more spacers are positioned such that at least one of the spacers is located adjacent to a guanine group. In various embodiments, an oligonucleotide with spacers can include one spacer adjacent to a guanine group, two spacers adjacent to guanine groups, three spacers adjacent to guanine groups, four spacers adjacent to guanine groups, or five spacers adjacent to guanine groups. In one embodiment, if counting from the 5' end of the oligonucleotide, a spacer immediately precedes a guanine group in the sequence. Thus, in various embodiments, an oligonucleotide with spacers can include one spacer that immediately precedes a guanine group, two spacers that each immediately precede a guanine group, three spacers that each immediately precede a guanine group, four spacers that each immediately precede a guanine group, or five spacers that each immediately precede a guanine group. In one embodiment, if counting from the 5' end of the oligonucleotide, a guanine group is immediately succeeded by a spacer. Thus, in various embodiments, an oligonucleotide with spacers can include one spacer that immediately succeeds a guanine group, two spacers that each immediately succeed a guanine group, three spacers that each immediately succeed a

guanine group, four spacers that each immediately succeed a guanine group, or five spacers that each immediately succeed a guanine group. In various embodiments, the spacers in the oligonucleotide can be positioned to maximize the number of spacers adjacent to guanine groups.

[00275] In various embodiments, the one or more spacers are positioned in the oligonucleotide to replace one or more adenosine or thymine nucleosides such that the one or more spacers are located adjacent guanine groups. For example, two spacers can replace adenosine or thymine nucleosides in the oligonucleotide, each of the two spacers being located adjacent to a guanine group.

[00276] In various embodiments, the STMN2 oligonucleotide with one or more spacers has a particular GC content. As used herein, GC content (or guanine-cytosine content) is the percentage of nitrogenous bases in the oligonucleotide that are either guanine (G) or cytosine (C). In various embodiments, the STMN2 oligonucleotide with one or more spacers has at least 10% GC content, at least 20% GC content, at least 25% GC content, at least 30% GC content, at least 35% GC content, at least 40% GC content, at least 45% GC content, at least 50% GC content, at least 55% GC content, at least 60% GC content, at least 65% GC content, at least 75% GC content, at least 80% GC content, at least 85% GC content, at least 90% GC content, or at least 95% GC content. In particular embodiments, the STMN2 oligonucleotide with one or more spacers has at least 30% GC content. In particular embodiments, the STMN2 oligonucleotide with one or more spacers has at least 40% GC content. In various embodiments, the one or more spacers are positioned in the STMN2 oligonucleotide to maximize GC content. For example, instead of selecting a guanine or cytosine for replacement by a spacer in the STMN2 oligonucleotide, a thymine or adenine can be selected for replacement by a spacer.

[00277] In various embodiments, a STMN2 oligonucleotide with spacers is designed such that 1) each segment of the STMN2 oligonucleotide has at most 7 linked nucleosides and 2) at least two, three, or four spacers are positioned adjacent to a guanine group. In some embodiments, a STMN2 oligonucleotide with spacers is designed such that 1) each segment of the STMN2 oligonucleotide has at most 7 linked nucleosides and 2) each of two spacers precede a guanine group.

[00278] In various embodiments, the inclusion of one or more spacers in the STMN2 oligonucleotide does not decrease the effectiveness of the STMN2 oligonucleotide with the spacers in restoring full length STMN2 protein or full length STMN2 mRNA in comparison to the effect of a corresponding STMN2 parent oligonucleotide. In various embodiments, the inclusion of one or more spacers in the STMN2 oligonucleotide increases the effectiveness of the STMN2

oligonucleotide with the spacers in restoring full length STMN2 protein or full length STMN2 mRNA in comparison to the effect of a corresponding STMN2 parent oligonucleotide. In various embodiments, the inclusion of one or more spacers in the STMN2 oligonucleotide does not decrease the effectiveness of the STMN2 oligonucleotide with the spacers in reducing quantity of STMN2 transcripts with a cryptic exon in comparison to the effect of a corresponding STMN2 parent oligonucleotide. In various embodiments, the inclusion of one or more spacers in the STMN2 oligonucleotide increases the effectiveness of the STMN2 oligonucleotide with the spacers in reducing quantity of STMN2 transcripts with a cryptic exon in comparison to the effect of a corresponding STMN2 parent oligonucleotide.

[00279] Tables 7A, 7B, 8, and 9 document example STMN2 oligonucleotides with one or more spacers and their relation to corresponding STMN2 parent oligonucleotides. Each STMN2 oligonucleotide is assigned a sequence name. As used hereafter, the nomenclature of the sequence name is expressed as “X_spA” (for a STMN2 AON with one spacer), “X_spA_spB” (for a STMN2 AON with two spacers), or “X_spA_spB_spC” (for a STMN2 AON with three spacers). Here, “X” refers to the length of the STMN2 AON, “A” refers to the position in the STMN2 AON where the first spacer is located, “B” refers to the position in the STMN2 AON where the second spacer is located, and if present, “C” refers to the position in the STMN2 AON where the third spacer is located.

[00280] In various embodiments, STMN2 oligonucleotides include one spacer. In various embodiments, the STMN2 oligonucleotides are oligonucleotide variants, such as any one of a 23mer, 21mer, or 19mer. In various embodiments, the inclusion of a spacer divides up the STMN2 oligonucleotide into two separate segments, where at least one of the segments is at most 11 linked nucleosides in length. In various embodiments, the inclusion of a spacer divides up the STMN2 oligonucleotide into two separate segments, where at least one of the segments is at most 10 linked nucleosides in length.

[00281] In various embodiments, the spacer is located between positions 10 and 15 of the oligonucleotide. In various embodiments, the spacer is located between positions 10 and 12 of the oligonucleotide. In particular embodiments, the spacer is located at position 10 of the oligonucleotide. In particular embodiments, the spacer is located at position 11 of the oligonucleotide. In particular embodiments, the spacer is located at position 12 of the oligonucleotide. In particular embodiments, the spacer is located at position 15 of the oligonucleotide. Example STMN2 AONs with one spacer are documented below in Table 7A.

Table 7A: Identification of STMN2 AONs with one spacer. Here, each STMN2 AON has 2 segments, where at least one of the segments has at most 11 linked nucleosides.

Sequence name	Relation to STMN2 oligonucleotide variant	Sequence ID Number (SEQ ID NO)	Sequence* (where X indicates a nucleoside of the STMN2 parent oligonucleotide and S _y indicates presence of a Spacer where y denotes the position) (5' → 3')
STMN2 parent oligonucleotide	N/A	1522	XXXXXXXXXXXXXXXXXXXXXXXXXXXXX (25mer)
STMN2 Oligonucleotide (25mer) with Spacer at position 15 (STMN2 AON 25_sp15)	Nucleoside at position 15 of 25mer is substituted with a spacer	1523	XXXXXXXXXXXXXXXXX _{S15} XXXXXXXXXX
STMN2 oligonucleotide variant (23mer)	N/A	1524	XXXXXXXXXXXXXXXXXXXXXXXXXXXXX (23mer)
STMN2 Oligonucleotide (23mer) with Spacer at position 12 (STMN2 AON 23_sp12)	Nucleoside at position 12 of 23mer is substituted with a spacer	1525	XXXXXXXXXXXXX _{S12} XXXXXXXXXXXXX
STMN2 oligonucleotide variant (21mer)	N/A	1526	XXXXXXXXXXXXXXXXXXXXXXXXXXXXX (21mer)
STMN2 Oligonucleotide (21mer) with Spacer at position 11 (STMN2 AON 21_sp11)	Nucleoside at position 11 of 21mer is substituted with a spacer	1527	XXXXXXXXXXXXX _{S11} XXXXXXXXXXXXX
STMN2 oligonucleotide variant (19mer)	N/A	1528	XXXXXXXXXXXXXXXXXXXXXXXXXXXXX (19mer)
STMN2 Oligonucleotide (19mer) with Spacer at position 10 (STMN2 AON 19_sp10)	Nucleoside at position 10 of 19mer is substituted with a spacer	1529	XXXXXXXXXXXXX _{S10} XXXXXXXXXXXXX

* At least one nucleoside linkage of the nucleobase sequence is selected from a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a phosphorodiamidate (*e.g.*, comprising a phosphorodiamidate morpholino (PMO), 3' amino ribose, or 5' amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a

thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage.

[00282] In various embodiments, STMN2 oligonucleotides include two spacers. In various embodiments, the inclusion of a spacer divides up the STMN2 oligonucleotide into three separate segments, where at least one of the segments is at most 7 linked nucleosides in length. Example STMN2 AONs with two spacers are documented below in Table 7B.

Table 7B: Identification of STMN2 AONs with two spacers. Here, each STMN2 AON has 3 segments, where at least one of the segments has at most 7 linked nucleosides.

Sequence name	Relation to STMN2 parent oligonucleotide	Sequence ID Number (SEQ ID NO)	Sequence* (where X indicates a nucleoside of the STMN2 parent oligonucleotide and S _y indicates presence of a Spacer where y denotes the position) (5' → 3')
STMN2 parent oligonucleotide	N/A	1530	XXXXXXXXXXXXXXXXXXXXXXXXXXXX
STMN2 Oligonucleotide with Spacers at positions 11 and 22 (STMN2 AON 25_sp11sp22)	Nucleosides at positions 11 and 22 are each substituted with a spacer	1531	XXXXXXXXXXS ₁₁ XXXXXXXXXXS ₂₂ XXX
STMN2 Oligonucleotide with Spacers at positions 7 and 14 (STMN2 AON 25_sp7sp14)	Nucleosides at positions 7 and 14 are each substituted with a spacer	1532	XXXXXXS ₇ XXXXXXS ₁₄ XXXXXXXXXXXX
STMN2 Oligonucleotide with Spacers at positions 8 and 19 (STMN2 AON 25_sp8sp19)	Nucleosides at positions 8 and 19 are substituted with spacers	1533	XXXXXXXS ₈ XXXXXXXXXXXXS ₁₉ XXXXXX
STMN2 Oligonucleotide with Spacers at positions 8 and 14 (STMN2 AON 25_sp8sp14)	Nucleosides at positions 8 and 14 are substituted with spacers	1534	XXXXXXXS ₈ XXXXXXS ₁₄ XXXXXXXXXXXX
STMN2 Oligonucleotide with Spacers at positions 9 and 14	Nucleosides at positions 9 and 14 are	1535	XXXXXXXXXS ₉ XXXXXS ₁₄ XXXXXXXXXXXX

(STMN2 AON 25 sp9sp14)	substituted with spacers		
STMN2 Oligonucleotide with Spacers at positions 10 and 14 (STMN2 AON 25 sp10sp14)	Nucleosides at positions 10 and 14 are substituted with spacers	1536	XXXXXXXXXXS ₁₀ XXXS ₁₄ XXXXXXXXXXXX
STMN2 Oligonucleotide with Spacers at positions 11 and 14 (STMN2 AON 25 sp11sp14)	Nucleosides at positions 11 and 14 are substituted with spacers	1537	XXXXXXXXXXS ₁₁ XXS ₁₄ XXXXXXXXXXXX
STMN2 Oligonucleotide with Spacers at positions 8 and 15 (STMN2 AON 25 sp8sp15)	Nucleosides at positions 8 and 15 are substituted with spacers	1538	XXXXXXXS ₈ XXXXXXS ₁₅ XXXXXXXXXXXX
STMN2 Oligonucleotide with Spacers at positions 9 and 15 (STMN2 AON 25 sp9sp15)	Nucleosides at positions 9 and 15 are substituted with spacers	1539	XXXXXXXXXS ₉ XXXXXS ₁₅ XXXXXXXXXXXX
STMN2 Oligonucleotide with Spacers at positions 10 and 15 (STMN2 AON 25 sp10sp15)	Nucleosides at positions 10 and 15 are substituted with spacers	1540	XXXXXXXXXXS ₁₀ XXXXS ₁₅ XXXXXXXXXXXX
STMN2 Oligonucleotide with Spacers at positions 11 and 15 (STMN2 AON 25 sp11sp15)	Nucleosides at positions 11 and 15 are substituted with spacers	1541	XXXXXXXXXXS ₁₁ XXXS ₁₅ XXXXXXXXXXXX
STMN2 Oligonucleotide with Spacers at positions 8 and 16 (STMN2 AON 25 sp8sp16)	Nucleosides at positions 8 and 16 are substituted with spacers	1542	XXXXXXXS ₈ XXXXXXS ₁₆ XXXXXXXXXXXX
STMN2 Oligonucleotide with Spacers at positions 9 and 16	Nucleosides at positions 9 and 16 are	1543	XXXXXXXXXS ₉ XXXXXXS ₁₆ XXXXXXXXXXXX

(STMN2 AON 25 sp9sp16)	substituted with spacers		
STMN2 Oligonucleotide with Spacers at positions 10 and 16 (STMN2 AON 25 sp10sp16)	Nucleosides at positions 10 and 16 are substituted with spacers	1544	XXXXXXXXXXS ₁₀ XXXXXS ₁₆ XXXXXXXXXX
STMN2 Oligonucleotide with Spacers at positions 11 and 16 (STMN2 AON 25 sp11sp16)	Nucleosides at positions 11 and 16 are substituted with spacers	1545	XXXXXXXXXXS ₁₁ XXXXS ₁₆ XXXXXXXXXX
STMN2 Oligonucleotide with Spacers at positions 8 and 17 (STMN2 AON 25 sp8sp17)	Nucleosides at positions 8 and 17 are substituted with spacers	1546	XXXXXXXS ₈ XXXXXXXXXS ₁₇ XXXXXXX
STMN2 Oligonucleotide with Spacers at positions 9 and 17 (STMN2 AON 25 sp9sp17)	Nucleosides at positions 9 and 17 are substituted with spacers	1547	XXXXXXXXXS ₉ XXXXXXXXXS ₁₇ XXXXXXXXX
STMN2 Oligonucleotide with Spacers at positions 10 and 17 (STMN2 AON 25 sp10sp17)	Nucleosides at positions 10 and 17 are substituted with spacers	1548	XXXXXXXXXXS ₁₀ XXXXXS ₁₇ XXXXXXXXXX
STMN2 Oligonucleotide with Spacers at positions 11 and 17 (STMN2 AON 25 sp11sp17)	Nucleosides at positions 11 and 17 are substituted with spacers	1549	XXXXXXXXXXXS ₁₁ XXXXXS ₁₇ XXXXXXXXXX
STMN2 Oligonucleotide with Spacers at positions 8 and 18 (STMN2 ATON 25 sp8sp18)	Nucleosides at positions 8 and 18 are substituted with spacers	1550	XXXXXXXS ₈ XXXXXXXXXXS ₁₈ XXXXXXX
STMN2 Oligonucleotide with Spacers at positions 9 and 18	Nucleosides at positions 9 and 18 are	1551	XXXXXXXXXS ₉ XXXXXXXXXXS ₁₈ XXXXXXX

(STMN2 AON 25 sp9sp18)	substituted with spacers		
STMN2 Oligonucleotide with Spacers at positions 10 and 18 (STMN2 AON 25 sp10sp18)	Nucleosides at positions 10 and 18 are substituted with spacers	1552	XXXXXXXXXXS ₁₀ XXXXXXXXS ₁₈ XXXXXX
STMN2 Oligonucleotide with Spacers at positions 11 and 18 (STMN2 AON 25 sp11sp18)	Nucleosides at positions 11 and 18 are substituted with spacers	1553	XXXXXXXXXXS ₁₁ XXXXXXS ₁₈ XXXXXX
STMN2 Oligonucleotide with Spacers at positions 9 and 19 (STMN2 AON 25 sp9sp19)	Nucleosides at positions 9 and 19 are substituted with spacers	1554	XXXXXXXXXS ₉ XXXXXXXXXXS ₁₉ XXXXXX
STMN2 Oligonucleotide with Spacers at positions 10 and 19 (STMN2 AON 25 sp10sp19)	Nucleosides at positions 10 and 19 are substituted with spacers	1555	XXXXXXXXXXS ₁₀ XXXXXXXXXXS ₁₉ XXXXXX
STMN2 Oligonucleotide with Spacers at positions 11 and 19 (STMN2 AON 25 sp11sp19)	Nucleosides at positions 11 and 19 are substituted with spacers	1556	XXXXXXXXXXS ₁₁ XXXXXXS ₁₉ XXXXXX
STMN2 Oligonucleotide with Spacers at positions 9 and 20 (STMN2 AON 25 sp9sp20)	Nucleosides at positions 9 and 20 are substituted with spacers	1557	XXXXXXXXXS ₉ XXXXXXXXXXS ₂₀ XXXXX
STMN2 Oligonucleotide with Spacers at positions 10 and 20 (STMN2 AON 25 sp10sp20)	Nucleosides at positions 10 and 20 are substituted with spacers	1558	XXXXXXXXXXS ₁₀ XXXXXXXXXXS ₂₀ XXXXX
STMN2 Oligonucleotide with Spacers at positions 11 and 20	Nucleosides at positions 11 and 20 are	1559	XXXXXXXXXXS ₁₁ XXXXXXXXXXS ₂₀ XXXXX

(STMN2 AON 25 sp11sp20)	substituted with spacers		
STMN2 Oligonucleotide with Spacers at positions 10 and 21 (STMN2 AON 25 sp10sp21)	Nucleosides at positions 10 and 21 are substituted with spacers	1560	XXXXXXXXXXS ₁₀ XXXXXXXXXXS ₂₁ XXXX
STMN2 Oligonucleotide with Spacers at positions 11 and 21 (STMN2 AON 25 sp11sp21)	Nucleosides at positions 11 and 21 are substituted with spacers	1561	XXXXXXXXXXS ₁₁ XXXXXXXXXXS ₂₁ XXXX
STMN2 Oligonucleotide with Spacers at positions 4 and 15 (STMN2 AON 25 sp4sp15)	Nucleosides at positions 4 and 15 are substituted with spacers	1562	XXXS ₄ XXXXXXXXXXS ₁₅ XXXXXXXXXX
STMN2 Oligonucleotide with Spacers at positions 7 and 19 (STMN2 AON 25 sp7sp19)	Nucleosides at positions 7 and 19 are substituted with spacers	1563	XXXXXXS ₇ XXXXXXXXXXS ₁₉ XXXXXX
STMN2 Oligonucleotide with Spacers at positions 7 and 18 (STMN2 AON 25 sp7sp18)	Nucleosides at positions 7 and 18 are substituted with spacers	1564	XXXXXXS ₇ XXXXXXXXXXS ₁₈ XXXXXX
STMN2 Oligonucleotide with Spacers at positions 9 and 21 (STMN2 AON 25 sp9sp21)	Nucleosides at positions 9 and 21 are substituted with spacers	1565	XXXXXXXXXS ₉ XXXXXXXXXXS ₂₁ XXXX

* At least one nucleoside linkage of the nucleobase sequence is selected from a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a phosphorodiamidate (*e.g.*, comprising a phosphorodiamidate morpholino (PMO), 3' amino ribose, or 5' amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a

thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage.

[00283] In various embodiments, STMN2 oligonucleotides include three spacers. The inclusion of three spacers divides up the STMN2 oligonucleotide into four separate segments. In various embodiments, the three spacers are located at different positions of the STMN2 oligonucleotide such that each of the segments of the STMN2 oligonucleotide are at most 7 linked nucleosides in length. Example STMN2 AONs with three spacers are documented below in Table 8.

Table 8: Identification of STMN2 AONs or AON variants with three spacers. Here, each STMN2 AON has 4 segments, where each segment has at most 7 linked nucleosides.

Sequence name	Relation to STMN2 parent oligonucleotide	Sequence ID Number (SEQ ID NO)	Sequence* (where <i>X</i> indicates a nucleoside of the STMN2 parent oligonucleotide and <i>S_y</i> indicates presence of a Spacer where <i>y</i> denotes the position) (5' → 3')
STMN2 Oligonucleotide with Spacers at positions 8 and 16 and 24 (STMN2 AON 25_sp8sp16sp24)	Nucleosides at positions 8 and 16 and 24 are substituted with spacers	1566	XXXXXXXXS ₈ XXXXXXXXS ₁₆ XXXXXXXXS ₂₄ X
STMN2 Oligonucleotide with Spacers at positions 8 and 16 and 23 (STMN2 AON 25_sp8sp16sp23)	Nucleosides at positions 8 and 16 and 23 are substituted with spacers	1567	XXXXXXXXS ₈ XXXXXXXXS ₁₆ XXXXXXS ₂₃ XX
STMN2 Oligonucleotide with Spacers at positions 2 and 10 and 18 (STMN2 AON 25_sp8sp16sp23)	Nucleosides at positions 2 and 10 and 18 are substituted with spacers	1568	XS ₂ XXXXXXXXS ₁₀ XXXXXXXXS ₁₈ XXXXXX
STMN2 Oligonucleotide with Spacers at positions 3 and 10 and 18 (STMN2 AON 25_sp8sp16sp23)	Nucleosides at positions 3 and 10 and 18 are substituted with spacers	1569	XXS ₃ XXXXXXXXS ₁₀ XXXXXXXXS ₁₈ XXXXXX

AON 25_sp8sp16sp23)			
STMN2 Oligonucleotide with Spacers at positions 4 and 12 and 19 (STMN2 AON 25_sp4sp12sp19)	Nucleosides at positions 4 and 12 and 19 are substituted with spacers	1570	XXXX ₄ XXXXXXXX ₁₂ XXXXXXXX ₁₉ XXXX
STMN2 Oligonucleotide with Spacers at positions 8 and 13 and 18 (STMN2 AON 25_sp8sp13sp18)	Nucleosides at positions 8 and 13 and 18 are substituted with spacers	1571	XXXXXXXX ₈ XXXX ₁₃ XXXX ₁₈ XXXX
STMN2 Oligonucleotide with Spacers at positions 5 and 13 and 21 (STMN2 AON 25_sp5sp13sp21)	Nucleosides at positions 5 and 13 and 21 are substituted with spacers	1572	XXXX ₅ XXXXXXXX ₁₃ XXXXXXXX ₂₁ XXXX
STMN2 Oligonucleotide with Spacers at positions 7 and 13 and 19 (STMN2 AON 25_sp7sp13sp19)	Nucleosides at positions 7 and 13 and 19 are substituted with spacers	1573	XXXXXX ₇ XXXX ₁₃ XXXX ₁₉ XXXX
STMN2 Oligonucleotide with Spacers at positions 6 and 13 and 20 (STMN2 AON 25_sp6sp13sp20)	Nucleosides at positions 6 and 13 and 20 are substituted with spacers	1574	XXXX ₆ XXXXXX ₁₃ XXXXXX ₂₀ XXXX
STMN2 Oligonucleotide with Spacers at positions 8 and 11 and 19 (STMN2 AON 25_sp8sp11sp19)	Nucleosides at positions 8 and 11 and 19 are substituted with spacers	1575	XXXXXXXX ₈ XX ₁₁ XXXXXXXX ₁₉ XXXX
STMN2 Oligonucleotide with Spacers at positions 8 and 11	Nucleosides at positions 8 and 11 and 16	1576	XXXXXXXX ₈ XX ₁₁ XXXX ₁₆ XXXX

and 16 (STMN2 AON 23 sp8sp11sp16)	are substituted with spacers		
STMN2 Oligonucleotide with Spacers at positions 7 and 14 and 22 (STMN2 AON 23 sp7sp14sp22)	Nucleosides at positions 7 and 14 and 22 are substituted with spacers	1577	XXXXXXS ₇ XXXXXXS ₁₄ XXXXXXS ₂₂ XXX

* At least one nucleoside linkage of the nucleobase sequence is selected from a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a phosphorodiamidate (*e.g.*, comprising a phosphorodiamidate morpholino (PMO), 3' amino ribose, or 5' amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage.

[00284] In various embodiments, STMN2 AONs with one or more spacers are reduced in length in comparison to the STMN2 AONs described above in Tables 7B and 8. For example, such STMN2 AONs may be STMN2 oligonucleotide variants with one or more spacers. In various embodiments, the STMN2 oligonucleotide variants with one or more spacers are 23mers, 21mers, or 19mers. In various embodiments, STMN2 oligonucleotide variants include two spacers such that the STMN2 oligonucleotide variant includes three segments that are divided up by the two spacers. In various embodiments, at least one of the three segments has at most 7 linked nucleosides. In various embodiments, each of the three segments has at most 7 linked nucleosides. Example STMN2 oligonucleotide variants with one or more spacers are shown below in Table 9.

Table 9: STMN2 AON variants with two spacers. Here, each STMN2 AON variant has 3 segments, where each segment has at most 7 linked nucleosides.

Sequence name	Relation to STMN2 oligonucleotide variant	Sequence ID Number (SEQ ID NO)	Sequence* (where X indicates a nucleoside of the STMN2 oligonucleotide variant and S _y indicates presence of a Spacer where y denotes the position) (5' → 3')
---------------	---	--------------------------------	--

STMN2 oligonucleotide variant (23mer)	N/A	1578	XXXXXXXXXXXXXXXXXXXXXXXXX (23mer)
STMN2 Variant Oligonucleotide (23mer) with Spacers at positions 8 and 16 (STMN2 AON variant 23 sp8sp16)	Nucleosides at positions 8 and 16 are substituted with spacers	1579	XXXXXXXXS ₈ XXXXXXXXS ₁₆ XXXXXXX
STMN2 oligonucleotide variant (21mer)	N/A	1580	XXXXXXXXXXXXXXXXXXXXXXX (21mer)
STMN2 Variant Oligonucleotide (21mer) with Spacers at positions 5 and 12 (STMN2 AON variant 21 sp5sp12)	Nucleosides at positions 5 and 12 are substituted with spacers	1581	XXXXS ₅ XXXXXXS ₁₂ XXXXXXXXX
STMN2 Variant Oligonucleotide (21mer) with Spacers at positions 8 and 16 (STMN2 AON variant 21 sp8sp16)	Nucleosides at positions 8 and 16 are substituted with spacers	1582	XXXXXXXXS ₈ XXXXXXXXS ₁₆ XXXXX
STMN2 Variant Oligonucleotide (21mer) with Spacers at positions 6 and 14 (STMN2 AON variant 21 sp6sp14)	Nucleosides at positions 6 and 14 are substituted with spacers	1583	XXXXXS ₆ XXXXXXXXS ₁₄ XXXXXXX
STMN2 Variant Oligonucleotide (21mer) with Spacers at positions 8 and 14 (STMN2 AON variant 21 sp8sp14)	Nucleosides at positions 8 and 14 are substituted with spacers	1584	XXXXXXXXS ₈ XXXXXS ₁₄ XXXXXXX
STMN2 Variant Oligonucleotide	Nucleosides at positions 6 and	1585	XXXXXS ₆ XXXXXXXXXXXXXXXS ₂₀ X

(21mer) with Spacers at positions 8 and 14 (STMN2 AON variant 21_sp8sp14)	20 are substituted with spacers		
STMN2 oligonucleotide variant (19mer)	N/A	1586	XXXXXXXXXXXXXXXXXXXXX (19mer)
STMN2 Variant Oligonucleotide (19mer) with Spacers at positions 5 and 12 (STMN2 AON variant 19_sp5sp12)	Nucleosides at positions 5 and 12 are substituted with spacers	1587	XXXXS ₅ XXXXXXS ₁₂ XXXXXX
STMN2 Variant Oligonucleotide (19mer) with Spacers at positions 8 and 15 (STMN2 AON variant 19_sp8sp15)	Nucleosides at positions 8 and 15 are substituted with spacers	1588	XXXXXXXS ₈ XXXXXXS ₁₅ XXXX

* At least one nucleoside linkage of the nucleobase sequence is selected from a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a phosphorodiamidate (*e.g.*, comprising a phosphorodiamidate morpholino (PMO), 3' amino ribose, or 5' amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage.

10 Performance of STMN2 Oligonucleotides

[00285] Generally, STMN2 oligonucleotides and/or STMN2 parent oligonucleotides (*e.g.*, STMN2 oligonucleotides with sequences of any of SEQ ID NOs: 1-466, SEQ ID NO: 893-1338, SEQ ID NOs: 1342-1366, and SEQ ID NOs: 1392-1664) target STMN2 transcripts (for example, a STMN2 pre-mRNA comprising a cryptic exon) comprising a sequence that shares at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to SEQ ID NO:

1339 or SEQ ID NO: 1341 in order to increase, restore, rescue, or stabilize levels of expression of STMN2 mRNA that is capable of translation to produce a functional STMN2 protein (*e.g.*, full length STMN2). In various embodiments, STMN2 AONs can exhibit at least a 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% increase of full length STMN2 protein. In various embodiments, STMN2 AONs can exhibit at least a 100%, 200%, 300%, or 400% increase of full length STMN2 protein. In some embodiments, the percent increase of the full length STMN2 protein is an increase in comparison to a reduced level of full length STMN2 protein achieved using a TDP43 antisense oligonucleotide. For example, a TDP43 antisense oligonucleotide can be used to deplete full length STMN2 protein followed by increase of the full length STMN2 protein using a STMN2 AON.

[00286] In some embodiments, STMN2 AONs can exhibit at least a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% rescue of full length STMN2 protein. In some embodiments, the percent rescue of full length STMN2 refers to the % of full length STMN2 following depletion using a TDP43 antisense oligonucleotide and a treatment using STMN2 AONs in comparison to a negative control (*e.g.*, cells that did not undergo depletion or treatment or cells that were treated with a vehicle solution).

Modifications

[00287] A nucleoside is a base-sugar combination. The nucleobase (also known as base) portion of the nucleoside is normally a heterocyclic base moiety. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to the 2', 3' or 5' hydroxyl moiety of the sugar. Oligonucleotides are formed through the covalent linkage of adjacent nucleosides to one another, to form a linear polymeric oligonucleotide. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside linkages of the oligonucleotide.

[00288] Modifications to antisense compounds encompass substitutions or changes to internucleoside linkages, sugar moieties, or nucleobases. Modified antisense compounds are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target, increased stability in the presence of nucleases, or increased inhibitory activity.

[00289] Chemically modified nucleosides may also be employed to increase the binding affinity of a shortened or truncated antisense oligonucleotide for its target nucleic acid. Consequently,

comparable results can often be obtained with shorter antisense compounds that have such chemically modified nucleosides.

Modified Internucleoside Linkages

[00290] The naturally occurring internucleoside linkage of RNA and DNA is a 3' to 5'

phosphodiester linkage. Antisense compounds having one or more modified, i.e. non-naturally occurring, internucleoside linkages are often selected over antisense compounds having naturally occurring internucleoside linkages because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for target nucleic acids, and increased stability in the presence of nucleases.

[00291] Oligonucleotides having modified internucleoside linkages include internucleoside linkages that retain a phosphorus atom as well as internucleoside linkages that do not have a phosphorus atom. Representative phosphorus containing internucleoside linkages include, but are not limited to, phosphodiesters, phosphotriesters, methylphosphonates, phosphoramidate, and phosphorothioates. Methods of preparation of phosphorous-containing and non-phosphorous-containing linkages are well known.

[00292] In certain embodiments, antisense compounds targeted to a STMN2 nucleic acid comprise one or more modified internucleoside linkages. In certain embodiments, the modified internucleoside linkages are interspersed throughout the antisense compound. In certain embodiments, the modified internucleoside linkages are phosphorothioate linkages. In certain embodiments, each internucleoside linkage of an antisense compound is a phosphorothioate internucleoside linkage. In certain embodiments, the antisense compounds targeted to a STMN2 nucleic acid comprise at least one phosphodiester linkage and at least one phosphorothioate linkage.

Modified Sugar Moieties

[00293] Antisense compounds can optionally contain one or more nucleosides wherein the sugar group has been modified. Such sugar modified nucleosides may impart enhanced nuclease stability, increased binding affinity, or some other beneficial biological property to the antisense compounds. In certain embodiments, nucleosides comprise chemically modified ribofuranose ring moieties. Examples of chemically modified ribofuranose rings include without limitation, addition of substituent groups (including 5' and 2' substituent groups, bridging of non-geminal ring atoms to form bicyclic nucleic acids (BNA), replacement of the ribosyl ring oxygen atom with S, N®, or C(R₁)(R₂) (R, R₁ and R₂ are each independently H, C₁-C₁₂ alkyl or a protecting group) and combinations thereof. Examples of chemically modified sugars include 2'-F-5'-methyl substituted

nucleoside (*see* PCT International Application WO 2008/101157 Published on Aug. 21, 2008 for other disclosed 5',2'-bis substituted nucleosides) or replacement of the ribosyl ring oxygen atom with S with further substitution at the 2'-position (*see* published U.S. Patent Application US2005-0130923, published on Jun. 16, 2005) or alternatively 5'-substitution of a BNA (*see* PCT International Application WO 2007/134181 Published on Nov. 22, 2007 wherein LNA is substituted with for example a 5'-methyl or a 5'-vinyl group).

[00294] Examples of nucleosides having modified sugar moieties include without limitation nucleosides comprising 5'-vinyl, 5'-methyl (R or 5), 4'-S, 2'-F, 2'-OCH₃, 2'-OCH₂CH₃, 2'-OCH₂CH₂F and 2'-O(CH₂)₂OCH₃ substituent groups. The substituent at the 2' position can also be selected from allyl, amino, azido, thio, O-allyl, O—C₁-C₁₀ alkyl, OCF₃, OCH₂F, O(CH₂)₂S CH₃, O(CH₂)₂—O—N(R_m)(R_n), O—CH₂—C(=O)—N(R_m)(R_n), and O—CH₂—C(=O)—N(R₁)—(CH₂)₂—N(R_m)(R_n)-, where each R₁, R_m and R_n is, independently, H or substituted or unsubstituted C₁-C₁₀ alkyl.

[00295] Additional examples of modified sugar moieties include a 2'-Ome modified sugar moiety, bicyclic sugar moiety, 2'-O-(2-methoxyethyl) (2'-MOE), 2'-deoxy-2'-fluoro nucleoside, 2'-fluoro-β-D-arabinonucleoside, locked nucleic acid (LNA), constrained ethyl 2'-4'-bridged nucleic acid (cEt), S-cEt, tcDNA, hexitol nucleic acids (HNA), and tricyclic analog (*e.g.*, tcDNA).

[00296] As used herein, "bicyclic nucleosides" refer to modified nucleosides comprising a bicyclic sugar moiety. Examples of bicyclic nucleosides include without limitation nucleosides comprising a bridge between the 4' and the 2' ribosyl ring atoms. In certain embodiments, antisense compounds provided herein include one or more bicyclic nucleosides comprising a 4' to 2' bridge. Examples of such 4' to 2' bridged bicyclic nucleosides, include but are not limited to one of the formulae: 4'-(CH₂)—O-2' (LNA); 4'-(CH₂)—S-2'; 4'-(CH₂)₂—O-2' (ENA); 4'-CH(CH₃)—O-2' and 4'-CH(CH₂OCH₃)—O-2' (and analogs thereof *see* U.S. Pat. No. 7,399,845, issued on Jul. 15, 2008); 4'-C(CH₃)(CH₃)—O-2' (and analogs thereof *see* published International Application WO/2009/006478, published Jan. 8, 2009); 4'-CH₂—N(OCH₃)-2' (and analogs thereof *see* published International Application WO/2008/150729, published Dec. 11, 2008); 4'-CH₂—O—N(CH₃)-2' (*see* published U.S. Patent Application US2004-0171570, published Sep. 2, 2004); 4'-CH₂—N®—O-2', wherein R is H, C₁-C₁₂ alkyl, or a protecting group (*see* U.S. Pat. No. 7,427,672, issued on Sep. 23, 2008); 4'-CH₂—C(H)(CH₃)-2' (*see* Chattopadhyaya et al., J. Org. Chem., 2009, 74, 118-134); and 4'-CH₂—C(=CH₂)-2' (and analogs thereof *see* published International Application WO 2008/154401, published on Dec. 8, 2008).

[00297] Further reports related to bicyclic nucleosides can also be found in published literature (see for example: Singh et al., Chem. Commun., 1998, 4, 455-456; Koshkin et al., Tetrahedron, 1998, 54, 3607-3630; Wahlestedt et al., Proc. Natl. Acad. Sci. U.S.A., 2000, 97, 5633-5638; Kumar et al., Bioorg. Med. Chem. Lett., 1998, 8, 2219-2222; Singh et al., J. Org. Chem., 1998, 63, 10035-10039; Srivastava et al., J. Am. Chem. Soc., 2007, 129(26) 8362-8379; Elayadi et al., Curr. Opinion Invest. Drugs, 2001, 2, 558-561; Braasch et al., Chem. Biol., 2001, 8, 1-7; and Orum et al., Curr. Opinion Mol. Ther., 2001, 3, 239-243; U.S. Pat. Nos. 6,268,490; 6,525,191; 6,670,461; 6,770,748; 6,794,499; 7,034,133; 7,053,207; 7,399,845; 7,547,684; and 7,696,345; U.S. Patent Publication No. US2008-0039618; US2009-0012281; U.S. Patent Ser. No. 60/989,574; 61/026,995; 61/026,998; 61/056,564; 61/086,231; 61/097,787; and 61/099,844; Published PCT International applications WO 1994/014226; WO 2004/106356; WO 2005/021570; WO 2007/134181; WO 2008/150729; WO 2008/154401; and WO 2009/006478.

Each of the foregoing bicyclic nucleosides can be prepared having one or more stereochemical sugar configurations including for example α -L-ribofuranose and β -D-ribofuranose (see PCT international application PCT/DK98/00393, published on Mar. 25, 1999 as WO 99/14226).

[00298] In certain embodiments, bicyclic sugar moieties of BNA nucleosides include, but are not limited to, compounds having at least one bridge between the 4' and the 2' position of the pentofuranosyl sugar moiety wherein such bridges independently comprises 1 or from 2 to 4 linked groups independently selected from $-\text{C}(\text{R}_a)(\text{R}_b)_n-$, $-\text{C}(\text{R}_a)=\text{C}(\text{R}_b)-$, $-\text{C}(\text{R}_a)=\text{N}-$, $-\text{C}(=\text{O})-$, $-\text{C}(=\text{NR}_a)-$, $-\text{C}(=\text{S})-$, $-\text{O}-$, $-\text{Si}(\text{R}_a)_2-$, $-\text{S}(=\text{O})_x-$, and $-\text{N}(\text{R}_a)-$; wherein:

x is 0, 1, or 2;

n is 1, 2, 3, or 4;

each R_a and R_b is, independently, H, a protecting group, hydroxyl, C_1 - C_{12} alkyl, substituted C_1 - C_{12} alkyl, C_2 - C_{12} alkenyl, substituted C_2 - C_{12} alkenyl, C_2 - C_{12} alkynyl, substituted C_2 - C_{12} alkynyl, C_5 - C_{20} aryl, substituted C_5 - C_{20} aryl, heterocycle radical, substituted heterocycle radical, heteroaryl, substituted heteroaryl, C_5 - C_7 alicyclic radical, substituted C_5 - C_7 alicyclic radical, halogen, OJ_1 , NJ_1J_2 , SJ_1 , N_3 , COOJ_1 , acyl ($\text{C}(=\text{O})-\text{H}$), substituted acyl, CN, sulfonyl ($\text{S}(=\text{O})_2-\text{J}_1$), or sulfoxyl ($\text{S}(=\text{O})-\text{J}_1$); and

each J_1 and J_2 is, independently, H, C_1 - C_{12} alkyl, substituted C_1 - C_{12} alkyl, C_2 - C_{12} alkenyl, substituted C_2 - C_{12} alkenyl, C_2 - C_{12} alkynyl, substituted C_2 - C_{12} alkynyl, C_5 - C_{20} aryl, substituted C_5 - C_{20} aryl, acyl ($\text{C}(=\text{O})-\text{H}$), substituted acyl, a heterocycle radical, a substituted heterocycle radical, C_1 - C_{12} aminoalkyl, substituted C_1 - C_{12} aminoalkyl or a protecting group.

[00299] In certain embodiments, the bridge of a bicyclic sugar moiety is $—[C(R_a)(R_b)]_n—$, $—[—C(R_a)(R_b)]_n—O—$, $—C(R_aR_b)—N^{\oplus}—O—$ or $—C(R_aR_b)—O—N^{\oplus}—$. In certain embodiments, the bridge is 4'-CH₂-2', 4'-(CH₂)₂-2', 4'-(CH₂)₃-2', 4'-CH₂-O-2', 4'-(CH₂)₂-O-2', 4'-CH₂-O-N[⊕]-2' and 4'-CH₂-N[⊕]-O-2' wherein each R is, independently, H, a protecting group or C₁-C₁₂ alkyl, each R_a and R_b is, independently, H, a protecting group, hydroxyl, C₁-C₁₂ alkyl, substituted C₁-C₁₂ alkyl, C₂-C₁₂ alkenyl, substituted C₂-C₁₂ alkenyl, C₂-C₁₂ alkynyl, substituted C₂-C₁₂ alkynyl, C₅-C₂₀ aryl, substituted C₅-C₂₀ aryl, heterocycle radical, substituted heterocycle radical, heteroaryl, substituted heteroaryl, C₅-C₇ alicyclic radical, substituted C₅-C₇ alicyclic radical, halogen, OJ₁, NJ₁J₂, SJ₁, N₃, COOJ₁, acyl (C(=O)—H), substituted acyl, CN, sulfonyl (S(=O)₂-J₁), or sulfoxyl (S(=O)-J₁); each J₁ and J₂ is, independently, H, C₁-C₁₂ alkyl, substituted C₁-C₁₂ alkyl, C₂-C₁₂ alkenyl, substituted C₂-C₁₂ alkenyl, C₂-C₁₂ alkynyl, substituted C₂-C₁₂ alkynyl, C₅-C₂₀ aryl, substituted C₅-C₂₀ aryl, acyl (C(=O)—H), substituted acyl, a heterocycle radical, a substituted heterocycle radical, C₁-C₁₂ aminoalkyl, substituted C₁-C₁₂ aminoalkyl or a protecting group; and R is H, C₁-C₁₂ alkyl, or a protecting group (see U.S. Pat. No. 7,427,672, issued on Sep. 23, 2008).

[00300] In certain embodiments, bicyclic nucleosides are further defined by isomeric configuration. For example, a nucleoside comprising a 4'-2' methylene-oxy bridge, may be in the α-L configuration or in the β-D configuration. Previously, α-L-methyleneoxy (4'-CH₂-O-2') BNA's have been incorporated into antisense oligonucleotides that showed antisense activity (Frieden et al., Nucleic Acids Research, 2003, 21, 6365-6372).

[00301] In certain embodiments, bicyclic nucleosides include, but are not limited to, α-L-methyleneoxy (4'-CH₂-O-2') BNA, β-D-methyleneoxy (4'-CH₂-O-2') BNA, ethyleneoxy (4'-(CH₂)₂-O-2') BNA, aminooxy (4'-CH₂-O-N[⊕]-2') BNA, 130yrrolid (4'-CH₂-N[⊕]-O-2') BNA, methyl(methyleneoxy) (4'-CH(CH₃)-O-2') BNA, methylene-thio (4'-CH₂-S-2') BNA, methylene-amino (4'-CH₂-N[⊕]-2') BNA, methyl carbocyclic (4'-CH₂-CH(CH₃)-2') BNA, and propylene carbocyclic (4'-(CH₂)₃-2') BNA; wherein R is H, C₁-C₁₂ alkyl, or a protecting group (see U.S. Pat. No. 7,427,672, issued on Sep. 23, 2008).

[00302] The present disclosure provide, in some embodiments, methods for treating, ameliorating, or preventing a neurological disease and/or a neuropathy further include methods of administering, to a patient, a pharmaceutically acceptable composition, for example, a pharmaceutically acceptable formulation that includes one or more STMN2 oligonucleotides. STMN2 oligonucleotides can increase, restore, or stabilize STMN2 activity, for example, STMN2

activity, and/or levels of STMN2 expression, for example, STMN2 mRNA and/or protein expression.

[00303] The present disclosure also provides pharmaceutical compositions comprising a STMN2 oligonucleotide formulated together with one or more pharmaceutically or cosmetically acceptable excipients. These formulations include those suitable for oral, sublingual, intratracheal, intranasal, transdermal, pulmonary, intrathecal, intrathalamic, intracisternal, intracerebroventricular, parenteral (*e.g.*, subcutaneous, intramuscular, intradermal, intraduodenal, or intravenous) administration, transmucosal (*e.g.*, buccal, vaginal, and rectal), or for topical use, *e.g.*, as part of a composition suitable for applying topically to skin and/or mucous membrane, for example, a composition in the form of a gel, a paste, a wax, a cream, a spray, a liquid, a foam, a lotion, an ointment, a topical solution, a transdermal patch, a powder, a vapor, or a tincture. Although the most suitable form of administration in any given case will depend on the degree and severity of the condition being treated and on the nature of the particular STMN2 oligonucleotide being used.

[00304] The present disclosure also provides a pharmaceutical composition comprising a STMN2 oligonucleotide or a pharmaceutically acceptable salt thereof (for example, a STMN2 AON that includes a sequence of any of SEQ ID NOs: 1-466, SEQ ID NO: 893-1338, SEQ ID NOs: 1342-1366, and SEQ ID NOs: 1392-1664).

[00305] The present disclosure also provides methods that include the use of pharmaceutical compositions comprising a STMN2 AON is formulated together with one or more pharmaceutically acceptable excipients. Exemplary compositions provided herein include compositions comprising a STMN2 AON, and one or more pharmaceutically acceptable excipients. Formulations include those suitable for oral, sublingual, intratracheal, intranasal, transdermal, pulmonary, intrathecal, intrathalamic, intracisternal, intracerebroventricular, parenteral (*e.g.*, subcutaneous, intramuscular, intradermal, intraduodenal, or intravenous) administration, transmucosal (*e.g.*, buccal, vaginal, and rectal), or for topical use. The most suitable form of administration in any given case will depend on the clinical symptoms, complications, or biochemical indicia of the state, disorder, disease, or condition that one is trying to prevent in a subject; the state, disorder, disease, or condition one is trying to prevent in a subject; and/or on the nature of the particular compound and/or the composition being used.

Additional Chemically Modified STMN2 Oligonucleotides

[00306] STMN2 AONs described herein, can include chemically modified nucleosides, including modified ribonucleosides and modified deoxyribonucleosides. Chemically modified nucleosides

include, but are not limited to, uracil, uracine, uridine, 2'-O-(2-methoxyethyl) modifications, for example, 2'-O-(2-methoxyethyl)guanosine, 2'-O-(2-methoxyethyl)adenosine, 2'-O-(2-methoxyethyl)cytosine, and 2'-O-(2-methoxyethyl)thymidine. In certain embodiments, mixed modalities, *e.g.*, a combination of a STMN2 peptide nucleic acid (PNA) and a STMN2 locked nucleic acid (LNA). Chemically modified nucleosides also include, but are not limited to, locked nucleic acids (LNAs), 2'-O-methyl, 2'-fluoro, and 2'-fluoro- β -D-arabinonucleotide (FANA), and Fluoro Cyclohexenyl nucleic acid (F-CeNA) modifications. Chemically modified nucleosides that can be included in STMN2 AONs described herein are described in Johannes and Lucchino, (2018) "Current Challenges in Delivery and Cytosolic Translocation of Therapeutic RNAs" *Nucleic Acid Ther.* 28(3): 178–93; Rettig and Behlke, (2012) "Progress toward in vivo use of siRNAs-II" *Mol Ther* 20:483–512; and Khvorova and Watts, (2017) "The chemical evolution of oligonucleotide therapies of clinical utility" *Nat Biotechnol.*, 35(3):238-48, the contents of each of which are incorporated by reference herein.

[00307] STMN2 AONs described herein can include chemical modifications that promote stabilization of an oligonucleotide's terminal 5'-phosphate and phosphatase-resistant analogs of 5'-phosphate. Chemical modifications that promote oligonucleotide terminal 5'-phosphate stabilization or which are phosphatase-resistant analogs of 5'-phosphate include, but are not limited to, 5'-methyl phosphonate, 5'-methylenephosphonate, 5'-methylenephosphonate analogs, 5'-*E*-vinyl phosphonate (5'-*E*-VP), 5'-phosphorothioate, and 5'-*C*-methyl analogs. Chemical modifications that promote AON terminal 5'-phosphate stabilization and phosphatase-resistant analogues of 5'-phosphate are described in Khvorova and Watts, (2017) "The chemical evolution of oligonucleotide therapies of clinical utility" *Nat Biotechnol.*, 35(3):238-48, the contents of which are incorporated by reference herein.

[00308] In some embodiments described herein, STMN2 AONs described herein can include chemically modified nucleosides, for example, 2' O-methyl ribonucleosides, for example, 2' O-methyl cytidine, 2' O-methyl guanosine, 2' O-methyl uridine, and/or 2' O-methyl adenosine. STMN2 AONs described herein can include one or more chemically modified bases, including a 5-methylpyrimidine, for example, 5-methylcytosine, and/or a 5-methylpurine, for example, 5-methylguanine. Chemically modified baess can further include pseudo-uridine or 5'methoxyuridine. STMN2 AONs described herein can include any of the following chemically modified nucleosides: 5-methyl-2'-O-methylcytidine, 5-methyl-2'-O-methylthymidine, 5-methylcytidine, 5-methyluridine, and/or 5-methyl 2'-deoxycytidine.

[00309] STMN2 AONs described herein can include a phosphate backbone where one or more of the oligonucleoside linkages is a phosphate linkage. STMN2 AONs described herein may include a modified oligonucleotide backbone, where one or more of the nucleoside linkages of the sequence is selected from the group consisting of a phosphorothioate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a thiophosphorodiamidate linkage, a phosphorodiamidate (*e.g.*, comprising a phosphorodiamidate morpholino (PMO), 3' amino ribose, or 5' amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage. In some embodiments of STMN2 AONs described herein, at least one (*i.e.*, one or more) internucleoside linkage of the oligonucleotide is a phosphorothioate linkage. For example, in some embodiments of STMN2 AONs described herein, one, two, three, or more internucleoside linkages of the oligonucleotide is a phosphorothioate linkage. In preferred embodiments of STMN2 AONs described herein, all internucleoside linkages of the oligonucleotide are phosphorothioate linkages. Thus, in some embodiments, all of the nucleotide linkages of a STMN2 AON of any of SEQ ID NOs: 1-466, SEQ ID NO: 893-1338, SEQ ID NOs: 1342-1366, and SEQ ID NOs: 1392-1664 are phosphorothioate linkages. In some embodiments, one or more of the nucleotide linkages of a STMN2 AON of any of SEQ ID NOs: 1-466, SEQ ID NO: 893-1338, SEQ ID NOs: 1342-1366, and SEQ ID NOs: 1392-1664 are phosphorothioate linkages.

[00310] In various embodiments, nucleotide linkages of STMN2 AON described herein such as any of SEQ ID NOs: 1-466, SEQ ID NO: 893-1338, SEQ ID NOs: 1342-1366, and SEQ ID NOs: 1392-1664 include a mix of phosphodiester and phosphorothioate linkages.

[00311] In some embodiments, nucleoside linkages linking a base at position 3 of a STMN2 AON described herein are phosphodiester bonds. For example, the base at position 3 may be linked to each adjacent base (*e.g.*, preceding base and succeeding base) through a phosphodiester bond. An example 25mer STMN2 AON with phosphodiester bonds linking the base at position 3 can be denoted as:

XXoDoXXXXXXXXXXXXXXXXXXXXXXX

where “o” represents a phosphodiester bond and “D” represents the base at position 3. Any nucleobase in the AON can be a nucleobase analog.

[00312] In some embodiments, one of the nucleoside linkages linking a base at position 3 of a STMN2 AON described herein is a phosphodiester bond. For example, the base at position 3 may be linked to either the preceding base or the succeeding base through a phosphodiester bond. An example 25mer STMN2 AON with a phosphodiester bond linking the base at position 3 to a preceding base can be denoted as:

XXoDXXXXXXXXXXXXXXXXXXXXXXX

where “o” represents a phosphodiester bond and “D” represents the base at position 3. Any nucleobase in the AON can be a nucleobase analog.

[00313] An example 25mer STMN2 AON with a phosphodiester bond linking the base at position 3 to a succeeding base can be denoted as:

XXDoXXXXXXXXXXXXXXXXXXXXXXX

where “o” represents a phosphodiester bond and “D” represents the base at position 3. Any nucleobase in the AON can be a nucleobase analog.

[00314] In various embodiments, in addition to one of the nucleoside linkages linking a base at position 3 of a STMN2 AON described herein being a phosphodiester bond, the STMN2 AON further includes two spacers. The two spacers can be positioned in the STMN2 AON such that the STMN2 AON includes a segment with at most 7 linked nucleosides. An example 25mer STMN2 AON with two spacers and with a phosphodiester bond linking the base at position 3 to a preceding base can be denoted as:

XxoDS₁XXXXXXXXXS₂XXXXXXXXXX

where “S₁” represents a first spacer, “S₂” represents a second spacer, “o” represents a phosphodiester bond and “D” represents the base at position 3. Any nucleobase in the AON can be a nucleobase analog.

[00315] An example 25mer STMN2 AON with two spacers and with a phosphodiester bond linking the base at position 3 to a succeeding base can be denoted as:

XXDoXXXXXXS₁XXXXXXXXXS₂XXXX

where “S₁” represents a first spacer, “S₂” represents a second spacer, “o” represents a phosphodiester bond and “D” represents the base at position 3. Any nucleobase in the AON can be a nucleobase analog.

[00316] In some embodiments, nucleoside linkages linking a base at position 4 of a STMN2 AON described herein are phosphodiester bonds. For example, the base at position 4 may be linked to each adjacent base (e.g., preceding base and succeeding base) through a phosphodiester bond. An

example 25mer STMN2 AON with phosphodiester bonds linking the base at position 4 can be denoted as:

XXXoDoXXXXXXXXXXXXXXXXXXXXXXX

where “o” represents a phosphodiester bond and “D” represents the base at position 4. Any nucleobase in the AON can be a nucleobase analog.

[00317] In some embodiments, one of the nucleoside linkages linking a base at position 4 of a STMN2 AON described herein is a phosphodiester bond. For example, the base at position 4 may be linked to either the preceding base or the succeeding base through a phosphodiester bond. An example 25mer STMN2 AON with a phosphodiester bond linking the base at position 4 to a preceding base can be denoted as:

XXXoDXXXXXXXXXXXXXXXXXXXXXXX

where “o” represents a phosphodiester bond and “D” represents the base at position 4. Any nucleobase in the AON can be a nucleobase analog.

[00318] An example 25mer STMN2 AON with a phosphodiester bond linking the base at position 4 to a succeeding base can be denoted as:

XXXDoXXXXXXXXXXXXXXXXXXXXXXX

where “o” represents a phosphodiester bond and “D” represents the base at position 4. Any nucleobase in the AON can be a nucleobase analog.

[00319] In some embodiments, nucleoside linkages linking both bases at position 3 and position 4 of a STMN2 AON described herein are phosphodiester bonds. For example, the base at position 3 may be linked to each adjacent base (e.g., preceding base and succeeding base) through a phosphodiester bond, and the base at position 4 may be linked to each adjacent base (e.g., preceding base and succeeding base) through a phosphodiester bond. An example 25mer STMN2 AON with phosphodiester bonds linking the bases at positions 3 and 4 can be denoted as:

XXoDoEoXXXXXXXXXXXXXXXXXXXXXXX

where “o” represents a phosphodiester bond, “D” represents the base at position 3, and “E” represents the base at position 4. In various embodiments, all other bases of the STMN2 AON are linked through phosphorothioate bonds. Any nucleobase in the AON can be a nucleobase analog.

[00320] In various embodiments, STMN2 AON described herein include one or more spacers and phosphodiester bonds are located relative to the one or more spacers. In some embodiments, the Y number of bases immediately preceding a spacer are linked through phosphodiester bonds. In various embodiments, Y is one, two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve bases. In particular embodiments, Y is two bases. For example, if the spacer is located at position

15, the bases at positions 13 and 14 of the STMN2 AON are each linked to their respective adjacent bases through phosphodiester bonds. As described herein, the spacer can be located at various positions in the STMN2 AON and therefore, the 2 bases immediately preceding the spacer can vary within the STMN2 AON depending on where the spacer is situated.

5 **[00321]** In various embodiments, the STMN2 AON may include more than one spacer. In some embodiments, only one of the spacers has Y number of bases immediately preceding the spacer that are linked through phosphodiester bonds. In such embodiments, the other spacers are linked to respective preceding bases through phosphorothioate bonds. In various embodiments, two of the spacers have Y number of bases immediately preceding the spacers that are linked through
10 phosphodiester bonds. In various embodiments, each of the spacers in the STMN2 AON have Y number of bases immediately preceding the spacers that are linked through phosphodiester bonds. In various embodiments, all other bases of the STMN2 AON are linked through phosphorothioate bonds.

[00322] In some embodiments, Y number of bases immediately preceding a spacer and Z number
15 of bases immediately succeeding a spacer are linked through phosphodiester bonds. In various embodiments, Y is one, two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve bases. In various embodiments, Z is one, two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve bases. Y and Z can be independent of each other. In particular embodiments, Y is one base and Z is one base. For example, if the spacer is located at position 15, the bases at positions
20 14 and 16 of the STMN2 AON are each linked to their respective adjacent bases through phosphodiester bonds. To provide an example, such a STMN2 AON (e.g., 25mer) can be denoted as:


XXXXXXXXXXXXXoDoSoEoXXXXXXXXXX

where “S” represents a spacer, “o” represents a phosphodiester bond, “D” represents a base
25 immediately preceding the spacer, and “E” represents the base immediately succeeding the spacer. Any nucleobase in the AON can be a nucleobase analog.

[00323] As described herein, the spacer can be located at various positions in the STMN2 AON and therefore, the bases immediately preceding or immediately succeeding the spacer can vary within the STMN2 AON depending on where the spacer is situated.

30 **[00324]** In various embodiments, the STMN2 AON may include more than one spacer. In some embodiments, only one of the spacers has Y number of bases immediately preceding the spacer and Z number of bases immediately succeeding the spacer that are linked through phosphodiester bonds. In such embodiments, the other spacers of the STMN2 AON are linked to respective


preceding and succeeding bases through phosphorothioate bonds. To provide an example, such a STMN2 AON (e.g., 25mer) can be denoted as:



where “S₁” represents a first spacer, “S₂” represents a second spacer, “o” represents a

- 5 phosphodiester bond, “D” represents a base immediately preceding the spacer, and “E” represents the base immediately succeeding the spacer. Any nucleobase in the AON can be a nucleobase analog.


[00325] As another example, such a STMN2 AON (e.g., 25mer) can be denoted as:



- 10 where “S₁” represents a first spacer, “S₂” represents a second spacer, “o” represents a phosphodiester bond, “D” represents a base immediately preceding the spacer, and “E” represents the base immediately succeeding the spacer. Any nucleobase in the AON can be a nucleobase analog.


[00326] In some embodiments, one of the spacers is linked to the immediately preceding base

- 15 through a phosphodiester bond. For example, a STMN2 AON includes a first spacer that is linked to the immediately preceding base through a phosphodiester bond, which can be denoted as:



where “S₁” represents a first spacer, “S₂” represents a second spacer, “o” represents a phosphodiester bond. Any nucleobase in the AON can be a nucleobase analog.

- 20 **[00327]** As another example, a STMN2 AON includes a second spacer that is linked to the immediately preceding base through a phosphodiester bond, which can be denoted as:




where “S₁” represents a first spacer, “S₂” represents a second spacer, “o” represents a phosphodiester bond. Any nucleobase in the AON can be a nucleobase analog.

- 25 **[00328]** In various embodiments, the STMN2 AON may be a AON variant (e.g., a 23mer, a 21mer, or a 19mer) where one of the spacers is linked to the immediately preceding base through a phosphodiester bond. For example, the STMN2 AON may be a 21mer with a first spacer that is linked to the immediately preceding base through a phosphodiester bond, which can be denoted as:




where “S₁” represents a first spacer, “S₂” represents a second spacer, “o” represents a phosphodiester bond. Any nucleobase in the AON can be a nucleobase analog.

[00329] As another example, the STMN2 AON may be a 21mer with a second spacer that is linked to the immediately preceding base through a phosphodiester bond, which can be denoted as:



5 where “S₁” represents a first spacer, “S₂” represents a second spacer, “o” represents a phosphodiester bond. Any nucleobase in the AON can be a nucleobase analog.

[00330] In some embodiments, the STMN2 AON may be a AON variant (e.g., a 23mer, a 21mer, or a 19mer) where one of the spacers is linked to the immediately preceding base through a phosphodiester bond and the immediately preceding base is further linked to the preceding base through a phosphodiester bond. An example 21mer STMN2 AON can be denoted as:



where “S₁” represents a first spacer, “S₂” represents a second spacer, “o” represents a phosphodiester bond, “D” represents the base immediately preceding S₁ and “E” represents the base immediately preceding “D.” Any nucleobase in the AON can be a nucleobase analog.

15 [00331] As another example, a 21mer STMN2 AON can be denoted as:



where “S₁” represents a first spacer, “S₂” represents a second spacer, “o” represents a phosphodiester bond, “D” represents the base immediately preceding S₂ and “E” represents the base immediately preceding “D.” Any nucleobase in the AON can be a nucleobase analog.

20 [00332] In some embodiments, the STMN2 AON may be a AON variant (e.g., a 23mer, a 21mer, or a 19mer) where a base that immediately precedes a first spacer is linked to another base through a phosphodiester bond. The base that immediately precedes the first spacer may be linked to the first spacer through a non-phosphodiester bond, such as a phosphorothioate bond. Additionally a second spacer is linked to an immediately preceding base through a phosphodiester bond. An example of a 21mer STMN2 AON can be denoted as:



where “S₁” represents a first spacer, “S₂” represents a second spacer, “o” represents a phosphodiester bond, “D” represents the base immediately preceding S₁ and “E” represents the base immediately preceding “D.” Here, the base “D” is linked to the first spacer S₁ through a non-phosphodiester bond (e.g., phosphorothioate bond). Additionally, the base “D” is linked to base “E” through a phosphodiester bond. The second spacer S₂ is linked to an immediately

25

30


preceding base through a phosphodiester bond. Any nucleobase in the AON can be a nucleobase analog.

[00333] Another example of such a 21mer STMN2 AON can be denoted as:



5 where “S₁” represents a first spacer, “S₂” represents a second spacer, “o” represents a phosphodiester bond, “D” represents the base immediately preceding S₂ and “E” represents the base immediately preceding “D.” Here, the base “D” is linked to the second spacer S₂ through a non-phosphodiester bond (e.g., phosphorothioate bond). Additionally, the base “D” is linked to base “E” through a phosphodiester bond. The first spacer S₁ is linked to an immediately
10 preceding base through a phosphodiester bond. Any nucleobase in the AON can be a nucleobase analog.

[00334] In some embodiments, one of the spacers is linked to the immediately succeeding base through a phosphodiester bond. For example, a STMN2 AON includes a first spacer that is linked to the immediately succeeding base through a phosphodiester bond, which can be denoted as:




15 where “S₁” represents a first spacer, “S₂” represents a second spacer, “o” represents a phosphodiester bond. Any nucleobase in the AON can be a nucleobase analog.

[00335] As another example, a STMN2 AON includes a second spacer that is linked to the immediately succeeding base through a phosphodiester bond, which can be denoted as:



20 where “S₁” represents a first spacer, “S₂” represents a second spacer, “o” represents a phosphodiester bond. Any nucleobase in the AON can be a nucleobase analog.

[00336] In various embodiments, the STMN2 AON may be a AON variant (e.g., a 23mer, a 21mer, or a 19mer) where one of the spacers is linked to the immediately succeeding base through
25 a phosphodiester bond. For example, the STMN2 AON may be a 21mer with a first spacer that is linked to the immediately succeeding base through a phosphodiester bond, which can be denoted as:



30 where “S₁” represents a first spacer, “S₂” represents a second spacer, “o” represents a phosphodiester bond. Any nucleobase in the AON can be a nucleobase analog.

[00337] As another example, the STMN2 AON may be a 21mer with a second spacer that is linked to the immediately succeeding base through a phosphodiester bond, which can be denoted as:

XXXXXXXXS₁XXXXXS₂oXXXXXX

where “S₁” represents a first spacer, “S₂” represents a second spacer, “o” represents a phosphodiester bond. Any nucleobase in the AON can be a nucleobase analog.

[00338] In various embodiments, two of the spacers have Y number of bases immediately

preceding the spacers and Z number of bases immediately succeeding the spacers that are linked through phosphodiester bonds. In various embodiments, each of the spacers in the STMN2 AON have Y number of bases immediately preceding the spacers and Z number of bases immediately succeeding the spacers that are linked through phosphodiester bonds. An example of such a STMN2 AON (e.g., 25mer) can be denoted as:

XXXXoDoS₁oEoXXXXXXXXXXoFoS₂oHoXXXX

where “S₁” represents a first spacer, “S₂” represents a second spacer, “o” represents a phosphodiester bond, “D” represents a base immediately preceding the first spacer, “E” represents the base immediately succeeding the first spacer, “F” represents a base immediately preceding the second spacer, and “H” represents the base immediately succeeding the second spacer. In various embodiments, all other bases of the STMN2 AON are linked through phosphorothioate bonds. Any nucleobase in the AON can be a nucleobase analog.

[00339] In various STMN2 AON includes two or more spacers and a range of bases located between the two spacers are linked through phosphodiester bonds. In various embodiments, the range of bases include two, three, four, five, six, or seven bases linked through phosphodiester bonds. In particular embodiments, the range of bases include two bases linked through phosphodiester bonds. In particular embodiments, the range of bases include four bases linked through phosphodiester bonds. In various embodiments, all other bases of the STMN2 AON are linked through phosphorothioate bonds. Any nucleobase in the AON can be a nucleobase analog.

[00340] In various embodiments, the range of bases linked through phosphodiester bonds are positioned Y number of bases succeeding the first spacer and Z number of preceding the second spacer. In various embodiments, Y is one, two, three, four, five, six, or seven bases. In various embodiments, Z is one, two, three, four, five, six, or seven bases. Y and Z can be independent on each other. Any nucleobase in the AON can be a nucleobase analog.

[00341] In particular embodiments, Y is five bases and Z is four bases. To provide an example, such a STMN2 AON (e.g., 25mer) can be denoted as:

XXXXXXXXS₁XXXXoDoEoFoHoXXXS₂XXXX

where “S₁” represents a first spacer, “S₂” represents a second spacer, and “o” represents a phosphodiester bond. The bases “D,” “E,” “F,” and “H” represent the range of bases that are

linked through phosphodiester bonds. In this example, the range of bases is located five bases after the first spacer (e.g., D is positioned five bases after the first spacer) and the range of bases is located four bases preceding the second spacer (e.g., H is positioned four bases before the second spacer). Any nucleobase in the AON can be a nucleobase analog.

- 5 **[00342]** In particular embodiments, Y is four bases and Z is three bases. To provide an example, such a STMN2 AON (e.g., 23mer) can be denoted as:

XXXXXXXXS₁XXXoDoEoXXS₂XXXXXXXX

- where “S₁” represents a first spacer, “S₂” represents a second spacer, and “o” represents a phosphodiester bond. The bases “D” and “E” represent the range of bases that are linked through phosphodiester bonds. In this example, the range of bases is located four bases after the first spacer (e.g., D is positioned four bases after the first spacer) and the range of bases is located three bases preceding the second spacer (e.g., E is positioned three bases before the second spacer). In various embodiments, the positions of the two spacers differ than shown above and therefore, the range of bases linked through phosphodiester bonds are differently positioned. In various embodiments, all other bases of the STMN2 AON are linked through phosphorothioate bonds. Any nucleobase in the AON can be a nucleobase analog.

- [00343]** Table 10 below further depicts examples of STMN2 AON with a mix of phosphodiester and phosphorothioate linkages. In particular, Table 10 depicts examples of STMN2 AONs including spacers and a mix of phosphodiester and phosphorothioate linkages. Any nucleobase in the AON can be a nucleobase analog.

Table 10: Example STMN2 AONs with a mixture of phosphodiester and phosphorothioate bonds.

SEQ ID NO:	AON Sequence* (5' → 3'), where “o” represents a phosphodiester bond, and where “S” indicates a spacer. All other linkages are phosphorothioate bonds.	Bases linked with phosphodiester bonds
173	GAGTCCTGCAATATGAATATAATTT	N/A
1451	GAoGo <u>So</u> CCTGCAATAT <u>SA</u> ATATAATTT	Bases at positions 3 and 4
1452	GAoGoToCCTGCA <u>STAT</u> GAATAT <u>SA</u> TTT	Bases at positions 3 and 4
1453	GAoGoToCC <u>SG</u> CAATATGAAT <u>STA</u> ATTT	Bases at positions 3 and 4
1454	GAoGoToCC <u>SG</u> CAATATGAAS <u>A</u> TAATTT	Bases at positions 3 and 4
1455	GToCoCoTGCS <u>A</u> TATGAAS <u>A</u> TAAT	Bases at positions 3 and 4
1456	GToCoCoT <u>SCA</u> ATATGS <u>A</u> TATAAT	Bases at positions 3 and 4

1457	GToCoCoTGCS <u>S</u> ATATGS <u>S</u> ATATAAT	Bases at positions 3 and 4
1458	GAG <u>S</u> CCTGCAAToAoTo <u>S</u> AATATAATTT	2 bases preceding a spacer
1459	GAGTCCTGCA <u>S</u> TATGAAToAoTo <u>S</u> ATTT	2 bases preceding a spacer
1460	GAGTCC <u>S</u> GCAATATGAoAoTo <u>S</u> TAATTT	2 bases preceding a spacer
1461	GAGTCC <u>S</u> GCAATATGoAoAo <u>S</u> ATAATTT	2 bases preceding a spacer
1462	GTCCTGC <u>S</u> ATATGoAoAo <u>S</u> ATAAT	2 bases preceding a spacer
1463	GTCCT <u>S</u> CAATAoToGo <u>S</u> ATATAAT	2 bases preceding a spacer
1464	GTCCTGC <u>S</u> ATAoToGo <u>S</u> ATATAAT	2 bases preceding a spacer
1465	G AoGo <u>S</u> oCoCTGCAATAT <u>S</u> AATATAATTT	1 base preceding and 1 base after a spacer
1466	GAGTCCTGCoAo <u>S</u> oToATGAATAT <u>S</u> ATTT	1 base preceding and 1 base after a spacer
1467	GAGTCoCo <u>S</u> oGoCAATATGAAT <u>S</u> TAATTT	1 base preceding and 1 base after a spacer
1468	GAGTCoCo <u>S</u> oGoCAATATGAAS <u>S</u> ATAATTT	1 base preceding and 1 base after a spacer
1469	GTCCTGoCo <u>S</u> oAoTATGAAS <u>S</u> ATAAT	1 base preceding and 1 base after a spacer
1470	GTCCoTo <u>S</u> oCoAATATGS <u>S</u> ATATAAT	1 base preceding and 1 base after a spacer
1471	GTCCTGoCo <u>S</u> oAoTATGS <u>S</u> ATATAAT	1 base preceding and 1 base after a spacer
1472	GAG <u>S</u> CCTGCAATAoTo <u>S</u> oAoATATAATTT	1 base preceding and 1 base after a spacer
1473	GAGTCCTGCA <u>S</u> TATGAATAoTo <u>S</u> oAoTTT	1 base preceding and 1 base after a spacer
1474	GAGTCC <u>S</u> GCAATATGAAoTo <u>S</u> oToAATTT	1 base preceding and 1 base after a spacer
1475	GAGTCC <u>S</u> GCAATATGAoAo <u>S</u> oAoTAATTT	1 base preceding and 1 base after a spacer
1476	GTCCTGC <u>S</u> ATATGAoAo <u>S</u> oAoTAAT	1 base preceding and 1 base after a spacer

1477	GTCCT <u>S</u> CAATAToGo <u>S</u> oAoTATAAT	1 base preceding and 1 base after a spacer
1478	GTCCTGC <u>S</u> ATAToGo <u>S</u> oAoTATAAT	1 base preceding and 1 base after a spacer
1479	GAoGo <u>S</u> oCoCTGCAATAoTo <u>S</u> oAoATATAATTT	1 base preceding AND 1 base after EACH spacer
1480	GAGTCCTGCoAo <u>S</u> oToATGAATAoTo <u>S</u> oAoTTT	1 base preceding AND 1 base after EACH spacer
1481	GAGTCoCo <u>S</u> oGoCAATATGA AoTo <u>S</u> oToAATTT	1 base preceding AND 1 base after EACH spacer
1482	GAGTCoCo <u>S</u> oGoCAATATGAoAo <u>S</u> oAoTAATTT	1 base preceding AND 1 base after EACH spacer
1483	GTCCTGoCo <u>S</u> oAoTATGAoAo <u>S</u> oAoTAAT	1 base preceding AND 1 base after EACH spacer
1484	GTCCoTo <u>S</u> oCoAATAToGo <u>S</u> oAoTATAAT	1 base preceding AND 1 base after EACH spacer
1485	GTCCTGoCo <u>S</u> oAoTAToGo <u>S</u> oAoTATAAT	1 base preceding AND 1 base after EACH spacer
197	CCTTTCTCTCGAAGGTCTTCTGCCG	N/A
1430	CCTTTCTCTCGAAGGTCTTCTGC	N/A
1431	CTTTCTCTCGAAGGTCTTCTGCC	N/A
1486	CCoToToTCTCTCGAAGGTCTTCTGCCG	Bases at positions 3 and 4
1487	CCoToToTCTC <u>S</u> CGAAGGTCTTC <u>S</u> GCCG	Bases at positions 3 and 4
1488	CToToToCTC <u>S</u> CGAAGGT <u>S</u> TTCTGCC	Bases at positions 3 and 4
1489	TToToCoTCT <u>S</u> GAAAGGTC <u>S</u> TCTGCCG	Bases at positions 3 and 4
1490	TToToCoTCTCGAAGGTCTTCTGCCG	Bases at positions 3 and 4
1491	CCoToToTCTCTCGAAGGTCTTCTGC	Bases at positions 3 and 4
1492	CCTTTCoToCo <u>S</u> CGAAGGTCTTC <u>S</u> GCCG	2 bases preceding a spacer
1493	CTTTCoToCo <u>S</u> CGAAGGT <u>S</u> TTCTGCC	2 bases preceding a spacer
1494	TTTCToCoTo <u>S</u> GAAAGGTC <u>S</u> TCTGCCG	2 bases preceding a spacer
1495	CCTTTCTC <u>S</u> CGAAGGTCToToCo <u>S</u> GCCG	2 bases preceding a spacer
1496	CTTTCTC <u>S</u> CGAAGoGoTo <u>S</u> TTCTGCC	2 bases preceding a spacer

1497	TTTCTCT <u>S</u> GAAGGoToCo <u>S</u> TCTGCCG	2 bases preceding a spacer
1498	CCTTTCToCo <u>S</u> oCoGAAGGTCTTC <u>S</u> GCCG	1 base preceding and 1 base after a spacer
1499	CTTTCToCo <u>S</u> oCoGAAGGT <u>S</u> TTCTGCC	1 base preceding and 1 base after a spacer
1500	TTTCTCoTo <u>S</u> oGoAAGGTC <u>S</u> TCTGCCG	1 base preceding and 1 base after a spacer
1501	CCTTTCTC <u>S</u> CGAAGGTCTToCo <u>S</u> oGoCCG	1 base preceding and 1 base after a spacer
1502	CTTTCTC <u>S</u> CGAAGGoTo <u>S</u> oToTCTGCC	1 base preceding and 1 base after a spacer
1503	TTTCTCT <u>S</u> GAAGGTCoCo <u>S</u> oToCTGCCG	1 base preceding and 1 base after a spacer
1504	CCTTTCToCo <u>S</u> oCoGAAGGTCTToCo <u>S</u> oGoCCG	1 base preceding AND 1 base after EACH spacer
1505	CTTTCToCo <u>S</u> oCoGAAGGoTo <u>S</u> oToTCTGCC	1 base preceding AND 1 base after EACH spacer
1506	TTTCTCoTo <u>S</u> oGoAAGGTCoCo <u>S</u> oToCTGCCG	1 base preceding AND 1 base after EACH spacer
1507	CCTTTCTC <u>S</u> CGAAoGoGoToCoTTC <u>S</u> GCCG	Range of 4 bases between two spacers
1508	CTTTCTC <u>S</u> CGAaAoGoGT <u>S</u> TTCTGCC	Range of 2 bases between two spacers
1509	TTTCTCT <u>S</u> GAAoGoGoTC <u>S</u> TCTGCCG	Range of 2 bases between two spacers
1510	GAoG <u>S</u> CCTGCAATAT <u>S</u> AATATAATTT	Base 3 linked to preceding base through phosphodiester linkage
1511	GAGoTCCTGCA <u>S</u> TATGAATAT <u>S</u> ATTT	Base 3 linked to preceding base through phosphodiester linkage

1512	GAGTCC <u>o</u> <u>S</u> GCAATATGAAT <u>S</u> TAATTT	First spacer linked to preceding base through phosphodiester linkage
1513	GAGTCC <u>S</u> <u>o</u> GCAATATGAAS <u>S</u> ATAATTT	First spacer linked to succeeding base through phosphodiester linkage
1514	GTCCTGC <u>S</u> <u>o</u> ATATGAAS <u>S</u> ATAAT	First spacer linked to succeeding base through phosphodiester linkage
1515	GTCCTGC <u>o</u> <u>S</u> ATATGS <u>S</u> ATATAAT	First spacer linked to preceding base through phosphodiester linkage
1516	GTCC <u>o</u> To <u>S</u> CAATATGS <u>S</u> ATATAAT	1 base preceding a first spacer linked through phosphodiester linkage
1517	GAGTCC <u>S</u> GCAATATGAAT <u>o</u> <u>S</u> TAATTT	Second spacer linked to preceding base through phosphodiester linkage
1518	GAGTCC <u>S</u> GCAATATGAAS <u>o</u> ATAATTT	Second spacer linked to succeeding base through phosphodiester linkage
1519	GTCCTGC <u>S</u> ATATGAA <u>o</u> <u>S</u> ATAAT	Second spacer linked to preceding base through phosphodiester linkage
1520	GTCCTGC <u>S</u> ATATGS <u>o</u> ATATAAT	First spacer linked to succeeding base through phosphodiester linkage
1521	GTCC <u>o</u> T <u>S</u> CAATATG <u>o</u> <u>S</u> ATATAAT	1 base preceding a first spacer linked through phosphodiester linkage and second spacer linked to

		preceding base through phosphodiester linkage
--	--	--

[00344] In some embodiments, a disclosed STMN2 AON may have at least one modified nucleobase, *e.g.*, 5-methylcytosine, and/or at least one methylphosphonate nucleotide, which is placed, for example, either at only one of the 5' or 3' ends or at both 5' and 3' ends or along the oligonucleotide sequence.

[00345] STMN2 AONs may include at least one modified sugar. For example, the sugar moiety of at least one nucleotide constituting the oligonucleotide is a ribose in which the 2'-OH group may be replaced by any one selected from the group consisting of OR, R, R'OR, SH, SR, NH₂, NR₂, N₃, CN, F, Cl, Br, and I (wherein R is an alkyl or aryl and R' is an alkylene). Examples of a modified sugar moiety include a 2'-Ome modified sugar moiety, bicyclic sugar moiety, 2'-O-(2-methoxyethyl) (2'MOE or MOE), 2'-deoxy-2'-fluoro nucleoside, 2'-fluoro-β-D-arabinonucleoside, locked nucleic acid (LNA), constrained ethyl 2'-4'-bridged nucleic acid (cEt), S-cEt, tcDNA, hexitol nucleic acids (HNA), and tricyclic analog (*e.g.*, tcDNA).


[00346] In some embodiments, STMN2 AONs comprise 2'Ome (*e.g.*, a STMN2 AON comprising one or more 2'Ome modified sugar), 2'MOE or MOE (*e.g.*, a STMN2 AON comprising one or more 2'MOE modified sugar), PNA (*e.g.*, a STMN2 AON comprising one or more *N*-(2-aminoethyl)-glycine units linked by amide bonds or carbonyl methylene linkage as repeating units in place of a sugar-phosphate backbone), LNA (*e.g.*, a STMN2 AON comprising one or more locked ribose, and can be a mixture of 2'-deoxy nucleotides or 2'Ome nucleotides), c-ET (*e.g.*, a STMN2 AON comprising one or more cET sugar), cMOE (*e.g.*, a STMN2 AON comprising one or more cMOE sugar), morpholino oligomer (*e.g.*, a STMN2 AON comprising a backbone comprising one or more PMO), deoxy-2'-fluoro nucleoside (*e.g.*, a STMN2 AON comprising one or more 2'-fluoro-β-D-arabinonucleoside), tcDNA (*e.g.*, a STMN2 AON comprising one or more tcDNA modified sugar), ENA (*e.g.*, a STMN2 AON comprising one or more ENA modified sugar), or HNA (*e.g.*, a STMN2 AON comprising one or more HNA modified sugar). In some embodiments, a STMN2 AON comprises one or more phosphorothioate linkage, phosphodiester linkage, phosphotriester linkage, methylphosphonate linkage, phosphoramidate linkage, a phosphoramidothioate linkage, a thiophosphorodiamidate linkage, morpholino linkage, PNA linkage, or any combination of phosphorothioate linkage, phosphodiester linkage, a phosphotriester linkage, methylphosphonate linkage, phosphoramidate linkage, morpholino

linkage, and PNA linkage. In some embodiments, a STMN2 AON comprises one or more phosphorothioate linkage, phosphodiester linkage, or a combination of phosphorothioate and phosphodiester linkages.

[00347] In some embodiments, STMN2 AONs with a sequence of any one of SEQ ID NOs: 1-

466, SEQ ID NO: 893-1338, SEQ ID NOs: 1342-1366, and SEQ ID NOs: 1392-1664 is a chirally controlled oligonucleotide, such as a chirally controlled oligonucleotide described in any of US Patent No. 9,982,257, US Patent No. 10,590,413, US 10,724,035, US 10,450,568, and PCT Publication No. WO2019200185, each of which is hereby incorporated by reference in its entirety.

[00348] For example, a STMN2 AON with a sequence of any one of SEQ ID NOs: 1-466, SEQ ID NO: 893-1338, SEQ ID NOs: 1342-1366, and SEQ ID NOs: 1392-1664 is a chirally controlled oligonucleotide comprising a plurality of oligonucleotides of at least one type, wherein each type is defined by: 1) base sequence; 2) pattern of backbone linkages; 3) pattern of backbone chiral centers; and 4) pattern of backbone X-moieties (---X-L-R^1); wherein: the oligonucleotides of the at least one type comprise one or more phosphorothioate triester internucleotidic linkages and one or more phosphate diester linkage; the oligonucleotides of the at least one type comprise at least two consecutive modified internucleotidic linkages; and oligonucleotides of the at least one oligonucleotide type comprise one or more modified internucleotidic linkages independently having the structure of:




wherein: P* is an asymmetric phosphorus atom and is either Rp or Sp;

W is O, S or Se; each of X, Y and Z is independently ---O--- , ---S--- , $\text{---N(---L-R}^1\text{)---}$, or L; L is a covalent bond or an optionally substituted, linear or branched C₁-C₅₀ alkylene, wherein one or more methylene units of L are optionally and independently replaced by an optionally substituted C₁-C₆ alkylene, C₁-C₆ alkenylene, $\text{---C}\equiv\text{C---}$, $\text{---C(R')}_2\text{---}$, ---Cy--- , ---O--- , ---S--- , ---S---S--- , ---N(R')--- , ---C(O)--- , ---C(S)--- , ---C(NR')--- , ---C(O)N(R')--- , $\text{---N(R')C(O)N(R')---}$, ---N(R')C(O)--- , ---N(R')C(O)O--- , ---OC(O)N(R')--- , ---S(O)--- , $\text{---S(O)}_2\text{---}$, $\text{---S(O)}_2\text{N(R')---}$, $\text{---N(R')S(O)}_2\text{---}$, ---SC(O)--- , ---C(O)S--- , ---OC(O)--- , or ---C(O)O--- ; R¹ is halogen, R, or an optionally substituted C₁-C₁₀ aliphatic wherein one or more methylene units are optionally and independently replaced by an optionally substituted C₁-C₆ alkylene, C₁-C₆ alkenylene, $\text{---C}\equiv\text{C---}$,

—C(R')₂—, —Cy—, —O—, —S—, —S—S—, —N(R')—, —C(O)—, —C(S)—, —C(NR')—, —C(O)N(R')—, —N(R')C(O)N(R')—, —N(R')C(O)—, —N(R')C(O)O—, —OC(O)N(R')—, —S(O)—, —S(O)₂—, —S(O)₂N(R')—, —N(R')S(O)₂—, —SC(O)—, —C(O)S—, —OC(O)—, or —C(O)O—; each R' is independently —R, —C(O)R, —CO₂R, or —SO₂R, or: two R' on the

same nitrogen are taken together with their intervening atoms to form an optionally substituted heterocyclic or heteroaryl ring, or two R' on the same carbon are taken together with their intervening atoms to form an optionally substituted aryl, carbocyclic, heterocyclic, or heteroaryl ring; —Cy— is an optionally substituted bivalent ring selected from phenylene, carbocyclylene, arylene, heteroarylene, or heterocyclylene; each R is independently hydrogen, or an optionally substituted group selected from C₁-C₆ aliphatic, phenyl, carbocyclyl, aryl, heteroaryl, or

heterocyclyl; and each  independently represents a connection to a nucleoside. In some embodiments, a STMN2 AON with a sequence of any one of SEQ ID NOs: 1-466, SEQ ID NO: 893-1338, SEQ ID NOs: 1342-1366, and SEQ ID NOs: 1392-1664 is a chirally controlled oligonucleotide comprising certain chemical modifications (e.g., 2'F (2' Fluoro, which contains a fluorine molecule at the 2' ribose position (instead of 2'-hydroxyl group in an RNA monomer)), 2'-Ome, phosphorothioate linkages, lipid conjugation, etc.), as described in U.S. Patent No. 10,450,568.

Motor Neuron Diseases

[00349] Motor neuron diseases are a group of diseases characterized by loss of function of motor neurons that coordinate voluntary movement of muscles by the brain. Motor neuron diseases may affect upper and/or lower motor neurons, and may have sporadic or familial origins. Motor neuron diseases include amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), progressive bulbar palsy, pseudobulbar palsy, progressive muscular atrophy, primary lateral sclerosis, spinal muscular atrophy, post-polio syndrome, and ALS with frontotemporal dementia.

[00350] Symptoms of motor neuron diseases include muscle decay or weakening, muscle pain, spasms, slurred speech, difficulty swallowing, loss of muscle control, joint pain, stiff limbs, difficulty breathing, drooling, and complete loss of muscle control, including over basic functions such as breathing, swallowing, eating, speaking, and limb movement. These symptoms are also sometimes accompanied by depression, loss of memory, difficulty with planning, language

deficits, altered behavior, and difficulty assessing spatial relationships and/or changes in personality.

[00351] Motor neuron diseases can be assessed and diagnosed by a clinician of skill, for example, a neurologist, using various tools and tests. For example, the presence or risk of developing a motor neuron disease can be assessed or diagnosed using blood and urine tests (for example, tests that assay for the presence of creatinine kinase), magnetic resonance imaging (MRI), electromyography (EMG), nerve conduction study (NCS), spinal tap, lumbar puncture, and/or muscle biopsy. Motor neuron diseases can be diagnosed with the aid of a physical exam and/or a neurological exam to assess motor and sensory skills, nerve function, hearing and speech, vision, coordination and balance, mental status, and changes in mood or behavior.

Amyotrophic Lateral Sclerosis

[00352] ALS is a progressive motor neuron disease that disrupts signals to all voluntary muscles. ALS results in atrophy of both upper and lower motor neurons. Symptoms of ALS include weakening and wasting of the bulbar muscles, general and bilateral loss of strength, spasticity, muscle spasms, muscle cramps, fasciculations, slurred speech, and difficulty breathing or loss of ability to breathe. Some individuals with ALS also suffer from cognitive decline. At the molecular level, ALS is characterized by protein and RNA aggregates in the cytoplasm of motor neurons, including aggregates of the RNA-binding protein TDP43.

[00353] ALS is most common in males above 40 years of age, although it can also occur in women and children. Risk of ALS is also heightened in individuals who smoke, are exposed to chemicals such as lead, or who have served in the military. Most instances of ALS are sporadic, while only about 10% of cases are familial. Causes of ALS include sporadic or inherited genetic mutations, high levels of glutamate, protein mishandling. Genetic mutations associated with ALS include mutations in the genes SOD1, C9orf72, TARDBP, FUS, ANG, ATXN2, CHCHD10, CHMP2B, DCTN1, ErbB4, FIG4, HNRPA1, MATR3, NEFH, OPTN, PFN1, PRPH, SETX, SIGMAR1, SMN1, SPG11, SQSTM1, TBK1, TRPM7, TUBA4A, UBQLN2, VAPB, and VCP.

Frontotemporal Dementia

[00354] Frontotemporal dementia (FTD) is a form of dementia that affects the frontal and temporal lobes of the brain. FTD includes frontotemporal lobar degeneration (FTLD). It has an earlier average age of onset than Alzheimer's disease – 40 years of age. Symptoms of FTD include extreme changes in behavior and personality, speech and language problems, and

movement-related symptoms such as tremor, rigidity, muscle spasm, weakness, and difficulty swallowing. Subtypes of FTD include behavior variant frontotemporal dementia (bvFTD), characterized by changes in personality and behavior, and primary progressive aphasia (PPA), which affects language skills, speaking, writing and comprehension. FTD is associated with tau protein accumulation (Pick bodies) and altered TDP43 function. About 30% of cases of FTD are familial, and no other risk factors other than family history of the disease are known. Genetic mutations associated with FTD include mutations in the genes C9orf72, Progranulin (GRN), microtubule-associated protein tau (MAPT), UBQLN2, VPC, CHMP2B, TARDBP, FUS, ITM2B, CHCHD10, SQSTM1, PSEN1, PSEN2, CTSE, CYP27A1, TBK1 and TBP.

10 **Amyotrophic lateral sclerosis with frontotemporal dementia**

[00355] Amyotrophic lateral sclerosis with frontotemporal dementia (ALS with FTD) is a clinical syndrome in which FTD and ALS occur in the same individual. Interestingly, mutations in C9orf72 are the most common cause of familial forms of ALS and FTD. Additionally, mutations in TBK1, VCP, SQSTM1, UBQLN2 and CHMP2B are also associated with ALS with FTD.

15 Symptoms of ALS with FTD include dramatic changes in personality, as well as muscle weakness, muscle atrophy, fasciculations, spasticity, dysarthria, dysphagia, and degeneration of the spinal cord, motor neurons, and frontal and temporal lobes of the brain. At the molecular level, ALS with FTD is characterized by the accumulation of TDP-43 and/or FUS proteins. TBK1 mutations are associated with ALS, FTD, and ALS with FTD.

20 **Limbic-predominant age-related TDP-43 encephalopathy (LATE)**

[00356] Limbic-predominant age-related TDP-43 encephalopathy (LATE) is characterized by accumulation of misfolded TDP-43 protein in the brain, specifically in the limbic system. LATE is a neurological disorder that typically manifests in older patients (e.g., greater than 80 years old). LATE can be a diagnosis for dementia and LATE often mimics the symptoms of Alzheimer's

25 Disease including memory loss, confusion, and mood changes.

Methods of Treatment

[00357] Further (for example, amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease, progressive supranuclear palsy (PSP), brain trauma, spinal cord injury, corticobasal degeneration (CBD), and Limbic-predominant age-related TDP-43 encephalopathy (LATE) in a patient in need thereof comprising administering a STMN2 AON. In some embodiments, provided herein are methods

for treatment of a neurological disease in a patient in need thereof, comprising administering a disclosed STMN2 AON. In some embodiments of the disclosure, an effective amount of a disclosed STMN2 oligonucleotide may be administered to a patient in need thereof to treat a neurological disease, and/or to increase, restore, or stabilize expression of STMN2 mRNA that is capable of translation to produce a functional STMN2 protein, thereby increase, restore, or stabilize STMN2 activity and/or function.

[00358] In some embodiments, treating a neurological disease comprises at least ameliorating or reducing one symptom associated with the neurological disease (for example, reducing muscle weakness in a patient with ALS). Methods of treating a neurological disease (for example, ALS, FTD, or ALS with FTD) in a patient suffering therefrom are provided, that include administering a disclosed STMN2 AON. In some embodiments, methods of slowing the progression of a neurological disease, for example, a motor neuron disease, are provided.

[00359] Provided herein are methods of treating, reducing the risk of developing, or delaying the onset of a neurological disease in a subject in need thereof comprising administering a disclosed STMN2 AON. The methods include for example, treating a subject at risk of developing a neurological disease; *e.g.*, administering to the subject an effective amount of a disclosed STMN2 AON. Neurological diseases that can be treated in this manner include motor neuron diseases, ALS, FTD, ALS with FTD, progressive bulbar palsy, pseudobulbar palsy, progressive muscular atrophy, primary lateral sclerosis, spinal muscular atrophy, and post-polio syndrome.

[00360] Methods of preventing or treating neurological diseases (for example, PD, ALS, FTD, and ALS with FTD) form part of this disclosure. Such methods may comprise administering to a patient in need thereof or a patient at risk, a pharmaceutical preparation comprising a STMN2 AON disclosed herein. For example, a method of preventing or treating a neurological disease is provided comprising administering to a patient in need thereof a STMN2 AON disclosed herein.

[00361] Patients treated using an above method may experience an increase, restoration of, or stabilization of STMN2 mRNA expression, which is capable of translation to produce a functional STMN2 protein, of at least about 5%, 10%, 20%, 30%, 40% or even 50%, thereby increase, restore, or stabilize STMN2 activity and/or function in a target cell (for example, a motor neuron) after administering a STMN2 oligonucleotide *e.g.* after 1 day, 2 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 1 month, 2 months, 3, months, 4 months, 5, months, or 6 months or more. In some embodiments, administering such a STMN2 oligonucleotide may be on, *e.g.*, at least a daily basis. The STMN2 oligonucleotide may be administered orally. In some embodiments, the STMN2 oligonucleotide is administered

intrathecally, intrathalamically, or intracisternally. For example, in an embodiment described herein, a STMN2 oligonucleotide is administered intrathecally, intrathalamically or intracisternally about every 3 months. The delay or amelioration of clinical manifestation of a neurological disease in a patient as a consequence of administering a STMN2 oligonucleotide disclosed here may be at least *e.g.*, 6 months, 1 year, 18 months or even 2 years or more as compared to a patient who is not administered a STMN2 oligonucleotide, such as one disclosed herein.

[00362] STMN2 oligonucleotides can be used alone or in combination with each other whereby at least two STMN2 oligonucleotides are used together in a single composition or as part of a treatment regimen. STMN2 oligonucleotides may also be used in combination with other drugs or AON for treating neurological diseases or conditions.

[00363] In various embodiments, disclosed herein is a method for treating amyotrophic lateral sclerosis (ALS) in a subject in need thereof, the method comprising administering to the subject an oligonucleotide comprising a segment with at most 7 linked nucleosides, and wherein oligonucleotide shares at least 85% identity with any one of SEQ ID NOs: 1-466, SEQ ID NO: 893-1338, SEQ ID NOs: 1342-1366, and SEQ ID NOs: 1392-1664, or a pharmaceutically acceptable salt thereof; wherein at least one (*i.e.*, one or more) nucleoside linkage of the oligonucleotide is independently selected from the group consisting of: a phosphodiester linkage, a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a thiophosphorodiamidate linkage, a phosphorodiamidate linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage, and/or wherein at least one (*i.e.*, one or more) nucleoside is substituted with a component selected from the group consisting of a 2'-O-(2-methoxyethyl) nucleoside, a 2'-O-methyl nucleoside, a 2'-deoxy-2'-fluoro nucleoside, a 2'-fluoro- β -D-arabinonucleoside, a locked nucleic acid (LNA), a tricyclic nucleic acid, constrained methoxyethyl (cMOE), constrained ethyl (cET), and a peptide nucleic acid (PNA), optionally wherein the oligonucleotide further comprises a spacer.

[00364] In various embodiments, disclosed herein is a method for treating frontotemporal dementia (FTD) in a subject in need thereof, the method comprising administering to the subject

an oligonucleotide comprising a segment with at most 7 linked nucleosides, and wherein oligonucleotide shares at least 85% identity with any one of SEQ ID NOs: 1-466, SEQ ID NO: 893-1338, SEQ ID NOs: 1342-1366, and SEQ ID NOs: 1392-1664, or a pharmaceutically acceptable salt thereof; wherein at least one (*i.e.*, one or more) nucleoside linkage of the oligonucleotide is independently selected from the group consisting of: a phosphodiester linkage, a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a thiophosphorodiamidate linkage, a phosphorodiamidate linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage, and/or wherein at least one (*i.e.*, one or more) nucleoside is substituted with a component selected from the group consisting of a 2'-O-(2-methoxyethyl) nucleoside, a 2'-O-methyl nucleoside, a 2'-deoxy-2'-fluoro nucleoside, a 2'-fluoro- β -D-arabinonucleoside, a locked nucleic acid (LNA), a tricyclic nucleic acid, constrained methoxyethyl (cMOE), constrained ethyl (cET), and a peptide nucleic acid (PNA), optionally wherein the oligonucleotide further comprises a spacer.

[00365] In various embodiments, disclosed herein is a method for treating amyotrophic lateral sclerosis (ALS) with frontotemporal dementia (FTD) in a subject in need thereof, the method comprising administering to the subject an oligonucleotide comprising a segment with at most 7 linked nucleosides, and wherein oligonucleotide shares at least 85% identity with any one of SEQ ID NOs: 1-466, SEQ ID NO: 893-1338, SEQ ID NOs: 1342-1366, and SEQ ID NOs: 1392-1664, or a pharmaceutically acceptable salt thereof; wherein at least one (*i.e.*, one or more) nucleoside linkage of the oligonucleotide is independently selected from the group consisting of: a phosphodiester linkage, a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a thiophosphorodiamidate linkage, a phosphorodiamidate linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage, and/or wherein at least one (*i.e.*, one or more) nucleoside is

substituted with a component selected from the group consisting of a 2'-O-(2-methoxyethyl) nucleoside, a 2'-O-methyl nucleoside, a 2'-deoxy-2'-fluoro nucleoside, a 2'-fluoro-β-D-arabinonucleoside, a locked nucleic acid (LNA), a tricyclic nucleic acid, constrained methoxyethyl (cMOE), constrained ethyl (cET), and a peptide nucleic acid (PNA), optionally
5 wherein the oligonucleotide further comprises a spacer.

Treatment and Evaluation

[00366] A patient, as described herein, refers to any animal at risk for, suffering from or diagnosed with a neurological disease, including, but not limited to, mammals, primates, and humans. In certain embodiments, the patient may be a non-human mammal such as, for example,
10 a cat, a dog, or a horse. A patient may be an individual diagnosed with a high risk of developing a neurological disease, someone who has been diagnosed with a neurological disease, someone who previously suffered from a neurological disease, or an individual evaluated for symptoms or indications of a neurological disease, for example, any of the signs or symptoms associated with neurological diseases such as: amyotrophic lateral sclerosis (ALS), frontotemporal dementia
15 (FTD), ALS with FTD, Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease, progressive supranuclear palsy (PSP), brain trauma, spinal cord injury, corticobasal degeneration (CBD), nerve injuries (e.g., brachial plexus injuries), neuropathies (e.g., chemotherapy induced neuropathy), and TDP43 proteinopathies (e.g., chronic traumatic encephalopathy, Perry Syndrome, Dementia with Lewy body in association with Alzheimer's
20 disease, Parkinson's disease with or without dementia, and Limbic-predominant age-related TDP-43 encephalopathy (LATE)).

[00367] "A patient in need," as used herein, refers to a patient suffering from any of the symptoms or manifestations of a neurological disease, a patient who may suffer from any of the symptoms or manifestations of a neurological disease, or any patient who might benefit from a
25 method of the disclosure for treating a neurological disease. A patient in need may include a patient who is diagnosed with a risk of developing a neurological disease, a patient who has suffered from a neurological disease in the past, or a patient who has previously been treated for a neurological disease.

[00368] "Effective amount," as used herein, refers to the amount of an agent that is sufficient to
30 at least partially treat a condition when administered to a patient. The therapeutically effective amount will vary depending on the severity of the condition, the route of administration of the component, and the age, weight, etc. of the patient being treated. Accordingly, an effective

amount of a disclosed STMN2 oligonucleotide is the amount of the STMN2 oligonucleotide necessary to treat a neurological disease in a patient such that administration of the agent prevents a neurological disease from occurring in a subject, prevents neurological disease progression (*e.g.*, prevents the onset or increased severity of symptoms of the neurological such as muscle
5 weakening, spasms, or fasciculation), or relieves or completely ameliorates all associated symptoms of a neurological disease, *i.e.* causes regression of the disease.

[00369] Efficacy of treatment may be evaluated by means of evaluation of gross symptoms associated with a neurological disease, analysis of tissue histology, biochemical assay, imaging methods such as, for example, magnetic resonance imaging, or other known methods. For
10 instance, efficacy of treatment may be evaluated by analyzing gross symptoms of the disease such as changes in muscle strength and control or other aspects of gross pathology associated with a neurological disease following administration, to a patient suffering from a neurological disease, a disclosed STMN2 oligonucleotide.

[00370] Efficacy of treatment may also be evaluated at the tissue or cellular level, for example, by
15 means of obtaining a tissue biopsy (*e.g.*, a brain, spinal, muscle, motor neuron tissue biopsy, or olfactory neurosphere cell biopsy) and evaluating gross tissue or cell morphology or staining properties. Biochemical assays that examine protein or RNA expression may also be used to evaluate efficacy of treatment. For instance, one may evaluate levels of a protein or gene product indicative of a neurological disease, in dissociated cells or non-dissociated tissue via
20 immunocytochemical, immunohistochemical, Western blotting, or Northern blotting methods, or methods useful for evaluating RNA levels such as quantitative or semi-quantitative polymerase chain (*e.g.*, digital PCR (DigitalPCR, dPCR, or dePCR), qPCR etc.) reaction. One may also evaluate the presence or level of expression of useful biomarkers (*e.g.*, neurofilament light (NEFL), neurofilament heavy (NEFH), TDP-43 or p75 extracellular domain (p75^{ECD})) found in
25 spinal cord fluid, cerebrospinal fluid, extracellular vesicles (for example, exosome-like cerebrospinal fluid extracellular vesicles (“CSF exosomes”), such as those described in Welton *et al.*, (2017) “Cerebrospinal fluid extracellular vesicle enrichment for protein biomarker discovery in neurological disease; multiple sclerosis” *J Extracell Vesicles.*, 6(1):1-10; and Street *et al.*, (2012) “Identification and proteomic profiling of exosomes in human cerebrospinal fluid” *J*
30 *Transl. Med.*, 10:5), urine, fecal matter, lymphatic fluid, blood, plasma, or serum to evaluate disease state and efficacy of treatment. One may also evaluate the presence or level of expression of useful biomarkers found in the plasma, neuronal extracellular vesicles/exosomes. Additional measurements of efficacy may include strength duration time constant (SDTC), short interval

cortical inhibition (SICI), dynamometry, accurate test of limb isometric strength (ATLIS), compound muscle action potential (CMAP), and ALSFRS-R. In certain embodiments, urinary neurotrophin receptor p75 extracellular domain (p75^{ECD}) is a disease progression and prognostic biomarker in amyotrophic lateral sclerosis (ALS). Phosphorylated neurofilament heavy chain (pNFH) in cerebrospinal fluid (CSF) predict disease status and survival in *C9ORF72*-associated amyotrophic lateral sclerosis (c9ALS) patients. CSF pNFH as a prognostic biomarker for clinical trials, which will increase the likelihood of successfully developing a treatment for c9ALS.

[00371] In evaluating efficacy of treatment, suitable controls may be chosen to ensure a valid assessment. For instance, one can compare symptoms evaluated in a patient with a neurological disease following administration of a disclosed STMN2 oligonucleotide to those symptoms in the same patient prior to treatment or at an earlier point in the course of treatment or in another patient not diagnosed with the neurological disease. Alternatively, one may compare the results of biochemical or histological analysis of tissue following administration of a disclosed STMN2 oligonucleotide with those of tissue from the same patient or from an individual not diagnosed with the neurological disease or from the same patient prior to administration of the STMN2 oligonucleotide. Additionally, one may compare blood, plasma, serum, cell, urine, lymphatic fluid, spinal cord fluid, cerebrospinal fluid, or fecal samples following administration of the STMN2 oligonucleotide with comparable samples from an individual not diagnosed with the neurological disease or from the same patient prior to administration of the STMN2 oligonucleotide. In some embodiments one may compare extracellular vesicles (for example CSF exosomes), following administration of the STMN2 oligonucleotide with extracellular vesicles from an individual not diagnosed with the neurological disease or from the same patient prior to administration of the STMN2 oligonucleotide.

[00372] Validation of STMN2 oligonucleotides may be determined by direct or indirect assessment of STMN2 expression levels or activity. For instance, biochemical assays that measure STMN2 protein or RNA expression may be used to evaluate overall effect on STMN2 transcripts (for example, a STMN2 pre-mRNA comprising a cryptic exon) comprising a sequence that shares at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to SEQ ID NO: 1339 or SEQ ID NO: 1341. For instance, one may measure STMN2 protein levels in cells or tissue by Western blot to evaluate overall STMN2 levels. One may also measure STMN2 mRNA levels by means of Northern blot or quantitative polymerase chain reaction to determine overall effect on STMN2 transcripts (for example, a STMN2 pre-mRNA comprising a cryptic exon) comprising a sequence that shares at least 90% (*e.g.*, 90%, 91%, 92%,

93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to SEQ ID NO: 1339 or SEQ ID NO: 1341. One may also evaluate STMN2 protein levels or levels of another protein indicative of STMN2 signaling activity in dissociated cells, non-dissociated tissue, extracellular vesicles (for example, CSF exosomes), blood, serum, or fecal matter via immunocytochemical or immunohistochemical methods.

[00373] Modulation of expression levels of STMN2 transcripts (for example, a STMN2 pre-mRNA comprising a cryptic exon) comprising a sequence that shares at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to SEQ ID NO: 1339 or SEQ ID NO: 1341 may also be evaluated indirectly by measuring parameters such as autophagy, endocytosis, protein aggregation, and the presence or level of expression of useful biomarkers (*e.g.*, neurofilament light (NEFL), neurofilament heavy (NEFH), TDP-43, or p75^{ECD} found in plasma, spinal cord fluid, cerebrospinal fluid, extracellular vesicles (for example, CSF exosomes), blood, urine, lymphatic fluid, fecal matter, or tissue to evaluate the modulation of expression of STMN2 transcripts (for example, a STMN2 pre-mRNA comprising a cryptic exon) comprising a sequence that shares at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to SEQ ID NO: 1339 or SEQ ID NO: 1341. Modulation of expression levels of STMN2 transcripts (for example, a STMN2 pre-mRNA comprising a cryptic exon) comprising a sequence that shares at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to SEQ ID NO: 1339 or SEQ ID NO: 1341 may also be evaluated indirectly by measuring parameters such as autophagy, endocytosis, protein aggregation, and the presence or level of expression of physiological biomarkers such as compound muscle action potential (CMAP). Additional measurements may include strength duration time constant (SDTC), short interval cortical inhibition (SICI), 157yrrolidiny, accurate test of limb isometric strength (ATLIS), compound muscle action potential, and ALSFRS-R. In certain embodiments, urinary neurotrophin receptor p75 extracellular domain (p75^{ECD}) is a disease progression and prognostic biomarker in amyotrophic lateral sclerosis (ALS). Phosphorylated neurofilament heavy chain (pNFH) in cerebrospinal fluid (CSF) predict disease status and survival in c9ALS patients. CSF pNFH as a prognostic biomarker for clinical trials, which will increase the likelihood of successfully developing a treatment for c9ALS.

[00374] The disclosure also provides methods of restoring expression of full length STMN2 transcripts in cells of a patient suffering from a neurological disease. Full length STMN2 transcripts may be restored in any cell in which STMN2 expression or activity occurs, including cells of the nervous system (including the central nervous system (*e.g.*, spinal cord or brain), the

peripheral nervous system, motor neurons, glial cells, astrocytes, oligodendrocytes, microglia, the brain, the brain stem, the frontal lobes, the temporal lobes, the spinal cord), the musculoskeletal system, spinal fluid, and cerebrospinal fluid. Cells of the musculoskeletal system include skeletal muscle cells (*e.g.*, myocytes). Motor neurons include upper motor neurons and lower motor neurons.

Pharmaceutical Compositions and Routes of Administration

[00375] The present disclosure also provides methods for treating a neurological disease via administration of a pharmaceutical composition comprising a disclosed STMN2 oligonucleotide. In another aspect, the disclosure provides a pharmaceutical composition for use in treating a neurological disease. The pharmaceutical composition may be comprised of a disclosed STMN2 oligonucleotide, and a pharmaceutically acceptable carrier. As used herein the term “pharmaceutical composition” means, for example, a mixture containing a specified amount of a therapeutic compound, *e.g.*, a therapeutically effective amount, of a therapeutic compound in a pharmaceutically acceptable carrier to be administered to a mammal, *e.g.*, a human, in order to treat a neurological disease. In some embodiments, described herein are pharmaceutical compositions comprising a disclosed STMN2 oligonucleotide, and a pharmaceutically acceptable carrier. In another aspect, the disclosure provides use of a disclosed STMN2 oligonucleotide in the manufacture of a medicament for treating a neurological disease. “Medicament,” as used herein, has essentially the same meaning as the term “pharmaceutical composition.”

[00376] As used herein, “pharmaceutically acceptable carrier” means buffers, carriers, and excipients suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. The carrier(s) should be “acceptable” in the sense of being compatible with the other ingredients of the formulations and not deleterious to the recipient. Pharmaceutically acceptable carriers include buffers, solvents, dispersion media, coatings, isotonic and absorption delaying agents, and the like, that are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is known in the art. In one embodiment the pharmaceutical composition is administered orally and includes an enteric coating suitable for regulating the site of absorption of the encapsulated substances within the digestive system or gut. For example, an enteric coating can include an ethylacrylate-methacrylic acid copolymer.

[00377] In one embodiment, a disclosed STMN2 oligonucleotide and any pharmaceutical composition thereof may be administered by one or several routes, including topically, intrathecally, intrathalamically, intracisternally, parenterally, orally, rectally, buccally, sublingually, vaginally, pulmonarily, intratracheally, intranasally, transdermally, or intraduodenally. The term parenteral as used herein includes subcutaneous injections, intrapancreatic administration, intravenous, intracisternal, intracerebroventricular, intrathecal, intrathalamic, intramuscular, intraperitoneal, intrasternal injection or infusion techniques. For example, a disclosed STMN2 oligonucleotide may be administered subcutaneously to a subject. In another example, a disclosed STMN2 oligonucleotide may be administered orally to a subject. In another example, a disclosed STMN2 oligonucleotide may be administered directly to the nervous system, or specific regions or cells of the nervous system (*e.g.*, the brain, brain stem, lower motor neurons, spinal cord, upper motor neurons) via parenteral administration, for example, a disclosed STMN2 oligonucleotide may be administered intrathecally, intrathalamically or intracisternally.

[00378] In various embodiments, a STMN2 oligonucleotide, for example a STMN2 AON, can be exposed to calcium-containing buffers prior to administration. Such calcium-containing buffers can mitigate toxicity adverse effects of the STMN2 oligonucleotide. Further details of exposing an example antisense oligonucleotide to calcium-containing buffers is described in Moazami, et al., Quantifying and Mitigating Motor Phenotypes Induced by Antisense Oligonucleotides in the Central Nervous System, [bioRxiv 2021.02.14.431096](https://doi.org/10.1101/2021.02.14.431096), which is hereby incorporated by reference in its entirety.

[00379] In some embodiments, a STMN2 oligonucleotide, for example a STMN2 AON, can be encapsulated in a nanoparticle coating. It is believed that nanoparticle encapsulation prevents AON degradation and enhances cellular uptake. For example, in some embodiments a STMN2 oligonucleotide is encapsulated in a coating of a cationic polymer, for example, a synthetic polymer (*e.g.*, poly-L-lysine, polyamidoamine, a poly(β -amino ester), and polyethyleneimine) or a naturally occurring polymer (*e.g.*, chitosan and a protamine). In some embodiments, a STMN2 oligonucleotide is encapsulated in a lipid or lipid-like material, for example, a cationic lipid, a cationic lipid-like material, or an ionizable lipid that is positively charged only at an acidic pH. For example, in some embodiments, a STMN2 oligonucleotide is encapsulated in a lipid nanoparticle that includes hydrophobic moieties, *e.g.*, cholesterol and/or a polyethylene glycol (PEG) lipid.

[00380] Pharmaceutical compositions containing a disclosed STMN2 oligonucleotide, such as those disclosed herein, can be presented in a dosage unit form and can be prepared by any suitable method. A pharmaceutical composition should be formulated to be compatible with its intended route of administration. Useful formulations can be prepared by methods well known in the pharmaceutical art. For example, see *Remington's Pharmaceutical Sciences*, 18th ed. (Mack Publishing Company, 1990).

[00381] Pharmaceutical formulations, in some embodiments, are sterile. Sterilization can be accomplished, for example, by filtration through sterile filtration membranes. Where the composition is lyophilized, filter sterilization can be conducted prior to or following lyophilization and reconstitution.

Parenteral Administration

[00382] The pharmaceutical compositions of the disclosure can be formulated for parenteral administration, *e.g.*, formulated for injection via the intravenous, intracisternal, intracerebroventricular, intramuscular, subcutaneous, intrathecal, intrathalamic, intralesional, or intraperitoneal routes. The preparation of an aqueous composition, such as an aqueous pharmaceutical composition containing a disclosed STMN2 oligonucleotide, will be known to those of skill in the art in light of the present disclosure. Typically, such compositions can be prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for using to prepare solutions or suspensions upon the addition of a liquid prior to injection can also be prepared; and the preparations can also be emulsified.

[00383] The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations including normal saline, artificial cerebrospinal fluid, sesame oil, peanut oil or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.

[00384] Solutions of active compounds as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. In addition, sterile, fixed oils may be employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid can be used in the preparation of injectables. The sterile injectable

preparation may also be a sterile injectable solution, suspension, or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P., and isotonic sodium chloride solution. In one embodiment, a disclosed STMN2 antisense

5 oligonucleotide may be suspended in a carrier fluid comprising 1% (w/v) sodium carboxymethylcellulose and 0.1% (v/v) TWEEN™ 80. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

[00385] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and
10 suspending agents. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. Sterile injectable solutions of the disclosure may be prepared by incorporating a disclosed STMN2 antisense oligonucleotide in the required amount of the appropriate solvent with various of the other ingredients enumerated
15 above, as required, followed by filtered sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. The injectable formulations can be sterilized, for example, by filtration through a bacteria-retaining filter.

20 **[00386]** The preparation of more, or highly concentrated solutions for intramuscular injection is also contemplated. In this regard, the use of DMSO as solvent is preferred as this will result in extremely rapid penetration, delivering high concentrations of the disclosed oligonucleotide to a small area.

[00387] Suitable preservatives for use in such a solution include benzalkonium chloride,
25 benzethonium chloride, chlorobutanol, thimerosal and the like. Suitable buffers include boric acid, sodium and potassium bicarbonate, sodium and potassium borates, sodium and potassium carbonate, sodium acetate, sodium biphosphate and the like, in amounts sufficient to maintain the pH at between about pH 6 and pH 8, and for example, between about pH 7 and pH 7.5. Suitable
30 tonicity agents are dextran 40, dextran 70, dextrose, glycerin, potassium chloride, propylene glycol, sodium chloride, and the like, such that the sodium chloride equivalent of the solution is in the range 0.9 plus or minus 0.2%. Suitable antioxidants and stabilizers include sodium bisulfite, sodium metabisulfite, sodium 161yrrolidiny, thiourea and the like. Suitable wetting and clarifying agents include polysorbate 80, polysorbate 20, poloxamer 282 and tyloxapol. Suitable viscosity-

increasing agents include dextran 40, dextran 70, gelatin, glycerin, hydroxyethylcellulose, hydroxymethylpropylcellulose, lanolin, methylcellulose, petrolatum, polyethylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, carboxymethylcellulose and the like.

Oral Administration

- 5 **[00388]** In some embodiments, contemplated herein are compositions suitable for oral delivery of a disclosed STMN2 oligonucleotide, *e.g.*, tablets that include an enteric coating, *e.g.*, a gastro-resistant coating, such that the compositions may deliver a STMN2 oligonucleotide to, *e.g.*, the gastrointestinal tract of a patient.
- [00389]** For example, a tablet for oral administration is provided that comprises granules (*e.g.*, is
10 at least partially formed from granules) that include a disclosed STMN2 oligonucleotide, *e.g.*, a STMN2 oligonucleotide represented by any SEQ ID NOs: 1-466, SEQ ID NO: 893-1338, SEQ ID NOs: 1342-1366, and SEQ ID NOs: 1392-1664 that targets a STMN2 transcript comprising a sequence that shares at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to SEQ ID NO: 1339 or SEQ ID NO: 1341, and pharmaceutically acceptable
15 excipients. Such a tablet may be coated with an enteric coating. Contemplated tablets may include pharmaceutically acceptable excipients such as fillers, binders, disintegrants, and/or lubricants, as well as coloring agents, release agents, coating agents, sweetening, flavoring such as wintergreen, orange, xylitol, sorbitol, fructose, and maltodextrin, and perfuming agents, preservatives and/or antioxidants.
- 20 **[00390]** In some embodiments, contemplated pharmaceutical formulations include an intra-granular phase that includes a disclosed STMN2 oligonucleotide, *e.g.*, a STMN2 oligonucleotide represented by any of SEQ ID NOs: 1-466, SEQ ID NO: 893-1338, SEQ ID NOs: 1342-1366, and SEQ ID NOs: 1392-1664 that targets a STMN2 transcript comprising a sequence that shares at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to
25 SEQ ID NO: 1339 or SEQ ID NO: 1341, and a pharmaceutically acceptable salt. In some embodiments, contemplated pharmaceutical formulations include an intra-granular phase that includes a disclosed STMN2 oligonucleotide, *e.g.*, a STMN2 oligonucleotide represented by any of SEQ ID NOs: 1-466, SEQ ID NO: 893-1338, SEQ ID NOs: 1342-1366, and SEQ ID NOs: 1392-1664 that targets a STMN2 transcript comprising a sequence that shares at least 90% (*e.g.*,
30 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to SEQ ID NO: 1339 or SEQ ID NO: 1341, and a pharmaceutically acceptable filler. For example, a disclosed STMN2 oligonucleotide and a filler may be blended together, optionally, with other excipients, and formed into granules. In some embodiments, the intragranular phase may be formed using wet

granulation, *e.g.*, a liquid (*e.g.*, water) is added to the blended STMN2 oligonucleotide and filler, and then the combination is dried, milled and/or sieved to produce granules. One of skill in the art would understand that other processes may be used to achieve an intragranular phase.

[00391] In some embodiments, contemplated formulations include an extra-granular phase, which may include one or more pharmaceutically acceptable excipients, and which may be blended with the intragranular phase to form a disclosed formulation.

[00392] A disclosed formulation may include an intragranular phase that includes a filler.

Exemplary fillers include, but are not limited to, cellulose, gelatin, calcium phosphate, lactose, sucrose, glucose, mannitol, sorbitol, microcrystalline cellulose, pectin, polyacrylates, dextrose, cellulose acetate, hydroxypropylmethyl cellulose, partially pre-gelatinized starch, calcium carbonate, and others including combinations thereof.

[00393] In some embodiments, a disclosed formulation may include an intragranular phase and/or an extragranular phase that includes a binder, which may generally function to hold the ingredients of the pharmaceutical formulation together. Exemplary binders of the disclosure may include, but are not limited to, the following: starches, sugars, cellulose or modified cellulose such as hydroxypropyl cellulose, lactose, pre-gelatinized maize starch, polyvinyl pyrrolidone, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, low substituted hydroxypropyl cellulose, sodium carboxymethyl cellulose, methyl cellulose, ethyl cellulose, sugar alcohols and others including combinations thereof.

[00394] Contemplated formulations, *e.g.*, that include an intragranular phase and/or an extragranular phase, may include a disintegrant such as but not limited to, starch, cellulose, crosslinked polyvinyl pyrrolidone, sodium starch glycolate, sodium carboxymethyl cellulose, alginates, corn starch, crosmellose sodium, crosslinked carboxymethyl cellulose, low substituted hydroxypropyl cellulose, acacia, and others including combinations thereof. For example, an intragranular phase and/or an extragranular phase may include a disintegrant.

[00395] In some embodiments, a contemplated formulation includes an intra-granular phase comprising a disclosed STMN2 oligonucleotide and excipients chosen from: mannitol, microcrystalline cellulose, hydroxypropylmethyl cellulose, and sodium starch glycolate or combinations thereof, and an extra-granular phase comprising one or more of: microcrystalline cellulose, sodium starch glycolate, and magnesium stearate or mixtures thereof.

[00396] In some embodiments, a contemplated formulation may include a lubricant, *e.g.* an extra-granular phase may contain a lubricant. Lubricants include but are not limited to talc, silica, fats, stearin, magnesium stearate, calcium phosphate, silicone dioxide, calcium silicate, calcium

phosphate, colloidal silicon dioxide, metallic stearates, hydrogenated vegetable oil, corn starch, sodium benzoate, polyethylene glycols, sodium acetate, calcium stearate, sodium lauryl sulfate, sodium chloride, magnesium lauryl sulfate, talc, and stearic acid.

[00397] In some embodiments, the pharmaceutical formulation comprises an enteric coating.

5 Generally, enteric coatings create a barrier for the oral medication that controls the location at which the drug is absorbed along the digestive track. Enteric coatings may include a polymer that disintegrates at different rates according to pH. Enteric coatings may include for example, cellulose acetate phthalate, methyl acrylate-methacrylic acid copolymers, cellulose acetate succinate, hydroxylpropylmethyl cellulose phthalate, methyl methacrylate-methacrylic acid
10 copolymers, ethylacrylate-methacrylic acid copolymers, methacrylic acid copolymer type C, polyvinyl acetate-phthalate, and cellulose acetate phthalate.

[00398] Exemplary enteric coatings include Opadry[®] AMB, Acryl-EZE[®], Eudragit[®] grades. In some embodiments, an enteric coating may comprise about 5% to about 10%, about 5% to about 20%, 8% to about 15%, about 8% to about 20%, about 10% to about 20%, or about 12% to about
15 20%, or about 18% of a contemplated tablet by weight. For example, enteric coatings may include an ethylacrylate-methacrylic acid copolymer.

[00399] For example, in a contemplated embodiment, a tablet is provided that comprises or consists essentially of about 0.5% to about 70%, *e.g.*, about 0.5% to about 10%, or about 1% to about 20%, by weight of a disclosed STMN2 oligonucleotide or a pharmaceutically acceptable
20 salt thereof. Such a tablet may include for example, about 0.5% to about 60% by weight of mannitol, *e.g.*, about 30% to about 50% by weight mannitol, *e.g.*, about 40% by weight mannitol; and/or about 20% to about 40% by weight of microcrystalline cellulose, or about 10% to about 30% by weight of microcrystalline cellulose. For example, a disclosed tablet may comprise an intragranular phase that includes about 30% to about 60%, *e.g.* about 45% to about 65% by
25 weight, or alternatively, about 5 to about 10% by weight of a disclosed STMN2 oligonucleotide, about 30% to about 50%, or alternatively, about 5% to about 15% by weight mannitol, about 5% to about 15% microcrystalline cellulose, about 0% to about 4%, or about 1% to about 7% hydroxypropylmethylcellulose, and about 0% to about 4%, *e.g.*, about 2% to about 4% sodium starch glycolate by weight.

30 **[00400]** In another contemplated embodiment, a pharmaceutical tablet formulation for oral administration of a disclosed STMN2 oligonucleotide comprises an intra-granular phase, wherein the intra-granular phase includes a disclosed STMN2 AON or a pharmaceutically acceptable salt thereof (such as a sodium salt), and a pharmaceutically acceptable filler, and which may also

include an extra-granular phase, that may include a pharmaceutically acceptable excipient such as a disintegrant. The extra-granular phase may include components chosen from microcrystalline cellulose, magnesium stearate, and mixtures thereof. The pharmaceutical composition may also include an enteric coating of about 12% to 20% by weight of the tablet. For example, a

5 pharmaceutically acceptable tablet for oral use may comprise about 0.5% to 10% by weight of a disclosed STMN2 AON, *e.g.*, a disclosed STMN2 AON or a pharmaceutically acceptable salt thereof, about 30% to 50% by weight mannitol, about 10% to 30% by weight microcrystalline cellulose, and an enteric coating comprising an ethylacrylate-methacrylic acid copolymer.

[00401] In another example, a pharmaceutically acceptable tablet for oral use may comprise an

10 intra-granular phase, comprising about 5 to about 10% by weight of a disclosed STMN2 AON, *e.g.*, a disclosed STMN2 AON or a pharmaceutically acceptable salt thereof, about 40% by weight mannitol, about 8% by weight microcrystalline cellulose, about 5% by weight hydroxypropylmethyl cellulose, and about 2% by weight sodium starch glycolate; an extra-granular phase comprising about 17% by weight microcrystalline cellulose, about 2% by weight

15 sodium starch glycolate, about 0.4% by weight magnesium stearate; and an enteric coating over the tablet comprising an ethylacrylate-methacrylic acid copolymer.

[00402] In some embodiments the pharmaceutical composition may contain an enteric coating comprising about 13% or about 15%, 16%, 17% or 18% by weight, *e.g.*, AcrylEZE® (*see, e.g.*, PCT Publication No. WO 2010/054826, which is hereby incorporated by reference in its entirety).

[00403] The rate at which the coating dissolves and the active ingredient is released is its

20 dissolution rate. In an embodiment, a contemplated tablet may have a dissolution profile, *e.g.*, when tested in a USP/EP Type 2 apparatus (paddle) at 100 rpm and 37 °C in a phosphate buffer with a pH of 7.2, of about 50% to about 100% of the STMN2 oligonucleotide releasing after about 120 minutes to about 240 minutes, for example after 180 minutes. In another embodiment,

25 a contemplated tablet may have a dissolution profile, *e.g.*, when tested in a USP/EP Type 2 apparatus (paddle) at 100 rpm and 37 °C in diluted HCl with a pH of 1.0, where substantially none of the STMN2 oligonucleotide is released after 120 minutes. A contemplated tablet, in another embodiment, may have a dissolution profile, *e.g.*, when tested in USP/EP Type 2 apparatus (paddle) at 100 rpm and 37 °C in a phosphate buffer with a pH of 6.6, of about 10% to

30 about 30%, or not more than about 50% of the STMN2 oligonucleotide releasing after 30 minutes.

[00404] In some embodiments, methods provided herein may further include administering at least one other agent that is directed to treatment of diseases and disorders disclosed herein. In

one embodiment, contemplated other agents may be co-administered (*e.g.*, sequentially or simultaneously).

Dosage and Frequency of Administration

[00405] The dosage or amounts described below refer either to the oligonucleotide or a pharmaceutically acceptable salt thereof.

[00406] In some embodiments, methods described herein include administering at least 1 µg, at least 5 µg, at least 10 µg, at least 20 µg, at least 30 µg, at least 40 µg, at least 50 µg, at least 60 µg, at least 70 µg, at least 80 µg, at least 90 µg, or at least 100 µg of a STMN2 antisense oligonucleotide *e.g.*, a STMN2 oligonucleotide. In some embodiments, methods include

administering from 10 mg to 500 mg, from 1 mg to 10 mg, from 10 mg to 20 mg, from 20 mg to 30 mg, from 30 mg to 40 mg, from 40 mg to 50 mg, from 50 mg to 60 mg, from 60 mg to 70 mg, from 70 mg to 80 mg, from 80 mg to 90 mg, from 90 mg to 100 mg, from 100 mg to 150 mg, from 150 mg to 200 mg, from 200 mg to 250 mg, from 250 mg to 300 mg, from 300 mg to 350 mg, from 350 mg to 400 mg, from 400 mg to 450 mg, from 450 mg to 500 mg, from 500 mg to 600 mg, from 600 mg to 700 mg, from 700 mg to 800 mg, from 800 mg to 900 mg, from 900 mg to 1 g, from 1 mg to 50 mg, from 20 mg to 40 mg, or from 1 mg to 500 mg of a STMN2 antisense oligonucleotide.

[00407] In some embodiments, methods described herein include administering formulations that include about 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, 1 g, 1.5 g, 2.0 g, 2.5 g, 3.0 g, 3.5 g, 4.0 g, 4.5 g, or 5.0 g of a disclosed STMN2 oligonucleotide. In some embodiments, a formulation may include about 40 mg, 80 mg, or 160 mg of a disclosed STMN2 oligonucleotide. In some embodiments, a formulation may include at least 100 µg of a disclosed STMN2 oligonucleotide. For example, formulations may include about 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 1 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, or 30 mg of a disclosed STMN2 oligonucleotide. The amount administered will depend on variables such as the type and extent of disease or indication to be treated, the overall health and size of the patient, the *in vivo* potency of the STMN2 oligonucleotide, the pharmaceutical formulation, and the route of administration. The initial dosage can be increased beyond the upper level in order to rapidly achieve the desired blood-level or tissue level. Alternatively, the initial dosage can be smaller than the optimum, and the dosage may be progressively increased during the course of treatment. Human dosage can be optimized, *e.g.*, in a conventional Phase I dose escalation study. Dosing

frequency can vary, depending on factors such as route of administration, dosage amount and the disease being treated. Exemplary dosing frequencies are once per day, once per week and once every two weeks. In some embodiments, dosing is once per day for 7 days. In some
embodiments, dosing is once every 4 weeks, once every 5 weeks, once every 6 weeks, once every
5 7 weeks, once every 8 weeks, once every 9 weeks, once every 10 weeks, once every 11 weeks, or
once every 12 weeks. In some embodiments, dosing is once a month to every three months.

Combination Therapies

[00408] In various embodiments, a STMN2 AON as disclosed herein can be administered in combination with one or more additional therapies. The combination therapy of the disclosed
10 oligonucleotide and the one or more additional therapies can, in some embodiments, be synergistic in treating any of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), ALS with FTD, Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease, progressive supranuclear palsy (PSP), brain trauma, spinal cord injury, corticobasal degeneration (CBD), nerve injuries (e.g., brachial plexus injuries), neuropathies (e.g.,
15 chemotherapy induced neuropathy), and TDP43 proteinopathies (e.g., chronic traumatic encephalopathy, Perry Syndrome, Dementia with Lewy body in association with Alzheimer's disease, Parkinson's disease with or without dementia, and Limbic-predominant age-related TDP-43 encephalopathy (LATE)).

[00409] Example additional therapies include any of Riluzole (Rilutek), Edaravone (Radicava),
20 rivastigmine, donepezil, galantamine, selective serotonin reuptake inhibitor, antipsychotic agents, cholinesterase inhibitors, memantine, benzodiazepine antianxiety drugs, AMX0035 (ELYBRIO), ZILUCOPLAN (RA101495), pridopidine, dual AON intrathecal administration (e.g., BIIB067, BIIB078, and BIIB105), BIIB100, levodopa/carbidopa, dopaminergic agents (e.g., ropinirole, pramipexole, rotigotine), medroxyprogesterone, KCNQ2/KCNQ3 openers (e.g., retigabine,
25 XEN1101, or QRL-101), anticonvulsants and psychostimulant agents. Additional therapies can further include breathing care, physical therapy, occupational therapy, speech therapy, and nutritional support. In various embodiments, an additional therapy can be a second antisense oligonucleotide. As an example, the second antisense oligonucleotide may target a STMN2 transcript (e.g., STMN2 pre-mRNA, mature STMN2 mRNA) to modulate the expression levels of
30 full length STMN2 protein.

[00410] In various embodiments, the disclosed oligonucleotide and the one or more additional therapies can be conjugated to one another and provided in a conjugated form. Further description regarding conjugates involving the disclosed oligonucleotide is described below. In

various embodiments, the disclosed oligonucleotide and one or more additional therapies are provided concurrently. In various embodiments, the disclosed oligonucleotide and one or more additional therapies are provided simultaneously. In various embodiments, the disclosed oligonucleotide and one or more additional therapies are provided sequentially.

5 **Conjugates**

[00411] In certain embodiments, provided herein are oligomeric compounds, which comprise an oligonucleotide (*e.g.*, STMN2 oligonucleotide) and optionally one or more conjugate groups and/or terminal groups. Conjugate groups include one or more conjugate moiety and a conjugate linker which links the conjugate moiety to the oligonucleotide. Conjugate groups may be attached to either or both ends of an oligonucleotide and/or at any internal position. In certain
10 embodiments, conjugate groups are attached to the 2'-position of a nucleoside of a modified oligonucleotide. In certain embodiments, conjugate groups that are attached to either or both ends of an oligonucleotide are terminal groups. In certain such embodiments, conjugate groups or terminal groups are attached at the 3' and/or 5'-end of oligonucleotides. In certain such
15 embodiments, conjugate groups (or terminal groups) are attached at the 3'-end of oligonucleotides. In certain embodiments, conjugate groups are attached near the 3'-end of oligonucleotides. In certain embodiments, conjugate groups (or terminal groups) are attached at the 5'-end of oligonucleotides. In certain embodiments, conjugate groups are attached near the 5'-end of oligonucleotides.

20 [00412] Examples of terminal groups include but are not limited to conjugate groups, capping groups, phosphate moieties, protecting groups, modified or unmodified nucleosides, and two or more nucleosides that are independently modified or unmodified.

Conjugate Groups

[00413] In certain embodiments, a STMN2 AON is covalently attached to one or more conjugate
25 groups. In certain embodiments, conjugate groups modify one or more properties of the attached oligonucleotide, including but not limited to pharmacodynamics, pharmacokinetics, stability, binding, absorption, tissue distribution, cellular distribution, cellular uptake, charge and clearance. In particular embodiments, conjugate groups modify the circulation time (*e.g.*, increase) of the oligonucleotides in the bloodstream such that increased concentrations of the oligonucleotides are
30 delivered to the brain. In particular embodiments, conjugate groups modify the residence time (*e.g.*, increase residence time) of the oligonucleotides in a target organ (*e.g.*, brain) such that increased residence time of the oligonucleotides improves their performance (*e.g.*, efficacy). In particular embodiments, conjugate groups increase the delivery of the oligonucleotide to the brain

through the blood brain barrier and/or brain parenchyma (e.g., through receptor mediated transcytosis). In particular embodiments, conjugate groups enable the oligonucleotide to target a specific organ (e.g., the brain). In certain embodiments, conjugate groups impart a new property on the attached oligonucleotide, e.g., fluorophores or reporter groups that enable detection of the oligonucleotide. Certain conjugate groups and conjugate moieties have been described previously, for example: cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 6553-6556), cholic acid (Manoharan et al., Bioorg. Med. Chem. Lett., 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Ann. NY. Acad. Sci., 1992, 660, 306-309; Manoharan et al., Bioorg. Med. Chem. Lett., 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20, 533-538), an aliphatic chain, e.g., do-decan-diol or undecyl residues (Saison-Behmoaras et al., EMBO J, 1991, 10, 1111-1118; Kabanov et al., FEBS Lett., 1990, 259, 327-330; Svinarchuk et al., Biochimie, 1993, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac - glycerol or triethyl -ammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654; Shea et al., Nucl. Acids Res., 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14, 969-973), or adamantane acetic acid a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264, 229-237), an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277, 923-937), a tocopherol group (Nishina *et al.*, Molecular Therapy Nucleic Acids, 2015, 4, e220; and Nishina *et al.*, Molecular Therapy, 2008, 16, 734-740), or a GalNAc cluster (e.g., WO2014/179620).

Conjugate Moieties

[00414] Conjugate moieties include, without limitation, intercalators, reporter molecules, polyamines, polyamides, peptides, carbohydrates, vitamin moieties, polyethylene glycols, thioethers, polyethers, cholesterol, thiocholesterols, cholic acid moieties, folate, lipids, phospholipids, biotin, phenazine, phenanthridine, anthraquinone, adamantane, acridine, fluoresceins, rhodamines, coumarins, fluorophores, and dyes. In particular embodiments, conjugate moieties are selected from a peptide, a lipid, N-acetylgalactosamine (GalNAc), cholesterol, vitamin E, lipoic acid, panthothenic acid, polyethylene glycol, an antibody (e.g., an antibody for crossing the blood brain barrier such as anti-transferrin receptor antibody), or a cell-penetrating peptide (e.g., transactivator of transcription (TAT) and penetratine).

[00415] In certain embodiments, a conjugate moiety comprises an active drug substance, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fenbufen, ketoprofen, (S)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triodobenzoic acid, fingolimod, flufenamic acid,

folinic acid, a benzothiadiazide, chlorothiazide, a diazepine, indomethacin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic.

Conjugate Linkers

[00416] Conjugate moieties are attached to a STMN2 AON through conjugate linkers. In certain oligomeric compounds, the conjugate linker is a single chemical bond (i.e., the conjugate moiety is attached directly to an oligonucleotide through a single bond). In certain embodiments, the conjugate linker comprises a chain structure, such as a hydrocarbon chain, or an oligomer of repeating units such as ethylene glycol, nucleosides, or amino acid units.

[00417] In certain embodiments, a conjugate linker comprises one or more groups selected from alkyl, amino, oxo, amide, disulfide, polyethylene glycol, ether, thioether, and hydroxylamino. In certain such embodiments, the conjugate linker comprises groups selected from alkyl, amino, oxo, amide and ether groups. In certain embodiments, the conjugate linker comprises groups selected from alkyl and amide groups. In certain embodiments, the conjugate linker comprises groups selected from alkyl and ether groups. In certain embodiments, the conjugate linker comprises at least one phosphorus moiety. In certain embodiments, the conjugate linker comprises at least one phosphate group. In certain embodiments, the conjugate linker includes at least one neutral linking group.

[00418] In certain embodiments, conjugate linkers, including the conjugate linkers described above, are bifunctional linking moieties, *e.g.*, those known in the art to be useful for attaching conjugate groups to parent compounds, such as the oligonucleotides provided herein. In general, a bifunctional linking moiety comprises at least two functional groups. One of the functional groups is selected to bind to a particular site on a parent compound and the other is selected to bind to a conjugate group. Examples of functional groups used in a bifunctional linking moiety include but are not limited to electrophiles for reacting with nucleophilic groups and nucleophiles for reacting with electrophilic groups. In certain embodiments, bifunctional linking moieties comprise one or more groups selected from amino, hydroxyl, carboxylic acid, thiol, alkyl, alkenyl, and alkynyl.

[00419] Examples of conjugate linkers include but are not limited to pyrrolidine, 8-amino-3,6-dioxaoctanoic acid (ADO), succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) and 6-aminohexanoic acid (AHEx or AHA). Other conjugate linkers include but are not limited to substituted or unsubstituted C₁-C₁₀ alkyl, substituted or unsubstituted C₂-C₁₀ alkenyl or substituted or unsubstituted C₂-C₁₀ alkynyl, wherein a nonlimiting list of preferred substituent groups includes hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro, thiol, thioalkoxy, halogen, alkyl, aryl, alkenyl and alkynyl.

[00420] In certain embodiments, conjugate linkers comprise 1-10 linker-nucleosides. In certain embodiments, conjugate linkers comprise 2-5 linker-nucleosides. In certain embodiments, conjugate linkers comprise 3 linker-nucleosides.

[00421] In certain embodiments, such linker-nucleosides are modified nucleosides. In certain
5 embodiments such linker-nucleosides comprise a modified sugar moiety. In certain embodiments, linker-nucleosides are unmodified. In certain embodiments, linker-nucleosides comprise an optionally protected heterocyclic base selected from a purine, substituted purine, pyrimidine or substituted pyrimidine. In certain embodiments, a cleavable moiety is a nucleoside selected from uracil, thymine, cytosine, 4-N-benzoylcytosine, 5-methyl cytosine, 4-N -benzoyl-5 -methyl
10 cytosine, adenine, 6-N-benzoyladenine, guanine and 2-N-isobutyrylguanine. It is typically desirable for linker-nucleosides to be cleaved from the oligomeric compound after it reaches a target tissue. Accordingly, linker-nucleosides are typically linked to one another and to the remainder of the oligomeric compound through cleavable bonds. In certain embodiments, such cleavable bonds are phosphodiester bonds.

[00422] Herein, linker-nucleosides are not considered to be part of the oligonucleotide.
15 Accordingly, in embodiments in which an oligomeric compound comprises an oligonucleotide consisting of a specified number or range of linked nucleosides and/or a specified percent complementarity to a reference nucleic acid and the oligomeric compound also comprises a conjugate group comprising a conjugate linker comprising linker-nucleosides, those linker-
20 nucleosides are not counted toward the length of the oligonucleotide and are not used in determining the percent complementarity of the oligonucleotide for the reference nucleic acid.

[00423] In certain embodiments, it is desirable for a conjugate group to be cleaved from the STMN2 AON. For example, in certain circumstances oligomeric compounds comprising a particular conjugate moiety are better taken up by a particular cell type, but once the oligomeric
25 compound has been taken up, it is desirable that the conjugate group be cleaved to release the unconjugated or parent oligonucleotide. Thus, certain conjugate linkers may comprise one or more cleavable moieties. In certain embodiments, a cleavable moiety is a cleavable bond. In certain embodiments, a cleavable moiety is a group of atoms comprising at least one cleavable bond. In certain embodiments, a cleavable moiety comprises a group of atoms having one, two,
30 three, four, or more than four cleavable bonds. In certain embodiments, a cleavable moiety is selectively cleaved inside a cell or subcellular compartment, such as a lysosome. In certain embodiments, a cleavable moiety is selectively cleaved by endogenous enzymes, such as nucleases.

[00424] In certain embodiments, a cleavable bond is selected from among: an amide, an ester, an ether, one or both esters of a phosphodiester, a phosphate ester, a carbamate, or a disulfide. In certain embodiments, a cleavable bond is one or both of the esters of a phosphodiester. In certain
5 embodiments, a cleavable moiety comprises a phosphate or phosphodiester. In certain
embodiments, the cleavable moiety is a phosphate linkage between an oligonucleotide and a
conjugate moiety or conjugate group.

[00425] In certain embodiments, a cleavable moiety comprises or consists of one or more linker-
nucleosides. In certain such embodiments, the one or more linker-nucleosides are linked to one
another and/or to the remainder of the oligomeric compound through cleavable bonds. In certain
10 embodiments, such cleavable bonds are unmodified phosphodiester bonds. In certain
embodiments, a cleavable moiety is 2'-deoxy nucleoside that is attached to either the 3' or 5'-
terminal nucleoside of an oligonucleotide by a phosphate internucleoside linkage and covalently
attached to the remainder of the conjugate linker or conjugate moiety by a phosphate or
phosphorothioate linkage. In certain such embodiments, the cleavable moiety is 2'-deoxy
15 adenosine.

Terminal Groups

[00426] In certain embodiments, oligomeric compounds comprise one or more terminal groups. In
certain such embodiments, oligomeric compounds comprise a stabilized 5'-phosphate. Stabilized
5'-phosphates include, but are not limited to 5'-phosphonates, including, but not limited to 5'-
20 vinylphosphonates. In certain embodiments, terminal groups comprise one or more abasic
nucleosides and/or inverted nucleosides. In certain embodiments, terminal groups comprise one or
more 2'-linked nucleosides. In certain such embodiments, the 2'-linked nucleoside is an abasic
nucleoside. In various embodiments, terminal groups comprise one or more spacers.

Diagnostic Methods

[00427] The disclosure also provides a method of diagnosing a patient with a neurological disease
that relies upon detecting levels of STMN2 expression signal in one or more biological samples of
a patient. As used herein, the term "STMN2 expression signal" can refer to any indication of
STMN2 gene expression, or gene or gene product activity. STMN2 gene products include RNA
(*e.g.*, mRNA), peptides, and proteins. Indices of STMN2 gene expression that can be assessed
30 include, but are not limited to, STMN2 gene or chromatin state, STMN2 gene interaction with
cellular components that regulate gene expression, STMN2 gene product expression levels (*e.g.*,
expression levels of STMN2 transcripts (for example, a STMN2 pre-mRNA comprising a cryptic
exon) comprising a sequence that shares at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%,

96%, 97%, 98%, 99%, or 100%) identity to SEQ ID NO: 1339 or SEQ ID NO: 1341, or interaction of STMN2 RNA or protein with transcriptional, translational, or post-translational processing machinery.

[00428] Detection of STMN2 expression signal may be accomplished through *in vivo*, *in vitro*, or *ex vivo* methods. In a preferred embodiment, methods of the disclosure may be carried out *in vitro*. Methods of detecting may involve detection in blood, serum, fecal matter, tissue, cerebrospinal fluid, spinal fluid, extracellular vesicles (for example, CSF exosomes), or cells of a patient. Detection may be achieved by measuring expression signal of STMN2 transcripts (for example, a STMN2 pre-mRNA comprising a cryptic exon) comprising a sequence that shares at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity to SEQ ID NO: 1339 or SEQ ID NO: 1341 in whole tissue, tissue explants, cell cultures, dissociated cells, cell extract, extracellular vesicles (for example, CSF exosomes), or body fluids, including blood, spinal fluid, cerebrospinal fluid, urine, lymphatic fluid, or serum. Methods of detection include assays that measure levels of STMN2 gene product expression such as Western blotting, FACS, ELISA, other quantitative binding assays, cell or tissue growth assays, Northern blots, quantitative or semi-quantitative polymerase chain reaction, medical imaging methods (*e.g.*, MRI), or immunostaining methods (*e.g.*, immunohistochemistry or immunocytochemistry).

Modifications in General

[00429] While certain compounds, compositions and methods described herein have been described with specificity in accordance with certain embodiments, the following examples serve only to illustrate the compounds described herein and are not intended to limit the same. Each of the references, GenBank accession numbers, and the like recited in the present application is incorporated herein by reference in its entirety.

[00430] Although the sequence listing accompanying this filing identifies each sequence as either “RNA” or “DNA” as required, in reality, those sequences may be modified with any combination of chemical modifications. One of skill in the art will readily appreciate that such designation as “RNA” or “DNA” to describe modified oligonucleotides is, in certain instances, arbitrary. For example, an oligonucleotide comprising a nucleoside comprising a 2'-OH sugar moiety and a thymine base could be described as a DNA having a modified sugar (2'-OH in place of one 2'-H of DNA) or as an RNA having a modified base (thymine (methylated uracil) in place of a uracil of RNA). Accordingly, nucleic acid sequences provided herein, including, but not limited to those in the sequence listing, are intended to encompass nucleic acids containing any combination of

natural or modified RNA and/or DNA, including, but not limited to such nucleic acids having modified nucleobases. By way of further example and without limitation, an oligomeric compound having the nucleobase sequence “ATCGATCG” encompasses any oligomeric compounds having such nucleobase sequence, whether modified or unmodified, including, but not limited to, such compounds comprising RNA bases, such as those having sequence “AUCGAUCG” and those having some DNA bases and some RNA bases such as “AUCGATCG” and oligomeric compounds having other modified nucleobases, such as “AT^mCGAUCG,” wherein ^mC indicates a cytosine base comprising a methyl group at the 5-position.

[00431] Certain compounds described herein (*e.g.*, modified oligonucleotides) have one or more asymmetric center and thus give rise to enantiomers, diastereomers, and other stereoisomeric configurations that may be defined, in terms of absolute stereochemistry, as R or (S), as α or β such as for sugar anomers, or as (D) or (L), such as for amino acids, etc. Compounds provided herein that are drawn or described as having certain stereoisomeric configurations include only the indicated compounds. Compounds provided herein that are drawn or described with undefined stereochemistry included all such possible isomers, including their stereorandom and optically pure forms, unless specified otherwise. Likewise, all tautomeric forms of the compounds herein are also included unless otherwise indicated. Unless otherwise indicated, compounds described herein are intended to include corresponding salt forms.

[00432] The compounds described herein include variations in which one or more atoms are replaced with a non-radioactive isotope or radioactive isotope of the indicated element. For example, compounds herein that comprise hydrogen atoms encompass all possible deuterium substitutions for each of the ¹H hydrogen atoms. Isotopic substitutions encompassed by the compounds herein include but are not limited to: ²H or ³H in place of ¹H, ¹³C or ¹⁴C in place of ¹²C, ¹⁵N in place of ¹⁴N, ¹⁷O or ¹⁸O in place of ¹⁶O, and ³³S, ³⁴S, ³⁵S, or ³⁶S in place of ³²S. In certain embodiments, non-radioactive isotopic substitutions may impart new properties on the oligomeric compound that are beneficial for use as a therapeutic or research tool.

EXAMPLES

[00433] The disclosure is further illustrated by the following examples. The examples are provided for illustrative purposes only, and are not to be construed as limiting the scope or content of the disclosure in any way.

Example 1: Design and Selection of STMN2 Oligonucleotides

[00434] STMN2 AONs oligonucleotides that target a STMN2 transcript including a cryptic exon are designed and tested to identify STMN2 AONs capable of reducing quantity of STMN2 transcripts that comprise a cryptic exon. Such STMN2 AONs include STMN2 parent
5 oligonucleotides represented by any of SEQ ID NOs: 1-446 or SEQ ID NOs: 893-1338. The STMN2 parent oligonucleotides are 25 nucleosides in length. Each of the nucleosides of the STMN2 parent oligonucleotides are modified nucleosides with 2'MOE sugar moieties, and each "C" is replaced with a 5-MeC. Additionally, each of the internucleoside linkages between the nucleosides of the STMN2 oligonucleotides are phosphorothioate internucleoside linkages.

10 [00435] FIG. 1 is a depiction of portions of the STMN2 transcript and STMN2 parent oligonucleotides that are designed to target certain portions of the STMN2 transcript including a cryptic exon. Specifically, regions of the STMN2 transcript include branch points (*e.g.*, branch point 1, 2, and 3) a 3' splice acceptor region, an ESE binding region, TDP43 binding sites, and a Poly A region. STMN2 oligonucleotides, are identified according to the position of the STMN2
15 transcript that the STMN2 oligonucleotide corresponds to. For example, FIG. 1 depicts a STMN2 oligonucleotide that targets positions 36 to 60 of the STMN2 transcript including a cryptic exon, which includes a branch point 1. Similarly, a different STMN2 oligonucleotide targets positions 144 to 178 of the STMN2 transcript including a cryptic exon, which includes a branch point 3. Other STMN2 oligonucleotides can be designed using any of the sequences disclosed above.

20 [00436] Generally, the length of the STMN2 antisense oligonucleotides are 25 nucleotide bases in length. However, variants of the STMN2 antisense oligonucleotides were also designed with varying lengths (*e.g.*, 23mers, 21mers, or 19mers). Examples of these variant STMN2 antisense oligonucleotides were designed to include the sequences of SEQ ID NOs: 1342-1366 or SEQ ID NOs: 1392-1521.

Example 2: Methods for Evaluating STMN2 Antisense Oligonucleotides

[00437] STMN2 antisense oligonucleotides were evaluated in SY5Y cells and human motor neurons (hMN). The cells were plated in 6-well or 96-well plates and cultured to 80% confluency. Antisense oligonucleotide (AON) to TDP43 was transfected with RNAiMax (Thermo Fisher Scientific, Waltham, MA, USA) to express the cryptic exon, thus preventing
30 transcription of full-length STMN2 (STMN2-FL) product. Vehicle was treated with RNAiMax alone. Positive controls included cells that were treated with TDP43 siRNA alone ("siRNA TDP43") and/or TDP43 AON alone ("AON TDP43" or "TDP43 AON"). siRNA TDP43 was

purchased as ON-TARGETplus Human TARDBP (23435) siRNA – SMARTpool (#L-012394-00-0005) from Horizon/Dharmacon. TARDBP (23435) siRNA includes four individual siRNAs that targets four separate sequences:

- 1) Target sequence 1: GCUCAAGCAUGGAUUCUAA (SEQ ID NO: 1665)
- 2) Target sequence 2: CAAUCAAGGUAGUAAUAUG (SEQ ID NO: 1666)
- 3) Target sequence 3: GGGCUUCGCUACAGGAAUC (SEQ ID NO: 1667)
- 4) Target sequence 4: CAGGGUGGAUUUGGUAUA (SEQ ID NO: 1668)

[00438] TDP43 AON is a gapmer oligonucleotide and has the following sequence and chemistry:

5' A*A*G*G*C*T*T*C*A*T*A*T*T*G*T*A*C*T*T*T 3' (SEQ ID NO: 1669)

where * = phosphorothioate, underlined = DNA, other=2'MOE RNA; each "C" is 5-MeC.

[00439] To evaluate STMN2 AON ability to restore STMN2-FL, antisense oligonucleotides to STMN2 were co-incubated with TDP43 AON in RNAiMax. After 96 hours, transcript levels (*e.g.*, STMN2 full length transcript, STMN2 transcript with cryptic exon, or TDP43 transcript) were detected by RT-qPCR using Taqman. Specifically, RT-qPCR was performed for detecting

GAPDH using Thermofisher TaqMan Gene Expression Assay Hs03929097_g1. RT-qPCR was performed for detecting STMN2 transcripts with cryptic exon using the following primer

sequences: 1) Forward primer: 5' – CTCAGTGCCTTATTCAGTCTTCTC – 3' (SEQ ID NO: 1670), 2) Reverse primer: 5' – TCTTCTGCCGAGTCCCATT-3' (SEQ ID NO: 1671) and 3) Probe: 5' -/56-FAM/ TCAGCGTCTGCACATCCCTACAAT /3BHQ_1/ -3' (SEQ ID NO:

1672). RT-qPCR was performed for detecting full length STMN2 transcripts using the following primer sequences: 1) Forward primer: 5' – CCACGAACTTTAGCTTCTCCA – 3' (SEQ ID NO: 1673), 2) Reverse primer: 5' – GCCAATTGTTTCAGCACCTG – 3' (SEQ ID NO: 1674), and 3) Probe: 5' -/56-FAM/ ACTTTCTTCTTTCCTCTGCAGCCTCC /3BHQ_1/ - 3' (SEQ ID NO: 1675).

[00440] RT-qPCR was performed on Applied Biosystems ® 7500 Real-time PCR systems. One cycle of reverse transcription was performed at a temperature of 50°C for 5 min. One cycle of RT inactivation/initial denaturation was performed at a temperature of 95°C for 20 seconds. Forty five cycles of amplification were performed at a temperature of 95°C for 1 second followed by 60°C for 20 seconds.

[00441] STMN2-FL or STMN2 cryptic signal (Ct) was normalized to GAPDH (deltaCt). To visualize the quantitative changes (*e.g.*, % increase of STMN-FL), the normalized STMN2-FL signal was further normalized to the vehicle (treated with RNAiMax alone, deltadeltaCt).

Relative quantity of transcript level was calculated using the equation $RQ=2^{-\Delta\Delta Ct}$ and is used to describe the treatment condition comparison to normal, healthy levels (1.0).

[00442] Percent decrease of STMN2 with cryptic exon expression was calculated using the equation of:

$$100 - \left(\frac{\text{Mean relative quantity of STMN2 with cryptic exon in response to STMN2 AON}}{\text{Mean relative quantity of STMN2 with cryptic exon in response to TDP43 AON}} * 100 \right)$$

The percent increase of full length STMN2 mRNA transcript was calculated using the equation of:

$$\left(\frac{\text{Mean relative quantity of FL STMN2 transcript in response to STMN2 AON}}{\text{Mean relative quantity of FL STMN2 transcript in response to TDP43 AON}} * 100 \right) - 100$$

[00443] STMN2 antisense oligonucleotides were also evaluated in human motor neurons for potency in reducing cryptic exon and increasing STMN2 full length transcript. iCell human motor neurons (Cellular Dynamics International) were plated at 15×10^3 cells/well in a 96-well plate for RT-qPCR RNA quantification or 3×10^5 cells/well in a 6-well plate for western blot protein quantification according to manufacturer's instructions. Neurons were transfected with TDP43 AON and/or STMN2 AON using endoport (GeneTools, LLC.) or treated with endoport alone. Treatment conditions were tested in biological triplicate (qRT-PCR) or duplicate (western blot) wells. The same TDP43 AON described above is used here for evaluating human motor neurons. TDP43 AON is a gapmer oligonucleotide and has the following sequence and chemistry:

5' A*A*G*G*C*T*T*C*A*T*A*T*TG*T*A*C*T*T*T 3' (SEQ ID NO: 1669)

where * = phosphorothioate, underlined = DNA, other=2'MOE RNA.

[00444] After 72 hours, antisense oligonucleotides and endoport were washed out and replaced with fresh media. After 72 additional hours, RNA was collected from the 96-well plates for RT-qPCR or protein collected from the 6-well plates for western blot. RNA was isolated, cDNA generated and multiplexed RT-qPCR assay performed with taqman probes for STMN2 cryptic exon, STMN2 full length transcript and reference GAPDH quantification. The same primers for detecting GAPDH, STMN2 transcript with cryptic exon, and full length STMN2, as described above in reference to SY5Y cells, were applied here for conducting RT-qPCR for human motor neurons. For protein quantification, the soluble portion of the protein collection was denatured and separated by SDS-PAGE, transferred to polyvinylidene difluoride membranes and probed

with antibodies against GAPDH (Proteintech, 60004-1-1g), TDP-43 (Proteintech, 10782-2-AP), and Stathmin-2 (ThermoFisher, PA5-23049).

Example 3: STMN2 Parent Oligonucleotides and Oligonucleotide Variants Restore Full Length STMN2 and Reduce STMN2 Transcripts with a Cryptic Exon

5 [00445] STMN2 parent oligonucleotides and oligonucleotide variants are tested for their ability to increase or restore full-length STMN2 mRNA (*i.e.*, mRNA from which full-length STMN2 is translated) levels in TDP43 silenced cells. In some cases, STMN2 oligonucleotides are tested for their ability to reduce STMN2 transcripts with a cryptic exon. As described further below, the quantified percentage increase/restoration of STMN2-FL and/or percentage reduction of STMN2

10 transcripts with cryptic exon is described in reference to levels of STMN-FL and/or STMN2 transcripts with cryptic exon in a control group (*e.g.*, cells treated with 500 nM TDP43 AON). [00446] Referring to FIG. 2, TDP43 transcript was decreased by around 52% and STMN2-FL was decreased by around 57% when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 parent AON with SEQ ID NO: 36 increased TDP43 levels by 25% and increased STMN-

15 FL levels by 55% (rescued to 67%). A 50 nM and a 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 177 increased STMN-FL levels by 58% (rescued to 66%) and 53% (rescued to 68%) respectively. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 203 increased TDP43 levels by 15% and STMN-FL levels by 72% (rescued to 74%). A 50 nM and a 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO:

20 395 increased STMN-FL levels by 49% (rescued to 64%) and 37% (rescued to 59%) respectively. [00447] Referring to FIG. 3, the quantity of STMN2 transcript with cryptic exon was increased more than 20-fold when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 173 reduced STMN2 transcript with cryptic exon levels by 68%. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 181 reduced

25 STMN2 transcript with cryptic exon levels by 65%. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 197 reduced STMN2 transcript with cryptic exon levels by 39%. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 215 reduced STMN2 transcript with cryptic exon levels by 31%. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 385 reduced STMN2 transcript with cryptic exon levels by

30 53%. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 400 reduced STMN2 transcript with cryptic exon levels by 74%.

[00448] Referring to FIG. 4, STMN2-FL was decreased by around 59% when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 173 increased STMN-FL levels by 66% (rescued to 68%). A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 197 increased STMN-FL levels by 46% (rescued to 60%).

[00449] Referring to FIG. 5A, the quantity of STMN2 transcript with cryptic exon was increased more than 36-fold when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 185 reduced STMN2 transcript with cryptic exon levels by 58%. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 237 reduced STMN2 transcript with cryptic exon levels by 87%. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 380 reduced STMN2 transcript with cryptic exon levels by 70%. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 390 reduced STMN2 transcript with cryptic exon levels by 58%.

[00450] Referring to FIG. 5B, STMN2-FL was decreased by 66% when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 185 increased STMN-FL levels by 109% (rescued to 71%). A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 237 increased STMN-FL levels by 247% (rescued to 118%).

[00451] Referring to FIG. 6A, the quantity of STMN2 transcript with cryptic exon was increased more than 20-fold when treated with 500 nM TDP43 AON (two different syntheses). A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 144 reduced STMN2 transcript with cryptic exon levels by 83 to 88%. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 237 reduced STMN2 transcript with cryptic exon levels by 92 to 93%.

[00452] Referring to FIG. 6B, STMN2-FL was decreased by about 80% when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 144 increased STMN-FL levels by 276% to 329% (rescued to 79% to 90%). A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 237 increased STMN-FL levels by 390% to 438% (rescued to 103% to 113 %).

[00453] Referring to FIG. 7A, the quantity of STMN2 transcript with cryptic exon was increased more than 23-fold when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 173 reduced STMN2 transcript with cryptic exon levels by 83%. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 177 reduced STMN2 transcript with cryptic exon levels by 83%. A 500 nM treatment of a STMN2 parent

oligonucleotide with SEQ ID NO: 181 reduced STMN2 transcript with cryptic exon levels by 72%.

[00454] Referring to FIG. 7B, STMN2-FL was decreased by about 58% when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 173 increased STMN-FL levels by 119% (rescued to 92%). A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 181 increased STMN-FL levels by 88% (rescued to 79%). A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 185 increased STMN-FL levels by 74% (rescued to 73%).

[00455] Referring to FIG. 8A, the quantity of STMN2 transcript with cryptic exon was increased more than 20-fold when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 197 reduced STMN2 transcript with cryptic exon levels by 65%. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 237 reduced STMN2 transcript with cryptic exon levels by 94%.

[00456] Referring to FIG. 8B, STMN2-FL was decreased by 59% when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 197 increased STMN-FL levels by 85% (rescued to 76%). A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 237 increased STMN-FL levels by 127% (rescued to 93%). A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 380 increased STMN-FL levels by 71% (rescued to 70%).

[00457] Referring to FIG. 9A, the quantity of STMN2 transcript with cryptic exon was increased more than 50-fold when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 144 reduced STMN2 transcript with cryptic exon levels by 92%. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 173 reduced STMN2 transcript with cryptic exon levels by 82%. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 237 reduced STMN2 transcript with cryptic exon levels by 96%.

[00458] Referring to FIG. 9B, STMN2-FL was decreased by 67% when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 144 increased STMN-FL levels by 135% (rescued to 87%). A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 173 increased STMN-FL levels by 132% (rescued to 86%). A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 237 increased STMN-FL levels by 143% (rescued to 90%).

[00459] Referring to FIG. 10A, the quantity of STMN2 transcript with cryptic exon was increased more than 65-fold when treated with 500 nM TDP43 AON. A 200 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 181 reduced STMN2 transcript with cryptic exon levels by 50%. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 181 reduced STMN2 transcript with cryptic exon levels by 73%. Referring to FIG. 10B, STMN2-FL was decreased by 67% when treated with 500 nM TDP43 AON. A 50 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 181 increased STMN-FL levels by 115% (rescued to 71%). A 200 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 181 increased STMN-FL levels by 97% (rescued to 65%). A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 181 increased STMN-FL levels by 94% (rescued to 64%).

[00460] Referring to FIG. 11A, the quantity of STMN2 transcript with cryptic exon was increased more than 26-fold when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 185 reduced STMN2 transcript with cryptic exon levels by 47%. Referring to FIG. 11B, STMN2-FL was decreased by 74% when treated with 500 nM TDP43 AON. A 50 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 185 increased STMN-FL levels by 73% (rescued to 45%). A 200 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 185 increased STMN-FL levels by 246% (rescued to 90%). A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 185 increased STMN-FL levels by 165% (rescued to 69%).

[00461] Referring to FIG. 12A, the quantity of STMN2 transcript with cryptic exon was increased more than 41-fold when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 197 reduced STMN2 transcript with cryptic exon levels by 51%. Referring to FIG. 12B, STMN2-FL was decreased by 65% when treated with 500 nM TDP43 AON. A 20 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 197 increased STMN-FL levels by 86% (rescued to 65%). A 50 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 197 increased STMN-FL levels by 131% (rescued to 81%). A 200 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 197 increased STMN-FL levels by 154% (rescued to 89%). A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 197 increased STMN-FL levels by 169% (rescued to 94%).

[00462] Referring to FIG. 13A, the quantity of STMN2 transcript with cryptic exon was increased more than 41-fold when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 144 reduced STMN2 transcript with cryptic exon levels by 93%. Referring to FIG. 13B, STMN2-FL was decreased by 84% when treated with 500 nM

TDP43 AON. A 50 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 144 increased STMN-FL levels by 75% (rescued to 28%). A 200 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 144 increased STMN-FL levels by 260% (rescued to 57%). A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 144 increased STMN-FL levels by 444% (rescued to 87%).

[00463] Referring to FIG. 14A, the quantity of STMN2 transcript with cryptic exon was increased more than 24-fold when treated with 500 nM TDP43 AON. A 200 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 173 reduced STMN2 transcript with cryptic exon levels by 59%. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 173 reduced STMN2 transcript with cryptic exon levels by 70%. Referring to FIG. 14B, STMN2-FL was decreased by 62% when treated with 500 nM TDP43 AON. A 200 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 173 increased STMN-FL levels by 100% (rescued to 76%). A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 173 increased STMN-FL levels by 158% (rescued to 98%).

[00464] Referring to FIG. 15A, the quantity of STMN2 transcript with cryptic exon was increased more than 70-fold when treated with 500 nM TDP43 AON. A 200 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 237 reduced STMN2 transcript with cryptic exon levels by 78%. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 237 reduced STMN2 transcript with cryptic exon levels by 92%. Referring to FIG. 15B, STMN2-FL was decreased by 77% when treated with 500 nM TDP43 AON. A 50 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 237 increased STMN-FL levels by 87% (rescued to 43%). A 200 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 237 increased STMN-FL levels by 135% (rescued to 54%). A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 237 increased STMN-FL levels by 209% (rescued to 71%).

[00465] Referring to FIG. 16, STMN2 protein levels were decreased by 44% when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 173 increased STMN protein levels by 52%. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 237 increased STMN protein levels by 34%.

[00466] Referring to FIG. 17A, the quantity of STMN2 transcript with cryptic exon was increased more than 30-fold when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 237 reduced STMN2 transcript with cryptic exon levels by 96%. A 500 nM treatment of a STMN2 oligonucleotide variant with SEQ ID NO: 1348 reduced STMN2 transcript with cryptic exon levels by 97%. A 500 nM treatment of a STMN2

oligonucleotide variant with SEQ ID NO: 1349 reduced STMN2 transcript with cryptic exon levels by 97%. A 500 nM treatment of a STMN2 oligonucleotide variant with SEQ ID NO: 1360 reduced STMN2 transcript with cryptic exon levels by 71%.

[00467] Referring to FIG. 17B, STMN2-FL was decreased by 76% when treated with 500 nM

5 TDP43 AON. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 237 increased STMN-FL levels by 238% (rescued to 81%). A 500 nM treatment of a STMN2

oligonucleotide variant with SEQ ID NO: 1348 increased STMN-FL levels by 63% (rescued to 39%). A 500 nM treatment of a STMN2 oligonucleotide variant with SEQ ID NO: 1359

increased STMN-FL levels by 96% (rescued to 47%). A 500 nM treatment of a STMN2

10 oligonucleotide variant with SEQ ID NO: 1360 increased STMN-FL levels by 125% (rescued to 54%).

[00468] Referring to FIG. 18A, the quantity of STMN2 transcript with cryptic exon was increased

more than 19-fold when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 185 reduced STMN2 transcript with cryptic exon levels

15 by 83%. A 500 nM treatment of a STMN2 oligonucleotide variant with SEQ ID NO: 1347

reduced STMN2 transcript with cryptic exon levels by 85%. A 500 nM treatment of a STMN2

oligonucleotide variant with SEQ ID NO: 1356 reduced STMN2 transcript with cryptic exon

levels by 56%. A 500 nM treatment of a STMN2 oligonucleotide variant with SEQ ID NO: 1357

reduced STMN2 transcript with cryptic exon levels by 78%. A 500 nM treatment of a STMN2

20 oligonucleotide variant with SEQ ID NO: 1364 reduced STMN2 transcript with cryptic exon levels by 78%.

[00469] Referring to FIG. 18B, STMN2-FL was decreased by 82% when treated with 500 nM

TDP43 AON. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 185

increased STMN-FL levels by 161% (rescued to 47%). A 500 nM treatment of a STMN2

25 oligonucleotide variant with SEQ ID NO: 1347 increased STMN-FL levels by 144% (rescued to 44%). A 500 nM treatment of a STMN2 oligonucleotide variant with SEQ ID NO: 1356

increased STMN-FL levels by 128% (rescued to 41%). A 500 nM treatment of a STMN2

oligonucleotide variant with SEQ ID NO: 1357 increased STMN-FL levels by 144% (rescued to

44%). A 500 nM treatment of a STMN2 oligonucleotide variant with SEQ ID NO: 1364

30 increased STMN-FL levels by 183% (rescued to 51%).

[00470] Referring to FIG. 19A, the quantity of STMN2 transcript with cryptic exon was increased

more than 23-fold when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2

parent oligonucleotide with SEQ ID NO: 173 reduced STMN2 transcript with cryptic exon levels

by 81%. A 500 nM treatment of a STMN2 oligonucleotide variant with SEQ ID NO: 1345 reduced STMN2 transcript with cryptic exon levels by 86%. A 500 nM treatment of a STMN2 oligonucleotide variant with SEQ ID NO: 1354 reduced STMN2 transcript with cryptic exon levels by 81%. A 500 nM treatment of a STMN2 oligonucleotide variant with SEQ ID NO: 1355 reduced STMN2 transcript with cryptic exon levels by 47%. A 500 nM treatment of a STMN2 oligonucleotide variant with SEQ ID NO: 1362 reduced STMN2 transcript with cryptic exon levels by 75%.

[00471] Referring to FIG. 19B, STMN2-FL was decreased by 83 % when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 173 increased STMN-FL levels by 265% (rescued to 62%). A 500 nM treatment of a STMN2 oligonucleotide variant with SEQ ID NO: 1345 increased STMN-FL levels by 206% (rescued to 52%). A 500 nM treatment of a STMN2 oligonucleotide variant with SEQ ID NO: 1354 increased STMN-FL levels by 212% (rescued to 53%). A 500 nM treatment of a STMN2 oligonucleotide variant with SEQ ID NO: 1355 increased STMN-FL levels by 88% (rescued to 32%). A 500 nM treatment of a STMN2 oligonucleotide variant with SEQ ID NO: 1362 increased STMN-FL levels by 188% (rescued to 49%).

[00472] Referring to FIG. 20A, the quantity of STMN2 transcript with cryptic exon was increased more than 35-fold when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 237 reduced STMN2 transcript with cryptic exon levels by 91%. A 500 nM treatment of a STMN2 oligonucleotide variant with SEQ ID NO: 1348 reduced STMN2 transcript with cryptic exon levels by 94%. A 500 nM treatment of a STMN2 oligonucleotide variant with SEQ ID NO: 1349 reduced STMN2 transcript with cryptic exon levels by 96%. A 500 nM treatment of a STMN2 oligonucleotide variant with SEQ ID NO: 1365 reduced STMN2 transcript with cryptic exon levels by 82%. A 500 nM treatment of a STMN2 oligonucleotide variant with SEQ ID NO: 1366 reduced STMN2 transcript with cryptic exon levels by 38%. A 500 nM treatment of a STMN2 oligonucleotide variant with SEQ ID NO: 1358 reduced STMN2 transcript with cryptic exon levels by 33%.

[00473] Referring to FIG. 20B, STMN2-FL was decreased by 80% when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 237 increased STMN-FL levels by 325% (rescued to 85%). A 500 nM treatment of a STMN2 oligonucleotide variant with SEQ ID NO: 1348 increased STMN-FL levels by 350% (rescued to 90%). A 500 nM treatment of a STMN2 oligonucleotide variant with SEQ ID NO: 1366 increased STMN-FL levels by 105% (rescued to 41%). A 500 nM treatment of a STMN2

oligonucleotide variant with SEQ ID NO: 1358 increased STMN-FL levels by 20% (rescued to 24%).

[00474] Referring to FIG. 21A, the quantity of STMN2 transcript with cryptic exon was increased more than 11-fold when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 173 reduced STMN2 transcript with cryptic exon levels by 72%. A 500 nM treatment of a STMN2 oligonucleotide variant with SEQ ID NO: 1346 reduced STMN2 transcript with cryptic exon levels by 85%. A 500 nM treatment of a STMN2 oligonucleotide variant with SEQ ID NO: 1353 reduced STMN2 transcript with cryptic exon levels by 55%. A 500 nM treatment of a STMN2 oligonucleotide variant with SEQ ID NO: 1662 (G*A*G*TCCTGCAATATGAATATA*AT*T*T, where * indicates phosphodiester linkage) reduced STMN2 transcript with cryptic exon levels by 49%. A 500 nM treatment of a STMN2 oligonucleotide variant with SEQ ID NO: 1663 (GAGTCCTG*C*A*A*T*A*TGAATATAATTT, where * indicates phosphodiester linkage) reduced STMN2 transcript with cryptic exon levels by 57%.

[00475] Referring to FIG. 21B, STMN2-FL was decreased by 73% when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 173 increased STMN-FL levels by 85% (rescued to 50%). A 500 nM treatment of a STMN2 oligonucleotide variant with SEQ ID NO: 1353 increased STMN-FL levels by 85% (rescued to 50%). A 500 nM treatment of a STMN2 oligonucleotide variant with SEQ ID NO: 1662 increased STMN-FL levels by 74% (rescued to 47%). A 500 nM treatment of a STMN2 oligonucleotide variant SEQ ID NO: 1663 increased STMN-FL levels by 89% (rescued to 51%).

[00476] Referring to FIG. 22A, the quantity of STMN2 transcript with cryptic exon was increased more than 13-fold when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 144 reduced STMN2 transcript with cryptic exon levels by 91%. A 500 nM treatment of a STMN2 oligonucleotide variant with SEQ ID NO: 1344 reduced STMN2 transcript with cryptic exon levels by 80%. A 500 nM treatment of a STMN2 oligonucleotide variant with SEQ ID NO: 1342 reduced STMN2 transcript with cryptic exon levels by 85%.

[00477] Referring to FIG. 22B, STMN2-FL was decreased by 65% when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 144 increased STMN-FL levels by 94% (rescued to 68%). A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 1343 increased STMN-FL levels by 11% (rescued to 39%). A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 1351 increased STMN-

FL levels by 9% (rescued to 38%). A 500 nM treatment of a STMN2 oligonucleotide variant with SEQ ID NO: 1344 increased STMN-FL levels by 114% (rescued to 75%). A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 1350 increased STMN-FL levels by 3% (rescued to 36%). A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 1361 increased STMN-FL levels by 9% (rescued to 38%).

Example 4: Neuropathy as an indication that can be targeted by a Stathmin-2 cryptic splicing modulator

[00478] Experimentally, iCell human motor neurons (Cellular Dynamics International) were plated at 19,000 cells/well in a 96-well plate according to manufacturer's instructions. Neurons were treated with SEQ ID NO: 237 and endoport (GeneTools, LLC.) or treated with endoport alone in triplicate wells at day 7 post-plating. After 72 hours, SEQ ID NO: 237 STMN2 parent oligonucleotide and endoport were washed out and MG132 added. After 18 hours, RNA was isolated, cDNA generated and multiplexed QPCR assay performed for STMN2 cryptic exon and reference GAPDH quantification.

[00479] Referring to FIG. 23, it illustrates a bar graph showing reversal of cryptic exon induction using SEQ ID NO: 237 STMN2 parent oligonucleotide even in view of increasing proteasome inhibition. As a control, cells that were treated with endoport alone (no AON) and then subsequently treated with MG132 (across all concentrations of MG132) demonstrated high levels of cryptic exon. This is indicative of TDP-43 pathology induced by proteasome inhibition in human motor neurons. Mislocalization of TDP-43 leads to STMN2 mis-splicing and increased cryptic exon expression. The addition of SEQ ID NO: 237 parent oligonucleotide reverses cryptic exon induction with high potency ($IC_{50} < 5nM$). As shown in FIG. 23, increasing concentrations of SEQ ID NO: 237 (ranging from 5 nM up to 500 nM) significantly reduces the cryptic exon relative quantity.

[00480] In totality, this data establishes that the SEQ ID NO: 237 parent oligonucleotide protects against proteotoxic stress induction of cryptic exon expression. This is applicable in settings where neurons are to be protected from proteotoxic stress present in neurodegenerative disorders.

Example 5: Dose response restoration of full length STMN2 mRNA and STMN2 protein using Stathmin-2 cryptic splicing modulator

[00481] The experiment was performed as previously described in human neuroblastoma SY5Y cells. The cells were plated in 6-well or 96-well plates and cultured to 80% confluency. TDP-43 expression in cells were knocked down using an AON to TDP43 to express the cryptic exon, thus preventing transcription of full-length STMN2 (STMN2-FL) product. Cells were additionally co-


transfected with a STMN2 oligonucleotide variant (specifically, SEQ ID NO: 1348) at varying doses (5nM, 50nM, 100nM, 200nM, and 500nM). RNA and protein were isolated for QPCR and western blot assays.

[00482] FIG. 24 shows the dose response curve illustrating increasing restoration of full length STMN2 transcript with increasing concentrations of STMN2 oligonucleotide variant with SEQ ID NO: 1348. Generally, increasing concentrations of the oligonucleotide increased full length STMN2 mRNA, decreased cryptic exon levels. Specifically, a 5nM treatment of the STMN2 oligonucleotide variant resulted in ~40% restoration of full length STMN2 transcript. A 500nM treatment of the STMN2 oligonucleotide variant resulted in nearly 100% restoration of full length STMN2 transcript. Additionally, the 500nM treatment of the STMN2 oligonucleotide variant resulted in the significant reduction (close to 0%) of cryptic exon.

[00483] FIG. 25A shows a protein blot assay demonstrating the qualitative increase of full length STMN2 protein in response to higher concentrations of STMN2 oligonucleotide variant with SEQ ID NO: 1348. FIG. 25B shows the quantitated levels of full length STMN2 protein normalized to GAPDH in response to different concentrations of STMN2 oligonucleotide variant. Generally, both FIG. 25A and 25B show that increasing concentrations of the STMN2 oligonucleotide variant resulted in increasing concentrations of full length STMN2 protein. Specifically, as shown in FIG. 25B, lower concentrations (5nM and 50nM) of the STMN2 oligonucleotide variant resulted in full length STMN2 protein concentrations that were ~60% of the control group (cell only). Notably, the 500nM treatment of the STMN2 oligonucleotide variant resulted in nearly 100% restoration of the full length STMN2 protein (in comparison to the cell only control group).

Example 6: STMN2 AONs with Spacer Technology Restore Full Length STMN2 and Reduces STMN2 Transcripts with a Cryptic Exon

[00484] STMN2 AONs with two or three spacers were developed. Here, a spacer is represented by Formula (I), wherein:



Formula (I)

X is -O-; and

n is 1.

[00485] STMN2 AONs (*e.g.*, STMN2 oligonucleotides each with two spacers) were tested in human motor neurons (hMN) for their ability to increase or restore full-length STMN2 mRNA (*i.e.*, mRNA from which full-length STMN2 is translated) levels in TDP43 silenced cells. In some cases, STMN2 oligonucleotides are tested for their ability to reduce STMN2 transcripts with a cryptic exon. As described further below, the quantified percentage increase/restoration of STMN2-FL and/or percentage reduction of STMN2 transcripts with cryptic exon is described in reference to levels of STMN-FL and/or STMN2 transcripts with cryptic exon in a control group (*e.g.*, cells treated with 500 nM TDP43 AON).

[00486] Three different STMN2 oligonucleotides with two spacers were generated. These three example STMN2 oligonucleotides are named 1) SEQ ID NO: 1589 (a 25mer with a first spacer at position 11 and a second spacer at position 22), 2) SEQ ID NO: 1590 (a 25mer with a first spacer at position 7 and a second spacer at position 14), and 3) SEQ ID NO: 1591 (a 25mer with a first spacer at position 8 and a second spacer at position 19). The STMN2 AONs are shown in Table 11.

Table 11: STMN2 AONs (including STMN2 parent oligonucleotides and STMN2 oligonucleotides with two spacers)

Sequence ID Number (SEQ ID NO)	Sequence (where <u>S</u> indicates presence of a Spacer) (5' → 3')
144	AATCCAATTAAGAGAGAGTGATGGG
1589	AATCCAATTA <u>S</u> GAGAGAGTGAS <u>S</u> GGG
173	GAGTCCTGCAATATGAATATAATTT
1590	GAGTCC <u>S</u> GCAATAS <u>S</u> GAATATAATTT
237	GCACACATGCTCACACAGAGAGCCA
1591	GCACACAS <u>S</u> GCTCACACAG <u>S</u> GAGCCA

[00487] Referring to FIG. 26A, the quantity of STMN2 transcript with cryptic exon was increased more than 27-fold when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 144 reduced STMN2 transcript with cryptic exon levels by 71%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 1589 reduced STMN2 transcript with cryptic exon levels by 88%. Here, SEQ ID NO: 1589 exhibited further reduction of STMN2 transcripts with cryptic exon in comparison to SEQ ID NO: 144 (without two spacers.) A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 173 reduced STMN2

transcript with cryptic exon levels by 77%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 1590 reduced STMN2 transcript with cryptic exon levels by 48%. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 237 reduced STMN2 transcript with cryptic exon levels by 93%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 1591 reduced STMN2 transcript with cryptic exon levels by 96%. Here, SEQ ID NO: 1591 exhibited similar reduction of STMN2 transcripts with cryptic exon in comparison to SEQ ID NO: 237 (without two spacers.)

[00488] Referring to FIG. 26B, STMN2-FL was decreased by 68% when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 144 increased STMN-FL levels by 165% (rescued to 85%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 1589 increased STMN-FL levels by 256% (rescued to 114%). Here, SEQ ID NO: 1589 exhibited improved restoration of STMN2 FL mRNA in comparison to SEQ ID NO: 144 (without two spacers.) A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 173 increased STMN-FL levels by 184% (rescued to 91%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 1590 increased STMN-FL levels by 156% (rescued to 82%). Here, SEQ ID NO: 1590 exhibited similar restoration of STMN2 FL mRNA in comparison to SEQ ID NO: 173 (without two spacers.) A 500 nM treatment of a STMN2 parent oligonucleotide with SEQ ID NO: 237 increased STMN-FL levels by 225% (rescued to 104%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 1591 increased STMN-FL levels by 225% (rescued to 104%). Here, SEQ ID NO: 1591 exhibited similar restoration of STMN2 FL mRNA in comparison to SEQ ID NO: 237 (without two spacers.).

[00489] Additional example STMN2 AONs (including STMN2 AONs described above in Table 11) are shown below in Table 12. Specifically, Table 12 includes example STMN2 AONs with two spacers and STMN2 AONs with three spacers. Furthermore, Table 12 includes example STMN2 AON variants with one or more spacers that are shorter in length (e.g., 23mer, 21mer or 19mer) in comparison to STMN2 parent oligonucleotides described above in Table 11.

Table 12: STMN2 AONs with two or three spacers and STMN2 AON variants with two spacers.

Sequence ID Number (SEQ ID NO).	Sequence (where <u>S</u> indicates presence of a Spacer) (5' → 3')
144	AATCCAATTAAGAGAGAGTGATGGG

1589	AATCCAATT <u>A</u> SGAGAGAGTG <u>A</u> SGGG
1592	AATCCA <u>A</u> STAAGAG <u>A</u> SGAGTGATG <u>S</u> G
1593	AATCCA <u>A</u> STAAGAGASAGTGAT <u>S</u> GG
1594	A <u>S</u> TCCAATT <u>S</u> AGAGAG <u>A</u> STGATGGG
1417	AATCC <u>S</u> ATT <u>A</u> SGAGAGAG <u>S</u> GATGGG
1595	TCCAATT <u>S</u> AGAGAG <u>A</u> STGATGGG
173	GAGTCCTGCAATATGAATATAATTT
1590	GAGTCC <u>S</u> GCAAT <u>A</u> SGAATATAATTT
1596	GAGTCCT <u>S</u> CAATATG <u>S</u> ATATAAT <u>S</u> T
1597	GAG <u>S</u> CCTGCA <u>A</u> SATGAAT <u>S</u> TAATTT
1418	GAGTCC <u>S</u> GCAAT <u>A</u> SGAATATA <u>S</u> TTT
1598	GTCCTGC <u>S</u> ATATGA <u>A</u> SATAAT
1599	GTCCT <u>S</u> CAATATG <u>S</u> ATATAAT
1419	GTCC <u>S</u> GCAAT <u>A</u> SGAATATA
237	GCACACATGCTCACACAGAGAGCCA
1591	GCACACA <u>S</u> GCTCACACAG <u>S</u> GAGCCA
1600	GCACACA <u>S</u> GCTCAC <u>A</u> SGAGAG <u>S</u> CA
1601	GC <u>S</u> CACATG <u>S</u> TCACACA <u>S</u> AGAGCCA
1420	GCACACA <u>S</u> GCTCAC <u>A</u> SGAGSGCCA
1602	GCACACA <u>S</u> GCTCAC <u>A</u> SGAGAGC
1603	AAT <u>S</u> CAATTAAGAG <u>S</u> SGAGTGATGGG
1604	AATCCAATT <u>A</u> SGAGAGAGTG <u>S</u> TGGG
1605	AATCCA <u>S</u> TTAAGAGAGAG <u>S</u> GATGGG
1606	AATCCA <u>S</u> TTAAGAGAG <u>A</u> STGATGGG
1607	AATCCA <u>A</u> STAAG <u>S</u> GAG <u>A</u> STGATGGG
1608	GAG <u>S</u> CCTGCAATAT <u>S</u> AATATAATTT
1609	GAGTCCTGCA <u>S</u> TATGAATAT <u>S</u> ATTT
1610	GAGTCC <u>S</u> GCAATATGAAT <u>S</u> TAATTT
1611	GAGTCC <u>S</u> GCAATATGA <u>A</u> SATAATTT
1612	GAGTCCT <u>S</u> CAAT <u>S</u> TGA <u>A</u> SATAATTT

1613	GAGTCC <u>S</u> GCAAT <u>S</u> TGAAT <u>S</u> TAATTT
1614	GAGTC <u>S</u> TGCAAT <u>S</u> TGAATA <u>S</u> AATTT
1615	GAGT <u>S</u> CTGCAAT <u>S</u> TGAATAT <u>S</u> AATTT
1616	GTCCTGC <u>S</u> ATATG <u>S</u> ATATAAT
1617	CCTTTCTC <u>S</u> CGAAGGTCTT <u>S</u> GCCG
1618	CTTTCTC <u>S</u> CGAAGGT <u>S</u> TTCTGCC
1619	TTTCTCT <u>S</u> GAAGGTC <u>S</u> TCTGCCG
1664	GCACACA <u>S</u> GC <u>S</u> CACACAG <u>S</u> GAGCCA
1621	GCACACA <u>S</u> GCTC <u>S</u> CACAS <u>S</u> AGAGCCA

[00490] Table 13 depicts the performance of STMN2 AONs, including STMN2 AONs with two or three spacers.

[00491] STMN2 AONs that included two spacers increased levels of STMN2-FL. For example, at a dose of 200nM ASO, SEQ ID NO: 1608 and SEQ ID NO: 1609 increased levels of STMN-FL to 0.65 and 0.78, respectively. Additionally, at a dose of 200nM ASO, SEQ ID NO: 1610 and SEQ ID NO: 1611 increased levels of STMN-FL to 0.95 and 1.09, respectively. Notably, a number of STMN2 AONs increased levels of STMN-FL to a lesser extent. Specifically, at a 200 nM dose of STMN2 AON, SEQ ID NO: 1612, SEQ ID NO: 1613, SEQ ID NO: 1614, and SEQ ID NO: 1615 increased levels of STMN-FL to between 0.10 and 0.20.

[00492] At a dose of 200nM AON, all STMN2 AON derived from SEQ ID NO: 197 significantly increased levels of STMN-FL. Specifically, SEQ ID NO: 1617, SEQ ID NO: 1618, and SEQ ID NO: 1619 increased levels of STMN-FL to 0.99, 0.94, and 1.00, respectively.

[00493] Altogether, these results demonstrate that different STMN2 AONs including two spacers are capable of increasing STMN-FL to levels that are close or comparable to their non-spacer counterparts (e.g., SEQ ID NO: 173 or SEQ ID NO: 197).

[00494] The differences in performance between STMN2 AONs derived from SEQ ID NO: 173, including SEQ ID NO: 1612, SEQ ID NO: 1613, SEQ ID NO: 1614, and SEQ ID NO: 1615 and STMN2 AONs derived from SEQ ID NO: 197 including SEQ ID NO: 1617, SEQ ID NO: 1618, and SEQ ID NO: 1619 may be attributable to GC content in the respective STMN2 AONs.

Specifically, as shown in Table 13, STMN2 AONs derived from SEQ ID NO: 173 had below 30% GC content, which may lead to their reduced performance. In contrast, as shown in Table

13, STMN2 AONs derived from SEQ ID NO: 197 had above 40% GC content. Thus, including two or more spacers in a higher GC content AON may be preferable.

[00495] In addition to GC content, the location of spacers relative to guanine and cytosine nucleobases can also impact the performance of the STMN2 AON. For example, at a 200 nM AON dose, SEQ ID NO: 1615, SEQ ID NO: 1596, and SEQ ID NO: 1597 increased levels of STMN2-FL to 0.12, 0.26, and 0.29. Each of these STMN2 AONs have three spacers. In comparison, at a 200 nM AON dose, SEQ ID NO: 1418 increased levels of STMN2-FL to 0.73. SEQ ID NO: 1418 includes spacers that are positioned to maximize the number of spacers that are immediately preceding a guanine base. Specifically, the first and second spacers of SEQ ID NO: 1418 each respectively precede a guanine base. Thus, maximizing the number of spacers in a STMN2 AON that immediately precede a guanine base can improve the performance of the STMN2 AON.

Table 13: Performance of varying STMN2 AONs, including STMN2 AONs with two or three spacers.


Sequence ID No. (SEQ ID NO)	Sequence (where <u>S</u> indicates presence of a Spacer) (5' → 3')	Relative Quantity of STMN-FL in response to 200 nM ASO Treatment	Relative Quantity of STMN-FL in response to 50 nM ASO treatment	GC content
169	CCTGCAATATGAATATAATTTTAAA	0.73	0.45	20%
1421	CCTGCAATATGAATATAATTTTA	1.19	0.48	22%
1422	TGCAATATGAATATAATTTTAAA	0.85	0.63	13%
1423	CTGCAATATGAATATAATTTTAA	0.93	0.69	17%
1424	TGCAATATGAATATAATTTTA	0.8	0.44	14%
170	TCCTGCAATATGAATATAATTTTAA	1.01	0.46	20%

1425	TCCTGCAATATGAATATAATTTT	0.83	0.49	22%
1426	CTGCAATATGAATATAATTTT	0.83	0.57	19%
171	GTCCTGCAATATGAATATAATTTTA	0.89	0.41	24%
1346	GTCCTGCAATATGAATATAATTT	1.1	1.13	26%
1355	CCTGCAATATGAATATAATTT	0.82	0.44	24%
172	AGTCCTGCAATATGAATATAATTTT	0.79	0.45	24%
1427	AGTCCTGCAATATGAATATAATT	0.89	0.52	26%
1428	TCCTGCAATATGAATATAATT	1.18	0.66	24%
252	CTCTCTCGCACACACGCACACATGC	0.67	0.43	60%
1432	CTCTCGCACACACGCACACATGC	0.67	0.52	61%
1433	CTCTCTCGCACACACGCACACAT	0.63	0.24	57%
1434	TCTCTCGCACACACGCACACATG	0.73	0.45	57%
1435	CTCTCGCACACACGCACACAT	0.84	0.36	57%
173	GAGTCCTGCAATATGAATATAATTT	1.12	0.6	28%
1608	GAG <u>S</u> CCTGCAATAT <u>S</u> AATATAATTT	0.65	0.19	24%
1609	GAGTCCTGCA <u>S</u> TATGAATAT <u>S</u> ATTT	0.78	0.25	28%
1610	GAGTCC <u>S</u> GCAATATGAAT <u>S</u> TAATTT	0.95	0.43	28%
1611	GAGTCC <u>S</u> GCAATATGA <u>A</u> <u>S</u> ATAATTT	1.09	0.32	28%

1612	GAGTCCT <u>S</u> CAAT <u>S</u> TGAASATAATTT	0.15	0.08	24%
1613	GAGTCC <u>S</u> GCAAT <u>S</u> TGAAT <u>S</u> TAATTT	0.2	0.13	28%
1614	GAGTC <u>S</u> TGCAAT <u>S</u> TGAATASAAATTT	0.13	0.18	24%
1615	GAGT <u>S</u> CTGCAAT <u>S</u> TGAATAT <u>S</u> ATTT	0.12	0.12	24%
1596	GAGTCCT <u>S</u> CAATATG <u>S</u> ATATAAT <u>S</u> T	0.26	0.13	24%
1597	GAG <u>S</u> CCTGCAASATGAAT <u>S</u> TAATTT	0.29	0.17	28%
1418	GAGTCC <u>S</u> GCAATASGAATATA <u>S</u> TTT	0.73	0.24	28%
1598	GTCCTGC <u>S</u> ATATGAASATAAT	0.72	0.31	29%
1599	GTCCT <u>S</u> CAATATG <u>S</u> ATATAAT	0.1	0.16	24%
1616	GTCCTGC <u>S</u> ATATG <u>S</u> ATATAAT	0.77	0.23	29%
197	CCTTTCTCTCGAAGGTCTTCTGCCG	1.04	0.44	56%
1429	TTTCTCTCGAAGGTCTTCTGCCG	1.35	1.06	48%
1430	CCTTTCTCTCGAAGGTCTTCTGC	0.98	0.44	48%
1431	CTTTCTCTCGAAGGTCTTCTGCC	1.33	0.55	48%
1617	CCTTTCTC <u>S</u> CGAAGGTCTTC <u>S</u> GCCG	0.99	0.69	56%
1618	CTTTCTC <u>S</u> CGAAGGT <u>S</u> TTCTGCC	0.94	0.58	48%
1619	TTTCTCT <u>S</u> GGAAGGTC <u>S</u> TCTGCCG	1	0.54	48%

Example 7: Additional Experiments Demonstrate STMN2 AONs with Spacer Technology Restore Full Length STMN2 and Reduces STMN2 Transcripts with a Cryptic Exon

[00496] STMN2 AONs with one, two, or three spacers were developed. Generally, in this Example, except for SEQ ID NO: 1649 described below, a spacer is represented by Formula (I), wherein:




Formula (I)

X is -O-; and

n is 1.

For SEQ ID NO: 1649, each spacer included in the ASO is represented by Formula (I), wherein:



Formula (I)

X is -O-; and

n is 2.

[00497] STMN2 AONs with spacers were characterized and compared to STMN2 AON without spacer counterparts. Specifically, the melting temperature of STMN2 AON with and without spacers were determined to demonstrate the structural differences of the STMN2 AONs. Table 14 shows the different melting temperatures of STMN2 AONs across two different replicates. STMN2 AONs with two spacers exhibited a lower melting temperature (approximately 10°C lower) in comparison to STMN2 AONs without spacers.

Table 14: Melting temperatures of STMN2 AONs with and without spacers.

ASO + RNA target (25bases)	T _m (°C) Replicate 1	T _m (°C) Replicate 2	ΔT _m °C Replicate 1	ΔT _m °C Replicate 2	%GC
----------------------------	---------------------------------	---------------------------------	--------------------------------	--------------------------------	-----

SEQ ID NO: 237 (no spacer)	86.6	86.5	11.6	11.4	56
SEQ ID NO: 1591 (2 spacers)	75.0	75.1			
SEQ ID NO: 144 (no spacer)	75.5	75.5	9.5	9.7	40
SEQ ID NO: 1589 (2 spacers)	66.0	65.8			
SEQ ID NO: 173 (no spacer)	71.2	71.1	13.5	13.5	28
SEQ ID NO: 1590 (2 spacers)	57.7	57.6			

[00498] STMN2 AONs (*e.g.*, STMN2 oligonucleotides with one, two, or three spacers) were tested for their ability to increase or restore full-length STMN2 mRNA (*i.e.*, mRNA from which full-length STMN2 is translated) levels in TDP43 silenced cells. In some cases, STMN2

oligonucleotides are tested for their ability to reduce STMN2 transcripts with a cryptic exon.

FIGs. 27-35 show effects of STMN2 AONs with spacers in increasing full-length STMN2 mRNA (“STMN2 FL”) and/or in reducing STMN2 transcripts with a cryptic exon (“STMN2 cryptic”).

Furthermore, Table 15 identifies the respective STMN2 AONs as well as their respective

performances. Treatment groups are identified on the X-axis of FIGs. 27-35 and include the

concentration of specific AON sequences. Here, specific AON sequences are labeled according to their corresponding SEQ ID NO.

[00499] FIG. 27A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels across different dosages of STMN2 AONs including

SEQ ID NO: 173, SEQ ID NO: 1608, SEQ ID NO: 1609, SEQ ID NO: 1610, SEQ ID NO: 1611, SEQ ID NO: 1612, SEQ ID NO: 1613, SEQ ID NO: 1614, SEQ ID NO: 1615, SEQ ID NO: 1596, SEQ ID NO: 1597, and SEQ ID NO: 1418. FIG. 27B is a bar graph showing the results of RT-

qPCR analysis of STMN2 full-length mRNA levels in the presence of TDP43 antisense, and restoration of the full-length STMN2 transcript across different dosages of STMN2 AONs

including SEQ ID NO: 173, SEQ ID NO: 1608, SEQ ID NO: 1609, SEQ ID NO: 1610, SEQ ID NO: 1611, SEQ ID NO: 1612, SEQ ID NO: 1613, SEQ ID NO: 1614, SEQ ID NO: 1615, SEQ ID NO: 1596, SEQ ID NO: 1597, and SEQ ID NO: 1418. Generally, FIGs. 27A and 27B

demonstrate the performance of STMN2 AONs with spacers (*e.g.*, SEQ ID NO: 1608, SEQ ID

NO: 1609, SEQ ID NO: 1610, SEQ ID NO: 1611, SEQ ID NO: 1612, SEQ ID NO: 1613, SEQ ID NO: 1614, SEQ ID NO: 1615, SEQ ID NO: 1596, SEQ ID NO: 1597, and SEQ ID NO: 1418) in comparison to STMN2 AON without spacers (SEQ ID NO: 173). Here, a number of STMN2 AON with spacers perform as well, or outperform the STMN2 AON without spacers (SEQ ID NO: 173). Specifically, 200 nM of SEQ ID NO: 1609, SEQ ID NO: 1610, and SEQ ID NO: 1611 achieve comparable levels of STMN2 transcript with cryptic exon mRNA levels and STMN2 full-length mRNA levels in the presence of TDP43 in comparison to STMN2 AON without spacers (SEQ ID NO: 173).

[00500] FIG. 28A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels across different dosages of STMN2 AONs including SEQ ID NO: 173, SEQ ID NO: 1632, SEQ ID NO: 1346, SEQ ID NO: 1631, SEQ ID NO: 1353, and SEQ ID NO: 1598. FIG. 28B is a bar graph showing the results of RT-qPCR analysis of STMN2 full-length mRNA levels in the presence of TDP43 antisense, and restoration of the full-length STMN2 transcript across different dosages of STMN2 AONs including SEQ ID NO: 173, SEQ ID NO: 1632, SEQ ID NO: 1346, SEQ ID NO: 1631, SEQ ID NO: 1353, and SEQ ID NO: 1598. Generally, FIGs. 28A and 28B demonstrate the performance of STMN2 AONs with spacers (e.g., SEQ ID NO: 1632, SEQ ID NO: 1631, and SEQ ID NO: 1598) in comparison to their STMN2 AON counterparts without spacer (e.g., SEQ ID NO: 173, SEQ ID NO: 1346, and SEQ ID NO: 1353). Here, a 50nM or 200 nM dose of SEQ ID NO: 1632 achieves comparable levels of STMN2 transcript with cryptic exon mRNA levels and STMN2 full-length mRNA levels in the presence of TDP43 in comparison to a 50nM or 200nM dose of the STMN2 AON counterpart without spacers (SEQ ID NO: 173). A 200 nM dose of SEQ ID NO: 1631 achieves comparable levels of STMN2 full-length mRNA levels in the presence of TDP43 in comparison to 200 nM dose of the STMN2 AON counterpart without spacers (SEQ ID NO: 1346).

[00501] FIG. 29A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels across different dosages of STMN2 AONs including SEQ ID NO: 173 and SEQ ID NO: 1610. FIG. 29B is a bar graph showing the results of RT-qPCR analysis of STMN2 full-length mRNA levels in the presence of TDP43 antisense, and restoration of the full-length STMN2 transcript across different dosages of STMN2 AONs including SEQ ID NO: 173 and SEQ ID NO: 1610. Generally, FIGs. 29A and 29B demonstrate the performance of STMN2 AONs with spacers (e.g., SEQ ID NO: 1610) in comparison to the

STMN2 AON counterpart without spacers (e.g., SEQ ID NO: 173). Across the different doses (e.g., 500 nM, 200 nM, 50 nM, 20 nM, and 5 nM), SEQ ID NO: 1610 achieves comparable levels of STMN2 transcript with cryptic exon mRNA levels and STMN2 full-length mRNA levels in the presence of TDP43 in comparison to the STMN2 AON counterpart without spacers (SEQ ID NO: 173).

[00502] FIG. 30A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels across different dosages of STMN2 AONs including SEQ ID NO: 185 and SEQ ID NO: 1635. FIG. 30B is a bar graph showing the results of RT-qPCR analysis of STMN2 full-length mRNA levels in the presence of TDP43 antisense, and restoration of the full-length STMN2 transcript across different dosages of STMN2 AONs including SEQ ID NO: 185 and SEQ ID NO: 1635. Generally, FIGs. 30A and 30B demonstrate the performance of STMN2 AONs with spacers (e.g., SEQ ID NO: 1635) in comparison to the STMN2 AON counterpart without spacers (e.g., SEQ ID NO: 185). Across the different doses (e.g., 500 nM, 200 nM, 50 nM, 20 nM, and 5 nM), SEQ ID NO: 1610 achieves comparable or reduced levels of STMN2 transcript with cryptic exon mRNA levels and comparable or increased STMN2 full-length mRNA levels in the presence of TDP43 in comparison to the STMN2 AON counterpart without spacers (SEQ ID NO: 185).

[00503] FIG. 31A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels across different dosages of STMN2 AONs including SEQ ID NO: 1347, SEQ ID NO: 1633, and SEQ ID NO: 1634. FIG. 31B is a bar graph showing the results of RT-qPCR analysis of STMN2 full-length mRNA levels in the presence of TDP43 antisense, and restoration of the full-length STMN2 transcript across different dosages of STMN2 AONs including SEQ ID NO: 1347, SEQ ID NO: 1633, and SEQ ID NO: 1634. Generally, FIGs. 31A and 31B demonstrate the performance of STMN2 AONs with spacers (e.g., SEQ ID NO: 1633 and SEQ ID NO: 1634) in comparison to the STMN2 AON counterpart without spacers (e.g., SEQ ID NO: 1347). Across the different doses (e.g., 500 nM, 200 nM, 50 nM, 20 nM, and 5 nM), SEQ ID NO: 1633 achieves comparable or reduced levels of STMN2 transcript with cryptic exon mRNA levels and comparable or increased STMN2 full-length mRNA levels in the presence of TDP43 in comparison to the STMN2 AON counterpart without spacers (SEQ ID NO: 1347). Similarly, across the different doses (e.g., 500 nM, 200 nM, 50 nM, 20 nM, and 5 nM), SEQ ID NO: 1634 achieves comparable or reduced levels of STMN2 transcript with cryptic exon

mRNA levels and comparable or increased STMN2 full-length mRNA levels in the presence of TDP43 in comparison to the STMN2 AON counterpart without spacers (SEQ ID NO: 1347).

[00504] FIG. 32A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels across different dosages of STMN2 AONs including SEQ ID NO: 197, SEQ ID NO: 1617, SEQ ID NO: 1618, and SEQ ID NO: 1619. FIG. 32B is a bar graph showing the results of RT-qPCR analysis of STMN2 full-length mRNA levels in the presence of TDP43 antisense, and restoration of the full-length STMN2 transcript across different dosages of STMN2 AONs including SEQ ID NO: 197, SEQ ID NO: 1617, SEQ ID NO: 1618, and SEQ ID NO: 1619. Generally, FIGs. 32A and 32B demonstrate the performance of STMN2 AONs with spacers (e.g., SEQ ID NO: 1617, SEQ ID NO: 1618, and SEQ ID NO: 1619) in comparison to the STMN2 AON counterpart without spacers (e.g., SEQ ID NO: 197). At a 50 nM or 200 nM dose, SEQ ID NO: 1617 achieves comparable or reduced levels of STMN2 transcript with cryptic exon mRNA levels and comparable or increased STMN2 full-length mRNA levels in the presence of TDP43 in comparison to a 50 nM or 200 nM dose of the STMN2 AON counterpart without spacers (SEQ ID NO: 197). At a 50 nM or 200 nM dose, SEQ ID NO: 1618 achieves comparable or reduced levels of STMN2 transcript with cryptic exon mRNA levels and comparable or increased STMN2 full-length mRNA levels in the presence of TDP43 in comparison to a 50 nM or 200 nM dose of the STMN2 AON counterpart without spacers (SEQ ID NO: 197). At a 50 nM or 200 nM dose, SEQ ID NO: 1619 achieves comparable or reduced levels of STMN2 transcript with cryptic exon mRNA levels and comparable or increased STMN2 full-length mRNA levels in the presence of TDP43 in comparison to a 50 nM or 200 nM dose of the STMN2 AON counterpart without spacers (SEQ ID NO: 197).

[00505] FIG. 33A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels across different dosages of STMN2 AONs including SEQ ID NO: 252, SEQ ID NO: 1650, SEQ ID NO: 1434, SEQ ID NO: 1651, and SEQ ID NO: 1620. FIG. 33B is a bar graph showing the results of RT-qPCR analysis of STMN2 full-length mRNA levels in the presence of TDP43 antisense, and restoration of the full-length STMN2 transcript across different dosages of STMN2 AONs including SEQ ID NO: 252, SEQ ID NO: 1650, SEQ ID NO: 1434, SEQ ID NO: 1651, and SEQ ID NO: 1620. Generally, FIGs. 33A and 33B demonstrate the performance of STMN2 AONs with spacers (e.g., SEQ ID NO: 1620) in comparison to the STMN2 AON counterpart without spacers (e.g., SEQ ID NO: 252, SEQ ID

NO: 1650, SEQ ID NO: 1434, and SEQ ID NO: 1651). At a 50 nM or 200 nM dose, SEQ ID NO: 1620 achieves comparable or reduced levels of STMN2 transcript with cryptic exon mRNA levels and comparable or increased STMN2 full-length mRNA levels in the presence of TDP43 in comparison to a 50 nM or 200 nM dose of the STMN2 AON counterparts without spacers (SEQ ID NO: 252, SEQ ID NO: 1650, SEQ ID NO: 1434, and SEQ ID NO: 1651).

[00506] FIG. 34A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels across different dosages of STMN2 AONs including SEQ ID NO: 1434 and SEQ ID NO: 1620. FIG. 34B is a bar graph showing the results of RT-qPCR analysis of STMN2 full-length mRNA levels in the presence of TDP43 antisense, and restoration of the full-length STMN2 transcript across different dosages of STMN2 AONs including SEQ ID NO: 1434 and SEQ ID NO: 1620. Generally, FIGs. 34A and 34B demonstrate the performance of STMN2 AONs with spacers (e.g., SEQ ID NO: 1620) in comparison to the STMN2 AON counterpart without spacers (e.g., SEQ ID NO: 1434). Across the different doses (e.g., 500 nM, 200 nM, 50 nM, 20 nM, and 5 nM), SEQ ID NO: 1620 achieves reduced levels of STMN2 transcript with cryptic exon mRNA levels and increased STMN2 full-length mRNA levels in the presence of TDP43 in comparison to the STMN2 AON counterpart without spacers (SEQ ID NO: 1434).

[00507] FIG. 35 is a bar graph showing normalized STMN2 protein levels following treatment with TDP43 antisense and restoration using 500 nM STMN2 AONs including SEQ ID NO: 144, SEQ ID NO: 1589, SEQ ID NO: 173, SEQ ID NO: 1616, SEQ ID NO: 237, and SEQ ID NO: 1591. Generally, FIG. 35 demonstrates the performance of STMN2 AONs with spacers (e.g., SEQ ID NO: 1589, SEQ ID NO: 1616, and SEQ ID NO: 1591) in comparison to their STMN2 AON counterparts without spacers (e.g., SEQ ID NO: 144, SEQ ID NO: 173, SEQ ID NO: 237).

Generally, STMN2 AONs with spacers are able to achieve comparable levels of STMN2 protein levels in comparison to their STMN2 AON counterparts. Specifically, SEQ ID NO: 1589 achieves comparable levels of STMN2 protein levels in comparison to SEQ ID NO: 144. SEQ ID NO: 1616 achieves comparable levels of STMN2 protein levels in comparison to SEQ ID NO: 173. SEQ ID NO: 1591 achieves comparable levels of STMN2 protein levels in comparison to SEQ ID NO: 237.

[00508] Referring to Tables 15 and 17, they show the performance of STMN2 AONs with spacers (e.g., Table 15) and performance of STMN2 AONs without spacers (e.g., Table 16) in human motor neurons. RT-qPCR results for STMN2 full-length transcript provided in Tables 15 and 17

are normalized values using the equation $((RQ_{ASO}-RQ_{TDP43})/(Rq_{endo}-RQ_{TDP43}))*100$ where RQ refers to Relative Quantity described above. RT-qPCR results for STMN2 transcript with a cryptic exon provided in Tables 15 and 17 are normalized values using the equation $(1-((RQ_{ASO}-RQ_{TDP43})/(Rq_{endo}-RQ_{TDP43}))*100$ where RQ refers to Relative Quantity described above.

- 5 Each RT-qPCR experiment was run in triplicate wells and performed N number of independent replicate runs. Standard deviation or SD is calculated as the SD between each run. Where N=1, SD was reported as the standard deviation between the triplicate well results in the single experiment. Notably, as shown in Table 15, a 200nM dose of SEQ ID NO: 1631 (GTCCTGCSATATGAASATAATTT with two spacers) rescued full length STMN2 mRNA to 10 69% and reduced STMN2 transcript with cryptic exon levels to 49% (reduced by 51%).
- [00509] Additionally, as shown in Table 15, a 200 nM dose of SEQ ID NO: 1633 (GTCTTCTSCCGAGTCSTGCAATA with two spacers) rescued full length STMN2 mRNA to 83% and reduced STMN2 transcript with cryptic exon levels to 10% (reduced by 90%). Comparatively, as shown in Table 16, a 200nM dose of SEQ ID NO: 1347 15 (GTCTTCTGCCGAGTCCTGCAATA with no spacers) rescued full length STMN2 mRNA to 40.2% and reduced STMN2 transcript with cryptic exon levels to 20.8% (reduced by 80.2%). This indicates that the addition of spacers improves the performance of SEQ ID NO: 1633 in comparison to the STMN2 AON counterpart without spacers (e.g., SEQ ID NO: 1347).
- [00510] Additionally, as shown in Table 15, a 200 nM dose of SEQ ID NO: 1618 20 (CTTTCTCSCGAAGGTSTTCTGCC with two spacers) rescued full length STMN2 mRNA to 82% and reduced STMN2 transcript with cryptic exon levels to 11% (reduced by 89%). A 200 nM dose of SEQ ID NO: 1619 (TTTCTCTSGAAGGTCSTCTGCCG with two spacers) rescued full length STMN2 mRNA to 80% and reduced STMN2 transcript with cryptic exon levels to 12% (reduced by 88%). Comparatively, as shown in Table 16, a 200nM dose of SEQ ID NO: 197 25 (CCTTTCTCTCGAAGGTCTTCTGCCG with no spacers) rescued full length STMN2 mRNA to 79.3% and reduced STMN2 transcript with cryptic exon levels to 12.1% (reduced by 87.9%). Here, at 200 nM dose, the performance of STMN2 AONs with two spacers (e.g., SEQ ID NO: 1618 and SEQ ID NO: 1619) is comparable to the STMN2 AON counterpart without spacers (e.g., SEQ ID NO: 197). Notably, at a 50nM dose, the performance of STMN2 AONs with two 30 spacers (e.g., SEQ ID NO: 1618 and SEQ ID NO: 1619) is improve din comparison to the STMN2 AON counterpart without spacers (e.g., SEQ ID NO: 197). Specifically, at the 50 nM dose, SEQ ID NO: 1618 rescued full length STMN2 mRNA to 46% and SEQ ID NO: 1619

rescued full length STMN2 mRNA to 42% whereas SEQ ID NO: 197 (without spacers) rescued full length STMN2 mRNA to 26.7%.

[00511] Additionally, as shown in Table 15, a 200 nM dose of SEQ ID NO: 1620

(TCTCTCGSACACACGSACACATG with two spacers) rescued full length STMN2 mRNA to

- 5 103% and reduced STMN2 transcript with cryptic exon levels to 1% (reduced by 99%). A 50 nM dose of SEQ ID NO: 1620 rescued full length STMN2 mRNA to 74% and reduced STMN2 transcript with cryptic exon levels to 5% (reduced by 95%). Comparatively, as shown in Table 16, a 200 nM dose and 50 nM dose of SEQ ID NO: 1434 (TCTCTCGCACACACGCACACATG with no spacers) rescued full length STMN2 mRNA to 77.5% and 16.6%, respectively and
- 10 reduced STMN2 transcript with cryptic exon levels to 2.7% (reduced by 97.3%) and 18.3% (reduced by 81.7%), respectively. This indicates that the addition of spacers improves the performance of SEQ ID NO: 1620 in comparison to the STMN2 AON counterpart without spacers (e.g., SEQ ID NO: 1434).

Table 15: Performance of STMN2 AONs (STMN2 oligonucleotides with one, two, or three spacers).

SEQ ID NO:	Sequence (where <u>S</u> indicates presence of a Spacer) (5' → 3')	QPCR potency in hMN STMN2 FL						QPCR potency in hMN STMN2 cryptic					
		50 nM			200 nM			50 nM			200 nM		
		N	Mean	SD	N	Mean	SD	N	Mean	SD	N	Mean	SD
1622	TGCAATASGAATATASTTTTAAA	1	1	1	1	47	12	1	76	24	1	340	92
1623	TCCTGCASTATGAATSTAAATTTT	1	6	3	1	31	16	1	82	17	1	100	44
1624	CTGCAATATGSATATAAATTTT	1	5	7	1	11	5	1	104	25	1	61	10
1625	CTGCAATSTGAATATSATTTTAA	1	2	8	1	-4	2	1	116	15	1	147	9
1626	CCTGCAATATSAAATATAATTT	1	2	2	1	42	7	1	65	5	1	59	14
1627	TCCTGCAATASGAATATAATT	1	19	5	1	65	1	1	85	17	1	36	2
1628	GTCCTGCSATATGAASATAAT	5	20	6	5	65	9	5	79	28	5	45	5
1629	GTCCTSCAATATGSATATAAT	4	5	6	4	13	22	4	119	31	4	133	53
1630	GTCCTGCSATATGSATATAAT	4	16	9	4	71	23	4	97	23	4	51	17
1631	GTCCTGCSATATGAASATAATTT	1	13	9	1	69	3	1	81	10	1	49	4
1596	GAGTCCTSCAATATGSATATAATST	1	3	4	1	18	9	1	52	41	1	50	41
1597	GAGSCCTGCAASATGAATSTAAATTT	1	7	11	1	20	15	1	79	1	1	82	24
1418	GAGTCCSGCAATASGAATATASTTT	1	15	2	1	69	13	1	70	23	1	48	8
1632	GAGTCCTGCAATATSAAATATAATTT	1	27	5	1	75	6	1	55	1	1	24	2
1608	GAGSCCTGCAATATSAAATATAATTT	1	10	8	1	60	15	1	44	34	1	30	14
1609	GAGTCCTGCASATGAATATSATTT	3	17	7	3	70	25	3	67	16	3	42	15

1610	GAGTCCSGCAATATGAATSTAATTT	4	29	11	4	83	21	4	76	20	4	40	17
1611	GAGTCCSGCAATATGAASATAATTT	3	23	3	3	95	46	3	60	22	3	41	8
1612	GAGTCTSCAAATSTGAASATAATTT	1	-2	2	1	5	3	1	106	26	1	92	22
1613	GAGTCCSGCAATSTGAATSTAATTT	1	3	2	1	11	3	1	100	37	1	96	18
1614	GAGTCTGCAATSTGAATASAATTT	1	8	1	1	2	4	1	94	38	1	101	4
1615	GAGTCTGCAATSTGAATATSATTT	1	1	2	1	2	5	1	90	10	1	99	19
1633	GTCTTCTSCCGAGTCSTGCAATA	2	53	3	2	83	23	2	45	8	2	10	2
1634	GTCTTCTGCCGSGTCCTGCAATA	2	31	21	2	74	0	2	41	6	2	12	5
1635	AGGTCTTCSGCCGAGTCCSGCAATA	1	23	2	0	N/A	N/A	1	43	6	0	N/A	N/A
1617	CCTTTCTCSCGAAGGTCTTCSGCCG	5	49	17	5	89	28	5	24	5	5	9	5
1618	CTTTCTCSCGAAGGTSTTCTGCC	3	46	13	3	82	22	3	35	15	3	11	3
1619	TTTCTCTSGAAGGTCTCTGCCC	2	42	8	2	80	28	2	40	3	2	12	1
1620	TCTCTCGSACACACGSACACATG	4	74	22	4	103	15	4	5	3	3	1	1
1589	AATCCAATTASGAGAGAGTGASGGG	1	7	1	1	32	1	1	107	14	1	47	22
1590	GAGTCCSGCAATASGAATATAATTT	1	23	2	1	63	1	1	76	4	1	47	4
1591	GCACACASGCTCACACAGSGAGCCA	1	45	5	1	86	6	1	11	5	1	2	1
1636	GT*C*C*TGCSATATGAASATAAT	1	18	7	1	53	3	1	75	13	1	74	9
1637	GT*C*C*TSCAATATGSATATAAT	1	4	7	1	2	3	1	130	12	1	105	34
1638	GT*C*C*TGCSATATGSATATAAT	1	24	19	1	41	5	1	75	1	1	68	9
1639	GTCTTCTSCCGAGT*C*S*T*GCAATA	1	26	7	1	67	15	1	60	33	1	30	4
1640	GT*CT*TC*TGCCGSGTCTCTGCAATA	1	33	8	1	63	11	1	36	9	1	17	6

1641	GTCTTCTGCC*G*S*G*TCCTGCAATA	1	21	11	1	91	11	1	34	23	1	23	4
1642	CCTTTCTCSCGAAGGTCT*T*C*SGCCG	2	40	11	2	77	21	2	28	13	2	14	4
1643	CCTTTCTCSCGAAGGTCTT*C*S*G*CCG	2	40	13	2	77	6	2	21	4	2	15	1
1644	CTTTCTCSCGAAGG*T*S*T*TCGTCC	1	28	5	1	46	17	1	60	7	1	36	13
1645	GC*A*CA*C*ASGCTCACASAGAGAGC	1	30	1	1	73	7	1	22	6	1	4	1
1646	GCACAC*A*S*G*CTCACASAGAGAGC	1	12	9	1	37	8	1	29	1	1	11	4
1647	TC*TC*TC*GSACACACGSACACATG	2	40	1	2	90	7	2	15	1	2	3	2
1648	TCTCTCGSACACACGSA*CA*CA*TG	2	58	5	2	108	7	2	19	2	2	7	4
1649	GTCTTCTS^CCGAGTCS^TGCAATA	3	26	9	3	71	9	3	19	5	3	21	9

indicates presence of phosphodiester linkage. All other linkages are phosphorothioate linkages.
^ indicates a spacer at the indicated position of the ASO, where the spacer is in accordance with Formula (I), where X is -O-; and n is 2.

Table 16: Performance of STMN2 AONs (STMN2 oligonucleotides without spacers).

SEQ ID NO:	Sequence (5' □ 3')	QPCR potency in hMN STMN2 FL						QPCR potency in hMN STMN2 cryptic					
		50 nM			200 nM			50 nM			200 nM		
		N	Mean	SD	N	Mean	SD	N	Mean	SD	N	Mean	SD
144	AATCCAAATTAAGAGAGAGTGATGGG	1	2	3	1	23	5	1	71	21	1	49	8
146	AAAATCCAATTAAGAGAGAGTGATG	1	11	4	1	19	5	1	45	5	1	36	4
150	TTTAAAAATCCAATTAAGAGAGAGT	3	43.7	39.4	3	46.7	13.7	3	38.7	20.6	3	17.7	7.1

169	CCTGCAATATGAATATAATTTTAAA	3	36.3	5.1	3	72.3	0.6	3	45.3	13.8	3	11.7	2.3
170	TCCTGCAATATGAATATAATTTTAA	3	28.3	13.1	3	86.3	12.3	3	69.3	34.7	3	25.3	10.1
171	GTCTGCAATATGAATATAATTTTA	3	30.7	6.5	3	85.0	8.9	3	56.3	10.5	3	12.3	2.5
172	AGTCCTGCAATATGAATATAATTTT	3	33.0	8.2	3	79.3	5.1	3	54.7	12.7	3	15.7	5.1
173	GAGTCCTGCAATATGAATATAATTT	6	29.0	13.3	6	81.5	16.1	6	61.3	14.2	6	21.0	7.3
197	CCTTTCTCTCGAAGGTCTTCTGCGG	8	26.7	14.5	8	79.3	31.3	8	44.4	15.4	8	12.1	7.2
237	GCACACATGCTCACACAGAGAGCCA	1	46	4	1	80	3	1	7	1	1	1	0
252	CTCTCTCGCACACACGCACACATGC	5	37.6	20.0	5	69.6	31.1	5	19.0	9.6	5	2.3	1.5
1343	AATCCAATTAAGAGAGAGTGATG	1	7	1	1	15	6	1	56	8	1	33	11
1346	GTCCTGCAATATGAATATAATTT	3	67.3	40.4	3	98.0	10.4	3	49.3	31.0	3	10.3	1.2
1347	GTCCTTCTGCCGAGTCCTGCAATA	2	12.5	3.6	2	40.2	16.7	2	55.7	13.2	2	20.8	15.9
1348	GCACACATGCTCACACAGAGAGC	2	45.6	13.6	2	89.5	2.1	2	11.6	7.6	2	0.7	0.4
1351	AATCCAATTAAGAGAGAGTGTA	1.0	10.0	2.0	1.0	12.0	2.0	1.0	69.0	5.0	1.0	35.0	9.0
1353	GTCCTGCAATATGAATATAAT	5	48.2	12.9	5	100.5	18.8	5	47.2	11.4	5	18.3	6.0
1353	GT*CC*TG*CAATATGAA*TA*TA*AT	1	36.4	7.0	1	84.3	7.0	1	64.0	5.0	1	32.8	12.0
1355	CCTGCAATATGAATATAATTT	4	50.0	9.3	4	79.0	19.5	4	21.5	7.2	4	7.0	2.2
1421	CCTGCAATATGAATATAATTTTA	1.0	44.0	18.0	1.0	120.0	39.0	1.0	32.0	1.0	1.0	8.0	1.0
1422	TGCAATATGAATATAATTTTAAA	4	43.9	14.5	4	80.7	3.9	4	40.5	8.8	4	24.0	16.3
1423	CTGCAATATGAATATAATTTTAA	3	48.0	17.6	3	88.7	9.5	3	38.3	13.2	3	10.7	4.9
1424	TGCAATATGAATATAATTTTA	1.0	40.0	5.0	1.0	79.0	13.0	1.0	33.0	5.0	1.0	15.0	0.0
1425	TCCTGCAATATGAATATAATTTT	4	39.0	5.1	4	95.8	9.8	4	40.6	14.9	4	12.0	2.9

1426	CTGCAATATGAATATAATTT	4	45.5	9.3	4	85.2	6.5	4	39.4	16.7	4	12.6	3.2
1427	AGTCCTGCAATATGAATATAATT	3	39.7	9.0	3	76.0	18.2	3	42.3	5.7	3	13.3	5.0
1428	TCCTGCAATATGAATATAATT	4	43.0	14.0	4	91.5	18.6	4	42.8	14.2	4	10.0	2.1
1429	TTTCTCTCGAAGGTCTTCTGCCG	3	49.5	49.5	3	85.5	44.5	3	40.9	22.8	3	9.5	6.6
1430	CCTTTCTCTCGAAGGTCTTCTGTC	1.0	41.5	5.0	1.0	98.2	10.0	1.0	27.5	8.0	1.0	5.9	1.0
1431	CTTTCTCTCGAAGGTCTTCTGCC	4	32.6	17.9	4	83.3	37.7	4	40.6	27.1	4	12.6	9.7
1432	CTCTCGCACACACGCACACATGC	4	34.0	12.7	4	51.8	10.5	4	25.5	8.0	4	3.1	2.1
1433	CTCTCTCGCACACACGCACACAT	1.0	20.2	2.0	1.0	60.8	6.0	1.0	6.5	7.0	1.0	2.9	2.0
1434	TCTCTCGCACACACGCACACATG	8	43.3	16.6	8	77.5	19.8	8	18.3	8.0	8	2.7	2.1
1435	CTCTCGCACACACGCACACAT	1.0	33.0	32.0	1.0	83.4	25.0	1.0	22.6	9.0	1.0	3.7	2.0
1650	CT*C*TC*T*CGCACACACGCACACATGC	1.0	26.6	4.0	1.0	68.8	1.0	1.0	40.3	3.0	1.0	13.3	3.0
1651	TC*TC*TC*GCACACACGCACACATG	1.0	46.1	7.0	1.0	91.0	6.0	1.0	32.4	1.0	1.0	8.9	1.0
1652	TTTCTCTCGAAGGTCTTCTGTC	2	26.0	2.4	2	75.9	6.0	2	49.4	2.7	2	8.9	0.8
1653	AAAATCCAATTAAGAGAGAGTGA	1.0	15.0	2.0	1.0	19.0	2.0	1.0	49.0	3.0	1.0	29.0	5.0
1654	AAATCCAATTAAGAGAGAGTGAT	1.0	12.0	1.0	1.0	18.0	2.0	1.0	55.0	2.0	1.0	31.0	4.0
1655	TAAAAATCCAATTAAGAGAGAGT	1.0	32.0	4.0	1.0	42.0	6.0	1.0	37.0	5.0	1.0	24.0	5.0
1656	TTTAAAAATCCAATTAAGAGAGA	1.0	25.0	1.0	1.0	32.0	1.0	1.0	37.0	4.0	1.0	29.0	2.0
1657	TTAAAAATCCAATTAAGAGAGAG	1.0	18.0	4.0	1.0	20.0	8.0	1.0	33.0	25.0	1.0	19.0	2.0
1658	TAAAAATCCAATTAAGAGAGA	3	21.7	7.5	3	52.0	29.1	3	60.0	29.0	3	42.0	18.1
1659	CC*T*T*TCCTCTCGAAGGTCTTCTGCCG	1.0	40.0	1.0	1.0	99.7	2.0	1.0	35.5	5.0	1.0	13.8	2.0
1660	GCACACATGCTCACACA*GA*GA*GC	1	40.8	4.0	1	85.1	6.0	1	12.9	2.0	1	3.4	0.0

1661	GC*A*CA*C*ATGCTCACACAGAGAGC	1	38.2	6.0	1	81.0	3.0	1	26.0	1.0	1	4.4	2.0
------	-----------------------------	---	------	-----	---	------	-----	---	------	-----	---	-----	-----

INCORPORATION BY REFERENCE

[00512] The entire disclosure of each of the patent documents and scientific articles cited herein is incorporated by reference for all purposes.

EQUIVALENTS

- 5 [00513] The disclosure can be embodied in other specific forms without departing from the essential characteristics thereof. The foregoing embodiments therefore are to be considered illustrative rather than limiting on the disclosure described herein. The scope of the disclosure is indicated by the appended claims rather than by the foregoing description, and all changes that come within the meaning and range of equivalency of the claims are intended
10 to be embraced therein.

CLAIMS

WHAT IS CLAIMED IS:

1. A compound comprising a modified oligonucleotide comprising a sequence that is between 85 and 98% complementary to an equal length portion of any one of SEQ ID NO: 1339 or SEQ ID NO: 1341, a sequence having 90% identity thereof, or to a 15 to 50 contiguous nucleobase portion thereof, wherein at least one (*i.e.*, one or more) nucleoside linkage of the oligonucleotide is a non-natural linkage, and further wherein the oligonucleotide comprises a spacer.
2. An oligonucleotide comprising a sequence that is between 85 and 98% complementary to an equal length portion of any one of SEQ ID NO: 1339 or SEQ ID NO: 1341, a sequence having 90% identity thereof, or to a 15 to 50 contiguous nucleobase portion thereof, wherein at least one (*i.e.*, one or more) nucleoside linkage of the oligonucleotide is a non-natural linkage, and further wherein the oligonucleotide comprises a spacer.
3. The compound of claim 1 or oligonucleotide of claim 2, wherein the oligonucleotide comprises a segment with at most 11 linked nucleosides.
4. The compound of claim 1 or 3, or oligonucleotide of claim 2 or 3, wherein the oligonucleotide comprises a segment with at most 10, 9, or 8 linked nucleosides.
5. The compound of any one of claims 1 or 3-4 or oligonucleotide of any one of claims 2-4, wherein the oligonucleotide comprises a segment with at most 7 linked nucleosides.
6. The compound of any one of claims 1 or 3-5 or oligonucleotide of any one of claims 1-5, wherein the oligonucleotide comprises a segment with at most 6, 5, 4, 3, or 2 linked nucleosides.
7. The compound of any one of claims 1 or 3-6 or oligonucleotide of any one of claims 1-6, wherein every segment of the oligonucleotide comprises at most 7 linked nucleosides.
8. The compound or oligonucleotide of any one of claims 3-7, wherein the oligonucleotide comprises a sequence that shares at least 85% identity with an equal length portion of any one of SEQ ID NOs: 1-466, SEQ ID NOs: 893-1338, SEQ ID NOs: 1342-1366, or SEQ ID NOs: 1392-1664.

9. The compound or oligonucleotide of any one of claims 3-8, wherein the oligonucleotide comprises a sequence that shares at least 90% identity with an equal length portion of any one of SEQ ID NOs: 1-466, SEQ ID NOs: 893-1338, SEQ ID NOs: 1342-1366, or SEQ ID NOs: 1392-1664.
- 5 10. The compound or oligonucleotide of any one of claims 3-9, wherein the oligonucleotide comprises a sequence that shares at least 95% identity with an equal length portion of any one of SEQ ID NOs: 1451-1664.
11. The compound or oligonucleotide of any one of claims 3-9, wherein the oligonucleotide comprises a sequence that shares 100% identity with an equal length portion
10 of any one of SEQ ID NOs: 1451-1664.
12. The compound of claim 1 or oligonucleotide of claim 2, wherein the oligonucleotide comprises a segment with at most 11 linked nucleosides or at most 7 linked nucleosides, and wherein the oligonucleotide comprises a sequence that is between 85 and 98% complementary to an equal length portion within any one of positions 144-168, 173-197,
15 185-209, or 237-261 of SEQ ID NO: 1339.
13. The compound or oligonucleotide of claim 12, wherein the oligonucleotide comprises a segment with at most 11 linked nucleosides or at most 7 linked nucleosides, and wherein the oligonucleotide comprises a sequence that is between 85 and 98% complementary to an equal length portion of nucleobases within any one of positions 144-164, 144-166, 145-167,
20 146-166, 146-168, 147-165, or 148-168 of SEQ ID NO: 1339.
14. The compound or oligonucleotide of claim 12, wherein the oligonucleotide comprises a segment with at most 11 linked nucleosides or at most 7 linked nucleosides, and wherein the oligonucleotide comprises a sequence that is between 85 and 98% complementary to an equal length portion of nucleobases within any one of positions 173-191, 173-193, 173-195,
25 173-197, 175-195, 175-197, 177-197, or 179-197 of SEQ ID NO: 1339.
15. The compound or oligonucleotide of claim 12, wherein the oligonucleotide comprises a segment with at most 11 linked nucleosides or at most 7 linked nucleosides, and wherein the oligonucleotide comprises a sequence that is between 85 and 98% complementary to an

equal length portion of nucleobases within any one of positions 185-205, 187-209, 189-209, or 191-209 of SEQ ID NO: 1339.

16. The compound or oligonucleotide of claim 12, wherein the oligonucleotide comprises a segment with at most 11 linked nucleosides or at most 7 linked nucleosides, and wherein the oligonucleotide comprises a sequence that is between 85 and 98% complementary to an equal length portion of nucleobases within any one of positions 237-255, 237-259, 239-259, 239-261, 241-261, or 243-261 of SEQ ID NO: 1339.

17. The compound or oligonucleotide of claim 12, wherein the oligonucleotide comprises a segment with at most 6, 5, 4, 3, or 2 linked nucleosides, and wherein the oligonucleotide comprises a sequence that is between 85 and 98% complementary to an equal length portion of nucleobases within any one of positions 144-168, 173-197, 185-209, or 237-261 of SEQ ID NO: 1339.

18. The compound or oligonucleotide of claim 12, wherein the oligonucleotide comprises a segment with at most 6, 5, 4, 3, or 2 linked nucleosides, and wherein the oligonucleotide comprises a sequence that is between 85 and 98% complementary to an equal length portion of nucleobases within any one of positions 144-164, 144-166, 145-167, 146-166, 146-168, 147-165, 148-168, 173-191, 173-193, 173-195, 173-197, 175-195, 175-197, 177-197, 179-197, 185-205, 187-209, 189-209, 191-209, 237-255, 237-259, 239-259, 239-261, 241-261, or 243-261 of SEQ ID NO: 1339.

19. The compound or oligonucleotide of claim 12, wherein the oligonucleotide comprises a segment with at most 11 linked nucleosides or at most 7 linked nucleosides, and wherein the oligonucleotide comprises a sequence that shares at least 85% identity with an equal length portion of any one of SEQ ID NOs: 1-466, SEQ ID NOs: 893-1338, SEQ ID NOs: 1342-1366, or SEQ ID NOs: 1392-1664.

20. The compound or oligonucleotide of claim 19, wherein the oligonucleotide comprises a segment with at most 6, 5, 4, 3, or 2 linked nucleosides, and wherein the oligonucleotide comprises a sequence that shares at least 85% identity with an equal length portion of any one of SEQ ID NOs: 36, 55, 144, 173, 177, 181, 185, 197, 203, 209, 215, 237, 244, 252, 380, 385, 390, 395, 400, 928, 947, 1036, 1065, 1069, 1073, 1077, 1089, 1095, 1101, 1107, 1129, 1136, 1144, 1272, 1277, 1282, 1287, or 1292.

21. The compound or oligonucleotide of claim 19 or 20, wherein the oligonucleotide comprises a segment with at most 6, 5, 4, 3, or 2 linked nucleosides, and wherein the oligonucleotide comprises a sequence that shares at least 90% identity with an equal length portion of any one of SEQ ID NOs: 36, 55, 144, 173, 177, 181, 185, 197, 203, 209, 215, 237, 244, 252, 380, 385, 390, 395, 400, 928, 947, 1036, 1065, 1069, 1073, 1077, 1089, 1095, 1101, 1107, 1129, 1136, 1144, 1272, 1277, 1282, 1287, or 1292.
22. The compound of any one of claims 1 and 3-21 or oligonucleotide of any one of claims 2-21, wherein the oligonucleotide is at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, or at least 25 oligonucleotide units in length.
23. The compound of claim 21 or oligonucleotide of claim 21, wherein the oligonucleotide is at least 19 oligonucleotide units in length.
24. The compound of any one of claims 1 and 3-23 or oligonucleotide of any one of claims 2-23, wherein the spacer is a nucleoside-replacement group comprising a non-sugar substitute that is incapable of linking to a nucleotide base.
25. The compound or oligonucleotide of claim 24, wherein the spacer is located between positions 10 and 15 of the oligonucleotide.
26. The compound or oligonucleotide of claim 24, wherein the spacer is located between positions 7 and 11 of the oligonucleotide.
27. The compound or oligonucleotide of claim 24 or 26, wherein the oligonucleotide further comprises a second spacer, wherein the second spacer is located between positions 14 and 22 of the oligonucleotide.
28. The compound or oligonucleotide of claim 27, wherein the spacer and the second spacer are separated by at least 5 nucleobases, at least 6 nucleobases, or at least 7 nucleobases in the oligonucleotide.
29. The compound or oligonucleotide of claim 27 or 28, wherein the spacer is located between positions 7 and 9 of the oligonucleotide, and wherein the second spacer is located between positions 15 and 18 of the oligonucleotide.

30. The compound or oligonucleotide of any one of claims 27-29, wherein the spacer is located at position 8 of the oligonucleotide, and wherein the second spacer is located at position 16 of the oligonucleotide.

31. The compound or oligonucleotide of any one of claims 27-30, wherein the
5 oligonucleotide further comprises a third spacer, wherein the third spacer is located between positions 21 and 24 of the oligonucleotide.

32. The compound or oligonucleotide of claim 24, wherein the spacer is located between positions 2 and 5 of the oligonucleotide.

33. The compound or oligonucleotide of claim 32, wherein the oligonucleotide further
10 comprises a second spacer, wherein the second spacer is located between positions 8 and 12 of the oligonucleotide.

34. The compound or oligonucleotide of claim 33, wherein the oligonucleotide further comprises a third spacer, wherein the third spacer is located between positions 18 and 22 of the oligonucleotide.


15 35. The compound or oligonucleotide of claim 24, wherein the oligonucleotide further comprises a second spacer and a third spacer, wherein the three spacers are located at positions in the oligonucleotide such that each segment of the oligonucleotide has at most 7 linked nucleosides.

20 36. The compound or oligonucleotide of claim 35, wherein at least two of the three spacers are adjacent to a guanine nucleobase.

37. The compound or oligonucleotide of claim 36, wherein each of the at least two of the three spacers immediately precede a guanine nucleobase.

38. The compound or oligonucleotide of any one of claims 24-37, wherein each of the first, second or third spacers is a nucleoside-replacement group comprising a non-sugar
25 substitute wherein the non-sugar substitute does not contain a ketone, aldehyde, ketal, hemiketal, acetal, hemiacetal, aminal or hemiaminal moiety and is incapable of forming a covalent bond with a nucleotide base.

39. The compound or oligonucleotide of any one of claims 24-37, wherein each of the first, second or third spacers is independently represented by Formula (X), wherein:




Formula (X)

Ring A is an optionally substituted 4-8 member monocyclic cycloalkyl group or a 4-8 member monocyclic heterocyclyl group, wherein the heterocyclyl group contains 1 or 2 heteroatoms selected from O, S and N, provided that A is not capable of forming a covalent bond to a nucleobase; and

the  symbol represents the point of connection to an internucleoside linkage.

40. The compound or oligonucleotide of claim 39, wherein each of the first, second or third spacers is independently represented by Formula (Xa), wherein:




Formula (Xa).

41. The compound or nucleotide of claim 39 or 40, wherein ring A is an optionally substituted 4-8 member monocyclic cycloalkyl group selected from cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl; or a 4-8 member monocyclic heterocyclyl group, selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, 1,4-dioxanyl, 2,6-pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl and azepanyl.

42. The compound or nucleotide of claim 41 wherein ring A is tetrahydrofuranyl.

43. The compound or nucleotide of claim 41 wherein ring A is tetrahydropyranyl.

44. The compound or oligonucleotide of any one of claims 24-37, wherein each of the first, second or third spacers is independently represented by Formula I, wherein:




Formula (I)

X is selected from -CH₂- and -O-; and

n is 0, 1, 2 or 3.

45. The compound or oligonucleotide of any one of claims 24-37, wherein each of the first, second or third spacers is independently represented by Formula I', wherein:




Formula (I')

X is selected from -CH₂- and -O-; and

n is 0, 1, 2 or 3.


46. The compound or oligonucleotide of any one of claims 24-37, wherein each of the first, second or third spacers is independently represented by Formula (Ia), wherein:



Formula (Ia); and

n is 0, 1, 2 or 3.


47. The compound or oligonucleotide of any one of claims 24-37, wherein each of the first, second or third spacers is independently represented by Formula (Ia'), wherein:



Formula (Ia'); and

n is 0, 1, 2 or 3.


48. The compound or oligonucleotide of any one of claims 24-37, wherein each of the first, second or third spacers is independently represented by Formula II, wherein:



5 Formula (II); and

X is selected from -CH₂- and -O-.


49. The compound or oligonucleotide of any one of claims 24-37, wherein each of the first, second or third spacers is independently represented by Formula II', wherein:



Formula (II'); and


10 X is selected from -CH₂- and -O-.

50. The compound or oligonucleotide of any one of claims 24-37, wherein each of the first, second or third spacers is independently represented by Formula (Iia), wherein:




Formula (Iia).

51. The compound or oligonucleotide of any one of claims 24-37, wherein each of the first, second or third spacers is independently represented by Formula (Iia'), wherein:



Formula (Iia').


52. The compound or oligonucleotide of any one of claims 24-37, wherein each of the first, second or third spacers is independently represented by Formula III, wherein:



Formula (III); and

X is selected from -CH₂- and -O-.


53. The compound or oligonucleotide of any one of claims 24-37, wherein each of the first, second or third spacers is independently represented by Formula III', wherein:



Formula (III'); and


X is selected from -CH₂- and -O-.

54. The compound or oligonucleotide of any one of claims 24-37, wherein each of the first, second or third spacers is independently represented by Formula (IIIa), wherein:



Formula (IIIa).

55. The compound or oligonucleotide of any one of claims 24-37, wherein each of the first, second or third spacers is independently represented by Formula (IIIa'), wherein:



Formula (IIIa').

56. The compound or oligonucleotide of any one of the above claims, wherein the
5 oligonucleotide comprising the spacer has a GC content of at least 10%.
57. The compound or oligonucleotide of any one of the above claims, wherein the oligonucleotide comprising the spacer has a GC content of at least 20%.
58. The compound or oligonucleotide of any one of the above claims, wherein the oligonucleotide comprising the spacer has a GC content of at least 25%.
- 10 59. The compound or oligonucleotide of any one of the above claims, wherein the oligonucleotide comprising the spacer has a GC content of at least 30%.
60. The compound or oligonucleotide of any one of the above claims, wherein the oligonucleotide comprising the spacer has a GC content of at least 40%.
61. The compound or oligonucleotide of any one of the above claims, wherein the
15 oligonucleotide comprising the spacer has a GC content of at least 50%.
62. The compound or oligonucleotide of any one of the above claims, wherein the oligonucleotide is between 12 and 40 oligonucleotide units in length.
63. The compound or oligonucleotide of any one of the above claims, wherein at least one
(*i.e.*, one or more) nucleoside linkage of the oligonucleotide is independently selected from
20 the group consisting of a phosphodiester linkage, a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a

thiophosphorodiamidate linkage, a phosphorodiamidate linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage.

- 5 64. The compound or oligonucleotide of any one of claims 1-63, wherein one or more nucleoside linkages that link a base at position 3 or position 4 of the oligonucleotide are phosphodiester linkages.
65. The compound or oligonucleotide of claim 64, wherein only one nucleoside linkage that links a base at position 3 or position 4 of the oligonucleotide is a phosphodiester linkage.
- 10 66. The compound or oligonucleotide of any one of claims 1-63, wherein nucleoside linkages that link bases at both position 3 and position 4 of the oligonucleotide are phosphodiester linkages.
67. The compound or oligonucleotide of any one of claims 1-63, wherein one or more bases immediately preceding a spacer in the oligonucleotide are linked through
15 phosphodiester bonds.
68. The compound or oligonucleotide of claim 67, wherein only the base immediately preceding the spacer in the oligonucleotide is linked to the spacer through a phosphodiester bond.
69. The compound or oligonucleotide of claim 68, wherein the base immediately
20 preceding the spacer in the oligonucleotide is further linked to a further preceding base through a phosphodiester bond.
70. The compound or oligonucleotide of claim 68, wherein the oligonucleotide comprises a second spacer, wherein a base immediately preceding the second spacer is linked to a further preceding base through a phosphodiester bond.
- 25 71. The compound or oligonucleotide of any one of claims 1-63, wherein one or more bases immediately succeeding a spacer in the oligonucleotide are linked through phosphodiester bonds.

72. The compound or oligonucleotide of claim 71, wherein only the base immediately succeeding the spacer in the oligonucleotide is linked to the spacer through a phosphodiester bond.

73. The compound or oligonucleotide of claim 67, wherein two bases immediately preceding the spacer in the oligonucleotide are linked through phosphodiester bonds.

74. The compound or oligonucleotide of any one of claims 1-63, wherein one or more bases immediately preceding a spacer in the oligonucleotide are linked through phosphodiester bonds and wherein one or more bases immediately succeeding the spacer in the oligonucleotide are linked through phosphodiester bonds.

75. The compound or oligonucleotide of claim 74, wherein one base immediately preceding the spacer and one base immediately succeeding the spacer are linked through phosphodiester bonds.

76. The compound or oligonucleotide of claim 74 or 75, wherein the oligonucleotide includes a second spacer, and wherein one or more bases immediately preceding the second spacer in the oligonucleotide are linked through phosphodiester bonds and wherein one or more bases immediately succeeding the second spacer in the oligonucleotide are linked through phosphodiester bonds.

77. The compound or oligonucleotide of claim 76, wherein one base immediately preceding the second spacer and one base immediately succeeding the second spacer are linked through phosphodiester bonds.

78. The compound or oligonucleotide of any one of claims 1-63, wherein the oligonucleotide comprises a range of bases that are linked through phosphodiester bonds, the range of bases comprising at least two bases.

79. The compound or oligonucleotide of any one of claims 1-63, wherein the oligonucleotide comprises a range of bases that are linked through phosphodiester bonds, the range of bases comprising at least five bases.

80. The compound or oligonucleotide of claim 78 or 79, wherein the oligonucleotide comprises two or more spacers, and wherein the range of bases are positioned between the at least two spacers.
81. A compound comprising an oligonucleotide comprising a nucleobase sequence that
5 shares at least 90% identity to an equal length portion of any one of SEQ ID NOs: 1-466, SEQ ID NOs: 893-1338, SEQ ID NOs: 1342-1366, or SEQ ID NOs: 1392-1664.
82. An oligonucleotide comprising a nucleobase sequence that shares at least 90% identity to an equal length portion of any one of SEQ ID NOs: 1-466, SEQ ID NOs: 893-1338, SEQ ID NOs: 1342-1366, or SEQ ID NOs: 1392-1664.
- 10 83. The compound of claim 81 or the oligonucleotide of claim 81 or 82, wherein the nucleobase sequence shares at least 95% identity to an equal length portion of any one of SEQ ID NOs: 1-466, SEQ ID NOs: 893-1338, SEQ ID NOs: 1342-1366, or SEQ ID NOs: 1392-1664.
84. The compound of claim 81 or the oligonucleotide of claim 81 or 82, wherein the
15 nucleobase sequence shares at least 100% identity to an equal length portion of any one of SEQ ID NOs: 1-466, SEQ ID NOs: 893-1338, SEQ ID NOs: 1342-1366, or SEQ ID NOs: 1392-1664.
85. The compound or oligonucleotide of any of claims 64-84, wherein the oligonucleotide is any one of a 19mer, 21mer, 23mer, or 25mer.
- 20 86. The compound or oligonucleotide of any one of the above claims, wherein one or more internucleoside linkage of the oligonucleotide is a modified internucleoside linkage.
87. The compound or oligonucleotide of claim 86, wherein the modified internucleoside linkage of the oligonucleotide is a phosphorothioate linkage.
88. The compound or oligonucleotide of claim 86 or 87, wherein all internucleoside
25 linkages of the oligonucleotide are phosphorothioate linkages.
89. The compound or oligonucleotide of claim 87, wherein the phosphorothioate linkage is in one of a *Rp* configuration or a *Sp* configuration.

90. The compound or oligonucleotide of any one of the preceding claims, wherein the oligonucleotide comprises at least one modified sugar moiety.
91. The compound or oligonucleotide of claim 90, wherein the modified sugar moiety is one of a 2'-OMe modified sugar moiety, bicyclic sugar moiety, 2'-*O*-(2-methoxyethyl) (2'-MOE), 2'-deoxy-2'-fluoro nucleoside, 2'-fluoro- β -D-arabinonucleoside, locked nucleic acid (LNA), constrained ethyl 2'-4'-bridged nucleic acid (cEt), *S*-cEt, tcDNA, hexitol nucleic acids (HNA), and tricyclic analog (*e.g.*, tcDNA).
92. The compound or oligonucleotide of any one of the above claims, wherein the oligonucleotide exhibits at least a 30%, 40%, 50%, 60%, 70%, 80%, or 90% increase of full length STMN2 protein.
93. The compound or oligonucleotide of any one of the above claims, wherein the oligonucleotide exhibits at least a 100% increase of full length STMN2 protein.
94. The compound or oligonucleotide of any one of the above claims, wherein the oligonucleotide exhibits at least a 200% increase of full length STMN2 protein.
95. The compound or oligonucleotide of any one of the above claims, wherein the oligonucleotide exhibits at least a 300% increase of full length STMN2 protein.
96. The compound or oligonucleotide of any one of the above claims, wherein the oligonucleotide exhibits at least a 400% increase of full length STMN2 protein.
97. The compound or oligonucleotide of any one of claims 92-96, wherein increase of the full length STMN2 protein is measured in comparison to a reduced level of full length STMN2 protein achieved using a TDP43 antisense oligonucleotide.
98. The compound or oligonucleotide of any one of the above claims, wherein the oligonucleotide exhibits at least a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% rescue of full length STMN2 protein.
99. The compound or oligonucleotide of any one of the above claims, wherein the oligonucleotide exhibits at least a 50%, 60%, 70%, 80%, or 90% reduction of a STMN2 transcript with a cryptic exon.

100. A method of treating a neurological disease and/or a neuropathy in a patient in need thereof, the method comprising administering to the patient a compound or an oligonucleotide of any one of claims 1-99.

101. The method of claim 100, wherein the neurological disease selected from the group
5 consisting of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), ALS with FTD, Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease, progressive supranuclear palsy (PSP), brain trauma, spinal cord injury, corticobasal degeneration (CBD), nerve injuries (e.g., brachial plexus injuries), neuropathies (e.g., chemotherapy induced neuropathy), and TDP43 proteinopathies (e.g., chronic traumatic encephalopathy, Perry
10 Syndrome, Dementia with Lewy body in association with Alzheimer's disease, Parkinson's disease with or without dementia, and Limbic-predominant age-related TDP-43 encephalopathy (LATE)).

102. The method of claim 101, wherein the neurological disease is ALS.

103. The method of claim 101, wherein the neurological disease is FTD.

15 104. The method of claim 101, wherein the neurological disease is ALS with FTD.

105. The method of claim 100, wherein the neuropathy is chemotherapy induced neuropathy.

106. A method of restoring axonal outgrowth and/or regeneration of a neuron, the method comprising exposing the neuron to a compound or an oligonucleotide of any one of claims 1-
20 99.

107. A method of increasing, promoting, stabilizing, or maintaining STMN2 expression and/or function in a neuron, the method comprising exposing the cell to a compound or an oligonucleotide of any one of claims 1-99.

108. The method of claim 106 or 107, wherein the neuron is a motor neuron.

25 109. The method of claim 106 or 107, wherein the neuron is a spinal cord neuron.

110. The method of any one of claims 106-109, wherein the neuron is a neuron of a patient in need of treatment of a neurological disease and/or a neuropathy.

111. The method of claim 110, wherein the neuropathy is chemotherapy induced neuropathy.

112. The method of any one of claims 106-111, wherein the exposing is performed *in vivo* or *ex vivo*.

5 113. The method of any one of claims 106-111, wherein the exposing comprises administering the oligonucleotide to a patient in need thereof.

114. The method of any one of claims 106-113, wherein the oligonucleotide is administered topically, parenterally, intrathecally, intrathalamically, intracisternally, orally, rectally, buccally, sublingually, vaginally, pulmonarily, intratracheally, intranasally,
10 transdermally, or intraduodenally.

115. The method of claim 114, wherein the oligonucleotide is administered orally.

116. The method of any one of claims 106-114, wherein a therapeutically effective amount of the oligonucleotide is administered intrathecally, intrathalamically or intracisternally.

117. The method of any one of claims 106-116, wherein the patient is a human.

15 118. A pharmaceutical composition comprising the oligonucleotide of any one of claims 1-99, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

119. The pharmaceutical composition of claim 118, wherein the pharmaceutical composition is suitable for topical, intrathecal, intrathalamic, intracisternal,
20 intracerebroventricular, parenteral, oral, pulmonary, intratracheal, intranasal, transdermal, rectal, buccal, sublingual, vaginal, or intraduodenal administration.

120. A method of treating a neurological disease or a neuropathy in a patient in need thereof, the method comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition of claim 118 or 119.

25 121. The method of claim 120, wherein the neurological disease is selected from the group consisting of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), ALS with FTD, Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease, progressive

supranuclear palsy (PSP), brain trauma, spinal cord injury, corticobasal degeneration (CBD), nerve injuries (e.g., brachial plexus injuries), neuropathies (e.g., chemotherapy induced neuropathy), and TDP43 proteinopathies (e.g., chronic traumatic encephalopathy, Perry Syndrome, Dementia with Lewy body in association with Alzheimer's disease, Parkinson's disease with or without dementia, and Limbic-predominant age-related TDP-43 encephalopathy (LATE)).

122. The method of claim 121, wherein the neurological disease is ALS.

123. The method of claim 121, wherein the neurological disease is FTD.

124. The method of claim 121, wherein the neurological disease is ALS with FTD.

125. The method of claim 120, wherein the neuropathy is chemotherapy induced neuropathy.

126. The method of any one of claims 120-125, wherein the pharmaceutical composition is administered topically, parenterally, orally, pulmonarily, rectally, buccally, sublingually, vaginally, intratracheally, intranasally, intracisternally, intrathecally, intrathalamically, transdermally, or intraduodenally.

127. The method of any one of claims 120-125, wherein the pharmaceutical composition is administered intrathecally, intrathalamically, or intracisternally.

128. The method of any one of claims 120-127, wherein a therapeutically effective amount of the oligonucleotide is administered intrathecally, intrathalamically or intracisternally.

129. The method of any one of claims 120-128, wherein the patient is human.

130. A method for treating a neurological disease in a subject in need thereof, the method comprising administering to the subject an oligonucleotide comprising a segment with at most 7 linked nucleosides, and wherein oligonucleotide shares at least 85% identity with any one of SEQ ID NOs: 1-466, SEQ ID NOs: 893-1338, SEQ ID NOs: 1342-1366, or SEQ ID NOs: 1392-1664, or a pharmaceutically acceptable salt thereof;

wherein at least one (*i.e.*, one or more) nucleoside linkage of the oligonucleotide is independently selected from the group consisting of: a phosphodiester linkage, a

phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a
 5 phosphoramidothioate linkage, a thiophosphorodiamidate linkage, a phosphorodiamidate linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage, and/or

wherein at least one (*i.e.*, one or more) nucleoside is substituted with a component
 10 selected from the group consisting of a 2'-O-(2-methoxyethyl) nucleoside, a 2'-O-methyl nucleoside, a 2'-deoxy-2'-fluoro nucleoside, a 2'-fluoro- β -D-arabinonucleoside, a locked nucleic acid (LNA), a tricyclic nucleic acid, constrained methoxyethyl (cMOE), constrained ethyl (cET), and a peptide nucleic acid (PNA)

optionally, wherein the oligonucleotide further comprises a spacer.

15 131. A method for treating amyotrophic lateral sclerosis (ALS) in a subject in need thereof, the method comprising administering to the subject an oligonucleotide comprising a segment with at most 7 linked nucleosides, and wherein oligonucleotide shares at least 85% identity with any one of SEQ ID NOs: 1-466, SEQ ID NOs: 893-1338, SEQ ID NOs: 1342-1366, or SEQ ID NOs: 1392-1664, or a pharmaceutically acceptable salt thereof;

20 wherein at least one (*i.e.*, one or more) nucleoside linkage of the oligonucleotide is independently selected from the group consisting of: a phosphodiester linkage, a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene
 25 phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a thiophosphorodiamidate linkage, a phosphorodiamidate linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage, and/or

wherein at least one (*i.e.*, one or more) nucleoside is substituted with a component selected from the group consisting of a 2'-O-(2-methoxyethyl) nucleoside, a 2'-O-methyl nucleoside, a 2'-deoxy-2'-fluoro nucleoside, a 2'-fluoro- β -D-arabinonucleoside, a locked nucleic acid (LNA), a tricyclic nucleic acid, constrained methoxyethyl (cMOE), constrained ethyl (cET), and a peptide nucleic acid (PNA)

optionally, wherein the oligonucleotide further comprises a spacer.

132. A method for treating frontotemporal dementia (FTD) in a subject in need thereof, the method comprising administering to the subject an oligonucleotide comprising a segment with at most 7 linked nucleosides, and wherein oligonucleotide shares at least 85% identity with any one of SEQ ID NOs: 1-466, SEQ ID NOs: 893-1338, SEQ ID NOs: 1342-1366, or SEQ ID NOs: 1392-1664, or a pharmaceutically acceptable salt thereof;

wherein at least one (*i.e.*, one or more) nucleoside linkage of the oligonucleotide is independently selected from the group consisting of: a phosphodiester linkage, a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a thiophosphorodiamidate linkage, a phosphorodiamidate linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage, and/or

wherein at least one (*i.e.*, one or more) nucleoside is substituted with a component selected from the group consisting of a 2'-O-(2-methoxyethyl) nucleoside, a 2'-O-methyl nucleoside, a 2'-deoxy-2'-fluoro nucleoside, a 2'-fluoro- β -D-arabinonucleoside, a locked nucleic acid (LNA), a tricyclic nucleic acid, constrained methoxyethyl (cMOE), constrained ethyl (cET), and a peptide nucleic acid (PNA)

optionally, wherein the oligonucleotide further comprises a spacer.

133. A method for treating amyotrophic lateral sclerosis (ALS) with frontotemporal dementia (FTD) in a subject in need thereof, the method comprising administering to the

subject an oligonucleotide comprising a segment with at most 7 linked nucleosides, and wherein oligonucleotide shares at least 85% identity with any one of SEQ ID NOs: 1-466, SEQ ID NOs: 893-1338, SEQ ID NOs: 1342-1366, or SEQ ID NOs: 1392-1664, or a pharmaceutically acceptable salt thereof;

5 wherein at least one (*i.e.*, one or more) nucleoside linkage of the oligonucleotide is independently selected from the group consisting of: a phosphodiester linkage, a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene
10 phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothioate linkage, a thiophosphorodiamidate linkage, a phosphorodiamidate linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage, and/or

15 wherein at least one (*i.e.*, one or more) nucleoside is substituted with a component selected from the group consisting of a 2'-O-(2-methoxyethyl) nucleoside, a 2'-O-methyl nucleoside, a 2'-deoxy-2'-fluoro nucleoside, a 2'-fluoro- β -D-arabinonucleoside, a locked nucleic acid (LNA), a tricyclic nucleic acid, constrained methoxyethyl (cMOE), constrained ethyl (cET), and a peptide nucleic acid (PNA)

20 optionally, wherein the oligonucleotide further comprises a spacer.

134. The method of any one of claims 130-133, wherein nucleoside linkages that link a base at position 3 or position 4 of the oligonucleotide are phosphodiester linkages.

135. The method of claim 134, wherein only one nucleoside linkage that links a base at position 3 or position 4 of the oligonucleotide is a phosphodiester linkage.

25 136. The method of any one of claims 130-133, wherein nucleoside linkages that link bases at both position 3 and position 4 of the oligonucleotide are phosphodiester linkages.

137. The method of any one of claims 130-133, wherein one or more bases immediately preceding a spacer in the oligonucleotide are linked through phosphodiester bonds.

138. The method of claim 137, wherein only the base immediately preceding the spacer in the oligonucleotide is linked to the spacer through a phosphodiester bond.

139. The method of claim 138, wherein the base immediately preceding the spacer in the oligonucleotide is further linked to a further preceding base through a phosphodiester bond.

5 140. The method of claim 138, wherein the oligonucleotide comprises a second spacer, wherein a base immediately preceding the second spacer is linked to a further preceding base through a phosphodiester bond.

141. The method of any one of claims 130-133, wherein one or more bases immediately succeeding a spacer in the oligonucleotide are linked through phosphodiester bonds.

10 142. The method of claim 141, wherein only the base immediately succeeding the spacer in the oligonucleotide is linked to the spacer through a phosphodiester bond.

143. The method of any one of claims 130-133, wherein two bases immediately preceding the spacer in the oligonucleotide are linked through phosphodiester bonds.

15 144. The method of any one of claims 130-133, wherein one or more bases immediately preceding a spacer in the oligonucleotide are linked through phosphodiester bonds and wherein one or more bases immediately succeeding the spacer in the oligonucleotide are linked through phosphodiester bonds.

145. The method of claim 144, wherein one base immediately preceding the spacer and one base immediately succeeding the spacer are linked through phosphodiester bonds.

20 146. The method of claim 144 or 145, wherein the oligonucleotide includes a second spacer, and wherein one or more bases immediately preceding the second spacer in the oligonucleotide are linked through phosphodiester bonds and wherein one or more bases immediately succeeding the second spacer in the oligonucleotide are linked through phosphodiester bonds.

25 147. The compound or oligonucleotide of claim 146, wherein one base immediately preceding the second spacer and one base immediately succeeding the second spacer are linked through phosphodiester bonds.

148. The method of any one of claims 130-133, wherein the oligonucleotide comprises a range of bases that are linked through phosphodiester bonds, the range of bases comprising at least two bases.

149. The method of any one of claims 130-133, wherein the oligonucleotide comprises a range of bases that are linked through phosphodiester bonds, the range of bases comprising at least five bases.

150. The method of claim 148 or 149, wherein the oligonucleotide comprises two or more spacers, and wherein the range of bases are positioned between the at least two spacers.

151. The method of any of claims 134-150, wherein the oligonucleotide is any one of a 19mer, 21mer, 23mer, or 25mer.

152. The method of any one of claims 130-133, wherein at least one (*i.e.*, one or more) internucleoside linkage of the oligonucleotide is a phosphorothioate linkage.

153. The method of any one of claims 130-133, wherein all internucleoside linkages of the oligonucleotide are phosphorothioate linkages.

154. An oligonucleotide and a pharmaceutically acceptable excipient, the oligonucleotide comprising a sequence that is between 85 and 98% complementary to an equal length portion of any one of SEQ ID NO: 1339 or SEQ ID NO: 1341, a sequence having 90% identity thereof, or to a 15 to 50 contiguous nucleobase portion thereof, optionally wherein the oligonucleotide comprises a spacer and wherein the oligonucleotide is capable of increasing, restoring, or stabilizing expression of the STMN2 mRNA capable of translation of a functional STMN2 and/or activity and/or function of STMN2 protein in a cell or a human patient of an immune-mediated demyelinating disease, and wherein the level of increase, restoration, or stabilization of expression and/or activity and/or function is sufficient for use of the oligonucleotide as a medicament for the treatment of the immune-mediated demyelinating disease.

155. The method of any one of claims 100-117 or 120-153, the pharmaceutical composition of claim 118 or 119, or the oligonucleotide of any one of claims 1-99 or 154, wherein the oligonucleotide comprises one or more chiral centers and/or double bonds.

156. The method of any one of claims 100-117, 120-153, or 155, the pharmaceutical composition of claim 118, 119, or 155, or the oligonucleotide of any one of claims 1-99 or 154-155, wherein the oligonucleotide exist as stereoisomers selected from geometric isomers, enantiomers, and diastereomers.

5 157. A method of treating a neurological disease and/or a neuropathy in a patient in need thereof, the method comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition of claim 118 or 119, in combination with a second therapeutic agent.

158. The method of claim 157, wherein the second therapeutic agent is selected from
10 Riluzole (Rilutek), Edaravone (Radicava), rivastigmine, donepezil, galantamine, selective serotonin reuptake inhibitor, antipsychotic agents, cholinesterase inhibitors, memantine, benzodiazepine antianxiety drugs, AMX0035 (ELYBRIO), ZILUCOPLAN (RA101495), pridopidine, dual AON intrathecal administration (*e.g.*, BIIB067, BIIB078, and BIIB105), BIIB100, levodopa/carbidopa, dopaminergic agents (*e.g.*, ropinirole, pramipexole,
15 rotigotine), medroxyprogesetrone, KCNQ2/KCNQ3 openers (*e.g.*, retigabine, XEN1101, or QRL-101), anticonvulsants and psychostimulant agents, and/or a therapy (*e.g.*, selected from breathing care, physical therapy, occupational therapy, speech therapy, nutritional support), for treating said neurologic disease.

159. A method of treating a neurological disease and/or a neuropathy in a patient in need
20 thereof, the method comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition of claim 118 or 119, wherein at least one nucleoside linkage of the oligonucleotide is a non-natural linkage, optionally wherein the oligonucleotide comprises a spacer, and wherein the oligonucleotide further comprises a targeting or conjugate moiety selected from cholesterol, lipoic acid, panthothenic acid,
25 polyethylene glycol, and an antibody for crossing the blood brain barrier.

160. The method of any one of claims 100-117, 120-153, or 155-159, wherein the spacer is a nucleoside-replacement group comprising a non-sugar substitute that is incapable of linking to a nucleotide base.

161. The method of claim 160, wherein the spacer is located between positions 10 and 15
30 of the oligonucleotide.

162. The method of claim 160, wherein the spacer is located between positions 7 and 11 of the oligonucleotide.

163. The method of claim 160 or 162, wherein the oligonucleotide further comprises a second spacer, wherein the second spacer is located between positions 14 and 22 of the oligonucleotide.

164. The method of claim 163, wherein the spacer and the second spacer are separated by at least 5 nucleobases, at least 6 nucleobases, or at least 7 nucleobases in the oligonucleotide.

165. The method of claim 163 or 164, wherein the spacer is located between positions 7 and 9 of the oligonucleotide, and wherein the second spacer is located between positions 15 and 18 of the oligonucleotide.

166. The method of any one of claims 163-165, wherein the spacer is located at position 8 of the oligonucleotide, and wherein the second spacer is located at position 16 of the oligonucleotide.

167. The method of any one of claims 163 -166, wherein the oligonucleotide further comprises a third spacer, wherein the third spacer is located between positions 21 and 24 of the oligonucleotide.

168. The method of claim 160, wherein the spacer is located between positions 2 and 5 of the oligonucleotide.

169. The method of claim 168, wherein the oligonucleotide further comprises a second spacer, wherein the second spacer is located between positions 8 and 12 of the oligonucleotide.

170. The method of claim 169, wherein the oligonucleotide further comprises a third spacer, wherein the third spacer is located between positions 18 and 22 of the oligonucleotide.

171. The method of claim 160, wherein the oligonucleotide further comprises a second spacer and a third spacer, wherein the three spacers are located at positions in the


oligonucleotide such that each segment of the oligonucleotide has at most 7 linked nucleosides.

172. The method of claim 171, wherein at least two of the three spacers are adjacent to a guanine nucleobase.

5 173. The method of claim 172, wherein each of the at least two of the three spacers immediately precede a guanine nucleobase.

174. The method of any one of claims 160-173, wherein each of the first, second or third spacers is a nucleoside-replacement group comprising a non-sugar substitute wherein the non-sugar substitute does not contain a ketone, aldehyde, ketal, hemiketal, acetal, hemiacetal,
10 amination or hemiaminal moiety and is incapable of forming a covalent bond with a nucleotide base.

175. The method of any one of claims 160-173, wherein each of the first, second or third spacers is independently represented by Formula (X), wherein:




Formula (X)

15 Ring A is an optionally substituted 4-8 member monocyclic cycloalkyl group or a 4-8 member monocyclic heterocyclyl group, wherein the heterocyclyl group contains 1 or 2 heteroatoms selected from O, S and N, provided that A is not capable of forming a covalent bond to a nucleobase; and

the $\sim$ symbol represents the point of connection to an internucleoside linkage.

20 176. The method of claim 175, wherein each of the first, second or third spacers is independently represented by Formula (Xa), wherein:




Formula (Xa).

177. The method of claim 175 or 176, wherein ring A is an optionally substituted 4-8 member monocyclic cycloalkyl group selected from cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl; or a 4-8 member monocyclic heterocyclyl group, selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, 1,4-dioxanyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl and azepanyl.

178. The method of claim 177, wherein ring A is tetrahydrofuranyl.

179. The method of claim 177, wherein ring A is tetrahydropyranyl.

180. The method of any one of claims 160-173 wherein each of the first, second or third spacers is independently represented by Formula (I), wherein:




Formula (I)

X is selected from -CH₂- and -O-; and


n is 0, 1, 2 or 3.

181. The method of any one of claims 160-173, wherein each of the first, second or third spacers is independently represented by Formula (I'), wherein:




Formula (I').

182. The method of any one of claims 160-173, wherein each of the first, second or third spacers is independently represented by Formula (Ia), wherein:




Formula (Ia).

183. The method of any one of claims 160-173, wherein each of the first, second or third spacers is independently represented by Formula (Ia'), wherein:



Formula (Ia').


5 184. The method of any one of claims 160-173, wherein each of the first, second or third spacers is independently represented by Formula II, wherein:



Formula (II); and

X is selected from -CH₂- and -O-.


10 185. The method of any one of claims 160-173, wherein each of the first, second or third spacers is independently represented by Formula II', wherein:



Formula (II'); and


X is selected from -CH₂- and -O-.

186. The method of any one of claims 160-173, wherein each of the first, second or third spacers is independently represented by Formula (IIa), wherein:




Formula (IIa).

187. The method of any one of claims 160-173, wherein each of the first, second or third spacers is independently represented by Formula (IIa'), wherein:



Formula (IIa').


5 188. The method of any one of claims 160-173, wherein each of the first, second or third spacers is independently represented by Formula III, wherein:



Formula (III); and

X is selected from -CH₂- and -O-.


10 189. The method of any one of claims 160-173, wherein each of the first, second or third spacers is independently represented by Formula III', wherein:



Formula (III'); and


X is selected from -CH₂- and -O-.

190. The method of any one of claims 160-173, wherein each of the first, second or third spacers is independently represented by Formula (IIIa), wherein:



Formula (IIIa).

191. The method of any one of claims 160-173, wherein each of the first, second or third spacers is independently represented by Formula (IIIa'), wherein:



Formula (IIIa').

5 192. The method of any one of claims 160-191, wherein the oligonucleotide comprising the spacer has a GC content of at least 10%.

193. The method of any one of claims 160-192, wherein the oligonucleotide comprising the spacer has a GC content of at least 20%.

10 194. The method of any one of claims 160-193, wherein the oligonucleotide comprising the spacer has a GC content of at least 25%.

195. The method of any one of claims 160-194, wherein the oligonucleotide comprising the spacer has a GC content of at least 30%.

196. The method of any one of claims 160-195, wherein the oligonucleotide comprising the spacer has a GC content of at least 40%.

15 197. The method of any one of claims 160-196, wherein the oligonucleotide comprising the spacer has a GC content of at least 50%.




FIG. 1





FIG. 2






FIG. 4




FIG. 5A




FIG. 5B




FIG. 6A




FIG. 6B




FIG. 7A




FIG. 7B




FIG. 8A




FIG. 8B




FIG. 9A




FIG. 9B




FIG. 10A




FIG. 10B




FIG. 11A




FIG. 11B




FIG. 12A




FIG. 12B




FIG. 13A




FIG. 13B




FIG. 14A




FIG. 14B




FIG. 15A











FIG. 15B












FIG. 20A




FIG. 20B




FIG. 21A






FIG. 21B






FIG. 23




FIG. 24





FIG. 25A



SEQ ID NO: 1348 | Log Conc (nM)

FIG. 25B




FIG. 26A





FIG. 26B






FIG. 27B




FIG. 28A




FIG. 28B




FIG. 29A




FIG. 29B




FIG. 30A




FIG. 30B




FIG. 31A





FIG. 31B






FIG. 33A

STMN2 FL




FIG. 33B




FIG. 34A




FIG. 34B

STMN2 protein levels

